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Abstract 
 
Cytochrome P450 enzymes (CYPs) are of great interest to pharmaceutical 
industry due to their major role in drug metabolism and drug-drug interactions in man. 
As CYPs also act on endogenous substrates and are regulated by nuclear receptors 
involved in biochemical pathways, their profiles are likely to affect endogenous 
metabolic profiles.  
The work in this thesis aimed to establish baseline rat liver CYP levels and 
assess relationships between CYP profiles and corresponding endogenous metabolic 
profiles, before introducing CYP inducers in subsequent projects to identify early 
biomarkers of CYP induction. 
An efficient and reproducible protocol was first developed and optimised for 
liver untargeted metabolic profiling by ultra performance liquid chromatography-mass 
spectrometry (UPLC-MS). Comparison of technical and biological variation for this liver 
protocol then demonstrated that sample preparation and UPLC-MS variability was 
mostly small compared to inter-animal variability. Subsequently, an in vivo study was 
designed including 20 male and 20 female Wistar rats. Liver mRNA of 81 CYPs was 
quantified, of which 23 exhibited significant gender differences with a gender ratio > 2. 
Clear gender differences were also observed in serum, urine and liver UPLC-MS 
metabolic profiles, e.g for metabolites belonging to steroid, triglyceride and 
phospholipid families. Multivariate models constructed to investigate relationships 
between CYP and metabolic profiles mainly highlighted the latent variable “gender”. 
Separate investigations for each gender yielded good prediction of CYP mRNA profiles 
from male liver aqueous metabolic profiles and female urine metabolic profiles. For 
prediction of CYP activities, the best models were obtained from serum metabolic 
profiles.  
In conclusion, this work improved our knowledge of rat basal CYP and 
metabolic profiles, and provides a strong basis for subsequent studies on CYP 
inducers. Importantly, strategies developed for UPLC-MS sample preparation, study 
design and data pre-processing/analysis are now routinely employed in our laboratory 
and have applications in many metabolic profiling studies. 
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« J’eus un geste de lassitude : il est absurde de chercher un puits, 
au hasard, dans l’immensité du désert. Cependant nous nous 
mîmes en marche. Quand nous eûmes marché, des heures, en 
silence, la nuit tomba, et les étoiles commencèrent de s’éclairer. 
[…] “Ce qui embellit le désert”, dit le petit prince, “c’est qu’il cache 
un puits quelque part...” [...] Et, marchant ainsi, je découvris le 
puits au lever du jour. »   
 
« I made a gesture of weariness. It is absurd to look for a well, at 
random, in the immensity of the desert. But nevertheless we started 
walking. When we had trudged along for several hours, in silence, the 
darkness fell, and the stars began to come out. [...] "What makes the 
desert beautiful," said the little prince, "is that somewhere it hides a 
well..." [...] And, as I walked on so, I found the well, at daybreak. » 
 
Antoine de Saint-Exupéry 
Le Petit Prince  
(The Little Prince) 
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Tbxas1   Thromboxane A2 synthase 1 (Cyp5a1) 
TIC   Total ion chromatogram 
TLE   Two-layer extraction 
TOF   Time-of-flight 
TLDA   TaqMan
®
 Low Density Arrays 
UPLC   Ultra performance liquid chromatography 
UV   Unit variance 
 
 
 
Analysis sites:  
BS   Biologie Servier (Gidy, France) 
ICL   Imperial College London (London, United Kingdom) 
TES   Technologie Servier (Orleans, France) 
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General introduction 
 
The work in this thesis forms part of a large pharmaceutical research project 
aiming to discover early biomarkers of cytochrome P450 induction during drug 
development studies through metabolic profiling approaches. 
Cytochrome P450 enzymes (CYPs) are of great interest to pharmaceutical 
industry as they play a major role in drug metabolism and drug-drug interaction. Many 
drug-drug interactions are due to induction or inhibition of CYPs metabolising a 
particular molecule by another co-administered molecule. This metabolism induction or 
inhibition can alter the drug plasma concentration, possibly resulting in inefficiency or 
toxicity of the drug treatment. Early determination of the impact of a new drug 
candidate on CYP-mediated metabolism is therefore crucial during drug development. 
During preclinical in vivo studies, CYP induction after drug administration is 
generally assessed through analysis of the liver, collected at study termination, which 
necessitates sacrificing test animals (usually rat, mouse, dog or monkey). Being able to 
observe early biomarkers of CYP induction through metabolic profiling of urine and 
serum, which can be obtained non- or minimally-invasively, would prove very useful 
and effort is therefore put on this approach. This could facilitate the investigation of 
CYP induction time courses and reduce the number of animals required for these 
studies. 
In this context, it was of interest to characterise liver CYP distribution and liver, 
serum and urine metabolic profiles in control rats and investigate relationships between 
them, before applying perturbations to these profiles in subsequent projects by 
introducing known inducers of CYPs. 
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Project objectives 
 
The overall aims of this project were: 
 
 To establish expression levels of a maximum number of cytochrome P450s in 
the liver of male and female control Wistar rats, and examine their consistency 
between multiple rat delivery batches received and housed several weeks apart 
under identical experimental conditions 
 
 To assess the feasibility of predicting these cytochrome P450 profiles from 
corresponding metabolic profiles in urine, serum and liver 
 
 
 
The specific objectives of this project were: 
 
 To develop an efficient and reproducible protocol for untargeted metabolic profiling 
of liver samples by ultra performance liquid chromatography-mass spectrometry 
(UPLC-MS) 
 To evaluate the ability of this protocol to detect differences in liver metabolic 
profiles between animals from the same experimental group, by comparing the 
relative importance of technical and biological variation 
 To quantify liver mRNA expression of a maximum number of cytochrome P450s 
(CYPs) in control Wistar rats and examine differences between males and females 
as well as between multiple rat delivery groups received several weeks apart 
 To determine CYP-related activities for a few selected CYPs (those usually 
evaluated in drug development studies) and compare the obtained results with 
those from mRNA quantification 
 To establish corresponding metabolic profiles in urine, serum and liver by UPLC-
MS, using both untargeted and targeted approaches, and examine the impact of 
rat delivery groups on these profiles 
 To assess the feasibility of constructing models predicting the CYP profiles from  
the corresponding metabolic profiles  
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Chapter I.  Introduction 
 
Cytochrome P450s (CYPs) are a superfamily of enzymes which play a major 
role in drug metabolism. During drug discovery process, determination of CYP isoforms 
responsible for the metabolism of a new drug candidate as well as the impact of this 
drug candidate on CYP profiles is critical to understanding both drug response and 
underlying mechanisms of drug-drug interactions.  
In addition to drug metabolism, CYP enzymes act on many exogenous and 
endogenous substrates. Besides, the nuclear receptors that regulate their expression 
can be activated or inhibited by endogenous ligands and are involved in endogenous 
pathways. CYPs and both exogenous and endogenous metabolites are therefore part 
of an intricate interacting network and we can expect CYP profiles to impact on 
metabolic profiles of the organism. 
In this context, global metabolic profiling could potentially be a powerful tool to 
assess CYP expression, as it offers the possibility of obtaining a fingerprint of the 
metabolome, non- or minimally-invasively by analysing urine, faeces or serum.  
The following sections describe the role of CYPs in drug metabolism and drug-
drug interactions, detail their links with metabolic profiles, and introduce the field of 
global metabolic profiling. 
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I.1. Cytochrome P450s (CYPs) 
I.1.1. Xenobiotic metabolism 
The metabolism of xenobiotics takes place mainly in the liver and generally 
consists of transforming hydrophobic compounds (which are able to cross cell 
membranes, accumulate and interact with cell metabolism) into more hydrophilic 
compounds in order to facilitate their elimination by the organism. It is usually broken 
down into three or four steps, depending if phase 0 is included in the description or not.  
Phase 0 describes the passage through the cell membrane to reach the cytosol, 
either by passive diffusion and/or by active transport performed by influx transporters 
belonging to the solute carrier (SLC) family. These transporters facilitate the cellular 
entry or exit of a wide range of compounds. They are divided into several families, 
including organic anion transporting polypeptides (OATPs), organic anion transporters 
(OATs) and organic cation transporters (OCTs).  
Phases I and II correspond to the biotransformation of the xenobiotic molecule 
with the aim of increasing its water-solubility, hence facilitating its excretion. 
Phase I metabolism mainly takes place inside the endoplasmic reticulum and 
consists of three types of chemical reactions: oxidations, reductions and hydrolyses, 
introducing (or unveiling) a functional group into the xenobiotic molecule. The resulting 
more polar compound can be excreted, or conjugated in phase II reactions to further 
increase its water solubility. The phase I metabolism is predominantly mediated by the 
cytochrome P450s, but can be performed by a wide range of other enzymes, such as 
flavin-containing monooxygenase, peroxidase, monoamine oxidase, alcohol 
dehydrogenase, aldehyde dehydrogenase, aldehyde oxidase, esterase, amidase, 
epoxide hydrolase and glutathione peroxidase1.  
Phase II reactions are conjugation reactions: the functional groups introduced in 
phase I metabolism (or already present in the parent compound) are conjugated with 
hydrophilic endogenous molecules such as glucuronic acid, sulphate, glutathione, 
glycine or taurine, which increases the molecule’s water solubility. These reactions are 
performed by a large group of enzymes, including uridine diphosphate-
glucuronosyltransferase, sulfotransferase, glutathione S-transferase, 
methyltransferase, acetyltransferase and amino acid conjugating enzymes1. 
Phase III corresponds to the excretion of the metabolised compound resulting 
from phases I and II out of the cell. It can either pass into the blood to be eliminated via 
urine, or into the bile to be eliminated via faeces. The excretion process generally 
involves efflux transporters belonging to the family of ATP-Binding Cassette (ABC) 
transporters, including multidrug resistance 1 (MDR1, also termed P-glycoprotein 
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(P−gP)), multidrug resistance associated proteins (MRPs) and breast cancer 
resistance protein (BCRP).  
 
 
I.1.2. Cytochrome P450s 
Cytochrome P450s (CYPs) play a major role in phase I metabolism. Their name 
is derived from their original identification as a liver pigment producing a 
spectrophotometric peak at 450 nm following binding to carbon monoxide2,3. They are 
found in many life forms, including animals, plants, fungi and bacteria3-5, and constitute 
a large family of heme-containing enzymes, subdivided into families and subfamilies 
according to the similarity of their amino acid structure. Each isoform is designated with 
the abbreviation CYP (or Cyp for rodents), followed by a number indicating its family 
(>40% amino-acid sequence similarity), a capital letter indicating its subfamily (>55%) 
(small letter for rodents), and a further number for the individual isoform (e.g. 
CYP1A2)3. For a few isoforms, the common name does not follow the nomenclature, 
reflecting instead the catalytic activity and the substrate, e.g. TBXAS1 (thromboxane 
A2 synthase 1) for CYP5A1 and PTGIS (Prostaglandin I2 (prostacyclin) synthase) for 
CYP8A1. 
CYPs catalyse a wide variety of reactions, the most common being a 
monooxygenase reaction, incorporating an oxygen atom into the oxidisable substrate 
RH to transform it into the hydroxylated metabolite ROH, following the equation1,2: 
RH + O2 + 2H
+ + 2e− → ROH + H2O. Most CYP isoforms can metabolise multiple 
substrates and catalyse multiple reactions.  
In humans, 57 CYP isoforms have been identified4,6 (Table I-1), mostly located 
in the endoplasmic reticulum although some isoforms are found in mitochondrial 
membranes. They are present in most tissues of the body, including liver, intestine, 
kidney, lung and skin. They are the major enzymes involved in drug metabolism, 
catalysing ~75% of drug metabolism reactions6. Of the 57 isoforms, just a few are 
responsible for most of the drug metabolism, namely CYPs 3A4, 2C9, 2C19, 2D6, 1A2, 
1A1, 2E1 and 2B66,7. Determination of the CYP isoforms responsible for the 
metabolism of a drug candidate is an important step in drug development, as it can 
affect inter-individual variability in drug response and drug-drug interactions.  
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Table I-1. Human cytochrome P450s 
Family 1 2 3 
Subfamily 1A 1B 2A 2B 2C 2D 2E 2F 2J 2R 2S 2U 2W 3A 
Isoforms 1A1 
1A2 
1B1 2A6 
2A7 
2A13 
2B6 2C8 
2C9 
2C18 
2C19 
2D6 2E1 2F1 2J2 2R1 2S1 2U1 2W1 3A4 
3A5 
3A7 
3A43 
 
Family 4 5 7 8 11 17 
Subfamily 4A 4B 4F 4V 4X 4Z 5A 7A 7B 8A 8B 11A 11B 17A 
Isoforms 4A11 
4A22 
4B1 4F2 
4F3 
4F8 
4F11 
4F12 
4F22 
4V2 4X1 4Z1 5A1 7A1 7B1 8A1 8B1 11A1 11B1 
11B2 
17A1 
 
Family 19 20 21 24 26 27 39 46 51 
Subfamily 19A 20A 21A 24A 26A 26B 26C 27A 27B 27C 39A 46A 51A 
Isoforms 19A1 20A1 21A2 24A1 26A1 26B1 26C1 27A1 27B1 27C1 39A1 46A1 51A1 
 
 
I.1.3. Inter-individual variability in CYP expression 
Many CYP genes are polymorphic, resulting in pharmacogenetic heterogeneity 
between individuals4,7-9. A well known example is CYP2D6, whose activity is decreased 
or absent in some people and amplified in others, with up to 10% of some populations 
affected by each of these extremes9,10. If an active drug is mainly metabolised by this 
enzyme and the same dose is administered to all people, it might result in toxic effects 
for the slow metabolisers due to increased drug plasma concentration, and in 
inefficiency in ultrafast metabolisers as the drug is metabolised too quickly. Due to this 
important variability, the pharmaceutical industry now tries to avoid compounds mainly 
metabolised by CYP2D6 when selecting drug candidates9. CYPs 2C9 and 2C19 also 
exhibit notable polymorphisms7,9,10. CYP polymorphism has been related to some 
genetic pathology, such as glaucoma, Parkinson’s disease and hypercholesterolemia7.  
External factors, such as environment, diet or age, can also impact on CYP 
distribution7,10-12. For instance, polycyclic aromatic hydrocarbons in tobacco smoke are 
believed to induce CYP1A1 and CYP1A2, affecting caffeine metabolism10,13,14. 
Regarding diet, grapefruit juice inhibits CYP3A4-mediated metabolism, while charcoal-
grilled food and cruciferous vegetables induce some CYPs10,13. As for alcohol, it can 
both induce and inhibit CYP activity, depending if the intake is acute or chronic15. CYP 
expression is also influenced by gender, especially in rats12.  
This inter-individual variability in CYP expression induces inter-individual 
differences in drug response and interactions. 
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I.1.4. Drug-drug interaction 
The metabolism of a particular drug by a CYP can be altered by co-
administering another drug that is a substrate of the same CYP and/or inhibits or 
induces this CYP. These drug-drug interactions (DDIs) are a significant source of side-
effects during medical treatments and have been reported to be responsible for millions 
of hospitalisations worldwide each year16. When a pharmaceutical company 
investigates new drug candidates, early identification and understanding of potential 
DDIs are fundamental in order to stop the development of a problematic molecule as 
soon as possible and to focus on the study of interactions likely to occur during the 
human clinical phase.  
Many DDIs are due to induction or inhibition of enzymes metabolising a 
molecule by another co-administered molecule. This induction or inhibition is likely to 
alter the metabolism and the clearance of the first drug molecule and consequently its 
plasma concentration, which can result in inefficiency of the molecule, or conversely in 
toxic effects. For example, if the co-administered drug inhibits the CYP-mediated 
metabolism of the first drug, it can accumulate in the body, resulting in possible toxic 
effects due to an overdose. Conversely, if the metabolism of the first drug is induced by 
the second drug, the medical treatment might fail due to insufficient drug plasma 
concentration. Among inhibition mechanisms, the most common is competitive 
inhibition, which occurs when the two co-administered drugs are metabolised by the 
same isoform and therefore compete for the enzyme.  
DDIs are more likely to occur for drugs with narrow therapeutic windows, as 
small changes in plasma concentration are likely to result in inefficiency or toxicity for 
these drugs. If a drug is metabolised almost exclusively by a single isoform, induction 
or inhibition of this enzyme will have a major effect on the drug plasma concentration. 
Pharmaceutical companies thus favour drug candidates that are metabolised by 
several isoforms.  
 An example of DDIs is the interaction observed between terfenadine and 
ketoconazole17,18. Terfenadine is an antihistamine, which was widely used in the 
treatment of allergies. It is a prodrug, metabolised by CYP3A4 to produce the active 
form. Terfenadine is highly metabolised and therefore usually not detectable in the 
plasma of patients taking the drug. It is cardiotoxic at high levels, while its metabolites 
are not. Ketoconazole, an antifungal drug, is a potent inhibitor of CYP3A4. When co-
administered with terfenadine, ketoconazole inhibits its metabolism to the active form, 
resulting in increased plasma concentration of terfenadine, leading to cardiotoxic 
effects.  
Occasionally, DDIs can be used to therapeutic advantage. For instance, 
ritonavir is often combined with other protease inhibitors in the treatment of HIV, as it 
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inhibits their CYP3A4-mediated metabolism and substantially increases their plasma 
concentration, allowing the patients to take lower drug doses19. 
 
 
I.1.5. Relationships between CYPs and metabolic 
profiles 
I.1.5.1. CYP-mediated metabolism of endogenous 
compounds 
In addition to drug metabolism, CYP enzymes are also involved in the 
metabolism and synthesis of a wide range of endogenous substrates, including 
steroids (oestrogens, testosterone, progesterone, cortisol) and sterols (cholesterol), 
bile acids, arachidonic acid and eicosanoids (prostaglandins, leukotrienes, 
prostacyclins and thromboxanes), saturated and unsaturated fatty acids, vitamin D3, 
retinoids, uroporphyrinogens and biogenic amines (melatonin)3,4,7,20,21.  
For instance, human CYP3A4, which contributes to the metabolism of 
approximately half of the drugs in use today, plays a predominant role in the 
metabolism of steroids such as testosterone, progesterone, estradiol and estrone7,22. It 
is also implicated in bile acid synthesis and vitamin D3 action
3. CYP1A2 is involved as 
well in the metabolism of estradiol and estrone22. 
Another example of CYP involvement in endogenous metabolism is arachidonic 
acid metabolism. At least 14 CYPs, belonging to the CYP families 1, 2, 3, 4, 5A and 
8A, play a direct or indirect role in this metabolism7.   
CYPs are also highly involved in cholesterol metabolism and bile acid synthesis. 
The synthesis of bile acids from cholesterol, the major pathway of cholesterol 
catabolism in human, is catalysed by at least 7 CYP isoforms, including members of 
CYP families 3, 7, 8, 27, 39 and 467. 
 
I.1.5.2. Regulation of CYP expression by nuclear receptors 
involved in endogenous pathways 
Nuclear receptors are a family of transcription factors which modulate tissue 
gene expression. Several nuclear receptors have been associated with CYP 
transcriptional regulation, including PXR (pregnane X receptor), CAR (constitutive 
androstane receptor), PPARs (peroxysome proliferative activated receptors, with three 
main forms: PPARα, PPARβ/δ and PPARγ), LXR (liver X receptor), FXR (farnesol X 
receptor) and VDR (Vitamin D3 Receptor)7,21,23,24.  
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Nuclear receptors can be activated or inhibited by both exogenous and 
endogenous ligands such as xenobiotics, steroids, fatty acids, eicosanoids and bile 
acids7,21,24-27. While PPARs, FXR, VDR and LXR are located in the nucleus, PXR and 
CAR bind their ligands in the cytoplasm24 (Figure I-1). In the absence of ligands, they 
are part of cytoplasmic complexes formed with chaperones and/or corepressors. 
Ligand binding induces a conformational change in the nuclear receptors resulting in 
their release from the cytoplasmic complexes, therefore allowing their translocation to 
the nucleus. In the nucleus, these nuclear receptors heterodimerise with RXR and bind 
to their respective response element on the DNA, which results in transcription initiation 
after recruitment of co-activator(s)24.  
 
 
 
Figure I-1. Schematic model of CYP regulation by nuclear receptors 
Ligand binding to PXR and CAR in the cytoplasm results in their release from cytoplasmic 
complexes and their translocation to the nucleus, where they heterodimerise with RXR and bind 
to their respective response element on the DNA (red rectangles). This triggers transcription of 
target genes. 
(adapted from Testa and Krämer
24
) 
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PXR and CAR, the two nuclear receptors most frequently involved in drug-
related enzyme induction24, have been implicated in regulation of CYPs 2A6, 2B6, 2C9, 
2C19 and 3A4 expression7,24. CYP3A4 expression is also regulated by FXR and 
VDR23,24, the latter being involved as well in regulation of CYPs 2B6 and 2C924.  As for 
PPARs, they activate transcription of CYPs from subfamilies 1A, 2A, 2C and 2E7.  
In addition to regulating CYP expression, nuclear receptors are also involved in 
endogenous pathways such as carbohydrate, bile acid, steroid and lipid 
homeostasis7,25-28.  
 
 
 
The involvement of CYP enzymes in the metabolism of both exogenous and 
endogenous substrates, as well as the regulation of their expression by nuclear 
receptors involved in endogenous pathways and activated by exogenous and 
endogenous ligands, show that CYPs and both exogenous and endogenous 
metabolites are part of an intricate network and interact with one another. The 
fingerprint of the CYP activity is therefore likely to have an impact on global metabolic 
profiles. Hence, metabolic profiles, which offer the great benefit of being obtainable 
non- or minimally-invasively by analysing urine or serum, could potentially be used as a 
tool to assess CYP profiles.  
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I.2. Global metabolic profiling 
I.2.1. Background 
Global metabolic profiling, also known as metabonomics/metabolomics, is a top-
down systems biology approach which provides insights into the metabolic status of 
complex living systems through the untargeted analysis of low molecular weight 
metabolites (< 1000 Da) in biological samples29-31. Levels of hundreds of metabolites 
can be determined simultaneously, and changes in metabolic profiles caused by stimuli 
such as diet, environment, disease processes or pharmaceutical interventions can be 
monitored over time29,32. The concepts of metabolomics and metabonomics were 
originally somewhat different: metabolomics aimed at the identification and 
quantification of all the small molecules in a given biological system33,34, while 
metabonomics was defined as “the quantitative measurement of the dynamic 
multiparametric metabolic response of living systems to pathophysiological stimuli or 
genetic modification”29. Nevertheless, both terms are increasingly used interchangeably 
in the literature35. In this work, the terms metabolic profiling and metabonomics will 
generally be employed, except when discussing papers specifically using the term 
metabolomics. 
Metabonomics is an approach complementary to genomics, transcriptomics and 
proteomics for studying complex living systems (the suffix “–omics” referring to the 
concept of considering the totality of the constituents collectively). Compared with other 
–omics technologies, metabonomics offers the advantage of taking into account the 
dynamic metabolic status of the whole organism and provides the ability to more 
accurately predict phenotypical properties29,36,37. Furthermore, it can be applied non-
invasively (e.g. urine analysis) or minimally invasively (e.g. serum analysis). 
 
 
I.2.2. Applications of metabolic profiling approaches 
Metabolic profiling approaches have been used for various environmental, 
preclinical and clinical applications38. Some examples are listed below. 
 Monitoring exposure to environmental stressors39-41 
 Investigating physiological effects, such as diet42,43, gender44-46 or diurnal 
variation42,45,47 
 Exploring interactions between the gut microbiome and host metabolic system48-51 
 Diagnosing/better understanding diseases, such as inborn errors of metabolism52, 
coronary heart disease53, heart failure54, diabetes55,56, Alzheimer’s disease57 or 
tumour development and progression58 
Introduction 
30 
 
 Identifying mechanisms and biomarkers of model toxin toxicity59-61 
 Investigating the impact of drug candidates on the metabolome as part of drug 
development studies, to obtain a global picture of their effects on the organism62-64 
 Predicting the outcome of a drug based on pre-dose metabolic profiles 
(pharmacometabonomics)65,66 
 Performing large-scale epidemiological studies43,67 
 
 
I.2.3. Workflow of a typical metabolic profiling study 
A workflow of a typical metabolic profiling study is shown in Figure I-2. After 
collection, samples have to be prepared for analysis. This step is highly dependent on 
sample type and analytical platform employed. Metabolic profiling has been largely 
applied to urine and serum samples as they are easily accessible45,54,59,60,68-76, but a 
large variety of other biological samples have also been profiled, including 
cerebrospinal fluid, amniotic fluid, seminal fluid, saliva, lung aspirates, bile, cells and a 
wide range of tissues, such as liver, gut and kidney32,50,77-83.  
Metabolic profiling is mainly performed using nuclear magnetic resonance 
(NMR) spectroscopy and/or mass spectrometry (MS), this latter technique being 
generally coupled with a prior separation stage, such as gas chromatography (GC), 
liquid chromatography (LC) or capillary electrophoresis (CE). Biological samples are 
complex mixtures containing a wide range of metabolites and therefore producing 
complex mass spectra. Introducing a prior separation stage reduces the complexity of 
the mass spectra by performing metabolite separation in a time dimension before mass 
separation84. This reduces the potential for ion suppression and can enable the 
separation of isomers according to their physico-chemical properties. NMR and LC-MS 
technologies will be detailed in Chapter II.  
For NMR analysis of biofluids such as urine or serum, sample preparation is 
usually minimal and can be a simple dilution with either a saline solution (0.9%) or a 
phosphate buffer (0.1 or 0.2M) containing D20
71. For LC-MS analysis, urine can be 
diluted likewise, whereas protein precipitation is generally performed for serum before 
the analysis to avoid a domination of proteins in the LC-MS signal71,85. As for GC-MS, it 
requires more extensive sample preparation, with chemical derivatisation procedures to 
increase volatility and thermal stability. For tissue analysis, when performed by 
conventional NMR spectroscopy or by LC-MS, metabolites are generally extracted from 
the tissue into a liquid solution71,86; intact tissues can be analysed using high resolution 
1H MAS-NMR spectroscopy or MALDI-MS.  
Metabolic profiling of samples by NMR or MS results in complex multivariate 
datasets, which require appropriate tools to afford meaningful interpretation. After data 
Introduction 
31 
 
pre-treatment and possibly normalisation, chemometric and mathematical modelling 
methods, such as principal components analysis (PCA) and partial least squares 
discriminant analysis (PLS-DA), are typically employed to interpret the complex 
resulting datasets87,88. These techniques reduce the dataset dimensionality, allowing 
visualisation of the data (e.g. identification of similarities/differences between 
observations or variables, deviating observations, trends in the data) as well as 
detection of discriminative variables between sample groups.  This will be detailed in 
Chapter II.  
Chemical identification of the discriminative metabolites from the 
spectroscopic/spectrometric signals remains an important challenge in metabolic 
profiling studies89. Putative identities are usually obtained from metabolite databases90. 
For NMR spectroscopy, comparison with databases is based on chemical shifts and 
signal multiplicities. For MS, comparison is based on masses, as chromatographic 
retention times are dependent on experimental conditions. The use of high-resolution 
MS provides masses with high accuracy, reducing the number of putative candidates. 
When authentic compounds corresponding to these candidates are available, common 
practice is to compare retention time and MS/MS fragmentation patterns of the 
“unknown” metabolites with those of these authentic compounds analysed under 
exactly the same experimental conditions. Employing a combination of analytical 
techniques can be extremely helpful for identification of “unknown” metabolites, e.g. 
NMR spectroscopy to obtain structural information, high-resolution MS to obtain 
accurate mass, and MS/MS to obtain fragmentation patterns.  
 
 
 
Figure I-2. A typical metabolic profiling workflow 
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Chapter II.  Analytical strategies 
 
II.1. Metabolic profiling 
II.1.1. Analytical techniques for metabolic profiling  
II.1.1.1. Background  
Achieving comprehensive metabolic profiles in biological samples is 
challenging, due to the large diversity of their metabolite composition in terms of 
molecular structure, chemical and physical properties, and physiological concentration 
ranges91,92. These molecules include, for instance, hydrophilic sugars, organic and 
amino acids, nucleotides, volatile alcohols, bile acids, fatty acids, triglycerides, 
phospholipids and other lipids91,92. No single analytical platform can detect and quantify 
all these metabolites, resulting in different platforms being used in metabolic profiling 
studies. The most widely employed are nuclear magnetic resonance (NMR) 
spectroscopy and mass spectrometry (MS)31,88. These two platforms can provide 
information on hundreds of metabolites in one sample in a single analytical run, 
enabling relatively high-throughput analysis at low cost per sample72. They offer the 
possibility of detecting a wide range of metabolite classes in an untargeted manner. 
NMR spectroscopy and MS provide complementary information on samples, and their 
combined use in metabolic profiling studies allows enhancing the metabolite coverage 
and facilitates the identification of unknown analytes93.  
1H-NMR spectroscopy has been used since the 1980s to analyse 
simultaneously the plethora of metabolites in biofluids94. It exploits the magnetic 
properties of hydrogen nuclei to produce detailed structural information on 1H 
containing molecules. 1H-NMR spectroscopy has been applied in a large number of 
metabolic profiling studies, including investigations on physiological variation in 
animals42,47,95, various diseases52,53,55,96, toxicology60,88 and epidemiology43. NMR 
spectroscopy is well suited for metabolic profiling studies, as it is non-selective, non-
destructive, highly reproducible and provides quick and accurate measurements of 
metabolites with minimal sample preparation71,97. Furthermore, it does not require prior 
analytical separation to identify and quantify compounds94. Besides, it is possible to 
analyse intact tissues with 1H MAS-NMR, removing the necessity of extracting 
metabolites in a liquid solution before analysis81 and therefore preserving the overall 
sample structure. However, NMR has limitations in terms of sensitivity and the 
identification of individual metabolites is not always possible in complex mixtures84.  
Compared with NMR, MS is highly sensitive and can therefore detect 
metabolites present at lower concentrations93. Furthermore, it can provide useful 
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information for metabolite identification, such as exact mass and fragmentation 
patterns84. However, identification is not straightforward and remains the bottleneck in 
MS-based metabolic profiling studies. 
Introduction of the sample in the mass spectrometer without prior analytical 
separation, either via direct injection/infusion (DI) or via flow injection (FI), has 
sometimes been used in metabolic profiling studies, e.g. for plant and microbial 
systems71,84,98, as it is a simple and fast way of generating sample metabolic 
fingerprints63. It produces a comprehensive snapshot of the chemical composition of a 
sample in a high throughput manner (metabolic fingerprints can be obtained in a few 
minutes). However, it is highly prone to ion suppression and enhancement due to the 
simultaneous introduction of all sample components into the mass spectrometer63,71,84. 
This ion suppression phenomena can nevertheless be minimised with the utilisation of 
nanoelectrospray ionisation sources74. Other disadvantages of direct introduction MS 
techniques include in source fragmentation of analytes and adduct formation, which 
complicate peak identification63, and the lack of separation between isobaric 
substances71,84. With the development of ultra high resolution mass spectrometers, 
such as orbitrap (resolution ~100 000) and Fourier transform ion cyclotron resonance 
(FT-ICR) instruments (resolution > 1 000 000), this problem has been greatly 
reduced99,100. Thus, several metabonomic studies using direct introduction MS with 
orbitrap or FT-ICR have recently been reported100-102. Nevertheless, whatever the mass 
resolution, direct introduction MS cannot discriminate between isomers, which can be 
problematic for certain compound classes such as bile acids. 
MS is therefore generally combined with separation techniques, such as gas 
chromatography (GC), liquid chromatography (LC) or capillary electrophoresis (CE), 
which reduce the complexity of the mass spectra by performing separation in both time 
and mass dimensions.  
GC-MS was the initial MS technique in metabolome analysis33,103. It has been 
widely used in plant metabolomics, but has also been applied to toxicology studies in 
mammalian systems, although less frequently than NMR and LC-MS71,73,104,105. 
Advantages include high resolution and sensitivity, and facilitated metabolite 
identification due to large database availability71.  GC-MS is particularly well-suited for 
analysis of volatile compounds. However, many interesting classes of metabolites, 
such as sugars, nucleosides and amino acids, are not volatile and need to be extracted 
and derivatised before analysis, resulting in lengthy and extensive sample 
preparation71.  
Because of these limitations of GC-MS, LC-MS has become a more popular 
choice for metabolic profiling studies74,103. Compared with GC-MS, LC-MS offers 
considerable advantages in terms of sample preparation for metabolic profiling of 
biofluids: urine can be injected directly and serum only requires minimal preparation 
Analytical strategies 
35 
 
(e.g. protein precipitation). High performance LC-MS (HPLC-MS) has been applied to a 
wide range of metabolic profiling studies, including investigations on physiological 
variation in animals and toxicity studies68,71,106-110. The introduction of ultra performance 
LC-MS (UPLC-MS), offering markedly enhanced chromatographic efficiency, provides 
higher sensitivity and resolution111, thereby reinforcing the usefulness of LC-MS in 
metabolic profiling studies. Although fairly recent (2004), there are already quite a 
number of published metabolic profiling studies using UPLC-MS45,73,76,78,79,112-120. 
CE is particularly well-suited for the separation of polar and charged 
compounds, providing high-separation efficiency121. Separation mechanisms are 
different from GC and LC, and CE can therefore provide complementary information on 
sample composition71,121. It requires small sample volumes (a few nanolitres) and 
minimal sample pretreatment122. Its main drawback is its low sensitivity due to the 
limited volume introduced in the capillary121. However, this sensitivity can be improved 
by combining CE with MS121. CE-MS is therefore an attractive complementary 
technique for metabolic profiling studies, although it has not been widely used so far122. 
In this work, UPLC-MS was employed for metabolic profiling. LC and MS are 
therefore further described in the following sections.  
 
II.1.1.2. Liquid Chromatography (LC) 
HPLC is a separation technique which consists of introducing the sample to be 
analysed into a high pressure liquid mobile phase that flows through a column 
containing a stationary phase. As the analytes contained in the sample pass through 
the column, they interact differently with both the stationary phase and the mobile 
phase depending on their physico-chemical properties (e.g. polarity and structure). This 
results in a separation of the analytes along the length of the column, the analytes 
having the lowest affinity for the stationary phase or the highest affinity for the mobile 
phase eluting first from the column. The time at which a particular analyte elutes is 
called its retention time (RT).  
One way of increasing the efficiency of the chromatographic separation is to 
decrease the size of the particles constituting the stationary phase. However, this 
results in an increase in column back pressure. UPLC employs smaller particles (1.4-
1.8 μm compared to 3-5 μm for HPLC) and higher pressure than HPLC (up to 15000 
psi), which results in better resolution (sharper peaks), increased sensitivity, lower ion 
suppression and faster analysis45,71,87,111. Moreover, retention time shifts, often 
observed in HPLC analysis, is considerably reduced with UPLC. This makes UPLC-MS 
a powerful technique for metabolic profiling.  
In metabolic profiling analyses, LC-MS separations are mostly performed using 
reversed-phase (RP) chromatography. This chromatography method employs a 
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column with a non polar stationary phase, for instance ethylene-bridged hybrid or alkyl-
derivatised silica particles. Elution is usually achieved by a mixture of water and 
organic solvent (e.g. acetonitrile or methanol), either with an isocratic flow (constant 
composition of the mobile phase) or with a gradient (typically from high aqueous to high 
organic), which allows for changing the polarity of the mobile phase over the analytical 
run. Polar compounds elute first, whereas retention times are longer for less polar 
compounds. Reversed-phase UPLC separations are often carried out on ethylene 
bridge hybrid (BEH) C18 or C8 columns. These columns provide stability over a wide 
pH range and produce sharp peaks. However, high polar compounds are not well 
retained on these columns and therefore co-elute at the beginning of the run, leading to 
ion suppression. Improved retention of some polar compounds can be achieved using 
RP chromatography with an high strength silica (HSS) T3 column123. This column 
provides a slightly more efficient retention and separation of organic polar compounds 
than the other columns used in RP chromatography, while also offering a good 
retention for hydrophobic species. HSS T3 columns were used for most UPLC-MS 
analyses carried out in this work.  
An alternative to RP-LC, offering better retention of polar analytes, is hydrophilic 
interaction chromatography (HILIC)124,125. HILIC has a different selectivity to RP, 
retaining a number of polar compounds typically not retained by RP. HILIC-LC-MS can 
therefore be used as an approach complementary to RP-LC-MS in metabolic profiling 
studies, enlarging the metabolome coverage. The application of HILIC-LC-MS to 
metabolic profiling studies has been reviewed in 2010126. We recently showed that 
HILIC-UPLC-MS was an effective and reproducible method for global metabolic 
profiling of urine, and its application to a toxicological study revealed discriminating 
polar metabolites that would have been poorly retained by RP, highlighting the 
complementarity of the two approaches120.   
 
II.1.1.3. Mass spectrometry (MS) 
After LC separation, molecules are introduced into a mass spectrometer. Mass 
spectrometry (MS) is an analytical technique measuring the mass-to-charge ratio (m/z)  
of charged analytes.  
There are three essential modules in a mass spectrometer (Figure II-1). First, 
analytes are converted into ions in an ion source (Figure II-1 (1)). Secondly, resulting 
ions are sorted and separated with the help of electric and magnetic fields according to 
their m/z ratio in a mass analyser (Figure II-1 (2)). Finally, ions are detected and 
counted by a detector (Figure II-1 (3)).  
Mass spectrometers function under high vacuum to allow ions to reach the 
detector without colliding with other gaseous molecules. 
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Figure II-1. Diagram of the different components of a mass spectrometer 
Ions formed in the source (1) from the analytes are separated according to their m/z ratio in the 
mass analyser (2) and then counted by the detector (3). 
(adapted from Want et al.
74
) 
 
 
II.1.1.3.1. Ion source 
The ion source is the part of the mass spectrometer in which the analytes are 
ionised prior to be analysed (Figure II-1 (1)). A large variety of ionisation techniques 
exist in MS, including electron ionisation (EI), chemical ionisation (CI), fast atom 
bombardment, matrix-assisted laser desorption ionisation (MALDI), atmospheric 
pressure chemical ionisation (APCI) and electrospray ionisation (ESI). Some ionisation 
techniques, such as EI, are very energetic and cause extensive fragmentations. Other 
techniques, such as CI, are softer and mainly produce ions of the molecular species103.  
The most commonly used technique in LC-MS analysis is ESI74, as it enables 
very high sensitivity to be achieved and is easy to couple to LC, the ions being 
generated directly from the liquid phase into the gas phase. ESI is a relatively soft 
technique, resulting in minimal fragmentation. A strong electric field is applied to the 
liquid coming from the LC and passing through a capillary tube. This field induces an 
accumulation of charges at the liquid surface resulting in the formation of highly 
charged droplets. The solvent then evaporates from the droplets (usually with the help 
of nitrogen and heating) which deform and release smaller droplets. These highly 
charged droplets in turn lose solvent, and ultimately, when the electrical field on their 
surface is large enough, desorption of ions from the surface occurs. Small molecules, 
typically < 1000 Da, produce mainly monocharged ions, but multiple charged ions can 
be produced from larger molecules with several ionisable sites, e.g. proteins103.  
ESI is often performed in both positive (ESI+) and negative (ESI−) mode 
(usually in two separate runs, although some instruments can acquire both modes in a 
single run) to maximise the coverage of detected metabolites, as some metabolites 
preferentially ionise in one mode69.  
 
1 32
column
source analyser detector
data
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II.1.1.3.2. Mass analysers 
Once ions have been produced, they are separated according to their m/z ratio 
in a mass analyser (Figure II-1 (2)). The mass analyser is a critical part of the 
spectrometer, determining its performance, which is characterised by its mass 
accuracy, resolution, mass range, scan speed and transmission103.  
 The mass accuracy is the ability of the analyser to provide an accurate m/z for the 
analysed ion (i.e. as close as possible to its theoretical m/z). It is generally expressed 
as the ratio of the m/z measurement error to the theoretical m/z, in parts per million 
(ppm).  
 The resolution or resolving power is the capacity of the analyser to separate two 
ions with close m/z values. It is often calculated for an isolated peak as the ratio 
R = m/∆m, where m is the measured peak mass and ∆m is the peak width at 50% of its 
maximal height (FWHM).  
 The mass range determines the range of m/z for which the mass analyser can 
measure ions.  
 The scan speed is the rate at which the analyser measures over a particular mass 
range, expressed in mass units per second.  
 The transmission is the ratio of the number of ions reaching the detector compared 
to the number of ions entering the mass analyser.  
 
The most common mass analysers include quadrupole (Q), ion trap, time-of-
flight (TOF), orbitrap and Fourier transform ion cyclotron resonance (FT-ICR)84. Many 
mass spectrometers use two or more of these mass analysers to perform multiple 
stages of separation (e.g. Q-TOF and triple quadrupole). Table II-1 gives typical 
resolution and mass accuracy values for the main analysers employed in 
metabonomics103,127, which are briefly described below.  Quadrupoles and ion traps are 
generally considered as low resolution analysers. The development of high resolution 
analysers (TOF and Q-TOF) and ultra high resolution analysers (orbitrap and FT-ICR) 
has greatly contributed to the increasing use of MS in metabolic profiling studies. 
Indeed, they give access to m/z of ions with high accuracy, thereby limiting the number 
of possible empirical chemical formulae and allowing separation between isobaric 
species. In this project, a TOF operated in ESI+ and ESI- modes was used for most 
MS analyses, as well as a Q-TOF to perform fragmentation for structural identifications. 
A Q-TRAP was also employed at Technologie Servier to perform targeted analysis of 
free fatty acids. 
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Table II-1. Resolution and mass accuracy for the main MS analysers103,127 
Analyser Resolution (m/∆m, FWHM) Mass accuracy 
Quadrupole 2000 100-200 ppm 
Ion trap 4000 100-200 ppm 
Time-of-flight 8 000-20 000 5-10 ppm 
Orbitrap Up to 100 000 < 3 ppm 
FT-ICR Up to 1 000 000 < 1 ppm 
Abbreviations: FWHM=Full width at half maximum. 
  
 
 Quadrupole analyser 
Quadrupole analysers consist of four parallel circular or hyperbolic rods, each 
opposing rod pair being connected electrically. A radio frequency (RF) voltage is 
applied between the two pairs, and a direct current voltage is superimposed on the RF 
voltage103,128. The quadrupole filters ions according to their m/z ratios. For a given ratio 
of voltages, only ions with a particular m/z ratio will reach the detector, while the others 
will hit the rods. This allows for selecting an ion with a specified m/z ratio or scanning a 
range of m/z ratios by continuously varying the voltage ratio. Quadrupole mass 
analysers can detect m/z ratios up to ~4000 and are relatively low cost, but they are 
limited in terms of mass accuracy and resolution.  
Three quadrupoles can be placed in series to perform tandem mass 
experiments (triple quadrupole instrument): the first and the last quadrupoles are used 
as mass analysers, and the centre quadrupole is used as a collision cell (RF-only 
quadrupole), in which ions undergo one or several collisions103. Triple quadruples can 
be operated in various modes, including “product ion scan” (all product ions of a 
precursor ion selected in Q1 are scanned in Q3) , “precursor ion scan” (all precursor 
ions producing a product ion selected in Q3 are scanned in Q1), “neutral loss scan” 
(Q1 and Q3 are scanned together, with a constant mass offset between both), and 
“selected reaction monitoring” (both Q1 and Q3 are focused on selected masses, 
implying that the precursor ion specified for Q1 must produce the product ion specified 
for Q3 to be detected)103. 
 
 Ion trap analyser 
Ion trap analysers use an RF quadrupolar field to trap ions in two or three 
dimensions103. A specific ion can be isolated by ejecting all the other ions from the trap, 
building an increasing population of the selected ion in the trap. It is possible to let this 
ion fragment in the trap and analyse the resulting fragments. A specific fragment can 
also be selected and left in the trap to fragment further, this process being possibly 
repeated several times103. This capacity of ion traps to produce sequential 
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fragmentations (MSn) is valuable in metabonomic studies to provide structural 
information for “unknown” metabolites.  
The Q-TRAP used in this work is a hybrid triple quadrupole/linear ion trap mass 
spectrometer: it is based on a triple quadrupole platform, in which the third quadrupole 
can be operated either as a standard quadrupole or as a linear ion trap129.  For the 
targeted analysis of free fatty acids (FFAs) realised in this work, the ion trap was not 
used: the analysis was performed in selected-ion monitoring (SIM) mode, which means 
that only ions with m/z values corresponding to the targeted FFAs were detected and 
counted during the chromatographic separation. 
 
 TOF analyser 
In linear TOF spectrometers, ionised analytes are accelerated by a difference of 
potential towards a field-free flight tube, in which they are separated according to their 
velocity, before reaching the detector at the extremity of the flight tube103. m/z ratios are 
obtained by measuring the time t the ions take to reach the detector (m/z is 
proportional to t2). Lighter ions will reach the detector more quickly than heavier ions. 
From the very precise measurement of the time-of-flight of the particles, m/z ratios are 
calculated with a high accuracy.  
An electrostatic reflector (reflectron) can be introduced in the flight tube, acting 
as an ion mirror that deflects the ions and sends them back into the flight tube (V-
shaped flight tube)103. The interest of this reflectron is mainly to correct the kinetic 
energy dispersion of the ions, but it also improves the resolution by increasing the flight 
path. This is nevertheless at the expense of sensitivity and it results in a mass range 
limitation. A second reflectron can be introduced (W-shaped flight tube), further 
enhancing the resolution but decreasing the sensitivity. Current reflectron TOF 
spectrometers can operate in both V and W modes. Reflectron TOF instruments have 
good mass range (up to ~10 000), fast scanning capabilities, relatively high resolution 
(8 000-20 000) and mass accuracy (~5-10 ppm), high sensitivity (resulting from their 
high transmission efficiency), and they can produce data for a large range of 
compounds in complex matrices74,103. They are therefore widely employed in metabolic 
profiling analysis.  
Q-TOF analysers combine a quadrupole and a TOF analyser, separated by a 
collision cell. The quadrupole can scan across a range of m/z ratios or select a 
precursor ion, which is fragmented in the collision cell, the resulting fragments being 
then analysed by the TOF analyser. Q-TOF analysers combine the ability of the 
quadrupole to select a particular ion and the ability of the TOF to produce simultaneous 
and accurate measurements of the fragment ions over the full mass range with high 
sensitivity. They are therefore useful for metabolic profiling studies, as they provide 
structural information on “unknown” compounds with high mass accuracy. 
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 Orbitrap analyser 
The orbitrap is an electrostatic ion trap, operating by radially trapping ions 
around a central spindle-shaped electrode located inside an outer electrode having the 
shape of a barrel cut into two parts separated by a small gap103. The ions, injected 
tangentially into the electric field generated between the electrodes by DC voltages, are 
trapped because their electrostatic attraction to the inner electrode is balanced by 
centrifugal forces128. They turn around the inner electrode in rings while oscillating back 
and forth along its axis, with an oscillation frequency inversely proportional to the 
square root of m/z103,128. The current induced by the oscillating ions is recorded and 
deconvoluted to single frequencies by Fourier transformation, which are then converted 
into m/z values103,128. The orbitrap allows achieving high resolution (up to 100 000) and 
high mass accuracy (< 3ppm)127,128. In the hybrid LTQ-Orbitrap instrument developed 
by Thermo Electron, the orbitrap is operated in combination with a linear ion trap, 
allowing two different scan types to be acquired simultaneously: the collection of an 
accurate mass spectrum in the orbitrap in parallel to the collection of single or multiple 
MS/MS spectra in the linear ion trap130.  
 
 FT-ICR analyser 
As the orbitrap, the FT-ICR analyser induces a cyclotron motion of trapped ions, 
but this is achieved via magnetism128. The ions are trapped in a strong magnetic field, 
which induces a cycling motion with a frequency depending on their m/z. An RF signal 
applied to the ICR cell induces the cyclotron of ions into a greater orbit. A pair of 
detector plate electrodes record the image current generated by the orbiting ions when 
they pass close to them. The signal is then amplified and Fourier transformed, and the 
resulting frequence spectrum is converted into a mass spectrum via the relationship 
linking m/z and frequency128. The frequency can be measured very precisely, resulting 
in high mass accuracy (< 1 ppm)127. This accurate mass measurement generally allows 
unambiguous assignment of a single molecular formula for metabolites up to a 
molecular weight of ~500 Da131 (a ~10 ppm accuracy (e.g. with a TOF) typically 
resulting in several possible formulae) and resolution of isotope peaks within isotope 
clusters127, which are highly helpful for structural elucidation of “unknown” metabolites 
in metabonomic studies. The FT-ICR also has MSn fragmentation capabilities with 
accurate mass measurements of the fragments131, facilitating their identification. 
Despite these excellent performances, FT-ICR analysers are not widespread in 
metabolic profiling studies due to the strong and maintenance-expensive magnetic 
fields they require127. Moreover, due to their low scan speed (typically ~1 s), their 
coupling with LC (especially UPLC) is limited127,128. 
 
 
Analytical strategies 
42 
 
II.1.1.3.3. Detector 
The ions from the mass analyser are detected and counted by a detector 
(Figure II-1 (3)). Detectors usually record the current produced or the charge induced 
when the ions hit the detector’s surface or pass close to it. The abundance of each ion 
is detected, and the signal produced by all the m/z ions during one scan produces a 
mass spectrum for this scan, displaying the ion abundance versus m/z ratios (either in 
a bar graph or table). The most intense peak of each scan is called the base peak. 
 
II.1.1.4. Different types of chromatograms and mass spectra 
Figure II-2 shows an example of chromatograms and mass spectra obtained 
from UPLC-MS analysis of a urine sample in ESI+ mode. On chromatograms (Figure 
II-2A-C), the x-axis represents chromatographic retention time in minutes and the y-
axis represents relative ion intensity. On mass spectra (Figure II-2D-E), the x-axis 
represents m/z ratios and the y-axis represents relative intensity of each ion.  
The first chromatogram (Figure II-2A) is a total ion chromatogram (TIC): the 
intensity displayed for each scan is the sum of the intensities of all m/z ions detected in 
this scan. The second chromatogram (Figure II-2B) is the corresponding base peak 
intensity (BPI) chromatogram: the intensity displayed for each scan is the intensity of 
the most intense peak in this scan. This reduces the background noise and results in a 
flatter baseline, with better resolved peaks. The third chromatogram (Figure II-2C) is 
an extracted ion chromatogram (EIC) corresponding to the m/z value 180.07 ([M+H]+ 
ion of hippuric acid), showing a peak with this mass at a RT of 4 minutes. Figure II-2D 
displays the mass spectrum of the scan corresponding to the top of this 
chromatographic peak, which indeed shows a very intense ion for m/z 180.07. Figure 
II-2E corresponds to the summed mass spectra across this chromatographic peak.  
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Figure II-2. Examples of chromatograms and mass spectra obtained from the 
UPLC-MS analysis of a urine sample in ESI+ mode 
(A) Total ion chromatogram (TIC); (B) Base peak intensity (BPI) chromatogram; (C) 
Extracted ion chromatogram (EIC) of m/z 180.07; (D) Mass spectrum of scan 549, 
corresponding to the top of the peak eluting at retention time 4.013 min; (E) Summed 
mass spectra, from scans 544 to 556, corresponding to the whole chromatographic 
peak at retention time 4.013 min. 
In the TIC, the intensity displayed for each scan is the sum of the intensities of all m/z ions 
detected in this scan, whereas the BPI chromatogram only shows the intensity of the most 
intense peak for each scan, resulting in a flatter baseline. The EIC allows visualisation of the 
chromatogram corresponding to a specific m/z value. 
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II.1.2. Monitoring the stability of the UPLC-MS 
platform: quality control (QC) strategy 
Key to metabolic profiling studies is the ability to distinguish biological, i.e. “true”, 
variation, from analytical variation. When analysing a batch of samples by UPLC-MS, 
analytical platform variability can arise from variations in sample injection, LC 
conditions (e.g. column ageing, contaminant build-up, variations in 
pressure/temperature/mobile phase composition) and MS conditions (e.g. source 
contamination, fluctuations in ionisation efficiency, decrease of detector 
sensitivity)90,132. This can result in retention time drifts, mass drifts and signal response 
variability. When analysing large batches of samples, sample stability may also be an 
issue and artificial variation can be observed due to metabolite decay or sample 
evaporation.  
It is possible to reduce some of these sources of variation, e.g. column 
temperature can be precisely controlled with a thermostated column oven, and the use 
of pure solvents mixed online by the UPLC instrument should facilitate reproducible 
mobile phase composition. Besides, mass drift can be highly reduced by the use of a 
lock mass: drifts are corrected in real time via the repeated acquisition over each 
sample run of data from a reference compound of known mass. However, even if using 
a lock mass for high mass accuracy, it is still essential to control the platform stability 
over the run in terms of intensities and retention times. 
In targeted analysis, an internal standard is often used to correct for analytical 
variability, and test mixtures, containing known concentrations of the targeted analyte, 
can be regularly injected to monitor platform stability. This approach is not adapted for 
global metabolic profiling, as the sample composition is unknown before the analysis 
and several hundreds of metabolites are analysed simultaneously, for which response 
variability may be different133. Stability of a few compounds in a test mixture over the 
run, in terms of retention time, mass and intensity, is a good starting point, but does not 
ensure that the platform is stable for the whole set of metabolites observed in the 
samples.  
The use of quality control (QC) samples, representative of the sample batch, is 
becoming widespread in LC-MS metabolic profiling studies to monitor analytical 
platform stability69,75,133-137. The QC sample is typically prepared by combining equal 
aliquots from all samples of the analytical batch, and can therefore be considered as an 
“average” metabolic profile, containing a large range of the metabolites that will be 
observed in the analysis. This QC sample is injected periodically throughout the UPLC-
MS run (e.g. every 5-10 injections) and these repeated injections of this representative 
sample are used to assess the platform variability. QC chromatograms can be overlaid 
to detect trends in the run, such as decrease/increase in signal intensity, peak shape 
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degradation, shifts in retention times. Univariate or/and multivariate analyses of the QC 
data are typically performed to evaluate the platform stability, e.g. calculation of 
coefficient of variations (CVs) of intensity among the QC samples for each metabolite 
feature and observation of QC behaviour in principal components analysis (PCA) 
space69,86,90,120,135,136. 
 The QC sample can also be used to condition the LC column at the beginning 
of the analytical run, before injecting the actual samples, as the first injections are often 
not reproducible in terms of signal intensities and retention times, particularly with a 
new column69,75,134,135. Comparing the last conditioning QC injections with the periodical 
QC injections performed throughout the analytical run allows ensuring that the UPLC-
MS platform had achieved stability before the analysis of the samples of interest.  
 
 
II.1.3. Run order design for UPLC-MS analysis 
Observing a drift of the QC injections over time is not unusual, especially for 
long analytical runs, as the UPLC-MS system becomes gradually contaminated69,75,90. 
This drift, if not major, should not affect the data analysis too much providing that the 
run order of the samples has been carefully designed, so that all the experimental 
groups are affected similarly. In particular, it is essential to spread the samples from the 
different experimental groups throughout the run. There are several ways of doing so. 
For instance, run order can be determined by randomly assigning a number to each 
sample and then sorting these numbers. This can however introduce bias. Two other 
ways of randomising sample lists were used in this work. For the method development 
study, in which several sample preparation methods were compared, a block design 
was used: randomly-constructed blocks, each containing one replicate of every 
method, were subsequently run. For the other studies, the run order was set to be 
orthogonal to the different factors of the experimental design, so as the run order effect 
not to be overlaid with the variation of interest.  
 
 
II.1.4. Analysis of UPLC-MS metabolic profiling data 
After acquisition of the data on the UPLC-MS platform, raw data files are 
obtained. Analysis of these data can be divided into two main steps: data pre-
processing and multivariate data analysis. Data pre-processing corresponds to the 
transformation of the set of raw data files into a table listing the metabolite features 
identified in the samples (m/z_RT pairs) with their intensity in each sample. Multivariate 
data analysis can then be applied on this data table.  
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II.1.4.1. Data pre-processing 
There are a large number of software packages available for MS data pre-
processing, including proprietary software provided with the analytical instruments as 
well as freely-available software90. At the start of this project, the use of XCMS (freely-
available software package138) and MarkerLynxTM (proprietary software from Waters) 
was investigated on raw data acquired as part of a method development study. After 
this comparison, it was decided to use XCMS software. Although it is not as user-
friendly as MarkerLynxTM, it allows, in my opinion, better optimisation of the parameters 
for each individual pre-processing step, depending on the objectives sought in the 
analysis of a particular data set. For instance, one can decide the minimal number of 
samples from one experimental class in which a peak should be present to be reported 
as a metabolite feature in the output table. This avoids having artefact peaks present 
only in one sample of the study to be reported as a feature with zero intensity in all but 
one sample (these peaks can nevertheless be reported if desired). Without this, one 
could end up with a table listing tens of thousands of metabolite features in the data, 
but containing a large percentage of zero values, which can have a negative impact for 
further data analysis.  
 
II.1.4.1.1. Data pre-processing with XCMS  
The first step of the pre-processing is to convert the raw data files into a format 
readable by XCMS (e.g. netCDF). Peak detection is then performed for each individual 
sample. Two algorithms are available for this peak picking step: “matchedFilter”, the 
original algorithm (2005)138, and “centWave”, an algorithm added in 2007139. The 
original algorithm was developed for low resolution LC/MS data and the “centWave” 
algorithm is better suited for high resolution LC/MS data. Note that at the start of this 
project (January 2008), the “centWave” algorithm had just been introduced, with the 
first paper describing it published in November 2008139. Therefore, the method 
development study performed at the beginning of this project was pre-processed with 
the “matchedFilter” algorithm, whereas all the other studies were pre-processed with 
the “centWave” algorithm.  
 Once the peaks have been detected, they are matched between samples. 
Retention time and m/z windows for matching need to be specified, as well as the 
minimal number of samples from one experimental class in which a peak should be 
present to be considered as a metabolite feature. Non-linear retention time correction is 
then performed to align the chromatograms of the different samples. Indeed, retention 
time drifts can occur for some peaks during the LC-MS run, due to 
pressure/temperature changes, variations in mobile phase composition, column 
degradation, contaminant build-up or changes in sample matrix effect (due to sample 
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degradation or evaporation). This drift is not linear across retention time, some peaks 
might be perfectly aligned while others might be shifted, and non-linear correction is 
therefore essential. It is crucial to properly align the features across all samples in order 
to accurately match the metabolites. After this retention time correction, the peaks need 
to be matched again between samples as they have been moved. Retention time 
correction can be performed a second time to further improve the alignment.  
 The last step before generating the report is to fill in missing data. Indeed, some 
of the grouped features might have no value in some samples. This can occur for 
instance because the intensity of a particular feature was below the signal-to-noise 
threshold value in a sample. This does not mean that the intensity in this sample was 
equal to zero. The raw data files are therefore read again and the regions of the 
missing peaks are integrated to fill in these missing intensities.  
After this last step, an output table is generated, containing a list of metabolite 
features, i.e. m/z_RT pairs (Figure II-3). For each metabolite feature (=each row in 
Figure II-3), several values are displayed including median, minimum and maximum 
m/z ratios (Figure II-3, col. C, D, E) and retention times (in seconds) (Figure II-3, col. 
F, G, H), the number of samples in which the metabolite feature was found for each 
experimental class (Figure II-3, col. I, J) and its intensity in each sample (Figure II-3, 
col. K, L, M…). It is possible to report either integrated peak intensities (area) or 
maximum peak intensities (height). All the work in this project used peak area, which is 
generally considered as more robust than peak height. 
 
 
 
Figure II-3. Simplified output table obtained after pre-processing raw data with XCMS  
Each row corresponds to one metabolite feature and contains information about its m/z ratio, 
retention time, occurrence in each class and intensity in each sample. 
 
 
Due to the limited number of columns available in Microsoft Excel, this output 
table shows the metabolite features as rows and the samples as columns. In pattern 
recognition methods, it is more conventional to have the observations (samples) as 
rows and the variables (metabolite features) as columns. We will therefore consider the 
output table as the transpose of the one in Figure II-3, that is a large matrix of 
dimensions N (observations) * K (variables). Before applying multivariate data analysis 
to this matrix, data can be normalised, transformed and scaled.  
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II.1.4.1.2. Normalisation 
The purpose of normalisation is to remove sources of systematic variation 
between samples that are irrelevant in regard to the study objectives, such as sample 
dilution or technical variation (e.g. sample preparation/analytical platform variation). 
This should allow biological variation of interest to be observed more clearly.  
Normalisation is particularly important in the case of urine samples, for which volumes 
and therefore metabolite concentrations can vary greatly between animals.  
Normalisation is typically performed by dividing all the intensities in a sample by 
a constant. There are several ways of choosing this constant, e.g. total integrated area, 
median fold change relative to a reference sample, creatinine concentration, osmolarity 
or volumes140,141. Creatinine and total integrated area can vary considerably between 
samples depending on the study design140,141 and are therefore often not appropriate. 
Conversely, median fold change relative to a reference sample has been shown to be a 
robust estimate of urine dilution factor141.  
When performing untargeted metabolic profiling by UPLC-MS, it is not unusual 
to have saturated metabolite features in the chromatograms (e.g. for some lipids when 
analysing serum or liver samples). Diluting the samples until these features are not 
saturated can result in the loss of detection of many low concentrated metabolites, so a 
balance has to be found for sample dilution, and a few saturated features can be 
judged acceptable. However, when some features are saturated in a sample, dividing 
these features by the same constant as the rest of the features will introduce artificial 
differences between samples for these saturated features. I therefore decided to use 
an intensity dependant factor for normalisation, based on locally weighted scatter plot 
smoothing (loess) normalisation, as sometimes applied for gene expression microarray 
data analysis142,143. This normalisation was performed in R using an in-house script 
written by Kirill Veselkov (Biomolecular Medicine, Imperial College London (ICL)). The 
correction factor was calculated by non-linear mapping of sample intensities into those 
of a reference sample, as illustrated in Figure II-4. Let xik be the logarithm to base 2 of 
the intensity of feature k in sample i. The reference sample was obtained by calculating 
the median mk of the xik among samples for all features (creating a “median” sample). 
For each individual sample, (xik − mk) was plotted versus mk, resulting in a scatter plot 
of features for each sample (Figure II-4).  A loess curve fi(x) was fitted through this 
scatter plot and subtracted from the xik. This was performed for all samples and 
repeated until the algorithm converged.  
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Figure II-4. Scatter plot of features used to fit the loess curve for normalisation of 
sample i in the dataset 
x-axis: mk = median of the logarithm to base 2 of the intensity of feature k among all samples. 
y-axis: xik − mk = difference between the logarithm to base 2 of the intensity of feature k in 
sample i (xik) and the median of the logarithm to base 2 of the intensity of feature k among all 
samples (mk).  
The blue cloud of points represents the feature density for the plotted sample. The “median” 
sample is represented by the black line. The fitted loess curve used for normalisation of the 
sample is shown in red. It can be seen from this scatter plot that the plotted sample is diluted 
compared to the median sample. 
 
 
Figure II-5 shows the distribution of intensities for each study sample as well as 
QC samples and serial dilutions of QC samples for a urine dataset (Figure II-5A-B) 
and a liver aqueous extract dataset (Figure II-5C-D), before and after loess 
normalisation. For the raw data (Figure II-5A and C), the global intensity distribution is 
quite variable between samples within an experimental group, especially for urine 
(Figure II-5A), illustrating the dilution differences between samples. After normalisation 
(Figure II-5B and D), the intensity distributions are similar between samples. The 
impact of this normalisation on subsequent data analysis is shown in section II.1.4.2.2. 
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Figure II-5. Comparison of intensity distributions between samples for urine and liver 
aqueous extracts, before and after normalisation 
Urine dataset: (A) before normalisation; (B) after normalisation. 
Liver aqueous extract dataset: (C) before normalisation; (D) after normalisation. 
The global intensity distributions, which differ between samples for the raw data, even within an 
experimental class, are made similar by the normalisation.  
Abbreviations: M=males; F=females; 08H=08h time point; 24H=24h time point; QC=quality control samples; 
QCdil=dilutions of QC samples.  
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II.1.4.1.3. Data Scaling/Transformation 
Before applying pattern recognition methods, such as principal components 
analysis (PCA) and partial least squares discriminant analysis (PLS-DA), to extract 
meaningful information from the data, data are usually mean-centred to remove the 
influence of the mean of the variables and to focus on the variation between 
samples144-146. This is done by subtracting from each variable its mean to centre it on 
zero.  
Due to the large range of metabolite concentrations in biological samples and 
differences in ionisation efficiency between metabolites, MS feature intensities can vary 
from a few dozens of ion counts to hundreds of thousands of ion counts (absolute 
values are detector dependent). As detailed in section II.1.4.2.2, PCA is a maximum 
variance projection method. If PCA is directly applied to the mean-centred UPLC-MS 
data, it is likely to focus on the high intensity metabolite features, prone to exhibit 
higher variance147. This can result in loss of interesting and important biological 
information, as these high metabolite features may not be the most biologically relevant 
for the study, features with lower intensities possibly being of higher biological 
relevance.  
To reduce the relative importance of the high intensity ions, data scaling is often 
performed. There are many ways of scaling the data145 and the choice of scaling has a 
large impact on PCA models, as reported previously for NMR spectroscopy144, GC-
MS145 and LC-MS90 metabolic profiling datasets. Two commonly employed methods for 
scaling analytical data are unit variance (UV) scaling144-146 and pareto scaling146. UV 
scaling gives equal importance to all the variables by dividing each one by its standard 
deviation, resulting in all variables having a variance equal to one. As a drawback, it 
inflates the impact of background noise and artifacts in the model. Pareto scaling is 
intermediate between no scaling and UV scaling and consists of dividing each variable 
by the square root of its standard deviation. Variables then have a variance equal to 
their initial standard deviation. Pareto scaling is commonly used for metabolic profiling 
datasets73,112,136,148-150. Another scaling method, less widespread, is level scaling, which 
consists of dividing the centred variables by their mean. This focuses on changes 
relative to the mean concentration of the metabolite features. This last scaling 
approach was used for the method development study, as it is an approach similar to 
the univariate CV assessment commonly used to evaluate reproducibility.  
Alternatively to scaling, another approach to stabilise the variance of high 
intensities is to perform logarithmic transformation147. As this may inflate the variance 
for low intensities (close to zero),  a constant is sometimes added to all the values 
before applying the logarithm (“started logarithm”151) to avoid this possible drawback. 
The effect of scaling/transformation to stabilise the variance across the intensity range 
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was investigated during this thesis as part of a study on technical and biological 
variation and is therefore further detailed in Chapter IV.  
 
II.1.4.2. Multivariate data analysis 
II.1.4.2.1. Why apply multivariate data analysis? 
The data matrix obtained after the pre-processing step is a large matrix of 
dimensions N (observations) * K (variables), generally including tens to hundreds of 
samples and thousands of metabolite features. Applying univariate statistics and 
testing differences between each variable individually is likely to produce a large 
number of false positives due to the high number of comparisons. Moreover, metabolite 
features show a high degree of correlation and interesting information is likely to be 
found in the correlation pattern rather than in the individual features. Multivariate 
analysis therefore increases the possibility of detecting meaningful information and 
reduces the risk of producing spurious results. 
Appropriate multivariate methods are needed to handle some characteristics of 
metabolic profiling data, such as high number of variables compared to the number of 
samples, high correlation between variables and missing values. Three projection 
methods, principal components analysis (PCA), partial least squares (PLS) analysis 
and orthogonal projection to latent structures (OPLS) analysis, are widely applied in 
metabolic profiling studies, and are described below. With these projection methods, 
the information contained in the large number of measured variables is summarised by 
a few new variables, referred to as latent variables. Hierarchical clustering analysis 
(HCA) is also briefly described, as it was used in the technical and biological variation 
comparison study (Chapter IV).  
 
II.1.4.2.2. Principal components analysis (PCA) 
PCA is an unsupervised technique, which means that the algorithm does not 
use any information on sample group membership or any other metadata. It is a useful 
tool to visualise the data and reveal similarities between observations, trends and 
deviating samples. PCA is a projection method which aims at describing, with only a 
few principal components (PCs), the maximum amount of variability within the data146. 
Each PC is a linear combination of the original variables and explains the maximum 
amount of variance possible, not accounted for by the previous PCs. PCs are 
orthogonal to each other and therefore independent. A schematic representation of 
PCA using samples containing three metabolite features is shown in Figure II-6.  
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Figure II-6. Schematic representation of PCA in the case of three variables 
Each red circle represents one sample in the 3D space formed by the three metabolite features. 
The first two PCs obtained by PCA form a plane on which the samples are projected. The 
projections are represented with blue circles. 
 
 
PCA results in two matrices called scores and loadings. The scores (t) 
correspond to the coordinates of the samples in the created model. The loadings (p) 
define the contribution of the original variables to form the scores. These two matrices 
can be visualised using scores and loadings plots. In a scores plot, each point 
represents a sample. In a loadings plot, each point represents a variable (metabolite 
feature). The metabolite features responsible for sample separation in a scores plot 
can be identified using the corresponding loadings plot, as illustrated in Figure II-7.  
 
 
 
Figure II-7. An example of PCA 
(A) PC1 vs. PC2 scores plot; (B) PC1 vs. PC2 loadings plot. 
Samples from groups G1 and G2 are separated by the first PC in the scores plot. From the 
loadings plot, we can observe that metabolite features M2 and M3 tend to be higher in group 
G1, while metabolite feature M1 tends to be higher in group G2.  
(from Want and Masson
90
) 
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The impact of loess normalisation on the PCA scores plot is shown in Figure 
II-8 for the urine dataset detailed in section II.1.4.1.2. There are four experimental 
groups in this dataset (male and female rats at two time points). In the PC1 vs. PC2 
scores plot of the UV-scaled raw data (Figure II-8A), summarising 52% of the variance 
in the dataset, separation can be seen between time points, but genders overlap. A 
clear dilution drift in the direction of the top left corner can be identified from the dilution 
of the QC samples. The third PC (explaining 11% of variance in the dataset) 
discriminates between genders (Figure II-8B). For the UV-scaled normalised data 
(Figure II-8C), perfect separation between the four experimental groups is observed in 
the PC1 vs. PC2 scores plot, summarising 42% of the variance in the dataset. PC1 
(30%) discriminates between time points, while PC2 (12%) discriminates between 
genders. The QC serial dilutions closely cluster together, indicating that the dilution 
factors have been corrected (not perfectly yet as the QC dilutions do not completely 
overlap).  
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Figure II-8. PCA of a urine dataset, before and after normalisation 
(A) PC1 vs. PC2 scores plot for the UV-scaled raw data; (B) PC2 vs. PC3 scores plot 
for the UV-scaled raw data; (C) PC1 vs. PC2 scores plot for the UV-scaled normalised 
data. 
For the raw data, separation is observed between time points in the PC1 vs. PC2 scores plot, 
but genders overlap and a third PC is required to discriminate between them. For the 
normalised data, perfect separation between the four experimental groups is obtained with the 
first two PCs. 
Abbreviations: T08H=08h time point; T24H=24h time point; QC=quality control samples; QCdil=dilutions of the 
QC sample. 
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PCA is a good starting point for data analysis, as it provides an overview of the 
data without any a priori information on the samples. It is therefore quite satisfying 
when a clear separation between sample groups is seen in PCA plots, as it shows that 
differences between sample groups are one of the main sources of variation in the 
dataset. However, the largest variation in the dataset does not always coincide with the 
maximum separation between groups, and other directions might be more pertinent to 
discriminate between them. These directions can be found using supervised 
approaches, such as PLS and OPLS.  
 
II.1.4.2.3. Partial least squares (PLS) analysis 
PLS is often regarded as a regression extension of PCA. It models the 
relationship between a data matrix X (which here contains the metabolic profiles) and a 
matrix of responses Y (e.g. sample characteristics, such as physiological parameters). 
While PCA is a projection of maximum variance in X, PLS is a maximum covariance 
model between X and Y 146. A specific case of PLS is PLS-discriminant analysis (PLS-
DA), in which case the Y matrix is constituted of dummy variables representing sample 
groups. Thus, a PLS-DA model attempts to predict the sample groups on the basis of 
the metabolic profiles.  
 
II.1.4.2.4. Orthogonal projection to latent structures (OPLS) analysis 
Interpretation of PLS models is negatively affected by systematic variation in the 
X matrix that is not related to the Y matrix, such as high within-group variance in the 
case of PLS-DA. A recent extension of the PLS method, termed orthogonal projection 
to latent structures (OPLS)152, can be used to facilitate the interpretation. OPLS 
separates the modelled variation of the data matrix X into two parts: one is the variation 
common to X and Y and the other one is the variation specific to X.  In other words, it 
divides the systematic variation in X between what is related to Y (Y-predictive 
variation) and what is not related to Y (Y-orthogonal variation). As PLS, OPLS can be 
applied with a dummy Y matrix representative of sample groups, which is called 
OPLS-DA153,154.  
OPLS and PLS have equivalent prediction performance but model interpretation 
is easier with OPLS. For instance, when performing PLS-DA with two classes, it can 
happen that the direction discriminating between sample groups is a combination of 
components, which complicates model interpretation. When applying OPLS-DA, the 
information relevant for group separation is summarised in one component (termed 
predictive component). This is illustrated in Figure II-9.  
O2PLS155,156 is a further extension of OPLS, which allows modelling and 
prediction in both directions between the two matrices X and Y. It separates the X-Y 
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common variation (predictive component) from the variation specific to X and the 
variation specific to Y. It can be applied to integrate two large datasets, e.g. metabolic 
profiles and proteomic data from the same study157. 
OPLS-DA was used in this work to detect the metabolite features responsible 
for separation between experimental groups. Validation and interpretation of OPLS-DA 
models is therefore further described below. 
 
 
 
Figure II-9. Comparison of scores plots obtained from PCA, PLS-DA and OPLS-DA of 
a metabolic profiling dataset 
(A) PCA scores plot; (B) PLS-DA scores plot; (C) OPLS-DA scores plots. 
The two experimental groups are separated by PCA, but there is some overlap in the PC1 vs. 
PC2 scores plot. The groups are perfectly separated by PLS-DA, but the direction of separation 
is a combination of the components. Using OPLS-DA, the first component (predictive 
component) separates the two groups, facilitating the identification of discriminating metabolite 
features.  
(from Want and Masson
90
) 
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  Determination of the number of orthogonal components and validation of 
OPLS-DA models 
Once a model has been created, it is essential to determine how well this model 
reflects the data and to what extent the conclusions based on this model can be relied 
on. Several parameters can be looked at to assess a model, however only those used 
in this work are detailed below. 
When modelling separation between two groups by OPLS-DA, several statistical 
models can be created, depending on the number of orthogonal components used. 
Several parameters can help in the choice of the optimal model, which is the one that 
best fits the data without overfitting. A widespread way of determining the optimal 
number of components is to look simultaneously at the explained variation in Y (R2Y) 
and the predicted variation in Y (Q2Y). Indeed, a good model should fit well the data 
and be predictive of new data. Q²Y is calculated by cross-validation. This consists of 
dividing the observations in the dataset in several subsets (typically seven), excluding 
one subset, constructing a new model with the remaining subsets, and using this model 
to predict the excluded observations. Each subset is excluded once and predicted from 
the model constructed from the remaining subsets. This allows calculation of the cross-
validated (predicted) percent of Y variance that is explained by the model, Q²Y, as well 
as cross-validated scores for each observation (a perfect group separation observed in 
cross-validated scores plot is a sign of good model quality). The higher Q²Y is, the 
more predictive the model is. However, it is good to be aware of R²Y as well. When 
adding a new component, if Q²Y slightly increases while R²Y largely increases, it 
means that the degree of overfit has been increased, and noise has been included in 
the model.  
Q²Y is used both to optimise the model and to assess its quality, which is not 
ideal. There are several ways of further validating a model, once it has been optimised. 
A widespread way of doing this is permutation tests: the Y-response is randomly 
permuted a large number of times (e.g. 1 000 to 1 000 000), and for each permutation, 
an OPLS model is constructed, with the same number of components as the actual 
model. These random models are expected to exhibit a low Q²Y value compared to the 
actual model. If models of similar quality as the actual model are obtained with random 
responses, it indicates that the actual model is not reliable. This powerful way of 
validating OPLS models is not available in Simca-P+ 12.0.1 (Umetrics, Umeå, Sweden) 
(it is available only for PLS models and allows only 999 permutations). The data from 
this work were therefore imported into Matlab (The MathWorks, Natick, Massachusetts) 
to perform permutation testing. As it requires quite intensive computing, this was 
carried out only for the O2PLS models constructed to link metabolic profiles and P450 
profiles, which were not of excellent quality and therefore required careful validation to 
ensure reliability. The large number of OPLS-DA models constructed for the metabolic 
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profiles, which were generally of excellent quality, were validated using a diagnostic 
tool implemented in Simca-P+ 12.0.1, called CV-ANOVA (Analysis of variance of 
cross-validated predictive residuals)158. This validation is based on an ANOVA 
assessment of the cross-validated predictive residuals of the OPLS model. It produces 
a p-value indicative of the significance of the model.  
 
  Interpretation of OPLS models 
Once a valid OPLS model has been constructed, interpretation of this model 
can be carried out to identify metabolic profiles responsible for the scores obtained in 
this model. This is generally done by looking at loading values p for each metabolite 
feature, which indicate the influence of the individual features on the model.  
Visualisation tools, combining covariance and correlation loadings profiles, have 
been developed to help with the interpretation of the data, first for 1D-NMR data153, 
then for MS data148. These tools are both based on the same principles, but the 
visualisation plots are different because 1D-NMR data are by definition one-
dimensional, making possible to reconstruct loadings that can be visualised as pseudo-
NMR spectra153, while MS data, when coupled with prior separation, are two-
dimensional (retention time and m/z values). As proposed by Wiklund et al.148, S-plots 
were used in this work to identify discriminating features in OPLS-DA models. An S-plot 
is a scatter plot of metabolite features, allowing visualising the influence of each feature 
on the OPLS-DA model. It consists of plotting the modelled correlation (p(corr)) versus 
the modelled covariance (p) between metabolite features (X matrix) and predictive 
scores tp
148. It therefore combines the contribution of each variable to the model 
(covariance) and its reliability (correlation)148. This plot is S-shaped (unless unit 
variance scaling is used), and variables at both ends of the “S” are considered as 
potentially biologically interesting metabolites as they combine high covariance and 
correlation with the predictive component of the model.  
 
II.1.4.2.5. Hierarchical cluster analysis (HCA) 
Another approach to investigate similarity between samples is to perform 
hierarchical cluster analysis (HCA). HCA is an unsupervised cluster analysis technique 
based on pairwise similarity between objects, which emphasises natural grouping 
existing in the data159. It was used in this work to cluster samples but it can also be 
employed to cluster metabolite features.  
There are two types of HCA: agglomerative and divisive159,160. Divisive HCA 
starts from one cluster containing all observations, which is recursively split into smaller 
clusters, while agglomerative HCA starts with n clusters each containing one 
observation, and pairs of clusters are successively combined. The results of HCA are 
Analytical strategies 
60 
 
usually shown as a dendrogram (tree structure representing the hierarchy of the 
clusters), which illustrates the divisions or fusions made at each stage of the analysis. 
Agglomerative HCA was used in this work: starting from n single sample clusters, the 
two closest clusters were merged to form one cluster with two samples, then the two 
closest clusters were merged and this was done until all samples were grouped in one 
cluster. This allowed visualisation of similarities between samples.  
HCA necessitates defining how to calculate the distance between two samples 
(metric), as well as the distance between two clusters of samples as a function of the 
pairwise sample distances (linkage criterion). There are many ways of defining the 
metric and the linkage criterion. For instance, the distance between two samples can 
be calculated as the Euclidian distance, the Manhattan distance or the cosine distance, 
and the distance between two clusters can be defined as the smallest, the largest or 
the average pairwise distance between observations from the two clusters. In this work, 
Euclidian distances were used as a measure of distances between observations and 
Ward’s linkage161 as a measure of distances between clusters. Ward’s linkage seeks to 
minimise the increase in the total within-cluster sum of squares when joining two 
clusters, this within-cluster sum of squares being defined as the sum of squares of 
distances between each observation in the cluster and the centroid of the cluster.  
 
 
II.1.5. Strategy for facilitating metabolite identification: 
construction of a standard compound database 
Chemical identification of the discriminating metabolite features obtained by 
UPLC-MS metabolic profiling remains an important challenge, these metabolites being 
often reported as unknowns. Matching with online databases is generally performed, 
but these databases typically report only masses, as chromatographic retention times 
are experiment dependent. 
To aid metabolite identification and make the most of both retention time and 
mass information, I decided to construct an in-house database of authentic metabolite 
standards, including a wide range of metabolites, such as amino acids, organic acids, 
sugars, porphyrins, purines/pyrimidines, vitamins, bile acids, fatty acids, phospholipids 
and lipids.  
I prepared all the standard solutions (163) (Appendix I) with the help of 
Konstantina Spagou (Biomolecular Medicine, ICL) and ran them individually by UPLC-
MS with the different gradients and conditions employed for each sample type (i.e. six 
UPLC-MS runs, corresponding to urine, serum/liver aqueous extracts (same gradient 
for both sample types) and organic liver extracts, analysed in both ESI modes). For all 
these runs, I listed in the database retention time and observed m/z values of each 
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injected standard compound, including main adducts, source multimers and fragments, 
as well as putative identity of the observed ions. It is indeed quite usual in ESI-MS 
datasets to observe multiple ionisation products for a single molecule, corresponding to 
various combinations of adducts, source multimers, isotopes and neutral losses99, as 
illustrated in the screenshot of the constructed database displayed in Figure II-10.  
 
 
 
Figure II-10. Screenshot of the constructed standard compound database 
The main ions observed for each injected standard compound have been listed in the database 
(m/z values, retention times with every LC gradient in each ESI mode, and ion putative 
identities). 
 
 
I then wrote a function in Matlab enabling the matching of the metabolite 
features found in any UPLC-MS metabolic profiling study dataset with the metabolite 
standards present in this database, letting the user choose mass and retention time 
accuracy. If a gradient different from those present in the database has been used for a 
study, matching with the database can be performed on masses only. An example of 
output file is displayed in Figure II-11. This database could be extended by running 
more authentic metabolite standards, especially more lipids, which are currently not 
well represented in the database as there were few available in our laboratory at the 
time the database was constructed. 
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Figure II-11. Example of output file obtained after matching a study dataset with the 
database 
The corresponding input file was composed of the first three columns of this output file (RTmed 
is in seconds, as in XCMS output file). The matching has been performed with a mass window 
of ± 0.05 Da and a retention time window of ± 0.5 min, specifying that the samples had been run 
with our in-house serum gradient in ESI+ mode. When a study metabolite feature matches with 
a standard feature from the database, the name of the authentic standard is displayed, with the 
m/z ratio, retention time and identity of the matching database feature, as well as the mass 
difference in ppm and in Da and the retention time difference in min.  
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II.2. Quantification of cytochrome P450 
messenger RNA (mRNA) 
II.2.1. Conventional techniques for mRNA 
quantification 
Quantification of mRNA can be performed by various methods, including 
Northern blotting, ribonuclease protection assays, in situ hybridisation, DNA 
microarrays and reverse transcription quantitative real time polymerase chain reaction 
(qRT-PCR)162.  
The Northern blotting technique163 consists of hybridising a labelled probe 
complementary to a RNA target sequence on a blotting membrane to which an RNA 
population, previously separated on an electrophoresis gel, has been transferred. It 
provides information on the presence of the target RNA sequence and its relative 
abundance, as well its size and quality (assessed on the gel), but is very time 
consuming for the assessment of the expression of a large number of genes, as only 
one gene is typically measured per analysis. Ribonuclease protection assays164, based 
on hybridisation of a labelled probe specific to the target RNA sequence and exposition 
to ribonucleases that specifically eliminate single stranded RNA, leaving intact the 
target sequence annealed to the probe, are more rapid and quantitative but provide no 
information on target RNA size. In situ hybridization165 allows localisation of RNA 
transcripts in tissue sections by hybridizing a labelled DNA or RNA probe to the target 
sequence.  
Although these three techniques are still in use today, two recently developed 
methods, DNA microarrays and qRT-PCR, offering higher throughput and degree of 
automation, have become predominant in recent years162,166,167. DNA microarrays are 
surfaces spotted with thousands of DNA probes to which labelled reverse transcribed 
RNA is hybridised, allowing for the analysis of the expression of thousands of genes 
simultaneously168. Compared with microarrays, qRT-PCR provides more precise 
quantification over a wider dynamic range of expression levels, but for a limited number 
of genes167. Therefore, microarrays are often used as a screening tool to identify 
differentially expressed genes, and qRT-PCR is then used on these genes to validate 
the microarray results and obtain precise quantification. As this thesis focuses on the 
expression of selected genes corresponding to cytochrome P450s, qRT-PCR was the 
method of choice. Principles of qRT-PCR and subsequent data analysis are therefore 
detailed below. 
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II.2.2. Principles of quantitative real time polymerase 
chain reaction 
Quantitative real time polymerase chain reaction (qPCR) is a technique based 
on the polymerase chain reaction (PCR) method. PCR169 is a molecular biology 
technique used to amplify a selected region of a DNA strand. It consists of a series of 
typically 30-40 cycles, in each of which: 1) the DNA is denatured by heating to separate 
the two strands (denaturation step, at ~95°C), 2) primers specific of the targeted DNA 
sequence are annealed to the strands (annealing step, at ~55-65°C), and 3) a 
polymerase synthesises new DNA strands complementary to the DNA target from the 
primers by adding dNTPs (extension step, at ~72°C when using Taq polymerase). This 
results in an exponential amplification of the target gene. 
Quantitative real time PCR170,171 (qPCR) follows the same principle, but the 
amplified DNA is detected as the reaction progresses, cycle by cycle, instead of 
measuring the reaction product only at the end of the 40 cycles as in standard PCR. To 
do so, a fluorophore is incorporated into the reaction, so that the fluorescence, 
monitored at each cycle, is proportional to the amount of DNA product formed. 
Assuming a certain amplification efficiency (typically close to doubling of the number of 
target gene copies at each PCR cycle), it is then possible to calculate the number of 
target gene copies initially present in the sample. 
When applying qPCR for gene expression analysis, it is necessary to first 
perform a reverse transcription (RT) step to generate complementary DNA (cDNA) 
from mRNA171. qPCR can then be applied on the cDNA to amplify and quantify target 
genes.  
Different probe and dye technologies are available for the fluorescence reporter 
used in qPCR171. Here the principle of Taqman probes® is described, as this was the 
technology used in this work. A Taqman® gene expression assay consists of 
amplification primers (reverse and forward) and a fluorescent-labelled probe, both 
specific to the target gene. During the annealing step, both primer and probe hybridise 
to the target gene (Figure II-12a). While the probe, consisting of a fluorescent reporter 
and a fluorescence quencher, is intact, the presence of the quencher greatly reduces 
the fluorescence emitted by the reporter. The extension step takes place and, when the 
Taq polymerase reaches the probe, the latter is cleaved (Figure II-12b), separating the 
quencher and the reporter, which increases the reporter signal (Figure II-12c). The 
probe is removed from the target gene and the polymerisation is completed (Figure 
II-12d). Additional reporters are cleaved from their quenchers at each cycle, resulting in 
an increase in fluorescence intensity proportional to the amount of target sequences 
produced. 
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Figure II-12. Mechanism of employed Taqman® probes 
(a) Primer and probe hybridise to the target gene. The probe is constituted of a fluorescent 
reporter (R) and a fluorescence quencher (Q). Q reduces the fluorescence emitted by R.  
(b) The extension step takes place and the Taq polymerase reaches the probe.  
(c) The quencher and the reporter are separated, which increases the reporter signal.  
(d) The probe is removed from the target gene and the polymerisation is completed.  
 
 
The shape of a classical qPCR response curve is shown in Figure II-13. During 
the first cycles, the fluorescence signal is weak and cannot be distinguished from the 
background. As the products accumulate, the fluorescence signal is detected and 
increases exponentially. A saturation phase is then reached as reagents deplete, 
resulting in the reaction slowing down, then plateauing. 
Gene expression differences between samples is quantified by comparing the 
number of cycles required for the response curve to reach a threshold fluorescence 
level set in the exponential phase. This number of cycles is called the CT value. The 
response curves are expected to be parallel in the exponential phase, resulting in the 
exact setting of the threshold level not being critical. The higher the initial target gene 
copy number is, the sooner the threshold will be reached and the lower the CT value 
will be.  
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Figure II-13. qPCR response curve 
After an initial phase in which the fluorescence signal is too weak to be distinguished from the 
background, the fluorescence signal increases exponentially, before reaching a plateau. The CT 
value corresponds to the number of cycles required for the response curve to reach a threshold 
fluorescence level set in the exponential phase 
 
 
qPCR can be used for both absolute and relative quantification. In absolute 
quantification, the initial number of copies of the target is interpolated from a standard 
curve, constructed from standards of known concentrations. Relative quantification 
determines the change in gene expression in a given sample relative to another 
sample. It can be used for instance to investigate the effect of a drug on the expression 
of a gene of interest. In this case, the gene expression level in a dosed sample would 
be compared relative to the gene expression level in a control sample. Relative 
quantification calculation can be performed by the relative standard curve method or 
the comparative CT method. The comparative CT method (ΔΔCT)
172 is useful when a 
high number of target genes and/or samples are tested, as it does not require 
construction of standard curves. This was the method used in this work, and therefore 
the only one detailed below.  
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II.2.3. Relative quantification using the comparative CT 
Method (ΔΔCT) 
When using the ΔΔCT method, CT values obtained for the target gene are first 
normalised by CT values obtained for a reference control gene, for each single sample. 
The normalised values (ΔCT) are then expressed relative to one sample or to the mean 
of one sample group, chosen as calibrator (resulting in ΔΔCT values). 
 
II.2.3.1. Choice of the reference control gene for data 
normalisation 
To quantify gene expression accurately, it is essential to normalise the data for 
possible variation in the amount and quality of RNA between different samples162,173, 
which is frequently performed with reference control genes167,173,174. The optimal 
reference control gene has a constant expression level in all study samples, and its 
measured expression therefore reflects the amount of cDNA in each reaction well. This 
reference control gene normalises for RNA measurement error and variation in reverse 
transcription efficiency.  
It is essential to validate the stability of a reference control gene for the study 
experimental design before using it for normalisation, as a control gene can have 
constant expression and be appropriate in a given sample type or experimental 
conditions, but have variable expression in another sample type or in response to a 
treatment167,173-175. Freely-available reference gene selection tools have been recently 
reviewed by Thellin et al.162. 
In this work, three potential reference control genes were amplified in the qPCR 
step. After inspecting the variation of these three genes among all samples, a gene 
stability measure was calculated for each of these reference genes, as suggested by 
Vandesompele167. The calculus of this measure is based on the principle that the ratio 
of expression of two ideal reference genes should be identical in all samples. Variation 
of this ratio between samples reflects the fact that one (or both) of the genes is not 
expressed constantly. This method was applied to select the best-performing reference 
gene among the three amplified genes. Although using this method with more potential 
reference genes would produce more accurate stability measures, a trade-off is 
necessary between accuracy and practical considerations: when realising experiments 
in pre-designed cards as was the case here, multiplying the number of reference genes 
is to the detriment of the number of genes of interest that can be quantified. Therefore, 
based on previous experiments of the qPCR laboratory, three reference control genes 
were selected for the cards: 18S, Gapdh and Rplp2. 
 
Analytical strategies 
68 
 
II.2.3.2. Calculation of gene expression ratios 
The number of target gene copies at cycle n, Xn, is linked to the initial number of 
target gene copies X0, by Xn = X0 × (1 + Ex)
n, where Ex is the amplification efficiency for 
gene X. If the efficiency is 100%, the copy number doubles at each cycle and 
Xn = X0 × 2
n.  
If the set fluorescence threshold corresponds to a number of copies XT for 
gene X, we obtain the following expression: XT = X0 × (1 + Ex)
CT,X,  where CT,X is the 
threshold cycle CT for gene X. A similar expression is obtained for the reference gene:               
RT = R0 × (1 + ER)
CT,R.  
XT and RT are not necessary equal, their values depend on the setting of the 
fluorescence threshold, the reporter dye, the efficiency of the probe cleavage and its 
purity.  
Assuming that the efficiency of the target gene and the reference gene are the 
same (written E), we obtain XT / RT = XN × (1 + E)
ΔCT, with XN the normalised initial 
amount of target gene copies (= X0 / R0) and ΔCT =
 CT,X − CT,R.  This can be rewritten  
XN = XT / RT × (1 + E)
−ΔCT. If the efficiency is 100%, then XN = XT / RT × 2
−ΔCT.  
The last step for relative quantification is to relate this XN value obtained for one 
sample s (XN,s) to the XN value obtained for the calibrator sample (XN,c). As the 
fluorescence threshold for one gene is set at the same value for all samples, the values 
of XT and RT are identical for the sample s and the calibrator. This gives the ratio of 
gene expression: XN,s  / XN,c = (1 + E)
−ΔΔCT where ΔΔCT = ΔCT,s − ΔCT,c. 
If the efficiency is 100%, the ratio of gene expression is 2−ΔΔCT.  
For the relative quantification using ΔΔCT calculation to be valid, the efficiency 
of the target gene amplification and the efficiency of the reference control gene 
amplification must be approximately equal. The gene expression assays implemented 
in the Taqman® array cards used here are certified by the supplier as having an 
efficiency close to 100%, enabling the use of the 2−ΔΔCT method. 
 
II.2.3.3. Multiple testing corrections 
 After calculating gene expression for each sample, this expression can be 
compared between experimental groups. In our case, gene expression was calculated 
and compared between groups for dozens of cytochrome P450s. When these 
comparisons are performed individually for each cytochrome (univariate statistics), it is 
necessary to correct the obtained results to take into account the multiple testing. 
Indeed, as the number of comparisons increases, there is an increased risk of 
obtaining false positives. Several techniques have been developed to perform multiple 
testing correction, including the Bonferroni correction176 and the Benjamini 
correction177.  
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The Bonferroni correction controls the family-wise error rate (FWER), which is 
the probability of producing one or more false positives. Assuming n tests are 
performed, if the significance level α for the whole set of tests is set at 0.05, applying 
the Bonferroni correction consists of using a significance level of 0.05/n for each 
individual test176. This ensures that the total FWER will not exceed 0.05. Another way 
of presenting Bonferroni correction results is to keep the significance level at 0.05 and 
adjust each p-value by multiplying it by n. This is a very stringent correction, giving a 
strong control of the FWER. A more powerful correction, derived from the Bonferroni 
correction, is the Holm-Bonferroni correction176,178. The calculated p-values are sorted 
from the smallest to the largest. The smallest p-value is adjusted by multiplying it by n 
(as with the Bonferroni correction), the second p-value is adjusted by multiplying it by 
n−1, the third by multiplying it by n−2, and so on. This method also gives a strong 
control of the FWER. 
Another correction approach is to control the false discovery rate (FDR), which 
is the expected proportion of false positives among all significant tests. This is a less 
stringent approach but with greater power than strong FWER control: it tolerates more 
false positives but also results in less false negatives. One popular correction method 
to control the FDR is the Benjamini-Hochberg correction177. The calculated p-values 
are sorted from the largest to the smallest. The largest p-value is kept as it is, while the 
second largest p-value is adjusted by multiplying it by n/(n-1), the third largest p-value 
by multiplying it by n/(n-2), and so on. This procedure is valid when the tests are 
independent or positively dependent. To take into account negative dependencies 
between tests, the Benjamini-Yekutieli179 correction can be applied by multiplying the 
Benjamini-Hochberg adjusted p-values by the sum of 1/i for i from 1 to n. 
 In summary, corrections based on FWER provide a strong control of the 
number of false positives but are not really adapted for a high number of tests as they 
then have low statistical power. Corrections based on FDR are more powerful but offer 
a weaker control of the number of false positives.   
In this work, the Benjamini-Yekutieli correction was applied when comparing 
gene expression between genders for the dozens of expressed genes. When a small 
number of comparisons were performed, e.g. for the physiological parameters (≤12), 
the Holm-Bonferroni correction was applied. 
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Chapter III.  Method development for 
metabolic profiling of liver samples 
by UPLC−MS 
 
 
 
 
OBJECTIVES 
 
 
 To develop an efficient and reproducible sample preparation protocol for 
untargeted metabolic profiling of liver samples by UPLC-MS  
 
 To optimise UPLC-MS methods (column type, mobile phases and gradients) for 
untargeted metabolic profiling of liver samples 
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III.1. Introduction 
The main aim of this project was to investigate relationships between liver 
cytochrome P450 (CYP) profiles and metabolic profiles of easily obtainable biological 
samples, such as urine and serum. However, as the CYP distribution would be 
assessed in liver, it was of interest to also investigate liver metabolic profiles and their 
relationship with the corresponding CYP profiles. Whereas methods were already 
available in our laboratory for UPLC-MS untargeted metabolic profiling of urine and 
serum, there was no such method for liver. The first part of this work was therefore 
dedicated to the development and optimisation of a method for untargeted profiling of 
liver samples by UPLC-MS.  
While sample preparation for LC-MS metabolic profiling of biofluids is often 
minimal, such as simple dilution for urine69 and bile78 or protein precipitation for 
serum85,180, tissue analysis generally requires more preparation: a preliminary step of 
metabolite extraction from the tissue into a liquid solution is necessary before LC-MS 
analysis. An efficient and reproducible extraction method is crucial in order to obtain 
reliable metabolic profile data.  
The liver contains a large variety of metabolites with different chemical 
properties. It is a lipid-rich tissue but also contains many polar metabolites. For 
untargeted analysis of liver samples, it is therefore essential to extract both polar and 
non-polar metabolites (and as a result to analyse two metabolic extracts for each 
sample). Two different approaches can be used for this purpose: 1) simultaneous 
extraction of polar and non-polar metabolites using a combination of water, methanol 
and chloroform, resulting into two layers separated by a protein pellet181-183 or, 2) two 
consecutive extractions: an aqueous extraction using perchloric acid or polar organic 
solvents (e.g. methanol or acetonitrile) mixed with water, followed by a lipid extraction 
of the remaining pellet, usually with chloroform/methanol83,184. This second approach 
avoids the difficult step of separating the two layers but is more time-consuming as two 
extractions are performed instead of one. 
Regarding aqueous extractions, several studies have compared the use of 
different solvents85,182,183. For liver samples, Lin et al.182 concluded that methanol/water 
(2:1), acetonitrile/water (1:1 or 2:1) and methanol/chloroform/ water all produced good 
consistent yields for NMR metabolic profiling (assessed from normalised total spectral 
area), although acetonitrile-based extractions tended to also extract some 
macromolecules and lipids into the aqueous layer. Concerning reproducibility among 
replicates, they found using principal components analysis that methanol/water 
extraction was more variable than acetonitrile/water and methanol/chloroform/water 
extractions. Conversely, Want et al.85 showed that methanol/water combination gave 
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more effective and reproducible results than acetonitrile/water for LC-MS based 
metabolic profiling for serum. 
For organic extractions, chloroform is the most widespread solvent, although it 
presents health and environmental hazards. It is often used in combination with 
methanol and water as in the Bligh and Dyer method181 (to perform organic and 
aqueous extractions simultaneously) or with methanol only (to perform only an organic 
extraction)82,83,185-187. Other solvents, such as hexane/isopropanol and ethylacetate, are 
sometimes used188,189, although Somashekar190 found that hexane/isopropanol (3:2) 
was less efficient than chloroform/methanol (2:1) for the extraction of lipid and fatty 
acids from fungal cultures. Carlson (1985) compared chloroform/methanol and 
dichloromethane/methanol for lipid extraction from human serum and rat liver tissue191. 
The quantity of cholesterol, triglycerides and phospholipids extracted with each 
combination of solvents were determined and both methods were found to give 
identical results. Therefore, it was suggested to use dichloromethane because of its 
lower toxicity (the threshold limit in the workplace is ~20 times higher for 
dichloromethane than for chloroform). More recently (2008), Sanchez et al.192 
compared the efficiency of chloroform and dichloromethane for the extraction of lipids 
from various kinds of samples (seeds, roe and dorsal muscle from fishes, plant hairy 
roots) and concluded that dichloromethane/methanol could readily be used instead of 
chloroform/methanol.  
Thus, many protocols can be employed to extract metabolites from liver 
samples. Comparing a series of protocols with a few replicates for each can quickly 
result in a large number of samples to analyse. However, when performing untargeted 
metabolic profiling by UPLC-MS, analysing a large number of samples in one analytical 
run can lead to instrumental drift, arising from column degradation or contamination of 
the MS source75. On the other hand, the comparison of data acquired within different 
batches of samples is non-trivial. Hence, to enable the investigation of many protocols, 
an initial study was performed, in which the consecutive extraction approach (8 
protocols) and the two-layer extraction approach (24 protocols) were examined 
separately. The six best performing protocols in terms of reproducibility and number of 
features extracted were then thoroughly compared in a second study (referred to as 
main study, and published in Analytical Chemistry86) in order to determine the optimal 
sample preparation protocol for UPLC-MS metabolic profiling of liver samples. After 
selection of this protocol, further optimisation was carried out on the UPLC-MS 
methods (column type, mobile phases, and gradients). 
Homogenisation of tissues is often achieved by grinding the frozen tissue with 
pestle and mortar182,183,192 or by using an electric homogenizer182,189, both methods 
necessitating a strong wash of the mortar/pestle or the electrical probe between each 
sample to avoid carryover. When analysing many different liver samples, this can be 
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highly time-consuming. Recently, new tissue homogenisers have been developed, 
resulting in higher throughput and lower hazard of cross-contamination, such as the 
Precellys 24 (Stretton-scientific)193,194 and the TissueLyser (Qiagen) 195,196 (Figure 
III-1), which was used here. This latter device provides the disruption and 
homogenisation of up to 48 tissue samples simultaneously by briefly shaking eppendorf 
tubes that each contain one tissue sample, some solvent and a stainless steel bead.  
 
 
 
Figure III-1. Picture of the TissueLyser from Qiagen 
The picture shows the TissueLyser (left) with the adapter plates (middle) and the beads (right). 
 
 
Key considerations for the selection of the optimal protocol were reproducibility, 
metabolite yield and sample throughput. A traditional statistic approach to look at the 
reproducibility of the measurement of one parameter is to calculate the coefficient of 
variation (CV=standard deviation/mean) of the values obtained when measuring this 
parameter several times. Similarly, for each metabolite feature, it is possible to 
calculate the CV of the intensities measured among replicates of a single method130. 
The distribution of these CVs can then be compared between the various methods to 
obtain an overview of differences in reproducibility. Another way of investigating 
method differences in terms of reproducibility is to apply pattern recognition methods, 
such as principal components analysis (PCA). PCA scores plots can be used to 
compare the clustering of the replicates between each method, e.g. by calculating the 
areas or volumes occupied by replicates of different methods in the PCA space182. 
Here, these two approaches were combined to compare reproducibility between 
methods in the initial study. For the main study, a multivariate statistical strategy was 
developed to take into account the variation in the whole multidimensional space and 
enhance the statistical comparison of the methods.  
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III.2. Experimental section 
III.2.1. Materials and test samples  
Materials and suppliers for all the metabolic profiling analyses performed at 
Imperial College London (ICL) (Chapters III, IV and VI) are shown in Appendix II.  
The liver samples used to evaluate the different protocols were obtained from a 
portion of a chicken liver from a single animal (standard commercially available fresh 
food product). It was stored at −80 °C until use. 1H NMR spectra were acquired to 
assess sample integrity and to confirm that global metabolite patterns were similar to 
those of previously acquired liver data, which ensured that the samples were fit for 
purpose for method development. 
 
 
III.2.2. Sample preparation 
III.2.2.1. Initial study 
Two different extraction strategies were investigated: 1) aqueous extraction of 
the tissue followed by organic extraction of the remaining pellet (consecutive extraction 
strategy), and 2) simultaneous extraction of polar and non polar metabolites using a 
biphasic separation (two-layer extraction strategy). For each strategy, several different 
solvents were tested both for metabolite extraction and resuspension, as solvents may 
have an impact on metabolite solubility and stability. 
 
III.2.2.1.1. Consecutive extraction (CE) strategy 
The following protocol was adaptated from Coen et al.83. Preweighed liver 
samples (50 mg) were placed in Eppendorf tubes and homogenised in 1.5 ml of 
acetonitrile/water (1:1) or methanol/water (1:1) in a TissueLyser (Qiagen) at 25 Hz for 5 
minutes (using 5 mm stainless steel beads). Eppendorf tubes were then centrifuged for 
10 minutes at 16,000g. The supernatants were collected and dried in a Savant 
Speedvac® (aqueous extracts). The remaining pellets were homogenised in 1.5 ml of 
chloroform/methanol (3:1) or dichloromethane/methanol (3:1) in the TissueLyser at 
25 Hz for 5 minutes. The homogenates were transferred into clean Eppendorf tubes 
and centrifuged for 10 minutes at 16,000g. The supernatants were collected and dried 
overnight in a fume cupboard. Dried aqueous and organic extracts were kept at -20°C 
until UPLC-MS analysis.  
Before analysis, the aqueous extracts were resuspended in 200 μl of either 
water, methanol/water (1:1) or acetonitrile/water (1:1). The organic extracts were 
resuspended in 200 μl of either methanol/water (1:1) or acetonitrile/water (1:1).  
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Hence, considering both metabolite extraction and resuspension solvents, 6 
conditions were tested for the aqueous extraction and 8 conditions for the organic 
extraction (Table III-1). The former were replicated on 9 samples and the latter on 6 or 
7 samples. Moreover, for each condition, the same protocol was followed for two or 
three “control” tubes, containing no liver, referred to as experimental blanks. 
 
 
Table III-1. Conditions tested for the CE strategy 
A) Aqueous extraction 
Condition Solvent for aqueous extraction Solvents for aqueous resuspension 
aA-rA Acetonitrile 
Acetonitrile/Water (1:1) 
aM-rA Methanol 
aA-rM Acetonitrile 
Methanol/Water (1:1) 
aM-rM Methanol 
aA-rW Acetonitrile 
Water 
aM-rW Methanol 
B) Organic extraction 
Condition 
Solvent for aqueous 
extraction 
Solvent for organic 
extraction 
Solvents for organic 
resuspension 
aA-oC-sA Acetonitrile 
Chloroform 
Acetonitrile/Water (1:1) 
aM-oC-sA Methanol 
aA-oD-sA Acetonitrile 
Dichloromethane 
aM-oD-sA Methanol 
aA-oC-sM Acetonitrile 
Chloroform 
Methanol/Water (1:1) 
aM-oC-sM Methanol 
aA-oD-sM Acetonitrile 
Dichloromethane 
aM-oD-sM Methanol 
Abbreviations: CE=consecutive extractions; a=aqueous extraction solvent; o=organic extraction solvent; 
r=resuspension solvent for aqueous extracts; s=resuspension solvent for organic extracts; A=acetonitrile; 
M=methanol; W=water; C=chloroform; D=dichloromethane.  
 
 
III.2.2.1.2. Two-layer extraction strategy (TLE) 
Four main protocols were investigated, TLEa, TLEb, TLEc and TLEd, all 
detailed in Table III-2. TLEa was an internal protocol commonly used in our laboratory, 
TLEb was adapted from the two-step method used by Wu et al.193, TLEc was similar to 
TLEa, but using the same volumes of solvents as in TLEb and TLEd was similar to 
TLEb, but using the same volumes of solvents as in TLEa. For each protocol, two 
organic solvents were tested, chloroform and dichloromethane. Le Belle183 showed that 
performing a re-extraction of the remaining pellet after a first extraction with 
methanol/chloroform/water allowed maximising the metabolite yield. As the re-
extraction step is time-consuming, it was decided to compare the results obtained with 
and without re-extraction of the remaining pellet for each protocol. For protocols TLEa 
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and TLEb, an increase of the partition time was also tested, as longer partition time 
improves partitioning of metabolites between the two phases but can result in 
metabolic decay193. The same protocols were used, but the samples were left for 10 
minutes on ice before being centrifuged. Hence, 8 conditions were tested for TLEa and 
TLEb and 4 conditions for TLEc and TLEd (Table III-3). Four replicates and two 
experimental blanks (protocol applied with no liver) were analysed for each condition.  
Aqueous and organic extracts were dried as described previously and kept at 
-20°C until UPLC-MS analysis. Before analysis, aqueous extracts were resuspended in 
100 μl of water. Organic extracts were resuspended in 200 μl of methanol/water 
(50:50). 
 
 
Table III-2. Details of the protocols tested for the TLE strategy 
TLEa TLEb TLEc TLEd 
50 mg of liver 
500 μl chloroform/methanol 
(2:1) or 
dichloromethane/methanol 
(2:1) 
400 μl methanol 
and 
125 μl water 
800 μl chloroform/methanol 
(1:1) or 
dichloromethane/methanol 
(1:1) 
166 μl methanol 
and 
166 μl water 
Samples homogenised in the TissueLyser (25 Hz, 5 min) 
500 μl water 
200 μl water and 
400 μl chloroform 
or 
dichloromethane 
325 μl water 
333 μl water and 
333 μl chloroform 
or 
dichloromethane 
Samples vortexed and centrifuged (16,000g, 10 min), resulting in a biphasic mixture 
Upper (polar) and lower (non polar) layers transferred into clean tubes 
To try to improve recovery, a second extraction was performed on the remaining pellet of half of the 
samples, using the same solvents as the 1
st
 extraction 
500 μl water and 500 μl 
chloroform/methanol (2:1) or 
dichloromethane/methanol 
(2:1) 
400 μl methanol, 
325 μl water, 
400 μl chloroform 
or 
dichloromethane 
325 μl water and 800 μl 
chloroform/methanol (1:1) or 
dichloromethane/methanol 
(1:1) 
166 μl methanol, 
500 μl water and 
333 μl chloroform 
or 
dichloromethane 
Samples vortexed and centrifuged (16,000g, 10 min), resulting in a biphasic mixture 
Upper (polar) and lower (non polar) fractions added to earlier fractions 
The ratio of added solvents (chloroform or dichloromethane: methanol: water) was 4:2:6 for TLEa and TLEd and 
4:4:3.25 for TLEb and TLEc.  
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Table III-3. Conditions investigated for the TLE strategy 
Partition time 
(min) 
Solvent for 
organic extraction 
Number of 
extraction 
Main 
Protocol 
Individual 
protocol 
labelling 
0 
Chloroform 
1 
TLEa TLEa-0C1 
TLEb TLEb-0C1 
TLEc TLEc-0C1 
TLEd TLEd-0C1 
2 
TLEa TLEa-0C2 
TLEb TLEb-0C2 
TLEc TLEc-0C2 
TLEd TLEd-0C2 
Dichloromethane 
1 
TLEa TLEa-0D1 
TLEb TLEb-0D1 
TLEc TLEc-0D1 
TLEd TLEd-0D1 
2 
TLEa TLEa-0D2 
TLEb TLEb-0D2 
TLEc TLEc-0D2 
TLEd TLEd-0D2 
10 
Chloroform 
1 
TLEa TLEa-10C1 
TLEb TLEb-10C1 
2 
TLEa TLEa-10C2 
TLEb TLEb-10C2 
Dichloromethane 
1 
TLEa TLEa-10D1 
TLEb TLEb-10D1 
2 
TLEa TLEa-10D2 
TLEb TLEb-10D2 
 
 
III.2.2.2. Main study 
The three best performing protocols for each approach were selected from the 
initial study and performed again, all in the same batch, with fifteen replicates and five 
experimental blanks for each. These six protocols were performed exactly as detailed 
for the initial study, except that the resuspension volume for the aqueous extracts of 
the TLE protocols was set to 200 μl (as opposed to 100 μl for the initial study) in order 
to use the same resuspension volume for all protocols. Dried aqueous and organic 
extracts were stored at −40°C until UPLC-MS analysis. 
 
 
III.2.3. UPLC-MS analysis 
Analyses were performed separately for aqueous and organic extracts on an 
Acquity UPLC® System (Waters, Elstree) coupled with an LCT Premier time-of-flight 
mass spectrometer (Waters, Manchester) for the initial study, and a Q-Tof Premier 
mass spectrometer (Waters, Manchester) for the main study. The mass spectrometers 
were operated in the positive (ESI+) and negative (ESI−) electrospray ionisation 
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modes. Samples were kept in the autosampler at 4°C during the analyses. For the 
initial study, due to the large number of samples, UPLC-MS analyses were conducted 
in separate batches corresponding to 1) protocol CE, 2) protocol TLEa, 3) protocols 
TLEb, TLEc and TLEd. 
Chromatography was carried out at 40°C on a Waters Acquity UPLC HSS T3 
column (1.8 μm, 2.1x100 mm) with the following solvent system: A = 0.1% formic acid 
in water, B = 0.1% formic acid in acetonitrile. Analyses were performed with a 0.5 
ml/min flow rate using a 21 minute gradient for the aqueous extracts and a 25 minute 
gradient for the organic extracts, both followed by a 5 minute re-equilibration phase 
(Table III-4). The injection volume was 5 μl.  
ESI conditions were: source temperature 120°C, desolvation temperature 
350°C, cone gas flow 25 L/h, desolvation gas flow 900 L/h, capillary voltage 3000V or 
3200 V for ESI+ and 2400 V for ESI-, cone voltage: 30-35V. The instrument was set to 
acquire over the m/z range 50-1000 in W-mode with scan time of 1 s and an interscan 
delay of 0.01 s for the initial study and in V-mode with scan time of 0.1 s and an 
interscan delay of 0.01 s for the main study. Data were collected in centroid mode. 
Leucine Enkephalin (200 pg/μl in acetonitrile/water (1:1)) was used as a lock mass with 
an analyte-to-reference scan ratio of 10:1 and the instrument was calibrated before 
analyses using 0.5 mM sodium formate solution (W-mode resolution ~11 000, V-mode 
resolution ~8 000, mass accuracy ~10 ppm for both modes). In the initial study, the 
samples were injected in a random order. For the main study, the order of injection was 
set by "supervised" randomisation (block-design), using the criterion that each of the 
sequences 1-6, 7-12, 13-18... should contain one replicate from each protocol. In 
addition, for the main study, a quality control (QC) sample, prepared by combining 
equal aliquots of replicates from each protocol, was injected regularly throughout each 
run to monitor the stability of the UPLC-MS platform (section II.1.2). This QC sample 
was also used to condition the column at the beginning of each analysis (8 injections). 
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Table III-4. UPLC gradient composition  
Aqueous extracts Organic extracts 
t (min) %A %B t (min) %A %B 
0 99.9 0.1 0 99.9 0.1 
2 99.9 0.1 2 99.9 0.1 
12 50.0 50.0 7 50.0 50.0 
13 50.0 50.0 8 50.0 50.0 
17 0.1 99.9 12 25.0 75.0 
21 0.1 99.9 14 25.0 75.0 
22 5.0 95.0 20 0.1 99.9 
23 99.9 0.1 25 0.1 99.9 
26 99.9 0.1 26 5.0 95.0 
 
27 99.9 0.1 
30 99.9 0.1 
 
 
III.2.4. Data analysis 
UPLC-MS raw data files were converted to netCDF format using the DataBridge 
tool implemented in MassLynx4.1TM software (Waters). They were then pre-processed 
using the freely available XCMS software138 in order to convert the three-dimensional 
LC-MS raw data (retention time, m/z, intensity) into a table of time-aligned detected 
features, with their retention time, m/z ratio and intensity in each sample. Isotope 
peaks, fragments and adducts were treated as separate features. Default settings were 
employed in XCMS with the exception of the minimum fraction of samples for grouping 
(minfrac=0.6) (main study only) and the bandwidth for the grouping performed after 
retention time correction (bw=10 s).  
 
III.2.4.1. Initial study 
III.2.4.1.1. Reproducibility analysis using metabolite feature intensity 
CVs  
For each analysis, each experimental condition was pre-processed separately in 
XCMS. As only two or three experimental blanks corresponded to each experimental 
condition, all experimental blanks for one analysis within a main protocol (CE, TLEa, 
TLEb, TLEc, TLEd) were processed together. For each experimental condition within a 
protocol, the metabolite features found in the batch of experimental blanks 
corresponding to the same protocol were removed in order to subtract the background 
and remove metabolite features not originating from the liver samples. 
For each remaining metabolite feature, the average intensity among replicates 
(μ), standard deviation (σ) of the intensities and coefficient of variation (CV =μ/σ) were 
calculated to investigate reproducibility. To compare the reproducibility of different 
conditions within a main protocol, distribution of CVs was assessed using Box and 
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Whisker plots (box plots). These box plots, commonly used to visualise differences 
between groups of data, allowed visualisation of the degree of dispersion of CVs of 
metabolite features for each condition. 
The ideal protocol should give reproducible data, but should also extract a high 
number of metabolites. To assess these two criteria simultaneously, an approach 
similar to the one used by Dunn et al.130 was applied. The number of metabolite 
features found by XCMS in at least 60% of the samples was calculated to assess the 
number of consistently detected peaks. This number should be as high as possible, but 
the ratio of this number to the total number of detected features should also be high, to 
ensure that most peaks are indeed detected consistently. In Dunn’s paper, the quality 
controls used for the reproducibility study were biologically identical serum samples 
and 15% and 20% tolerance tests for CVs were performed. However, here, one had to 
keep in mind that calculated CVs included biological, experimental and analytical 
variability. For this reason, values of 20% and 40% were used for tolerance tests. 
Biological and analytical variability should be similar between conditions; therefore a 
better CV reproducibility should be indicative of a better extraction method 
reproducibility. The numbers of consistently detected peaks with CVs < 20% and < 
40%, which represent the number of metabolites with reproducible intensity, should be 
as high as possible. These numbers of peaks were also compared to the number of 
consistently detected peaks. A high ratio ensured that most consistently detected 
peaks had reproducible intensity values.  
 
III.2.4.1.2. Reproducibility analysis using PCA  
All samples (experimental blanks and liver) analysed in the same batch with 
UPLC-MS were pre-processed together in XCMS and the same was performed for liver 
samples only. The resulting tables were then used as an input for Simca-P+ 11.5 
(Umetrics, Umeå, Sweden) to perform PCA.  
Data were scaled using level scaling, which consists of centring the variables 
and dividing them by their mean. This scaling focuses on changes relative to the mean 
concentration of the metabolite features. The resulting values are percentage changes 
compared to the average concentration. PCA models variance, so the use of level 
scaling is an approach similar to the CV assessment commonly used to monitor 
reproducibility.  
The number of components for each model was chosen considering the values 
of Q2, which is the fraction of the total variation of the data that can be predicted by a 
component, as estimated by cross-validation. For each component added to the model, 
Simca-P+ displays the value of Q2 for this component and the cumulative value of Q2 
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(Q2cum) for the extracted components. Components were added until the ratio of the 
increase in Q2cum value to the previous Q2cum value was < 5%.  
2D score plots were used to assess sample clustering for each experimental 
condition. To attempt to quantify these observations, variance of score values within a 
condition was calculated for each component of the model and the variances then 
added to obtain a global variance Vg for each class. This value was used as an 
indicator for the comparison of the clustering of the conditions within a PCA model: the 
lower the value of Vg, the more clustered and similar the replicates.  
 
III.2.4.2. Main study 
All samples (experimental blanks and liver) analysed in the same batch with 
UPLC-MS were pre-processed together in XCMS. For each dataset, samples were 
grouped by protocol, separating liver samples and corresponding experimental blanks, 
and QC samples were treated as a separate group, resulting in 13 classes. Four output 
tables were thereby obtained (one for each dataset), summarising the intensities of the 
detected features in each sample (liver, experimental blanks and QC samples).  
 
III.2.4.2.1. Data visualisation using PCA 
The XCMS output tables were used as an input for Simca-P+ 11.5 to visualise 
each dataset with PCA. Data were scaled using level scaling as in the initial study. 
Scores plots were examined to assess the degree of similarity between methods and 
identify potential outliers or trends in the data.  
 
III.2.4.2.2. Metabolite feature selection 
For each dataset, statistical tests were performed in Matlab (The MathWorks, 
Natick, Massachusetts) to remove features arising from the extraction solvents and 
mobile phases. Due to the low number of experimental blanks for each protocol and 
the very low breakdown point of the mean statistics, a non-parametric approach was 
followed. For each method, the features statistically significantly different from the 
corresponding experimental blanks were selected using a test of differences in 
medians197 based on the two-sided bootstrap confidence interval inversion (=0.05) 
with correction of the false discovery rate (FDR=0.05) for multi-comparison with 
dependencies179. These metabolite features were then used to investigate 
reproducibility and extraction efficiency.  
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III.2.4.2.3. Evaluation of Method Reproducibility 
Univariate statistics were used initially to visualise differences in reproducibility 
between methods. As several thousand metabolite features were obtained for each 
dataset, a multivariate strategy was subsequently developed in collaboration with 
Alexessander Couto Alves (Biomolecular Medicine, ICL) to enhance the statistical 
comparison of the methods. 
 
a) Univariate statistics 
As with the initial study, the CV distribution of feature intensities among the 15 
replicates was compared between the different methods using box plots. For each 
method, all features selected as different from the corresponding experimental blanks 
were used.  
 
b) Multivariate statistics 
Only the metabolite features common to all methods were retained in order to 
make methods comparable. To combine information from these multiple features, and 
since there is no standard method for computing multivariate variation, a multivariate 
statistical test was developed, based on a dimensionless statistic representative of the 
multivariate relative variation within the replicates of each method. Let ijx  be the 
intensity of the feature j in sample i. The statistic i was based on the overall ℓ1 norm of 
each sample’s relative deviation vector iZ . The elements ijZ of the relative deviation 
vector were the absolute differences between the sample’s feature intensities ijx  and 
the replicates’ medians jx
~ , divided by the replicates' medians, i.e. .~/~ jjijij xxxZ   
The ℓ1 norm of the vector was normalised by the number of common metabolites K, 
resulting in 
1
/1 ii ZK  . The median of the statistic among replicates 
~  was then 
calculated for each method with its 95% confidence interval computed using the 
Studentised bootstrap percentile T with double bootstrap variance estimate197. The 
statistic was plugged-in to the Conover’s nonparametric test of differences in 
medians198 to perform pair-wise comparisons of the multivariate relative variation 
between methods.  
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III.3. Results and discussion 
III.3.1. Initial study: screening of 32 protocols 
III.3.1.1. Consecutive extraction (CE) approach 
III.3.1.1.1. Aqueous extracts 
As detailed in the experimental section of this chapter (Table III-1), six different 
protocols were investigated for the aqueous extracts based on a consecutive extraction 
(CE) approach: aqueous extraction with methanol/water (aM) or acetonitrile/water (aA), 
and for each of these, resuspension of dried extracts in acetonitrile/water (rA), 
methanol/water (rM) or water (rW).  
 
a) Analysis of efficiency and reproducibility based on CVs 
To assess the reproducibility of the different protocols, the CV distribution of 
metabolite feature intensities among replicates was compared for ESI+ and ESI− 
modes using box plots (Figure III-2). These box plots display the minimum CV (end of 
the bottom whisker), the 25th percentile (bottom of the box), the median (white band in 
the box), the mean (red diamond), the 75th percentile (top of the box) and the maximum 
CV (end of the top whisker). A large spread of CVs was observed for all protocols in 
both ESI+ (Figure III-2A) and ESI− (Figure III-2C) modes. There was a sizeable 
difference between the 75th percentile and the maximum values. One had to keep in 
mind that these CVs included at the same time the biological variability in the piece of 
liver, the experimental variability and the analytical variability. Hence, it was not 
surprising to have high CVs for some peaks. However, as biological and analytical 
variability should be similar for all samples (the same piece of liver was used for all the 
experiments and comparisons were performed for UPLC-MS analysis conducted in a 
same batch), CV differences should reflect primarily differences between protocols. 
Figure III-2B (ESI+) and Figure III-2D (ESI−) zoom in on the boxes, i.e. on the spread 
of the values between the 25th and the 75th percentiles. Protocols aM-rM and aA-rW 
had the lowest 25th percentile, mean, median and 75th percentile in ESI− mode (Figure 
III-2D). The same was also true for ESI+ mode (Figure III-2B), except for the 25th 
percentile, for which protocol aM-rW exhibited a value slightly lower than protocol aA-
rW.  
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Figure III-2. Box plots comparing the distribution of metabolite feature intensity CVs 
among replicates for the 6 protocols tested for the CE aqueous extracts 
(A) ESI+ mode, complete distribution; (B) ESI+ mode, zoom in on distribution between 
25th and 75th percentile; (C) ESI− mode, complete distribution; (D) ESI− mode, zoom in 
on distribution between 25th and 75th percentile. 
Protocols aM-rM and aA-rW exhibit the lowest mean, median and 75th percentile in both ESI 
modes. 
Abbreviations: aqueous extraction with acetonitrile/water (aA) or methanol/water (aM); aqueous extract 
resuspension in acetonitrile/water (rA), methanol/water (rM) or water (rW). 
 
 
Considering the large spread of the CVs, reproducibility was further investigated 
using thresholds of 20% and 40%. Figure III-3 shows the differences between 
protocols (one dot = one protocol) for the number of peaks detected in at least 60% of 
samples with a CV < 20% (y-axis, left plots) or 40% (y-axis, right plots) in comparison 
to the number of peaks detected in at least 60% of samples (x-axis). The aim was to 
obtain a high number of reproducible peaks, in others words a high number of peaks 
with a low CV (high value for y-coordinate). The reasoning was not as simple for the x-
coordinate. Although a high number of consistently detected peaks was desirable (x-
axis), it would not have been relevant to have a lot of peaks consistently detected but 
only few with a low CV. Hence, a high ratio of y-coordinate to x-coordinate was also 
desired. Table III-5 summarises the values plotted in Figure III-3 and also give the 
ratios of these values. For each column, the three highest values are highlighted, as a 
protocol with both high numbers and high ratios was desirable.  
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Figure III-3. Assessment of peak reproducibility (y-axis) and number of consistently 
detected peaks (x-axis) for the 6 protocols tested for the CE aqueous extracts 
(A) ESI+ mode, 20% CV threshold; (B) ESI+ mode, 40% CV threshold; (C) ESI− mode, 
20% CV threshold; (D) ESI− mode, 40% CV threshold. 
In both ESI modes, protocol aA-rW exhibits the highest number of reproducible peaks (y-
coordinate) for both CV thresholds. 
Abbreviations: aqueous extraction with acetonitrile/water (aA) or methanol/water (aM); aqueous extract 
resuspension in acetonitrile/water (rA), methanol/water (rM) or water (rW). 
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Table III-5. Summary table for the numbers and percentages of consistently detected 
peaks and of reproducible peaks (CV≤20% and CV≤40%) for the analysis of the CE 
aqueous extracts  
ESI+ mode 
Protocols 
Number 
of peaks 
(N) 
Number 
of peaks 
present 
in at least 
60% 
samples 
(N60) 
% of 
N 
Number 
of peaks 
present 
in at least 
60% 
samples 
and with 
CV<=20% 
(N6020%) 
% of 
N 
% of 
N60 
Number 
of peaks 
present 
in at least 
60% 
samples 
and with 
CV<=40% 
(N6040%) 
% of 
N 
% of 
N60 
aA-rA 3251 2771 85.2% 378 11.6% 13.6% 1664 51.2% 60.1% 
aM-rA 2820 2377 84.3% 251 8.9% 10.6% 1191 42.2% 50.1% 
aA-rM 2793 2400 85.9% 365 13.1% 15.2% 1271 45.5% 53.0% 
aM-rM 2241 1882 84.0% 478 21.3% 25.4% 1401 62.5% 74.4% 
aA-rW 3459 2996 86.6% 581 16.8% 19.4% 1944 56.2% 64.9% 
aM-rW 2535 2178 85.9% 423 16.7% 19.4% 1351 53.3% 62.0% 
ESI− mode 
 
Number 
of peaks 
(N) 
Number 
of peaks 
present 
in at least 
60% 
samples 
(N60) 
% of 
N 
Number 
of peaks 
present 
in at least 
60% 
samples 
and with 
CV<=20% 
(N6020%) 
% of 
N 
% of 
N60 
Number 
of peaks 
present 
in at least 
60% 
samples 
and with 
CV<=40% 
(N6040%) 
% of 
N 
% of 
N60 
aA-rA 3392 2890 85.2% 247 7.3% 8.5% 1370 40.4% 47.4% 
aM-rA 2809 2308 82.2% 72 2.6% 3.1% 723 25.7% 31.3% 
aA-rM 2712 2215 81.7% 175 6.5% 7.9% 924 34.1% 41.7% 
aM-rM 2428 2049 84.4% 303 12.5% 14.8% 1114 45.9% 54.4% 
aA-rW 3245 2834 87.3% 497 15.3% 17.5% 1569 48.4% 55.4% 
aM-rW 2363 1955 82.7% 216 9.1% 11.0% 888 37.6% 45.4% 
Abbreviations: aqueous extraction with acetonitrile/water (aA) or methanol/water (aM); aqueous extract 
resuspension in acetonitrile/water (rA), methanol/water (rM) or water (rW). 
 
 
It was interesting to notice that by doubling the CV threshold, the number of 
reproducible peaks trebled or quadrupled (Figure III-3, right plots vs. left plots). The 
choice of CV threshold also had an impact on the interpretation of the results: protocol 
aA-rA for instance seemed to perform well when a CV threshold of 40% was used 
(Figure III-3, B and D), but did not appear better than the other protocols with a CV 
threshold of 20% (Figure III-3, A and C). For both CV thresholds, considering the 
number of peaks with a CV less than the CV threshold (y-coordinate in subplots of 
Figure III-3, values for N6020% and N6040% in Table III-5), protocol aA-rW was the most 
reproducible protocol in both ESI modes, followed by aM-rM for 20% CV threshold and 
by aA-rA for 40% CV threshold. Looking at the proportion of reproducible peaks (ratio 
Method development for metabolic profiling of liver samples by UPLC−MS 
88 
 
of y-coordinate to x-coordinate in Figure III-3, percentages for N6020% and N6040% in 
Table III-5), aA-rW and aM-rM were the most promising protocols in both ESI modes.  
To summarise, with this analysis of efficiency and reproducibility based on CVs, 
compromising between numbers of metabolite features detected and percentages in 
both modes, protocols aA-rW (extraction with acetonitrile/water, resuspension in water) 
and aM-rM (extraction with methanol/water, resuspension in methanol/water) appeared 
as the best protocols.  
 
b) Analysis of reproducibility based on PCA 
First, all samples (liver and experimental blanks) were pre-processed together in 
XCMS and analysed by PCA. In the PC1 vs. PC2 scores plot (Figure III-4A-B), 
experimental blanks clustered in the lower left quadrant in both ESI modes and were 
well separated from the liver samples. Separation was observed between the liver 
samples extracted with the different protocols in both ESI modes. However, overlap 
was seen between some protocols, indicating similarity between protocols aM-rM 
(yellow triangles) and aM-rW (red triangles) in ESI+ mode, and between protocols aA-
rA (black triangles) and aA-rM (green triangles) in both ESI modes. There was a clear 
separation between liver samples extracted with methanol (aM) and those extracted 
with acetonitrile (aA). Protocols aM-rM (yellow triangles) and aM-rW (red triangles) 
produced the most tightly clustered replicates in the PC1 vs. PC2 scores plot for both 
modes. 
To further investigate this clustering, liver samples were pre-processed in XCMS 
without the experimental blanks and data then analysed by PCA. Both models (ESI+ 
and ESI− modes) were fitted using 6 components and the values of R2 (cumulative) 
and Q2 (cumulative) were 66% and 53% for ESI+ mode, 60% and 44% for ESI− mode. 
In the PC1 vs. PC2 scores plot (Figure III-4C-D), the protocols were well separated, 
indicative of differences between the protocols in terms of metabolic profiles. Overlap 
could still be seen for protocols aA-rA (black triangles) and aA-rM (green triangles). In 
both ESI modes, replicates from protocol aM-rM (yellow triangles) were the most 
clustered, followed by protocol aM-rW (red triangles).   
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Figure III-4. PC1 vs. PC2 scores plots for the CE aqueous extracts  
(A) Experimental blanks and liver samples, ESI+ mode; (B) Experimental blanks and 
liver samples, ESI− mode; (C) Liver samples only, ESI+ mode; (D) Liver samples only, 
ESI− mode. 
In PC1 vs. PC2 scores plot of experimental blanks and liver samples, experimental blanks are 
tightly clustered and separation is observed between liver samples extracted with methanol and 
those extracted with acetonitrile. In PC1 vs. PC2 scores plot of liver samples only, the different 
protocols are separated, the most tightly clustered replicates being obtained for protocols aM-rM 
and aM-rW.  
Abbreviations: aqueous extraction with acetonitrile/water (aA) or methanol/water (aM); aqueous extract 
resuspension in acetonitrile/water (rA), methanol/water (rM) or water (rW). 
 
 
This observation of replicate clustering in the scores plot only took into account 
the first two PCs. To consider all components of the PCA models and to try to quantify 
what was observed, a global variance was calculated for each protocol by calculating 
the variance in scores among replicates for each PC and then summing the obtained 
variances. Table III-6 shows the total variance obtained for each protocol. Replicates 
from protocols aM-rM and aM-rW resulted in a low total variance compared to the other 
protocols, indicating that the replicates were more clustered in the PCA space for these 
two protocols. Consequently, looking at PCA output, it seemed that metabolite 
extraction with methanol/water (aM) and resuspension with either methanol/water (rM) 
or pure water (rW) were the most reproducible protocols.  
 
  
aA-rA
aM-rA
aA-rM
aM-rM
aA-rW
aM-rW
BlanksLiver
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Table III-6. Global variances obtained from PCA scores of the CE aqueous extracts  
Protocols ESI+ mode ESI− mode 
aA-rA 1047 1175 
aM-rA 730 1078 
aA-rM 761 665 
aM-rM 193 240 
aA-rW 1102 1091 
aM-rW 262 271 
Abbreviations: aqueous extraction with acetonitrile/water (aA) or methanol/water (aM); aqueous extract 
resuspension in acetonitrile/water (rA), methanol/water (rM) or water (rW). 
 
 
III.3.1.1.2. Organic extracts 
As detailed in the experimental section of this chapter (Table III-1), two solvents 
were investigated for organic extraction, chloroform (oC) and dichloromethane (oD), 
and for each of these, resupension of dried extracts in acetonitrile/water (sA) or 
methanol/water (sM). As the organic extraction followed the aqueous extraction 
performed either with acetonitrile/water (aA) or methanol/water (aM), this resulted in 8 
tested protocols for the organic extracts based on a CE approach.  
 
a) Analysis of efficiency and reproducibility based on CVs 
Figure III-5 shows the box plots depicting the CV distribution for replicates of 
organic extracts in ESI+ and ESI− mode. Similar to the plots for the aqueous extracts, 
the left plots in Figure III-5 showed a sizeable difference between the 75th percentile 
and the maximum values. Zooming in on the distribution between the 25th and 75th 
percentiles, the best protocols seemed to be aM-oD-sA in ESI+ mode (Figure III-5B), 
and aM-oC-sA, aM-oC-sM, aA-oD-sM and aM-oD-sM in ESI− mode (Figure III-5D). 
Among these last four protocols, aA-oD-sM and aM-oD-sM performed better than aM-
oC-sA and aM-oC-sM in ESI+ mode (Figure III-5B).  
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Figure III-5. Box plots comparing the distribution of metabolite feature intensity CVs 
among replicates for the 8 protocols tested for the CE organic extracts  
(A) ESI+ mode, complete distribution; (B) ESI+ mode, zoom in on distribution between 
25th and 75th percentile; (C) ESI− mode, complete distribution; (D) ESI− mode, zoom in 
on distribution between 25th and 75th percentile. 
Focusing on CV distributions between 25
th
 and 75
th
 percentiles, the most reproducible protocols 
are aM-oD-sA in ESI+ mode, and aM-oC-sA, aM-oC-sM, aA-oD-sM and aM-oD-sM in ESI− 
mode. 
Abbreviations: aqueous extraction with acetonitrile/water (aA) or methanol/water (aM); organic extraction with 
chloroform/methanol (oC) or dichloromethane/methanol (oD); organic extract resuspension in acetonitrile/water 
(sA) or methanol/water (sM). 
 
 
Figure III-6 shows the differences between protocols for the number of peaks 
detected in at least 60% of samples with a CV < 20% (y-axis, left plots) or 40% 
(y-axis, right plots) in comparison to the number of peaks detected in at least 60% of 
samples (x-axis). In Figure III-6A (ESI+ mode, 20% CV-threshold), aM-oD-sA clearly 
emerged as the most efficient and reproducible protocol. The same was true with a 
40% CV-threshold (Figure III-6B), but aM-oD-sM also performed well with this CV-
threshold. For ESI− mode (Figure III-6C-D), aM-oC-sA and aM-oD-sM seemed to be 
the most interesting protocols. However, in ESI+ mode (Figure III-6A-B), aM-oC-sA 
had a low number of reproducible peaks (y-coordinate) compared with the number of 
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consistently detected peaks (x-coordinate). Tables summarising the total number of 
metabolite features, the number of consistently detected metabolite features, the 
number of reproducible features and the corresponding ratios can be found in 
Appendix III.  
 
 
 
 
Figure III-6. Assessment of peak reproducibility (y-axis) and number of consistently 
detected peaks (x-axis) for the 8 protocols tested for the CE organic extracts 
(A) ESI+ mode, 20% CV threshold; (B) ESI+ mode, 40% CV threshold; (C) ESI− mode, 
20% CV threshold; (D) ESI− mode, 40% CV threshold. 
The highest number of reproducible peaks is obtained for aM-oD-sA in ESI+ mode, and for aM-
oC-sA and aM-oD-sM in ESI− mode. 
Abbreviations: aqueous extraction with acetonitrile/water (aA) or methanol/water (aM); organic extraction with 
chloroform/methanol (oC) or dichloromethane/methanol (oD); organic extract resuspension in acetonitrile/water 
(sA) or methanol/water (sM). 
 
 
Compromising between performance in both ESI modes, aM-oD-sA and aM-oD-
sM appeared as the most efficient and reproducible protocols. These protocols 
corresponded both to aqueous extraction with methanol/water (aM) and organic 
extraction with dichloromethane/methanol (oD). Only the resuspension solvent of the 
dried organic extracts was different (acetonitrile/water for aM-oD-sA and 
methanol/water for aM-oD-sM).  
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b) Analysis of reproducibility based on PCA 
In the same manner as the aqueous extracts, PCA was performed for both ESI 
modes, first with both experimental blanks and liver samples, then with liver samples 
only. The corresponding PC1 vs. PC2 scores plots are shown in Figure III-7. 
Separation was seen between experimental blanks and liver samples along PC1 
(Figure III-7A-B). In ESI+ mode (Figure III-7A), the experimental blanks were spread 
out along PC2 and some samples from protocol aA-oC-sM and aA-oC-sA were quite 
close to the experimental blanks. There was no obvious separation between protocols 
for liver samples. Liver samples were then pre-processed in XCMS without the 
experimental blanks. For ESI+ mode, the optimised PCA model had 6 PCs and the 
values of R2 (cumulative) and Q2 (cumulative) were 62% and 41%. For ESI− mode, the 
optimised PCA model had 4 components and the values of R2 (cumulative) and Q2 
(cumulative) were 48% and 35%. No separation was seen between protocols in ESI+ 
mode (Figure III-7C). Conversely, in ESI− mode (Figure III-7D), there was some 
separation between protocols, except for protocol aA-oD-sA, whose replicates were 
quite spread out. Distinction could be made along PC2 between samples resuspended 
in acetonitrile/water (sA) (upper part) and samples resuspended in methanol/water 
(sM) (lower part).  
 
 
 
Figure III-7. PC1 vs. PC2 scores plot for the CE organic extracts  
(A) Experimental blanks and liver samples, ESI+ mode; (B) Experimental blanks and 
liver samples, ESI− mode; (C) Liver samples only, ESI+ mode; (D) Liver samples only, 
ESI− mode. 
Separation is observed between liver samples and experimental blanks. With liver samples 
only, there is some separation between protocols in ESI− mode, but not in ESI+ mode.  
Abbreviations: aqueous extraction with acetonitrile/water (aA) or methanol/water (aM); organic extraction with 
chloroform/methanol (oC) or dichloromethane/methanol (oD); organic extract resuspension in acetonitrile/water 
(sA) or methanol/water (sM). 
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Table III-7 shows the total variance obtained for each protocol.  The values 
were quite different between protocols in ESI+ mode and protocols aA-oC-sA and aA-
oD-sM resulted in the most clustered replicates. The differences were smaller in ESI− 
mode. Protocols aM-oD-sA and aM-oD-sM, which appeared as the best when focusing 
on CVs, did not perform particularly well with PCA. However, the R2 and Q2 values 
obtained for the PCA models were low, implying that the models were not really good. 
 
 
Table III-7. Global variances obtained from PCA scores of the CE organic extracts  
 ESI+ mode ESI− mode 
aA-oC-sA 537 350 
aM-oC-sA 2129 387 
aA-oD-sA 912 633 
aM-oD-sA 1046 484 
aA-oC-sM 1059 330 
aM-oC-sM 932 369 
aA-oD-sM 601 306 
aM-oD-sM 1403 547 
Abbreviations: aqueous extraction with acetonitrile/water (aA) or methanol/water (aM); organic extraction with 
chloroform/methanol (oC) or dichloromethane/methanol (oD); organic extract resuspension in acetonitrile/water 
(sA) or methanol/water (sM). 
 
 
III.3.1.1.3. Selection of best-performing CE protocols 
For the aqueous extracts, with the CV-based analysis, aA-rW (extraction with 
acetonitrile/water, resuspension in water) and aM-rM (extraction with methanol/water, 
resuspension in methanol/water) were the best protocols in terms of efficiency and 
reproducibility. Based on PCA results, protocol aM-rM was part of the best protocols 
too, as well as protocol aM-rW (extraction with methanol/water, resuspension in water). 
For the organic extracts, with the CV-based analysis, the best-performing 
protocols were aM-oD-sA and aM-oD-sM, both corresponding to aqueous extraction 
with methanol/water (aM) and organic extraction with dichloromethane/methanol (oD), 
with only the resuspension solvent being different (acetonitrile/water for aM-oD-sA and 
methanol/water for aM-oD-sM). Based on PCA results, protocols aA-oC-sA and aA-oD-
sM were the best choices, the latter performing better based on CV results. 
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III.3.1.2. Two-layer extraction (TLE) approach 
As detailed in the experimental section of this chapter (Table III-2 and Table 
III-3), four main protocols were investigated for the TLE approach and each of these 
protocols was tested with chloroform and dichloromethane, and with or without re-
extraction of the remaining pellet after the first extraction. Moreover, for the first two 
protocols, two partition times were tested. This resulted in 24 protocols as shown in 
Table III-3. For these protocols, due to analytical issues, only the aqueous extracts 
were analysed. Data analysis was conducted in the same way as explained above for 
the consecutive extractions. Data for TLE1 protocol were analysed in one batch and 
data for the other protocols in a second batch as the UPLC-MS analysis was performed 
separately for TLE1. For brevity purpose, results obtained for these protocols are not 
detailed here, but the plots and corresponding tables can be found in Appendix III. The 
best results for efficiency and reproducibility were obtained for conditions TLEa-10D1, 
TLEb-0D1 and TLEc-0D1 (cf. Table III-2 and Table III-3 for experimental details of 
these conditions).  
 
III.3.1.3. Discussion 
Two different approaches were tested to extract metabolites from liver samples 
for untargeted metabolic profiling by UPLC-MS: consecutive extractions (CE) and 
simultaneous extraction by biphasic separation (TLE). Experiments for these two 
approaches were conducted separately and several protocols within each approach 
were investigated. Comparisons of the protocols were performed within an approach in 
order to determine the protocols giving the best results in terms of extraction 
reproducibility and efficiency. However, as the UPLC-MS analysis for the two 
approaches was performed at two different times and with two LC-columns (of the 
same type), comparison between the two approaches was not straightforward. 
Moreover, the organic extracts for the second approach could not be analysed. As for 
the aqueous extracts, the number of replicates was not the same between the two 
approaches (nine for the first approach, four for the second one). For these reasons, it 
was decided to use the obtained results to select the best-performing protocols within 
each approach and to repeat these experimental protocols all together and with the 
same number of replicates.  
As seen in the results, determination of the best protocols was not obvious and 
some trade-off was necessary to obtain a method that extracted many metabolites 
reproducibly in both ESI modes. The optimisation was complicated by the fact that two 
extracts had to be analysed for each sample (aqueous and organic). Reproducibility of 
each extract can be assessed independently, with the requirement that both extracts 
produce good results. However, this is not as simple for the extraction efficiency. One 
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protocol could be judged as unsatisfying in terms of efficiency because fewer 
metabolites were found in organic extracts compared with other protocols, while the 
“absent” metabolites could have been extracted in the corresponding aqueous extracts. 
Therefore, the efficiency should be calculated by combining the metabolites found in 
aqueous and organic extracts. However, as the number of obtained metabolites was 
also found to depend on the resuspension solvent, this was not practically feasible.  
 
Considering all these aspects, three protocols were selected for each approach 
to be further investigated in a second study. These protocols are displayed in Table 
III-8, which also summarises their main characteristics.  
 
 
Table III-8. Best performing experimental protocols selected for further investigation 
Consecutive extractions (CE) 
Name 
Aqueous 
protocol 
Organic 
protocol 
Extraction solvents Resuspension solvents 
Aqueous Organic Aqueous Organic 
CE1 aM-rM aM-oD-sA 
1.5 ml 
Methanol/ 
Water (1:1) 
1.5 ml 
Dichloro-
methane/ 
Methanol (3:1) 
200 μl 
Methanol/ 
Water (1:1) 
200 μl 
Acetonitrile/ 
Water (1:1) 
CE2 aA-rW aA-oD-sM 
1.5 ml 
Acetonitrile/ 
Water (1:1) 
1.5 ml 
Dichloro-
methane/ 
Methanol (3:1) 
200 μl 
Water 
200 μl 
Methanol/ 
Water (1:1) 
CE3 aM-rW aM-oD-sM 
1.5 ml 
Methanol/ 
Water (1:1) 
1.5 ml 
Dichloro-
methane/ 
Methanol (3:1) 
200 μl 
Water 
200 μl 
Methanol/ 
Water (1:1) 
Two-layer extraction (TLE) 
Name Protocol 
Homogenisation 
solvents 
After 
homogenisation 
before 
centrifugation 
# 
extrac
-tions 
Resuspension solvents 
Aqueous Organic 
TLE1 TLEa-10D1 
500 μl 
Dichloromethane/ 
Methanol (2:1) 
500 μl Water 
Samples left 
on ice 10 min 
1 
200 μl 
Water 
200 μl 
Methanol/ 
Water (1:1) 
TLE2 TLEb-0D1 
400 μl Methanol 
+ 125 μl Water 
200 μl Water + 
400 μl Dichloro-
methane 
1 
200 μl 
Water 
200 μl 
Methanol/ 
Water (1:1) 
TLE3 TLEc-0D1 
800 μl 
Dichloromethane/ 
Methanol (1:1) 
325 μl Water 1 
200 μl 
Water 
200 μl 
Methanol/ 
Water (1:1) 
Full protocol details are given in sections III.2.2.1.1 and III.2.2.1.2. 
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Several conclusions could be drawn from this selection.  
Regarding the CE approach, it was interesting to notice that aqueous extraction 
with methanol was found to produce reproducible results both with resuspension in 
water and in methanol/water. For organic extraction, it seemed that dichloromethane 
performed better than chloroform, as the three selected protocols employed 
dichloromethane. This could be related with the fact that organic supernatant collection 
was easier with dichloromethane compared to chloroform. Indeed, tubes containing 
dichloromethane presented a compact pellet and a clear supernatant after 
homogenisation and centrifugation, whereas in tubes containing chloroform, there was 
no proper pellet: liver was floating and supernatant was cloudy. The two best protocols 
for the organic extracts based on CV analysis, CE1 and CE3, were identical concerning 
the aqueous and organic extraction solvents. Only the resuspension solvents were 
different. Thus, it seemed that aqueous extraction with methanol and organic extraction 
with dichloromethane was the best choice.  
Concerning the TLE approach, the three selected protocols had in common 
dichloromethane as the organic solvent, with no second extraction to improve the 
recovery. Interestingly, condition 0D1 (dichloromethane as organic solvent, samples 
centrifuged immediately after adding all the solvents and vortexing, only one extraction) 
was chosen twice: once for protocol TLEb and once for protocol TLEc. The volumes of 
solvents were the same for these two protocols; only the order of introduction of the 
solvents differed.  
Experiments were performed again for these six selected protocols, with 
15 replicates for liver samples and 5 for experimental blanks, in order to 
thoroughly compare them and determine the optimal protocol for UPLC-MS 
metabolic profiling of liver samples. 
 
 
III.3.2. Main study: determination of the optimal 
protocol 
Comparison of the six selected protocols resulted in 120 aqueous extracts and 
120 organic extracts analysed in both ESI+ and ESI− modes. Within each UPLC-MS 
run, in addition to the liver extracts, quality control (QC) samples, prepared by 
combining equal aliquots from all extracts, were injected at regular time intervals to 
monitor analytical platform stability69,75,133,136 (section II.1.2). Each of the four datasets 
obtained (two extract types in both ESI modes) was initially visualised with PCA plots. 
Efficiency and reproducibility were then investigated using univariate and multivariate 
statistics to select the optimal protocol.  
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III.3.2.1. Data visualisation using PCA 
PCA was used to visualise the data. Of particular interest was the clustering of 
the multiple injections of the QC sample in the PCA space. A tight clustering of these 
injections in the PCA scores plot ensures that the analytical platform variability is small 
compared to the other sources of variation observed. For each dataset, the PC1 vs. 
PC2 scores plot showed a tight clustering of the experimental blanks and some 
separation between the different protocols, indicating differences in metabolic profiles. 
 
III.3.2.1.1. Aqueous extracts 
In ESI− mode (Figure III-8A), a drift was observed for the last three QCs in the 
PC1 vs. PC2 scores plot, indicating that there had been some instrumental drift over 
the UPLC-MS run. Therefore, for this dataset, the last third of the analytical run was 
discarded for the analysis of reproducibility and efficiency (10 replicates and 3 
experimental blanks remained for each protocol) (Figure III-8B). This highlighted the 
importance of injecting QC samples to verify the consistency of the analytical run over 
time. 
In ESI+ mode, the first and the last QC samples did not cluster with the other 
QC samples (Figure III-8C). Lack of clustering of the first QC sample with the others 
could indicate that the column had not been sufficiently conditioned before starting the 
run. After removing the beginning and the end of the run (12 replicates and 4 
experimental blanks remained for each protocol) (Figure III-8D), the scores plots were 
similar for both ESI modes. A clear separation was seen between the different 
protocols, except for TLE2 (orange diamond) and TLE3 (red triangle), which 
overlapped. These two protocols were highly similar and used the same volume of 
each solvent, the only differences being the order of addition of these solvents (and 
therefore the solvents in which homogenisation was performed). The PCA scores plots 
indicated that these differences did not seem to have a major impact on the metabolite 
extraction.  
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Figure III-8. PCA scores plot for the aqueous extracts analysed in the main study 
(A) ESI− mode; (B) ESI− mode, after removing the last third of the analytical run; (C) 
ESI+ mode; (D) ESI+ mode, after removing the beginning and the end of the analytical 
run.  
The imperfect clustering of the QC samples reveals a drift during the analyses. The different 
protocols are separated, except for TLE2 and TLE3, which overlap. 
Protocols details are given in Table III-8 
 
 
III.3.2.1.2. Organic extracts 
In the PC1 vs. PC2 scores plot, separation was seen between the CE approach 
and the TLE approach, while replicates from the different protocols overlapped within 
each approach (Figure III-9). CE1 replicates (black circles), the only samples to be 
resuspended in acetonitrile/water (methanol/water for all other extracts), showed more 
spread than the replicates of other protocols. In ESI+ mode (Figure III-9A), TLE1 
(yellow dots) clustered very close to the experimental blanks, which may indicate that 
the organic extraction was less efficient with this protocol. 
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Figure III-9. PCA scores plot for the organic extracts analysed in the main study 
(A) ESI+ mode; (B) ESI− mode. 
The TLE approach and the CE approach are separated. Within each approach, the different 
protocols overlap. 
Protocols details are given in Table III-8 
 
 
III.3.2.2. Evaluation of method reproducibility based on 
univariate statistics 
As in the initial study, box plots (Figure III-10) were used to visualise the 
distribution of metabolite feature intensity CVs among replicates for each protocol, as 
well as among multiple injections of the QC sample (UPLC-MS platform variability). QC 
variability was lower than experimental variability, and higher for the organic extracts 
than the aqueous extracts (median CV ~ 20% and ~10% respectively). This could be 
explained by the high lipid content in the organic extracts, which can induce carryover 
between samples and saturation of the MS detector, affecting reproducibility. For both 
types of extracts, the mean was generally notably higher than the median and the 
distributions were positively skewed. This was not very surprising as it is quite common 
to observe a few metabolite features exhibiting very high intensities compared to the 
others, which strongly affects the mean but not the median value.   
For the aqueous extracts (Figure III-10A-B), taking into account both ESI− and 
ESI+ modes, the most reproducible protocols were CE1 and TLE2, showing a median 
CV of 16.9% and 17.3% respectively for ESI− mode (Figure III-10A) and 19.2% and 
19.8% for ESI+ mode (Figure III-10B). In ESI− mode, the CV distribution was highly 
skewed for the TLE1 protocol, which exhibited a median value similar to the other 
protocols, while its 75th percentile was clearly higher than the other protocols. This 
illustrated the importance of looking at CV distribution rather than median value only.   
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For the organic extracts (Figure III-10C-D), the two-layer extractions showed a 
higher variability than the consecutive extractions. The most reproducible protocols 
were CE3 and CE2 in both ESI modes, with median CVs of 29.0% and 32.1% 
respectively for ESI− mode and 26.1% and 31.6% respectively for ESI+ mode. These 
protocols both involved an organic extraction with dichloromethane/methanol (3:1) with 
resuspension of extracts in methanol/water (1:1) (following an aqueous extraction with 
methanol/water for CE3 and with acetonitrile/water for CE2). 
 
 
 
 
Figure III-10. Box plots comparing the distribution of metabolite feature intensity CVs 
among replicates for the different protocols tested in the main study 
(A) Aqueous extracts, ESI− mode; (B)  Aqueous extracts, ESI+ mode; (C) Organic 
extracts, ESI− mode; (D)  Organic extracts, ESI+ mode. 
The far right box on each subplot, representing the variability in QC injections, shows that the 
UPLC-MS platform variability is lower than the experimental variability. The most reproducible 
protocols are CE1 and TLE2 for the aqueous extracts and CE3 and CE2 for the organic 
extracts. 
For each box, bottom=25th percentile, middle band=median, red dot=mean, top=75th percentile. Protocol 
details are given in Table III-8. 
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III.3.2.3. Evaluation of method reproducibility based on 
multivariate statistics 
The box plots (Figure III-10) allowed visualisation of the CV distribution for each 
protocol and provided an overview of differences in reproducibility. In order to 
statistically compare these differences, a dimensionless statistic representative of the 
multidimensional variation was calculated for each method, as well as its confidence 
interval (Figure III-11). Pair-wise comparisons of this statistic were performed so as to 
determine whether differences in variability observed between two methods were 
significant. The corresponding p-values are displayed in Table III-9.  
 
 
 
Figure III-11. Multivariate relative variation calculated for each protocol with its 95% 
confidence interval 
(A) Aqueous extracts, ESI− mode; (B)  Aqueous extracts, ESI+ mode; (C) Organic 
extracts, ESI− mode; (D)  Organic extracts, ESI+ mode. 
The calculation of this multivariate relative variation, representative of the spread of the 
replicates in the multidimensional space formed by the metabolite features, is detailed in the 
experimental section of this chapter (paragraph III.2.4.2.3). For the aqueous extracts, TLE2 
produces the lowest multivariate relative variation, followed by CE1, while for the organic 
extracts, CE3 and CE2 show the lowest relative variation.  
Protocol details are given in Table III-8. 
A B
C D
Aqueous extracts, ESI− Aqueous extracts, ESI+
Organic extracts, ESI− Organic extracts, ESI+
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Table III-9. p-values obtained from pair-wise comparisons of the developed multivariate 
statistic between protocols 
 Aqueous extracts, ESI− mode 
  CE1aq CE2aq CE3aq TLE1aq TLE2aq TLE3aq 
CE1aq 1 0.371 0.371 <0.001 0.371 0.007 
CE2aq 
  
1 1.000 0.007 0.371 0.007 
CE3aq 
  
1 0.074 0.371 0.074 
TLE1aq 
  
1 0.007 0.371 
TLE2aq 
  
1 0.007 
TLE3aq   1 
 Aqueous extracts, ESI+ mode 
  CE1aq CE2aq CE3aq TLE1aq TLE2aq TLE3aq 
CE1aq 1 0.414 1.000 0.014 0.102 0.102 
CE2aq 
  
1 0.414 0.414 0.102 0.414 
CE3aq 
  
1 0.102 0.102 0.414 
TLE1aq 
  
1 0.014 0.414 
TLE2aq 
  
1 0.102 
TLE3aq   1 
 Organic extracts, ESI− mode 
  CE1org CE2org CE3org TLE1org TLE2org TLE3org 
CE1org 1 0.715 0.273 0.715 0.715 0.273 
CE2org 
  
1 0.715 0.068 0.715 0.068 
CE3org 
  
1 0.068 0.273 0.068 
TLE1org 
  
1 0.715 0.715 
TLE2org 
  
1 0.715 
TLE3org   1 
 Organic extracts, ESI+ mode 
  CE1org CE2org CE3org TLE1org TLE2org TLE3org 
CE1org 1 0.068 0.011 0.715 0.715 0.715 
CE2org 
  
1 0.068 0.011 0.011 0.068 
CE3org 
  
1 0.001 0.011 0.001 
TLE1org 
  
1 0.715 0.715 
TLE2org 
  
1 0.715 
TLE3org   1 
p-values <0.05 are coloured in red, p-values between 0.05 and 0.1 are coloured in purple. 
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III.3.2.3.1. Aqueous extracts 
For the aqueous extracts in ESI− mode, protocols TLE1 and TLE3 showed the 
highest variation (Figure III-11A), consistent with observations from the CV box plots 
(Figure III-10A). Pair-wise comparisons (Table III-9) confirmed these differences 
(p<0.008 for comparisons with CE1, CE2 and TLE2, p<0.08 with CE3). The difference 
between TLE2, which showed the lowest variation, and the CE methods was not 
significant in ESI− mode. In ESI+ mode (Figure III-11B), TLE2 also produced the 
lowest variation, with larger differences than in ESI− mode (p<0.015 for comparison 
with TLE1, p<0.103 for comparisons with all other conditions).  
 
III.3.2.3.2. Organic extracts 
For the organic extracts, the relative variations and their confidence intervals 
were smaller for CE3 and CE2 than for the other protocols, making these two protocols 
more reliable (Figure III-11C-D), and confirming the observations from the CV box 
plots (Figure III-10C-D). In ESI+ mode (Figure III-11D), CE3 clearly appeared to be 
the most reproducible condition. Pair-wise comparisons with the other conditions 
(Table III-9) confirmed this result to be significant (p<0.011 with all conditions except 
with CE2 (p<0.068)). In ESI− mode (Figure III-11C), the difference was still obvious 
compared with TLE1 and TLE3 (p<0.068), not significant but still important for CE1 and 
TLE2 (p<0.274), and negligible compared with CE2 (p>0.715).  
Therefore, CE3 (organic extraction with dichloromethane/methanol (3:1) with 
resuspension of extracts in methanol/water (1:1), following an aqueous extraction with 
methanol/water (1:1)) was the optimal choice for organic extracts, followed by CE2 
(same as CE3 except aqueous extraction with acetonitrile/water (1:1)).  
 
III.3.2.3.3. Effect of resuspension solvent 
It is interesting to note that CE1 and CE3 were the same extraction protocols, 
only the resuspension solvents were different. For the aqueous extracts, resuspension 
in methanol/water (CE1) rather than in water (CE3) seemed slightly more reproducible 
in ESI− mode but not significantly so (p=0.371). No difference was detected in ESI+ 
mode (p=1). Conversely, for the organic extracts, choice of resuspension solvent had a 
noticeable impact on the reproducibility, especially in ESI+ mode: resuspension in 
methanol/water (CE3) gave more reproducible results compared to acetonitrile/water 
(CE1).  
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III.3.2.4. Selection of the best-performing protocol in terms of 
reproducibility 
As the selected protocol will be applied for untargeted metabolic profiling of 
liver, it must give reproducible results for both aqueous and organic extracts. Among 
the TLE protocols, TLE1 and TLE3 showed high variation for both aqueous and organic 
extracts and could therefore be eliminated. TLE2, which gave good results in terms of 
reproducibility for aqueous extracts, did not give satisfactory results for organic extracts 
and was also excluded.  
To obtain reproducible results for organic extracts, the optimal protocol was to 
perform two consecutive extractions, with organic extraction using 
dichloromethane/methanol and resuspension of organic extracts in methanol/water 
(protocols CE3 (aqueous extraction with methanol/water) and CE2 (aqueous extraction 
with acetonitrile/water)). These two protocols gave similar results for ESI− mode, 
whereas, in ESI+ mode, CE3 was more reproducible than CE2. These better results in 
terms of reproducibility for the organic extracts with the CE approach compared to the 
TLE approach could be linked with the absence of the delicate step of separating the 
two layers in the CE protocols.  
For the aqueous extracts, the optimal protocol among consecutive extractions 
was CE1 (aqueous extraction with methanol/water and resuspension in 
methanol/water), which was compatible with protocol CE3 for organic extracts.  
In summary, combining the results from both extract types in ESI− and ESI+ 
modes, the most reproducible protocol was to perform two consecutive extractions: an 
aqueous extraction with methanol/water (1:1) followed by an organic extraction with 
dichloromethane/methanol (3:1), with resuspension of both extracts in methanol/water 
(1:1). This resulted in a median CV of feature intensities among experimental replicates 
of <20% for aqueous extracts and <30% for organic extracts. 
 
III.3.2.5. Number of extracted features 
The number of metabolite features statistically significantly different from the 
experimental blanks for each protocol is shown in Figure III-12, together with the 
number of metabolite features common to all conditions.  
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Figure III-12. Number of features statistically significantly different from the 
experimental blanks obtained with each protocol 
(A) Aqueous extracts; (B) Organic extracts.  
The far right bar on each subplot represents the number of features common to all conditions. 
For the aqueous extracts, the number of extracted features is similar between protocols. This is 
also true for the organic extracts, except for TLE1, which shows a low number of features 
compared with the other protocols.   
Protocol details are given in Table III-8. 
 
 
III.3.2.5.1. Aqueous extracts 
For the aqueous extracts, the efficiency was similar between protocols (~3000 
features per mode) and > 75% of features extracted by each protocol were common to 
all conditions (Figure III-12A). Focusing on the optimal method for reproducibility 
(CE1aq), the number of metabolite features common to CE1aq and each of the other 
protocols was calculated to examine the difference in terms of extracted metabolites. 
For all protocols, at least 90% of the metabolite features found in the aqueous extracts 
were also extracted using CE1aq. 
 
III.3.2.5.2. Organic extracts 
For the organic extracts, the efficiency was similar between protocols (~2000 
features per mode), except for TLE1, which extracted substantially fewer metabolites 
(~1000 features per mode), resulting in a low number of common features (Figure 
III-12B). This lower efficiency of TLE1 could explain its clustering close to the 
experimental blanks in the PCA scores plot (Figure III-9A). The number of metabolites 
common to the optimal method for reproducibility (CE3org) and every other protocol 
was calculated; for all protocols, at least 85% of the metabolite features found in the 
organic extracts were also extracted using CE3org.   
 
A BAqueous extracts Organic extracts
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Thus, comparing the optimal method in terms of reproducibility to the other 
tested protocols did not show major differences in the extracted metabolites. 
 
III.3.2.6. Discussion  
On the basis of this main study, the following protocol was retained for liver 
sample preparation for our UPLC-MS metabolic profiling studies: aqueous extraction 
with methanol/water (1:1) followed by organic extraction with 
dichloromethane/methanol (3:1), with resuspension of both extracts in methanol/water 
(1:1) (protocol CE1aq followed by CE3org). 
A recent study (2009) investigating sample preparation for metabolic profiling of 
rat liver samples reported an overall mean CV (mean of CVs of all ions calculated 
separately for each ESI mode and then mean of both means) of 57% for the most 
reproducible method199. The investigated preparation methods differed from the ones 
described in this chapter, consisting of a homogenisation step in a buffer followed by 
acidification and solid-phase extraction using cartridges. The optimal protocol selected 
in this chapter seemed more reproducible, with overall mean CVs of 23.0% for 
aqueous extracts and 33.1% for organic extracts. This notable difference in mean CV 
may arise from the sample preparation or from the difference in analytical platform 
(direct injection MS was used in the study mentioned above, which is more prone to ion 
suppression).  
Comparing the reproducibility of our liver preparation approach with data 
published for urine or serum is not straightforward, as CVs of feature intensities among 
sample preparation replicates are often reported for only a small subset (~10) of 
metabolites or labelled internal standards150,180. For serum samples profiled via LC-MS 
in ESI+ mode, a mean CV for all detected features ranging from 19% to 36% was 
reported, depending on the extraction solvent85. More detailed information concerning 
CV distribution of feature intensities has however been published for replicate 
injections of a QC sample during urine136 and plasma135 UPLC-MS analyses (assessing 
only analytical platform variability, not sample preparation). For both biofluids, the 
median CV of feature intensities among replicate QC injections was between 15 and 
20%. Similar values were obtained here for QCs during liver analysis (~10% for 
aqueous extracts and ~20% for organic extracts).   
 
III.3.2.7. Reproducibility of known metabolites 
Once the optimal method for untargeted metabolic profiling had been chosen, 
analytical and extraction reproducibility were further investigated using selected 
compounds. Metabolites were identified based on matching their m/z and retention 
time with those of authentic standards injected within the batches of samples.  
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Table III-10 lists the metabolites identified in the aqueous extracts, with their 
measured m/z values, retention times, CV among replicates of the investigated 
protocols and among QC injections (UPLC-MS platform variability). All CV values for 
the selected protocol (CE1aq) were <15% and most were close to the platform 
variability, indicating good extraction reproducibility for the targeted compounds.  
 
 
Table III-10. Metabolites identified in the aqueous extracts with their observed retention 
time, m/z values in ESI+ and ESI– modes and CVs obtained among replicates of the 
investigated protocols and QC injections 
Metabolite ID 
Retention 
time  
(seconds) 
m/z 
ESI+ 
m/z 
ESI– 
CV ESI+ (%) CV ESI– (%) 
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Arginine 30.7 175.12 - 12.0 12.9 13.3 13.1 13.1 6.1 6.2 - - - - - - - 
Aspartic acid 30.9 - 132.03 - - - - - - - 4.6 6.1 5.8 7.6 4.2 7.7 3.7 
Glutamic acid 32.8 148.06 146.05 8.0 15.3 9.6 11.5 11.1 9.0 5.0 3.7 6.1 6.2 13.2 4.0 5.6 2.0 
Betaine 33.5 118.09 - 6.0 13.3 9.7 13.1 10.4 13.7 8.0 - - - - - - - 
Carnitine 33.5 162.11 - 12.3 23.5 6.5 16.7 9.9 16.3 4.3 - - - - - - - 
Alanine 33.7 90.05 88.04 9.4 19.0 7.2 13.5 16.5 8.3 5.9 4.9 5.8 3.6 5.8 6.9 5.1 3.5 
Proline 38.1 116.07 - 7.7 13.0 8.5 15.5 26.9 10.1 7.6 - - - - - - - 
Succinic acid 100.1 - 117.02 - - - - - - - 11.1 26.6 29.4 29.8 21.3 17.7 7.0 
Tyrosine 116.1 182.08 180.07 14.8 12.6 11.3 25.6 9.5 15.8 5.0 5.7 9.9 10.1 12.3 8.2 7.4 3.6 
Phenylalanine 231.6 166.09 164.07 11.3 13.1 13.2 20.4 13.1 11.3 8.4 8.0 9.8 14.9 10.8 13.9 6.5 8.6 
Pantothenic acid 258.6 220.12 218.10 9.2 15.5 12.1 17.9 9.9 12.2 8.9 7.4 6.7 8.8 12.0 10.7 14.0 8.1 
 TCA 593.3 480.28 514.28 7.8 14.5 14.0 18.8 21.3 25.4 4.1 10.0 17.8 14.1 15.6 28.5 28.7 3.3 
TCDCA 657.1 464.28 498.29 10.0 18.8 20.3 29.1 32.0 36.7 2.8 12.9 16.3 15.9 24.9 41.1 41.8 3.7 
CA 723.8 355.26 407.28 8.9 17.2 10.8 24.1 23.4 30.2 8.7 9.7 15.5 12.2 22.3 30.2 27.5 6.3 
Median 9.3 14.9 11.1 17.3 13.1 12.9 6.0 7.7 9.9 11.2 12.8 12.3 10.8 3.7 
Abbreviations: TCA=taurocholic acid; TCDCA=taurochenodeoxycholic acid; CA=cholic acid. 
Observed ions were [M+H]
+
 in ESI+ mode and [M–H]
–
 in ESI– mode except for bile acids in ESI+ mode 
 ([M–2H2O+H]
+
 for TCA and TCDCA and [M–3H2O+H]
+
 for CA).  
Values for the selected protocol are highlighted in yellow, values for the QC injections in orange.  
Protocol details are given in Table III-8. 
 
 
In the organic extracts, four lysophosphatidylcholines (LPCs) were examined 
(Table III-11), as these metabolites dominated the chromatograms. For these LPCs, 
CVs among replicates of the CE protocols were clearly lower than those of the TLE 
protocols, and were ~20% for the selected protocol (CE3org). As observed for the 
untargeted analysis, UPLC-MS platform variability was higher for the organic extracts 
than for the aqueous extracts. Many lipids and phospholipids were also detected but 
could not be unambiguously identified in the absence of appropriate standards. 
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Table III-11. Metabolites identified in the organic extracts with their observed retention 
time, m/z values in ESI+ and ESI– modes and CVs obtained among replicates of the 
investigated protocols and QC injections  
Metabolite 
ID 
Retention 
time  
(seconds) 
m/z 
ESI+ 
m/z 
ESI– 
CV ESI+ (%) CV ESI– (%) 
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LPC 16:0 656.9 496.34 540.33 40.1 24.7 20.8 102.7 54.3 48.8 13.7 22.9 16.1 18.0 42.5 53.8 39.1 14.2 
LPC 18:0 755.1 524.37 568.36 40.9 25.5 19.7 114.1 52.1 50.9 20.8 25.2 15.4 20.0 58.2 46.8 41.0 17.0 
LPC 18:1 679.9 522.36 566.35 45.5 32.2 23.3 106.9 72.7 59.3 18.5 33.2 20.1 24.0 56.6 63.8 55.5 17.2 
LPC 18:2 613.4 520.34 564.33 39.6 33.3 22.0 89.7 66.3 56.8 12.6 20.7 24.6 22.5 26.4 40.3 41.3 16.0 
Median 40.5 28.8 21.4 104.8 60.3 53.8 16.1 24.1 18.1 21.2 49.5 50.3 41.1 16.5 
Abbreviations: LPC=lysophosphatidylcholine 
Observed ions were [M+H]
+
 in ESI+ mode and [M+HCOO]
–
 in ESI– mode.  
Values for the selected protocol are highlighted in yellow, values for the QC injections in orange. 
Protocol details are given in Table III-8. 
 
 
III.3.2.8. Conclusion 
These two studies enabled the selection of a protocol for liver sample 
preparation for UPLC-MS metabolic profiling studies: aqueous extraction with 
methanol/water (1:1) followed by organic extraction with dichloromethane/methanol 
(3:1), with resuspension of both extracts in methanol/water (1:1). 
Once this was achieved and before applying this protocol to the subsequent 
studies, UPLC-MS methods were optimised, as briefly detailed in the section below. 
 
 
III.3.3. Optimisation of UPLC-MS methods 
As part of the comparative study on sources of variation in rat liver metabolic 
profiling by UPLC-MS described in Chapter IV, an additional sample was prepared to 
optimise the UPLC-MS methods (column, mobile phases, and gradients). The liver 
extraction was performed using the optimal protocol previously selected. To enable the 
possibility of analysing the samples by NMR spectroscopy, the extracted supernatants 
were halved before drying.  
 
III.3.3.1. UPLC-MS mobile phases and gradients for aqueous 
extracts 
First, the use of methanol instead of acetonitrile as UPLC-MS mobile phase B 
(with 0.1% formic acid) was assessed for the aqueous extracts, keeping water with 
0.1% formic acid as mobile phase A. The flow rate was set at 0.4 ml/min (instead 
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of 0.5 ml/min) and the column temperature at 50°C (instead of 40°C) as methanol 
resulted in higher system pressure than acetonitrile. Methanol gave better separation of 
the polar lipids eluting at the end of the UPLC run and resulted in less carryover 
between samples. It was therefore decided to use methanol rather than acetonitrile for 
mobile phase B. 
Gradients were then optimised individually for both ESI modes, using water with 
0.1% formic acid as mobile phase A, and methanol with 0.1% formic acid as mobile 
phase B. Details of the optimised gradients will be provided in the experimental section 
of Chapter IV (section IV.2.3). 
In addition, different resuspension volumes were tried, and a 200 µl volume was 
chosen, based on avoiding as much as possible peak saturation for high intensities 
without losing too many small peaks. 
The gradients optimised for the aqueous liver extracts were then tried for serum 
samples and found to give better separation for the lipids eluting at the end of the 
UPLC run compared to the gradients employed in our laboratory at that time. 
Therefore, it was decided for the serum metabolic profiling study conducted as part of 
this work to employ the gradients developed for aqueous liver extracts.  
 
III.3.3.2. UPLC-MS column, mobile phases and gradients for 
organic extracts 
For the organic extracts, containing many lipids, a C8 column was tried, as it 
retains less strongly the lipophilic compounds and has been shown to result in 
improved washing of the column between injections and less carryover compared with 
C18 columns200.  
To further improve the column washing, 15% isopropanol in methanol (with 
0.1% formic acid) was tested as mobile phase B (keeping water with 0.1% formic acid 
as mobile phase A). This was found to result in better lipid separation and decrease in 
carryover between samples.  
Gradients were therefore optimised for both ESI modes using a C8 column, 
water with 0.1% formic acid as mobile phase A, and 15% isopropanol in methanol with 
0.1% formic acid as mobile phase B. Details of the optimised gradients will be provided 
in the experimental section of Chapter IV (section IV.2.3). 
At the same time, resuspension volume was also optimised as with the aqueous 
extracts, and a 1 ml resuspension volume was selected.   
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III.4.  Conclusion 
The work exposed in this chapter enabled the establishment of a protocol for 
sample preparation and analysis in untargeted metabolic profiling studies of liver 
samples by UPLC-MS.  
Before applying this protocol to the liver samples from the rat CYP study 
(Chapter VI), it was decided to employ liver samples from an existing hepatotoxicity 
study to assess the relative importance of variability sources when applying this 
protocol (Chapter IV). More precisely, the objective was to compare sample 
preparation and UPLC-MS platform variability with inter-animal variability within and 
between treatment groups. Ensuring that differences between extracts coming from the 
same rat were small compared to differences between individual animals was essential 
in order to be sure that differences in liver metabolic profiles detected between two 
animals during analyses of the samples from the CYP study could be considered as 
real.  
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Chapter IV.  Evaluation of the 
developed liver metabolic profiling 
protocol: comparison of technical 
and biological variation 
 
 
 
 
 
OBJECTIVES 
 
 
 To compare sample preparation and UPLC-MS platform variability with inter-
animal variability within and between treatment groups when applying the protocol 
developed in Chapter III for untargeted metabolic profiling of liver samples by 
UPLC-MS 
 
 To determine an appropriate data transformation/scaling strategy in order to 
stabilise the variance before applying principal components analysis 
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IV.1. Introduction 
The ability to distinguish biological, i.e. “true”, variation from technical variation 
is a key concern in metabolic profiling studies, regardless of the analytical platform and 
sample type60,75,97,132,136,201-203. In the case of untargeted metabolic profiling of liver 
samples by UPLC-MS, technical variation can arise among others from sampling, 
metabolite extraction and instrumental platform variability.  
Concerning sampling, metabolite extracts are generally obtained from a small 
liver portion, cut from a section collected during in vivo studies at the time of study 
termination. These sections, although taken from a small, pre-defined part of the liver, 
are often not homogeneous and may lead to variable results depending on the 
sampled portion204. Additional variation arises from the sample preparation step, i.e. 
liquid extraction of metabolites from the samples. When metabolites are extracted from 
replicate portions of a liver section to investigate reproducibility, sampling variation and 
extraction variation overlap. This sampling/extraction variability is likely to be higher for 
tissue samples compared to biofluids, which are more homogeneous and usually 
require a simpler preparation step.  
Platform variability can arise from variations in sample injection, 
chromatographic conditions, MS conditions and detector electronic noise (section 
II.1.2). A widespread strategy to monitor this instrument variability in MS metabolic 
profiling studies is to inject a Quality Control (QC) sample, representative of the entire 
sample batch, at regular intervals throughout the analytical run69,75,133-135 (section II.1.2). 
The study reported here was designed to assess the relative importance of 
these different sources of variation when applying the protocol developed in Chapter III 
for metabolite extraction and UPLC-MS untargeted metabolic profiling of liver samples. 
More precisely, the aim was to compare sample preparation and UPLC-MS platform 
variability with inter-animal variability within and between treatment groups.  
Sections of liver used as test samples were part of a COMET 2 (second 
Consortium on Metabonomic Toxicology60,88) study investigating galactosamine 
hepatotoxicity and the protective effects of co-treatment with uridine, and had 
previously been analysed by MAS-NMR spectroscopy205. Galactosamine has been 
used historically as a model hepatotoxin, but its toxicity mechanism is still unclear. It is 
believed to form conjugates with uridine-5’-diphosphate sugars, resulting in depletion of 
the hepatic uridine nucleotide pool and inhibition of RNA and protein synthesis205. The 
metabolic profiling data obtained by NMR spectroscopy reflected the protective effects 
of co-treatment with uridine205 and it was of interest to also analyse the liver samples by 
UPLC-MS to provide complementary information and enhance the mechanistic 
understanding of galactosamine toxicity.  
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Before applying the liver protocol developed in the previous chapter to the 
complete set of samples from the study and to other liver studies, a small subset of 
samples from this study was employed to assess the protocol. For three rats from two 
treatment groups (inter-rat variability within and between groups), three liver portions 
were cut and underwent metabolite extraction (sampling/extraction variability) and each 
of the 18 resulting extracts (6 rats × 3 portions) was analysed in triplicate by UPLC-MS 
(instrument variability). The results reported here have been published in Analytical 
Chemistry206.  
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IV.2. Experimental section 
IV.2.1. Test samples 
Liver left lobe sections from 6 male Sprague-Dawley rats from a COMET 260,88 
galactosamine (galN) toxicology study were used as test samples (full study details can 
be found in Coen et al.205). Rats were housed in temperature and humidity controlled 
rooms with a 12-hour light cycle. Food (powdered Lab Diet 5002, Purian Mills, 
Richmond, IN) and water were available ad libitum throughout the study. After 6 days 
of acclimatisation, all rats received a single intraperitoneal injection of 415 mg/kg galN, 
and two hours after this dose, 3 were given 0 mg/kg uridine (treatment A) and 3 given 
2000 mg/kg uridine (treatment B). The 6 rats were euthanised 24 hours after the galN 
injection. Clear galN-induced toxicity was observed for the 3 rats dosed with treatment 
A, while only minimal toxic effects were detected for the 3 rats dosed with 
treatment B205.  
 
 
IV.2.2. Sample preparation 
The liver samples were prepared using the protocol developed in Chapter III. 
For each of the 6 rats, three 50 mg portions were taken from the liver section and 
treated separately, resulting in 18 portions. Portions were homogenised in 1.5 ml of 
pre-chilled methanol/water (1:1) in the TissueLyser (25 Hz, 5 min). Supernatants were 
collected after centrifugation and 650 µL transferred in Eppendorf tubes and dried in a 
Savant Speedvac (aqueous extracts). The remaining pellets were homogenised in 1.5 
ml of pre-chilled dichloromethane/methanol (3:1) in the TissueLyser (25 Hz, 5 min). 
Supernatants were collected after centrifugation and 650 µL transferred in glass vials 
and dried overnight in a fume cupboard (organic extracts). Dried aqueous and organic 
extracts were stored at −40°C until UPLC-MS analysis. Before analysis, aqueous 
extracts were resuspended in 200 µL of methanol/water (1:1) and organic extracts in 
1 ml of methanol/water (1:1). 
 
 
IV.2.3. UPLC-MS analysis 
Analyses were performed separately for aqueous and organic extracts on an 
Acquity UPLC® System (Waters, Elstree) coupled with an LCT Premier time-of-flight 
mass spectrometer (Waters, Manchester) operated in the positive (ESI+) and negative 
(ESI−) electrospray ionisation modes. Samples were kept at 4°C during the analyses. 
The injection volume was 5 μl. Reversed-phase chromatography was carried out at 
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50°C with previously optimised gradients using a 0.4 ml/min flow rate, on a Waters 
AcquityTM UPLC HSS T3 column (1.8 μm, 2.1x100 mm) for the aqueous extracts 
(Table IV-1) and on a Waters AcquityTM UPLC BEH C8 column (1.7 μm, 2.1x100 mm) 
for the organic extracts (Table IV-2). For the aqueous extracts, mobile phase A was 
0.1% formic acid in water and mobile phase B was 0.1% formic acid in methanol (23 
min gradient for ESI+ mode, 21 min for ESI− mode). For the organic extracts, mobile 
phase A was 0.1% formic acid in water and mobile phase B was 15% isopropanol 0.1% 
formic acid in methanol (32 min for ESI+ mode, 20 min for ESI− mode). All gradients 
were followed by a 3 min re-equilibration phase. 
 
 
Table IV-1. Optimised UPLC gradients for the aqueous liver extracts 
ESI+ mode ESI− mode 
t (min) %A %B t (min) %A %B 
0 99.9 0.1 0 99.9 0.1 
2 99.9 0.1 2 99.9 0.1 
6 75.0 25.0 6 75.0 25.0 
10 20.0 80.0 8 20.0 80.0 
12 10.0 90.0 14 7.0 93.0 
21 0.1 99.9 15 3.0 97.0 
23 0.1 99.9 19 0.1 99.9 
24 99.9 0.1 21 0.1 99.9 
26 99.9 0.1 22 99.9 0.1 
   
24 99.9 0.1 
A = 0.1% formic acid in water; B = 0.1% formic acid in methanol. 
 
 
Table IV-2. Optimised UPLC gradients for the organic liver extracts 
ESI+ mode ESI− mode 
t (min) %A %B t (min) %A %B 
0 25.0 75.0 0 30.0 70.0 
1 25.0 75.0 2 30.0 70.0 
6 15.0 85.0 7 15.0 85.0 
10 15.0 85.0 11 15.0 85.0 
15 10.0 90.0 15 10.0 90.0 
17 10.0 90.0 17 10.0 90.0 
18 9.0 91.0 18 0.1 99.9 
21 9.0 91.0 20 0.1 99.9 
22 8.0 92.0 21 30.0 70.0 
27 8.0 92.0 23 30.0 70.0 
29 0.1 99.9 
   32 0.1 99.9 
   33 25.0 75.0 
   35 25.0 75.0 
   A = 0.1% formic acid in water; B = 15% isopropanol 0.1% formic acid in methanol. 
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ESI conditions were as follows: source temperature 120°C, desolvation 
temperature 350°C, cone gas flow 25 L/h, desolvation gas flow 900 L/h, capillary 
voltage 3200 V for ESI+ and 2400 V for ESI−, cone voltage 35V. The instrument was 
set to acquire over the m/z range 50-1000 in V-mode with scan time of 0.2 s and an 
interscan delay of 0.01 s. Data were collected in centroid mode. Leucine Enkephalin 
(200 pg/μl in acetonitrile/water (1:1)) was used as a lock mass with an analyte-to-
reference scan ratio of 24:1 and the instrument was calibrated before analyses using 
0.5 mM sodium formate solution (resolution ~8 000 and mass accuracy ~10 ppm).  
The 18 samples were injected in triplicate, resulting in 54 samples, with an 
injection order set to minimise its correlation with the experimental factors of interest. 
For each analysis, a quality control (QC) sample, prepared by combining equal aliquots 
of all samples (40 μl for aqueous extracts, 60 μl for organic extracts), was injected 
every 9 samples to monitor UPLC-MS platform reproducibility69,75,133-135. This QC 
sample was also used to condition the column at the beginning of each analysis 
(10 injections).  
 
 
IV.2.4. Data pre-processing 
UPLC-MS raw data files were converted to netCDF format using the DataBridge 
tool implemented in MassLynx4.1TM software (Waters). UPLC-MS analyses resulted in 
four datasets, two for the aqueous extracts and two for the organic extracts (ESI− and 
ESI+ modes). Each dataset was pre-processed with XCMS software138 (version 
1.20.0). The centWave algorithm139 was used for peak picking with a peak width 
window of 3-20 seconds, the m/z width for the grouping was changed to 0.1 Da, the 
bandwidth parameter was kept to default (30 s) for the first grouping, then determined 
from the time deviation profile after retention time correction. Isotope peaks, fragments 
and adducts were treated as separate features. Four output tables were thereby 
obtained (one for each dataset), listing m/z ratio and retention time of the detected 
features with their intensities in each liver and QC sample. After normalising the data in 
R using a loess normalisation as described in Chapter II (section II.1.4.1.2), features 
with a coefficient of variation (CV=standard deviation/mean) ≥ 30% in replicate 
injections of the QC samples were removed. Before mean-centring the variables, log-
transformation (with a 20 offset) was performed to stabilise the variance throughout the 
intensity range151, as explained in the results. 
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IV.2.5. Data analysis 
The four pre-processed datasets were used as an input for Simca-P+ 11.5 
(Umetrics, Umeå, Sweden) to perform principal components analysis (PCA) and for 
Matlab (The MathWorks, Natick, Massachusetts) to perform agglomerative hierarchical 
cluster analysis (HCA), employing Euclidian distances and ward linkage.  
PCA 2D and 3D scores plots were used to visualise the relative importance of 
the different sources of variation. In order to quantify this importance and to take into 
account more variation in these data than that contained only in the first three principal 
components (PCs), distances between replicates, portions, rats and treatment groups 
were calculated in the PCA space formed by the number of PCs obtained in models 
optimised by cross-validation, and these distances were subsequently compared. Let 
tak and tbk be the scores of items a and b on the k
th PC, and n the total number of PCs 
in the optimised model. The distance between items a and b was calculated as the 
square root of the sum of the n squared differences between tak and tbk (Euclidean 
distance in n-dimensional space).  
Scores for each replicate were available from the PCA. Scores for each liver 
portion were calculated as the mean of the three corresponding replicate injections, 
then scores for each rat were calculated as the mean of the three corresponding 
portions, and finally scores for each treatment group were calculated as the mean of 
the three rats in the group. 
For each portion, the distance between replicates DistRep was calculated as the 
mean of pair-wise distances between the three injections of the portion (instrument 
variability). For each rat, the distance between portions DistPn was calculated as the 
mean of pair-wise distances between the three corresponding portions 
(sampling/extraction variability). For each treatment group, the distance between rats 
DistRat was calculated as the mean of pair-wise distances between the three rats in this 
treatment (intra-group variability). Finally, the distance between the two treatments was 
calculated (inter-group variability).  
The different levels of variation were compared by calculating the ratios of these 
distances, and permutation tests were performed to evaluate the statistical significance 
of these ratios. For instance, to compare extraction variability with instrument variability 
for rat 1, the ratio of DistPn for rat 1 (distance between portions) to the mean of the 
three corresponding DistRep (distance between replicate injections for each portion from 
rat 1) was calculated. This ratio was also calculated for each of the 279 possible 
permutations allocating the nine replicate injections to the three portions, and these 
279 ratios were ranked from highest to lowest. The rank of the real observed ratio in 
this list was calculated and divided by 279 to obtain the p-value. If the observed ratio 
was bigger than all the ratios calculated by permutations, it meant that the probability of 
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obtaining this ratio by chance was less than 0.0036 (1/279). The same approach was 
followed to compare intra-group variability with extraction variability, calculating, for 
each treatment group, the ratio of DistRat (distance between rats in the group) to the 
mean of the three corresponding DistPn (distance between portions for each rat in the 
group). There were also 279 possible permutations for each treatment group to allocate 
the nine portions to the three rats, so the minimal obtainable p-value was 0.0036. 
Finally, to compare inter-group variability with intra-group variability, the ratio of DistTreat 
(distance between treatments) to the mean of the two DistRat (distance between rats for 
each group) was calculated. In this case, there were only 9 possible permutations to 
divide the six rats into two groups, so the minimal obtainable p-value was 0.1111. 
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IV.3. Results and discussion 
IV.3.1. Inspection of QC chromatograms 
Figure IV-1 shows representative base peak intensity (BPI) chromatograms 
obtained for the QC samples during the UPLC-MS analyses of aqueous (Figure IV-1A-
B) and organic (Figure IV-1C-D) extracts. The gradients optimised for each analysis as 
described in Chapter III (section III.3.3) allowed separation of a high number of peaks. 
For each of the four runs, the inspection of the chromatograms of the repeated QC 
sample injections with regard to retention times, intensities and peak shapes indicated 
overall good analytical platform stability. 
 
 
 
Figure IV-1. Representative base peak intensity (BPI) chromatograms obtained for the 
QC samples 
(A) Aqueous extracts in ESI+ mode; (B) Aqueous extracts in ESI− mode; (C) Organic 
extracts in ESI+ mode; (D) Organic extracts in ESI− mode. 
For both types of extracts, a high number of peaks are separated in each ESI mode. 
 
 
IV.3.2. Data Pretreatment 
After data pre-processing with XCMS, 3268 (ESI−) and 3570 (ESI+) metabolite 
features (m/z_RT pairs) were obtained for the aqueous extracts, and 3450 (ESI−) and 
4354 (ESI+) for the organic extracts (including adducts and isotopes). PCA was used 
to extract meaningful information from these large datasets. To produce adequate 
models of the data, PCA requires that the measurement errors have a uniform variance 
across the dataset (homoscedastic noise)207.  
To investigate this measurement error, the standard deviation of each feature 
was calculated for the replicate injections of the QC sample, representative of the 
UPLC-MS platform variability. A perfectly reproducible platform would result in all these 
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injections being absolutely identical, and the standard deviation of each feature would 
be zero. This can obviously not be achieved in an actual functioning system due to 
inevitable variation in the platform response (e.g. detector electronic noise and 
ionisation efficiency fluctuation). 
In Figure IV-2A, these standard deviations are plotted versus the rank of the 
mean intensity for each metabolite feature for the organic extracts analysed in ESI+ 
mode. This figure shows that the most intense features (on the right) exhibited high 
standard deviation compared to the rest of the dataset. These features would therefore 
have dominated the PCA if data were not scaled. Due to the large range of metabolite 
concentrations in liver samples and differences in ionisation efficiency between 
metabolites, MS feature intensities can vary from a few dozens of ion counts to 
hundreds of thousands of ion counts (absolute values are detector dependent). 
Focusing on the subset consisting of the most intense ions could result in loss of 
interesting and important biological information, as metabolite features exhibiting lower 
intensities might have higher biological relevance.  
To reduce the importance of these ions, pareto scaling is often used in MS 
metabolic profiling studies73,112,136,148-150. However, as shown in Figure IV-2B, pareto 
scaling of the data did not change the overall appearance of the plot, with high intensity 
features still exhibiting high standard deviation in analytical replicates, although the 
range of variation was smaller.  
Although UV scaling would avoid this domination of the most intense features in 
the PCA, a drawback, in addition to inflating background noise, is that if a variable 
exhibits high intensity in one treatment group and low intensity in another one, all these 
intensities are divided by the same value (despite the variable being likely to exhibit 
high variance in one group and low variance in the other one due to the difference in 
intensity ranges).  
A simple approach to stabilise the variance across the intensity range is to 
perform logarithmic transformation147. Figure IV-2C shows the same plot as Figure 
IV-2A-B after log-transforming the raw data with an offset of 20 (this value was chosen 
to avoid an increase in standard deviation for low intensity signals151) and mean-
centring the variables. After this transformation, standard deviations were uniform 
across the range of intensities and focus would not be on high intensity signals when 
applying PCA. Similar effects were observed for all the four datasets and log-
transformation was therefore used for all of them.  
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Figure IV-2. Standard deviations vs. rank of mean intensities for the replicate injections 
of the QC sample for the organic extracts analysed in ESI+ mode 
Standard deviations are calculated on (A) mean-centred data, (B) pareto-scaled data, 
(C) mean-centred data after log-transformation with a 20-offset. 
Each dot represents one feature. Features are sorted by increasing mean intensities calculated 
on raw data. For mean-centred data and pareto-scaled data, the most intense features exhibit 
high standard deviation compared to the rest of the dataset. With log-transformation, standard 
deviations become uniform across the intensity range. 
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IV.3.3. Principal components analysis (PCA) 
After log-transforming the data to stabilise the variance across the intensity 
range, PCA was applied, first on the aqueous extracts then on the organic extracts, to 
visualise the data and assess the relative importance of the different sources of 
variation. 
 
IV.3.3.1. Aqueous extracts 
PC1 vs. PC2 scores plots of the aqueous liver extracts were similar for both ESI 
modes, as shown in Figure IV-3A-B.  
Replicate injections of the QC sample clustered tightly, illustrating the stability of 
the UPLC-MS platform throughout the whole run. The first PC separated the two 
treatment groups, the major source of variation in the samples. The nine injections from 
the same animal (triplicate injections of each of the three liver portions) clustered 
together, meaning that sampling/extraction and UPLC-MS platform variability could not 
be distinguished in the first two PCs. The three animals from each group were 
separated, showing that, in terms of polar metabolites, inter-animal variability was 
higher than the variability observed between the three portions from a single rat liver 
section.  
To illustrate the impact of the transformation/scaling step on the PCA, Figure 
IV-3C shows the same dataset as Figure IV-3B without variance stabilising 
transformation, but using pareto scaling. PC1 still distinguished between the two 
treatment groups. For treatment A, animals were separated as with mean-centred log-
transformed data, but injections from each single animal were more spread. For 
treatment B, samples from different animals overlapped and liver portions from animal 
5 did not cluster together. This was also true for some replicate injections of a single 
liver portion, e.g. from rats 5 and 6. 
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Figure IV-3. PC1 vs. PC2 scores plot for the aqueous liver extracts analysed by UPLC-
MS 
(A) ESI− mode, mean-centred data after log-transformation; (B) ESI+ mode, mean-
centred data after log-transformation; (C) ESI+ mode, pareto-scaled data with no log-
transformation. 
The QC injections are tightly clustered. The first PC separates the two treatment groups. For 
log-transformed data, the nine injections from the same animal cluster closely. 
 
 
For the log-transformed data (Figure IV-3A-B), the amount of variation in the 
dataset explained by the first two PCs was 67% and 60% for ESI− and ESI+ mode 
respectively. Optimisation of the number of PCs by cross-validation resulted in 9 PCs, 
corresponding to 89% and 85 % for ESI− and ESI+ mode respectively. To take into 
account all this explained variation, distances between samples were calculated in 
these 9-dimensional PCA spaces, as detailed in the experimental section of this 
chapter (section IV.2.5). 
For ESI− mode (Figure IV-4A), the distance between UPLC-MS replicates 
(instrument variability) was of the same order of magnitude for all portions. The 
distance between portions for a single rat was higher for rats 5 and 6 than for the other 
rats, indicating that the sampling/extraction variability was more elevated for these two 
rats. This could indicate that the liver sections from these two rats, which had received 
uridine to protect from galactosamine toxicity, were less homogenous than sections 
from the other rats. The most interesting information was the ratios of distance between 
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animals within a group to distance between liver portions from a single animal, 
                           , comparing the inter-animal biological variability within a group with 
the technical variability. Values for these ratios were 4.4 for treatment A and 2.3 for 
treatment B, with both p<0.0036, which was the lowest p-value that could be obtained 
by the permutation validation (the smaller ratio for treatment B resulted from the high 
portion distance values obtained for rats 5 and 6, as distance between rats were similar 
for both treatments). These two ratios were almost identical for ESI+ mode: 4.4 for 
treatment A and 2.2 for treatment B, with both p<0.0036 (Figure IV-4B). This 
confirmed that inter-animal variability within a group was higher than 
sampling/extraction variability for polar metabolites, as observed in the PC1 vs. PC2 
scores plot. The ratio of inter- to intra-group biological variability was also similar 
between both modes (1.4 in ESI− mode and 1.3 in ESI+), with both p<0.112. Although 
these p-values can seem elevated, it is reminded that this value was the lowest 
obtainable p-value by permutation generation for the inter- to intra-group ratios, 
meaning that the observed ratio was bigger than all the ratios that could be generated 
by permutations. This confirmed that inter-group variability was higher than intra-group 
variability.  
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Figure IV-4. Distances between samples calculated in the 9-dimensional PCA space 
for the aqueous liver extracts, and ratios of these distances  
(A) ESI− mode; (B) ESI+ mode. 
The distance displayed at the centre of the triangles corresponds to the mean of the pair-wise 
distances between the samples indicated at the apexes. Ratios displayed between levels 
correspond to the ratio of the distance at the level below to the mean of the distances at the 
level above. Replicate UPLC-MS injections of an extracted liver portion are labelled a, b and c; 
the three portions sampled and extracted from each single rat are labelled A, B and C.  
Values obtained for the ratios                            in both ESI modes show that inter-animal 
variability within a group is higher than sampling/extraction variability. 
Abbreviations: Pn=portion, Rep=UPLC-MS replicate, Treat=treatment.  
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IV.3.3.2. Organic extracts. 
 PC1 vs. PC2 scores plots of the organic liver extracts are shown in Figure 
IV-5A (ESI−) and Figure IV-5C (ESI+). As with the aqueous extracts, replicate 
injections of the QC sample clustered tightly and triplicate injections of each portion 
clustered together. PC1 separated the two treatment groups.  
For ESI− mode, the PC1 vs. PC2 scores plot (Figure IV-5A) was similar to that 
observed with aqueous extracts, except that rats in treatment B group overlapped. For 
rats 5 and 6, some separation could be seen between liver portions coming from the 
same animal. By adding a third PC (Figure IV-5B), all rats were separated.  
For ESI+ mode (Figure IV-5C), overlap between animals from the same 
treatment group was seen in the PC1 vs. PC2 scores plot, and portions from 
individuals rats did not cluster, especially for treatment B. By adding a third PC (Figure 
IV-5D), separation could be seen between rats, except for rats 5 and 6, which 
overlapped.  
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Figure IV-5. PCA scores plot for the organic liver extracts analysed by UPLC-MS 
(A) ESI− mode, mean-centred log-transformed data, PC1 vs. PC2; (B) ESI− mode, 
mean-centred log-transformed data, PC1 vs. PC2 vs. PC3; (C) ESI+ mode, mean-
centred log-transformed data, PC1 vs. PC2; (D) ESI+ mode, mean-centred log-
transformed data, PC1 vs. PC2 vs. PC3. 
The QC injections cluster tightly and triplicate injections of each portion cluster together. PC1 
separates the two treatment groups. In PC1 vs. PC2 scores plot, there is some overlap between 
animals from the same treatment group. By adding a third PC, animals are separated, except 
rats 5 and 6 in ESI+ mode. 
 
 
This difference between ESI modes was confirmed by calculation of distances 
and ratios of these distances in the PCA space formed by the first 6 PCs. For ESI− 
mode (Figure IV-6A), the ratios of the distance between animals within a group to the 
mean of the distances between portions of a single animal,                            , were 3.5 
for treatment A (p<0.0036) and 1.7 for treatment B (p<0.0036), showing that variation 
between rats within a group was bigger than sampling/extraction variability. This was 
also the case in ESI+ mode (Figure IV-6B) for treatment A (ratio=3.1, p<0.0036), but 
not treatment B, for which the ratio was equal to 1.0, meaning that distance between 
rats within a group was similar to distance between portions of a single rat. For this ESI 
mode, sampling/extraction variability was clearly bigger than instrument variability 
(distance ratios                            ranging from 2 to 14, p<0.0072), while these two 
sources of variability could not be distinguished in ESI− mode (most ratios were ~ 1).  
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Figure IV-6. Distances between samples calculated in the 6-dimensional PCA space 
for the organic liver extracts, and ratios of these distances 
(A) ESI− mode; (B) ESI+ mode. 
The distance displayed at the centre of the triangles corresponds to the mean of the pair-wise 
distances between the samples indicated at the apexes. Ratios displayed between levels 
correspond to the ratio of the distance at the level below to the mean of the distances at the 
level above. Replicate UPLC-MS injections of an extracted liver portion are labelled a, b and c; 
the three portions sampled and extracted from each single rat are labelled A, B and C.  
Values obtained for                        show that variation between rats within a group is bigger 
than sampling/extraction variability except for treatment B in ESI+ mode, for which distance 
between rats within a group is similar to distance between portions of a single rat. 
Abbreviations: Pn=portion, Rep=UPLC-MS replicate, Treat=treatment.  
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IV.3.4. Hierachical cluster analysis (HCA) 
To further investigate similarities between samples, agglomerative HCA159,160,208 
was performed on the log-transformed data. A dendrogram resulting from HCA of the 
aqueous extracts in ESI− mode is shown in Figure IV-7A. Triplicate injections were 
grouped together and then portions were grouped, except for rats 2 and 6, for which 
the replicate injections of two portions from the same liver section were merged 
(portions 2A-2C and 6B-6C), illustrating that UPLC-MS platform and 
sampling/extraction variability could barely be distinguished for these portions. The 
nine injections from each rat were grouped and treatment groups were separated, as 
observed with PCA.  
For the organic extracts, triplicate injections clustered together. Portions from 
the same rat were then grouped, with the exception of portions B of rat 4 and A of rat 6, 
which clustered together for ESI+ mode (Figure IV-7B). These two portions shared 
more similarities with each other than with the other two portions from their respective 
animal. This was consistent with observations from the corresponding PC1 vs. PC2 
scores plot (Figure IV-5C), on which these two portions were very close. Rats given 
the same treatment were then grouped together, resulting in separation between the 
two treatments.  
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Figure IV-7. Dendrograms resulting from agglomerative hierarchical clustering analysis 
(A) Aqueous extracts in ESI− mode; (B) Organic extracts in ESI+ mode 
For both types of extracts, the treatment groups are separated. Triplicate injections are grouped 
together and then portions are grouped, except for portions 2A-2C and 6B-6C in aqueous 
extracts for which replicate injections from two portions of the same liver section are merged, 
and for portions 4B and 6A in organic extracts, which cluster together. 
Sample labelling: 2-B_c = rat 2, portion B, UPLC-MS injection c.  
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IV.3.5. Discussion 
PCA and HCA sample clustering behaviours were similar. For both aqueous 
and organic liver extracts, triplicate injections of the same extract were closely 
clustered in PCA plots and grouped together in HCA dendrograms, indicating low 
UPLC-MS platform variability compared to biological variation. The stability of the 
UPLC-MS platform was also supported by the clustering of the multiple injections of the 
QC sample over the runs.  
A key question that often arises when analysing samples from metabolic 
profiling studies by UPLC-MS is that of replicate injections. Although it is useful to have 
triplicate values for each sample, which makes the results more reliable, this is not 
always practically feasible. Indeed, it requires increased sample volume and amplifies 
the length of the run, which raises the issues of stability of the samples in the 
autosampler (even at 4°C), as well as stability of the analytical platform over a longer 
period of time (and it also consequently decreases the sample throughput). This is 
especially true when the study contains a substantial number of samples, which is not 
unusual in metabolic profiling investigations. Given the results obtained in this study, it 
seems that a single injection of each sample might be sufficient, as long as a stringent 
QC approach is used to monitor platform stability.  
This QC approach also offers the possibility of investigating the error 
measurement for all variables. If this error is not homoscedastic, appropriate 
transformation/scaling should be used to stabilise the variance before applying PCA. 
Plotting the standard deviations of the intensities among replicate QC injections for 
various transformations/scalings can help in this choice, as shown in Figure IV-2. In 
our liver MS datasets, we observed that started log-transformation gave satisfactory 
results in terms of variance stabilisation, clearly improved compared to pareto scaling. 
For each MS metabolic profile dataset subsequently analysed in this thesis, this plot 
was investigated to decide if log-transformation should be applied, and when this was 
the case, to determine which offset value should be used to avoid a variance increase 
for small intensities.  
For the aqueous liver extracts, the nine injections from each rat liver section 
clustered, resulting in separation between the three animals from each group. This 
showed that, in terms of polar metabolites, the inter-animal variability was higher than 
the technical variability (sampling/extraction and UPLC-MS platform). Thus, if 
differences are seen between rats within a group when analysing aqueous liver 
extracts using the approach detailed here, they may merit further investigation.  
For the organic extracts, inter-animal variability was also higher than technical 
variability for ESI− mode, as well as for treatment A in ESI+ mode. Conversely, for 
treatment B in ESI+ mode, intra-group animal variability and technical variability were 
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of the same order of magnitude. For this ESI mode, extraction variability was higher 
than UPLC-MS platform variability for the organic liver extracts, resulting in 3 groups 
(=portions) of 3 points (replicated injections) for some rats. This could come from the 
non-homogeneity of liver sections in terms of lipid content or from the sample 
preparation step. Therefore, it will be difficult to draw conclusions from within group 
differences observed in organic extracts without having replicate metabolite extractions 
for each rat. Nevertheless, the technical variability was lower than differences between 
treatment groups, which were clearly separated, so differences between treatment 
groups in nonpolar metabolic profiles could still be investigated.  
For practical reasons, the number of samples analysed in this preliminary 
experiment was small and would need to be scaled up to investigate more deeply the 
sampling/extraction variability observed for the organic extracts in ESI+ mode. 
Nevertheless, the results obtained here were very encouraging, as technical variation 
was shown to be smaller than the information of interest in the study, which was the 
difference in liver metabolic profiles between the treatment groups. Although this 
protocol was designed for toxicity studies, where large differences may be expected 
between groups, it would be worth applying it to liver samples from studies likely to 
present more subtle animal differences, such as dietary studies. The excellent 
separation observed here between animals within a single group for aqueous extracts 
indicates that small differences in metabolic profiles can be observed. Therefore, it 
would be of value to extend this investigation to explore technical versus biological 
variability where less obvious differences are expected between groups, in order to 
provide valuable information regarding differences between metabolic profiles.  
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IV.4. Conclusion 
This experiment was designed to assess the reproducibility of the UPLC-MS 
metabolic profiling protocol of rat liver samples developed in the previous chapter 
before applying it to the rat CYP study (Chapter VI) and more generally to large 
toxicology studies. 
For both aqueous and organic liver extracts, UPLC-MS platform variability was 
small compared to biological variation, as illustrated by the tight clustering of replicate 
injections. The QC approach employed during the study proved to be very useful for 
monitoring platform stability and investigating error measurement before applying PCA. 
It was therefore decided to apply this QC approach for all the metabolic profiling 
analyses subsequently performed in this project. 
For aqueous extracts, differences between rats within a group were more 
important than technical variability. This observation is particularly valuable for the 
assessment of relationships between CYPs and liver metabolic profiles that will be 
conducted in this project, as it ensures that the major part of differences observed 
between rats in aqueous extracts cannot be attributed to UPLC-MS or sample 
preparation variability.  
For the organic extracts, the results were similar for ESI− mode, as well as for 
rats with treatment A (galactosamine only) in ESI+ mode. However, for treatment B 
(galactosamine+uridine) in ESI+ mode, variation between portions from a single rat and 
variation between rats within a group were of the same order of magnitude. Therefore, 
with extraction of only one liver portion from each rat, it will be difficult to know if 
differences observed between rats within a group are real or if they are due to technical 
variation. As we will not be able to perform multiple extractions for each sample for 
practical reasons, if relationships between metabolic profiles and CYP profiles within a 
group are found for the organic extracts in one experimental group, the results will 
require extensive validation to ensure that they are reliable.  
Nevertheless, for most metabolic profiling toxicity studies, the interest is mainly 
on biological differences between experimental groups, which were here the principal 
source of variation in the datasets for both aqueous and organic extracts. The analysis 
of the whole set of samples in this galactosamine toxicity study will therefore allow 
deep investigation of liver metabolic profile differences between the treatment groups, 
with the aim of gaining better understanding of underlying mechanisms of toxicity. This 
is under the responsibility of another PhD student and is thus not detailed in this thesis. 
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Chapter V.  Assessment of 
cytochrome P450 expression 
in male and female Wistar rats 
 
 
 
 
OBJECTIVES 
 
 
 To quantify liver mRNA expression of a maximum number of cytochrome P450s 
(CYPs) in control Wistar rats  
 
 To examine differences between males and females as well as between multiple 
rat delivery batches received and housed several weeks apart under identical 
experimental conditions 
 
 To assess CYP-related activities for a few selected CYPs commonly evaluated in 
drug development studies  
 
 To compare CYP mRNA expression and activity results 
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V.1. Introduction 
Cytochrome P450s are involved in the metabolism of many endogenous and 
exogenous compounds, including a wide range of drugs, steroids, bile acids and 
lipids3,4,6,7,20,21 (section I.1). Investigation of their implication in the metabolism of new 
drug candidates, as well as the modification of their activity resulting from these drugs, 
is an important step during drug development studies (section I.1). Rats are widely 
used as model organisms during preclinical studies to predict pharmacokinetics, 
metabolism and toxicity of new drug candidates in humans209. In terms of metabolism, 
this approach has some limitations as specific CYP isoforms are expressed in each 
species. Whereas 57 isoforms have been identified in humans (section I.1.2), 88 rat 
CYP isoforms are currently listed in the rat genome database210. Compared with 
humans, several CYP subfamilies are more expanded in rat, e.g. subfamilies 2J (1 
isoform in human vs. 5 in rat) and 2C (4 isoforms in human vs. 11 in rat). However, 
despite these differences, many human isoforms have homologs in rat. Table V-1 
gives a list of the known CYP isoforms for the rat with their human homologs (where 
existing). As this chapter focuses on assessment of CYP expression in the liver of male 
and female rats, information about rat liver expression and possible gender differences 
is also provided, when it was found in the literature.  
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Table V-1. Rat CYP isoforms currently listed in the Rat Genome Database 
Rat  
CYP 
Human 
homo- 
log* 
Rat liver gene expression 
 
Rat  
CYP 
Human 
homo-
log* 
Rat liver gene expression 
1a1 1A1 low
211,212
 
 
3a2 3A4 expressed (male predominant)
12,213,214
  
1a2 1A2 expressed
211,213
 
 
3a9 3A5 expressed (higher in females)
210,213,215
 
1b1 1B1 undetected
212
 
 
3a18   expressed (higher in males)
210,215
 
2a1   expressed (higher in females)
12,213,214,216,217
   
 
3a23-3a1   expressed
210,213
 
2a2   expressed (male predominant)
12,214,216,218
  
 
3a62   undetected
219
 
2a3 2A6 undetected
211,213,216
  
 
3a73   
 
2b1   expressed
220,221
 
 
4a1 4A11  expressed
222,223
  
2b2 2B6 low
213
  
 
4a2   expressed
222,223
 
2b3   expressed
210
 
 
4a3   expressed
222,223
 
2b12   undetected
224
 
 
4a8 4A22 expressed
222
 
2b15   undetected
225
 
 
4b1 4B1 expressed
226
 
2b21   undetected
213
 
 
4f1 4F12 expressed
217,227
 
2b31     
 
4f4 4F2 expressed
227,228
 
2c6   expressed
213,229
 
 
4f5   low
227,228
 
2c7   expressed (higher in females)
12,214,218
  
 
4f6   expressed
227,228
 
2c11   expressed (male predominant)
12,210,213,214,218
  
 
4f17 4F8 
 
2c12   expressed (female predominant)
12,210,214,218
 
 
4f18 4F3   
2c13   expressed (male predominant)
12,210,214,218
   
 
4f37     
2c22   expressed
210
 
 
4f39 4F22   
2c23   expressed
210,217
 
 
4f40 4F11   
2c24   expressed
230
 
 
4v3 4V2   
2c37   expressed
210
 
 
4x1 4X1 undetected
231
 
2c79 2C8   
 
5a1-Tbxas1 5A1 low
232
 
2c80 2C18   
 
7a1 7A1 expressed
233
 
2d1   expressed
213
 
 
7b1 7B1 expressed
234
 
2d2   expressed
213,235
 
 
8a1- Ptgis 8A1 expressed
236
 
2d3   expressed
235
 
 
8b1 8B1 expressed
210
 
2d4 2D6 expressed
213,237
 
 
11a1 11A1 
 
2d5   expressed
238
 
 
11b1 11B1 
 
2e1 2E1 expressed
210,229,239
 
 
11b2 11B2 
 
2f4 2F1 
 
 
11b3   
 
2g1   undetected
213
 
 
17a1 17A1   
2j3   expressed
217,240
 
 
19a1 19A1 
 
2j4 2J2 expressed
210,213
 
 
20a1 20A1 expressed
241
 
2j10   
 
 
21a1 21A2 expressed
210
 
2j13   undetected
242
 
 
24a1 24A1 
 
2j16     
 
26a1 26A1 expressed
243
 
2r1 2R1 expressed
244
 
 
26b1 26B1   
2s1 2S1 expressed
245
 
 
26c1 26C1   
2t1   
 
 
27a1 27A1 expressed
244,246
 
2u1 2U1 undetected
247
 
 
27b1 27B1 
 
2w1 2W1   
 
39a1 39A1   
2ab1     
 
46a1 46A1 
 
2ac1     
 
51 51A1 expressed
248
 
*as listed in the Rat Genome Database
210
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The study described in this chapter aims to establish baseline levels for a 
maximum number of CYPs in male and female Wistar rats, and examine their 
consistency between different rat deliveries. CYP gene expression can be assessed at 
different levels, namely enzyme activity, protein and mRNA.  
Although enzyme activities are closer to the phenotype, their measurement 
relies on the identification of substrate biotransformations specific to each isoform. 
Probe substrates have been identified for the most common CYPs involved in drug 
metabolism249,250 but are not available for all the existing isoforms, and this technique 
was therefore not suitable to profile the 89 rat isoforms.  
The Western blot method251 has been widely employed to evaluate the 
expression of specific CYPs252-258, but it requires antibodies specific to each isoform 
and is a very time-consuming technique for the assessment of a large number of 
proteins, as only one isoform is typically quantified per analysis. Proteomic 
approaches, based on electrophoretic separation followed by mass spectrometry (MS) 
analysis of the gel fragments (identification of CYPs by their peptide mass fingerprints), 
have recently been used to profile CYPs259-262. However, these techniques were not 
widespread at the start of this PhD and developing them in our laboratory was not 
practically feasible due to instrumentation demands.  
Quantification of mRNA can be performed by various methods, including 
Northern blotting, ribonuclease protection assays, in situ hybridisation, DNA 
microarrays and reverse transcription real time polymerase chain reaction (qRT-
PCR)162 (section II.2.1). For this study, it was decided to quantify CYP gene expression 
at the mRNA levels with qRT-PCR as it offered the possibility of specifically evaluating 
all the rat CYP isoforms in a reproducible, sensitive and relatively high-throughput 
manner. This approach had previously been employed to assess mRNA expression of 
a wide range of human CYP isoforms in various organs257,263. However, it is, to the best 
of our knowledge, the first time it has been applied to evaluate simultaneously all the 
CYP isoforms in rat liver, i.e. CYPs involved in drug metabolism and therefore 
commonly assessed in drug development studies, as well as all the other CYPs, 
involved essentially in endogenous metabolism and less frequently studied.  
This investigation was performed on four rat deliveries to examine the 
consistency of CYP expression between deliveries. Although rats employed within a 
single preclinical study are generally coming from the same delivery, it appeared of 
interest to determine how consistent these deliveries were in terms of CYP expression 
and metabolic profiles, to ensure that results obtained during a study were delivery-
independent and to assess the possibility of combining data from different studies.   
The in-life phase described in the experimental section of this chapter (section 
V.2.1) was designed to encompass both aims of this thesis project: evaluate liver CYP 
profiles in rats and assess the possibility of predicting these profiles from 
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corresponding metabolic profiles in serum, urine and liver. Samples were therefore 
collected for both CYP profiling and metabolic profiling. This chapter focuses on the 
CYP expression results, while the next chapter is dedicated to the metabolic profiling 
results and the relationships between CYP profiles and metabolic profiles. Results from 
these two chapters will be discussed together in Chapter VII.  
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V.2. Experimental section 
V.2.1. Animal handling  
I wrote this protocol in collaboration with Catherine Spire (Biologie Servier (BS), 
Gidy, France) and Claire Boursier-Neyret (Technologie Servier (TES), Orleans, 
France). The in-life phase took place at BS under the supervision of Catherine Spire.  
The study was conducted on 20 male and 20 female Wistar rats, divided into 
four groups of 5 males and 5 females corresponding to four separate delivery batches 
of animals. The same protocol was applied for each group, with intervals of 2 to 6 
weeks between groups.  
After 5 to 7 days of acclimatisation, the animals were housed in metabolic cages 
at the start of the experiment (at 9 weeks old) until 24 hours afterwards (termination 
time). Rat body weights were recorded on Day 1 before starting the experiment. Water 
was available ad libitum throughout the duration of the study. Food was available ad 
libitum for the first 8 hours, after which time the animals were fasted for the following 16 
hours (i.e. until termination time).  
Urine was collected separately over the intervals 0-8 hours and 8-24 hours. 
Urine weights and specific gravity were immediately measured. The urine was then 
centrifuged and aliquoted.  
Blood sampling was performed at 8 h and 24 h on isofluorane anaesthetised 
rats at the jugular vein into tubes containing a serum separator, which were centrifuged 
rapidly after clotting. Serum was then collected and aliquoted. 
 After collection, all urine and serum samples were frozen and stored at −40°C 
or below until metabolic profiling analysis.   
Rats were killed 24 h after starting the experiment under isoflurane anaesthesia. 
Livers were collected, washed using RNAse free water at 4°C and weighed. For CYP 
mRNA expression analysis, two portions of around 50 mg were collected from the left 
lobe, cut into fragments and put into tubes containing 1 ml of RNA Later (for RNAse 
free storage conditions). They were stored at 4°C for 24 hours then at −20°C until CYP 
mRNA analysis. For metabolic profiling analysis, sections of the left lobe of around 150 
mg each were placed into cryotubes, flash frozen in liquid nitrogen within 15 minutes of 
exsanguination and subsequently stored at -80°C. The rest of the left lobe was also 
flash frozen in liquid nitrogen and stored at -80°C for hepatic enzyme evaluation.  
Rats were numbered as follows:  
- Delivery 1 (G1):    males = rats 1 to 5  females = rats 21 to 25 
- Delivery 2 (G2):    males = rats 6 to 10  females = rats 26 to 30 
- Delivery 3 (G3):      males = rats 11 to 15  females = rats 31 to 35 
- Delivery 4 (G4):    males = rats 16 to 20  females = rats 36 to 40 
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V.2.2. CYP mRNA expression 
I conducted these experiments with Marie-Pierre Renaud at BS, under the 
supervision of Catherine Spire. Total RNA was extracted from the liver samples and 
reverse transcribed to cDNA. cDNA of targeted CYPs was then amplified and 
quantified by quantitative real-time polymerase chain reaction (qPCR). This last step 
was performed using custom 384-well microfluidic cards (TaqMan® Low Density Arrays 
(TLDA) from Applied Biosystems). These TLDA cards enable 384 qPCRs to take place 
simultaneously: 8 samples can be run in parallel on 48 wells, each well being pre-
loaded with a TaqMan® gene expression assay. One assay consists of a fluorescent-
labelled probe and amplification primers (forward and reverse), which are specific to 
the targeted CYP.  
 
V.2.2.1. Design of the TLDA cards for the qPCR 
I designed the TLDA cards with the help of Nicolas Sajot from BS. In the first 
step, all Taqman® assays available for rat CYPs were listed from the Applied 
Biosystem website (www3.appliedbiosystems.com). 353 assays were found, 
corresponding to 81 single CYP isoforms, with one to eleven assays available for each 
isoform. For an 82nd isoform, Cyp4f37, the only assay available was targeting both 4f37 
and 4f5 isoforms. Out of the 88 isoforms known in rat (Table V-1), there was no assay 
available for CYPs 2b15, 2b31, 2c24, 2ab1, 2ac1, 3a73 and 26c1. Conversely, one of 
the 82 isoforms found on the Applied Biosystem website was not listed in Table V-1 as 
it was targeting a pseudogene (Cyp2j5-ps).  
When several assays targeting the same reference sequence (RefSeq264) were 
available for one isoform, assay selection was performed based mainly on the assay 
location (preference for probes spanning an exon junction when available, as they do 
not detect genomic DNA) and the number of GenBank transcripts recognised. If a 
combination of these two criteria was not sufficient to discriminate between two assays, 
the shorter targeted sequence was chosen, as shorter sequences usually produce 
better efficiency265.  
As the TLDA cards consist of 8 sample loading ports connected to 48 wells, the 
number of selected assays had to be a multiple of 48. In our case, as assays had been 
found for 82 CYP isoforms, it was decided to select 96 assays. Among these 96 
assays, it was necessary to include some reference control genes for normalisation of 
cDNA concentration, as explained in section II.2.3. Based on previous laboratory 
experience, three reference control genes were chosen for the cards: 18S, Gapdh and 
Rplp2. After this, it was possible to select 93 assays for the 82 CYPs. Therefore, for 
some genes for which both selection criteria could not be filled in simultaneously, 
several assays were retained (Table V-2). 
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Table V-2. Taqman® assays employed in the study 
 Gene RefSeq Assay ID
c
   Gene RefSeq Assay ID
c
 
1 Cyp1a1 NM_012540 Rn00487218_m1  49 Cyp3a62 NM_001024232 
 
Rn01409583_m1 
2 Cyp1a2 NM_012541 
 
Rn00561082_m1  50 Cyp4a1 NM_175837 
 
Rn00598510_m1 
3 Cyp1b1 NM_012940 
 
Rn00564055_m1  51 Cyp4a2 NM_001044770 
 
Rn01417066_m1 
4 Cyp2a1 NM_012692 
 
Rn00562200_m1  52 Cyp4a3 NM_175760 
 
Rn00598411_m1 
5 Cyp2a2 NM_012693 
 
Rn00562207_m1  53 Cyp4a8 NM_031605 
 
Rn00581081_m1 
6 Cyp2a3 NM_012542 
 
Rn00561086_m1  54 Cyp4b1 NM_016999 
 
Rn00566515_m1 
7 Cyp2b1 NM_001134844 
 
Rn01457875_m1  55 Cyp4f1 NM_019623 
 
Rn00571492_m1 
8 Cyp2b2 XM_001062335 
 
Rn02786833_m1  56 Cyp4f4 NM_173123 
 
Rn00597513_m1 
9 Cyp2b3 NM_173294 
 
Rn01476085_m1  57 Cyp4f5 NM_173124 
 
Rn00687553_m1 
10 Cyp2b3 NM_173294 
 
Rn02786829_sH  58
a
 Cyp4f5;Cyp4f37 NM_173124 | 
XM_001077664 
Rn00687557_gH 
11 Cyp2b12 NM_017156 
 
Rn00755182_g1  
12 Cyp2b21 NM_198733 
 
Rn01475826_m1  59 Cyp4f6 NM_153318 
 
Rn00686847_m1 
13 Cyp2c6 XM_001066767 
 
Rn02786821_m1  60 Cyp4f17 XM_576190 
 
Rn01408612_m1 
14 Cyp2c7 NM_017158 
 
Rn01529602_mH  61 Cyp4f18 NM_001033686 
 
Rn01420067_m1 
15 Cyp2c11 NM_019184 
 
Rn00569868_m1  62 Cyp4f39 XM_234837 
 
Rn01408191_m1 
16 Cyp2c12 NM_031572 
 
Rn00755856_m1  63 Cyp4f40 NM_001109360 
 
Rn01408132_m1 
17 Cyp2c13 NM_138514 
 
Rn00593388_g1  64 Cyp4v3 XM_001064152 
 
Rn01488162_m1 
18 Cyp2c22 NM_138512 
 
Rn00593377_m1  65 Cyp4x1 NM_145675 
 
Rn00595521_m1 
19 Cyp2c23 NM_031839 
 
Rn00582954_m1  66 Cyp5a1 (Tbxas1) NM_012687 
 
Rn00562160_m1 
20 Cyp2c37 XM_001063361 
 
Rn02786817_m1  67 Cyp7a1 NM_012942 
 
Rn00564065_m1 
21 Cyp2c79 XM_219933 
 
Rn02047662_s1  68 Cyp7b1 NM_019138 
 
Rn01461859_m1 
22 Cyp2c80 NM_001106213 
 
Rn01454089_m1  69 Cyp7b1 NM_019138 
 
Rn01461862_m1 
23 Cyp2d1 NM_153313 
 
Rn01775090_mH  70 Cyp8a1 (Ptgis) NM_031557 
 
Rn00580687_m1 
24 Cyp2d2 NM_012730 
 
Rn00562419_m1  71 Cyp8b1 NM_031241 
 
Rn00579921_s1 
25 Cyp2d3 NM_173093 
 
Rn00597330_m1  72 Cyp11a1 NM_017286 
 
Rn00568733_m1 
26 Cyp2d4 NM_138515 
 
Rn01504629_m1  73 Cyp11a1 NM_017286 
 
Rn01421681_g1 
27 Cyp2d4 NM_138515 
 
Rn00696505_g1  74 Cyp11a1 NM_017286 
 
Rn01421674_m1 
28 Cyp2d5 NM_173304 
 
Rn01790051_s1  75 Cyp11b1 NM_012537 
 
Rn02607234_g1 
29 Cyp2e1 NM_031543 
 
Rn00580624_m1  76 Cyp11b2 NM_012538 
 
Rn01767818_g1 
30 Cyp2f4 NM_019303 
 
Rn00570779_m1  77 Cyp11b3 NM_181824 
 
Rn00822066_g1 
31 Cyp2g1 NM_012787 
 
Rn01454738_m1  78 Cyp17a1 NM_012753 
 
Rn00562601_m1 
32 Cyp2j3 NM_175766 
 
Rn00598500_m1  79 Cyp17a1 NM_012753 
 
Rn00664858_m1 
33 Cyp2j4 NM_023025 
 
Rn00576482_m1  80 Cyp17a1 NM_012753 
 
Rn01444704_g1 
34 Cyp2j5-ps XM_001062259 
 
Rn01771422_m1  81 Cyp19a1 NM_017085 Rn00567222_m1 
35 Cyp2j10 XM_233199 
 
Rn01433143_m1  82 Cyp19a1 NM_017085 Rn01422547_m1 
36 Cyp2j13 XM_233198 
 
Rn01763811_g1  83 Cyp20a1 NM_199401 
 
Rn01644438_g1 
37 Cyp2j16 XM_578474 
 
Rn01433366_m1  84 Cyp21a1 NM_057101 
 
Rn00588996_g1 
38 Cyp2r1 NM_001108499 
 
Rn01754616_m1  85 Cyp24a1 NM_201635 
 
Rn01423143_m1 
39 Cyp2s1 NM_001107495 
 
Rn01475871_m1  86 Cyp26a1 NM_130408 
 
Rn00590308_m1 
40 Cyp2s1 - Rn01476074_s1  87 Cyp26b1 NM_181087 
 
Rn00710376_m1 
41 Cyp2t1 NM_134369 
 
Rn00592635_m1  88 Cyp27a1 NM_178847 
 
Rn00710297_m1 
42 Cyp2u1 NM_001024779 
 
Rn01522408_m1  89 Cyp27b1 NM_053763 
 
Rn00587137_m1 
43 Cyp2w1 XM_221971 
 
Rn01412757_m1  90 Cyp27b1 NM_053763 
 
Rn01647147_g1 
44 Cyp3a2 NM_153312 
 
Rn00756461_m1  91 Cyp39a1 NM_001106893 
 
Rn01757120_m1 
45 Cyp3a2 NM_153312 
 
Rn01412889_mH  92 Cyp46a1 NM_001108723 
 
Rn01430188_m1 
46 Cyp3a9 NM_147206 
 
Rn00595977_m1  93 Cyp51 NM_012941 
 
Rn01526553_m1 
47 Cyp3a18 NM_145782 
 
Rn00595752_m1  94 18S X03205
b
 Hs99999901_s1 
48 Cyp3a23(3a1) NM_013105 
 
Rn01412959_g1  95 Gapdh NM_017008 
 
Rn99999916_s1 
     96 Rplp2 NM_001030021 
 
Rn01479927_g1 
RefSeq: Reference Sequence from the National Center for Biotechnology Information (NCBI) database
264
  
a
 Assay 58, targeting both CYPs 4f5 and 4f37, was chosen as no other assays were available for Cyp4f37. 
Another assay (number 57) had been selected for Cyp4f5. 
b
 GenBank reference 
c
 Assay ID legend (adapted from “Online Selection Guide for TaqMan
®
 Gene Expression Assays” available on 
www3.appliedbiosystems.com): 
Rn=Rattus norvegicus / Hs=Homo sapiens 
_m: probe spans an exon junction and will not detect genomic DNA 
_s: probes and primers are designed within a single exon. Such assays will detect genomic DNA. 
_g: may detect genomic DNA. The assay probe and primers may be within a single exon. 
_mH, _sH, or _gH: assay designed to a transcript belonging to a gene family with high sequence homology 
(designed to give between 1,000–30,000-fold greater discrimination from the closest homologous transcript) 
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V.2.2.2. Total RNA extraction 
Liver samples (~50 mg) were collected from the RNAlater and homogenised in 
750 µl Qiazol in a TissueLyser (Qiagen) (25 Hz, 10 min with inversion of the two racks 
after 5 min). Homogenates were left 5 min at room temperature, then 150 µl of 
chloroform was added. Samples were vortexed and centrifuged (12 000g, 4°C, 5 min). 
Approximately 300 µl of the aqueous phases were collected and transferred in 2 ml 
tubes. Total RNA was extracted from the aqueous phases with the Biorobot M48® 
using the “MagAttract RNA Universal Tissue M48 kit®” (Qiagen) in a unique batch for 
the 40 samples.  
A volume of 1.5 µl of each sample was analysed with a NanoDrop® ND-1000 
spectrophotometer (NYXOR Biotech) to determine the concentration and assess the 
quality of the extracted total RNA. Criteria for acceptable quality were: OD260nm/ OD280nm 
within the range 1.9-2.2, and OD260nm/ OD230nm within the range 1.8-2.3 (OD260nm (optical 
density at 260 nm) corresponds to nucleic acids, OD280nm to proteins and OD230nm to 
aromatic compounds). Nuclease free water was then added to each sample to 
normalise the concentration to 100 ng(total RNA)/µL. RNA quality of the normalised 
samples was then further controlled using an Agilent 2100 Bioanalyzer®. Criteria for 
acceptable quality were: correct RNA profiles, RNA Integrity Number (RIN) > 7, and 
rRNA ratio [28S/18S] close to 1.5. 
 
V.2.2.3. RNA reverse transcription and qPCR 
Before RNA reverse transcription and quantification by qPCR for all samples, a 
preliminary study (pre-study) was performed on four arbitrarily selected samples (1 
male and 1 female from the first and fourth delivery batches) to check the absence of 
genomic DNA contamination and potential inhibitors of qPCR reaction, and to evaluate 
the optimal quantity of reverse transcribed RNA for the qPCR. Three reference control 
genes were quantified in this pre-study (18S, Gapdh and Rplp2) with the same assays 
as loaded in the TLDA cards designed for the study.   
 
V.2.2.3.1. Reverse transcription (RT) 
Reverse transcription (RT) was performed on the “Mastercycler 5333®” 
(Eppendorf) using the “High capacity cDNA reverse transcription kit” (Applied 
Biosystems). With the kit, a RT mix was prepared containing buffer, deoxynucleotides 
triphosphate, random primers, reverse transcription enzyme, RNAse inhibitor and 
water. The program used for the RT was: 10 min at 25°C, followed by 120 min at 37°C, 
then 5 sec at 85°C and finally 4°C until collection of the samples, which were then 
stored at −20°C until use for amplification.  
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a) Reverse transcription step in the pre-study: 
The RT was performed for the four arbitrarily selected samples using 500 ng of 
total RNA in a final volume of 50 µl (final concentration 10 ng/µl), with and without the 
reverse transcription enzyme. Tubes without enzymes (RT-negative) were used as a 
quality control in the amplification step to check the absence of genomic DNA 
contamination. A commercial human control RNA (referred later on in this thesis as 
“cDNA control”) was used as a positive control for the RT step. 
 
b) Reverse transcription step in the study: 
The RT was performed on the 40 individual rat samples using 500 ng of total 
RNA in a final volume of 50 µl (final concentration 10 ng/µl). Additionally, RT-negative 
controls were performed with the 4 samples selected in the pre-study (no reverse 
transcription enzyme in the tubes). RT for the 44 tubes was performed in one batch.  
 
V.2.2.3.2. Amplification by qPCR 
The qPCR amplification was performed on a “Fast-real time 7900 HT” (Applied 
Biosystems).  
 
a) Amplification step in the pre-study: 
The pre-study was performed in one “Optical 96-well fast thermal cycling plate” 
(Applied Biosystems) using “Taqman® Fast universal PCR Master Mix 2X” (Applied 
Biosystems) and AmpErase UNG (Applied Biosystems). Three Taqman® assays 
(Applied Biosystems) were used in this pre-study, targeting 18S, Rplp2 and Gapdh 
genes (rows 94 to 96 in Table V-2). For each cDNA sample, a series of five dilutions 
(1/10) was performed with nuclease free water, corresponding to equivalent 
concentrations of RNA ranging from 10 000 to 1 pg/µl. A volume of 0.5 µl of each 
dilution was submitted to amplification in a final volume of 20 µl/well. Various positive 
and negative controls were subjected to similar qPCR conditions, as detailed below: 
  Negative controls: 
- No template control: amplification performed on water instead of cDNA sample  
check the absence of DNA contamination of the mix 
- RT-negative controls: amplification performed on RNA samples “reverse-
transcribed” without reverse transcription enzyme  check the absence of genomic 
DNA  
- RT-minus controls: amplification performed directly on RNA samples without the RT 
step  check the absence of genomic DNA  
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  Positive controls: 
- cDNA control obtained from RNA control in the RT step  positive control for the 
reverse transcription step 
- Commercial human cDNA  positive control for the amplification step 
 
For the 18S and Rplp2 genes, duplicates of the wells were performed in a 
second well plate for each sample (this could not be done for the Gapdh gene due to 
technical reasons). The run of the two plates was performed within a day with the 
following thermal cycling conditions: 2 min at 50°C (AmpErase UNG activation), then 
20 s at 95°C (enzyme activation), followed by 40 cycles consisting of 1 s at 95°C 
(denaturation) and 20 s at 60°C (extension). 
 
b) Amplification step in the study: 
The amplification step for the study was performed on the pre-designed TLDA 
cards (384 wells corresponding to 4 samples × 96 assays) using “Taqman® Universal 
Master Mix” (Applied Biosystems) and following the supplier’s instructions. The 40 
cDNA samples were allocated to the card loading ports to minimise potential analytical 
bias (factors taken into account for the allocation were gender, delivery group, 
extraction technician and termination time). Each card (1 to 10) was prepared and run 
twice independently: all the samples were run once, then the same card design was 
observed for the second run, with mirrored card order. Between both runs, a control 
card was amplified with the four RT-negative controls. The amplification run was 
performed on 3 to 5 cards per day over 5 days for a total of 21 cards with the following 
thermal cycling conditions: 2 min at 50°C (AmpErase UNG activation), then 10 min at 
94.5°C (enzyme activation), followed by 40 cycles consisting of 30 s at 97°C 
(denaturation) and 60 s at 60°C (extension). 
 
V.2.2.4. Data analysis 
The quantification of gene expression was performed with SDS Enterprise 2.2 
and RQ Manager 1.1 software programs (Applied Biosystems). This produced a table 
listing the CT (threshold cycle) values obtained in all samples for each gene.  
Forty amplification cycles were performed during the qPCR. Amplifications for 
which the fluorescence curve did not reach the threshold within the 40 cycles resulted 
in a CT value reported as “Undetermined” by the software. For calculation purposes, 
these values were replaced by 40 in the table.  
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  Pre-study: 
For the pre-study, performed on 96 well plates, genes with CT values higher 
than 35 were considered out of quantification range (as recommended by the supplier).  
For Rplp2 and 18s, the mean CT of the technical duplicates was calculated and 
used for further calculation.  
To determinate efficiency of each reference gene, CT values were plotted versus 
the log10 of RNA concentrations and linear regression was performed to obtain the 
qPCR dilution curve. When the reaction efficiency is 100%, the amplicon quantity 
doubles every cycle, which results in a 10-fold increase every 3.32 cycles (=log2 10). 
Efficiency was estimated with the formula: E=10−1/slope−1. A dilution curve slope of -3.32 
indicates 100% efficiency. Dilution curves were considered as acceptable when 
efficiency of amplification was between 85% and 120% (for 4 dilution points) or 
between 92% and 110% (for 5 dilution points) and when the coefficient of 
determination R2 was higher than 0.99.  
 
  Study:  
For the study, performed on TLDA cards, genes with CT values higher than 32 
were considered out of quantification range (as recommended by the supplier).  
The choice of the reference control gene (among the 3 present in the TLDA 
cards) was based on a stability measure, calculated for each gene, which has been 
developed by Vandesompele167. For control gene i, another control gene j was used as 
normaliser and ΔCTij = CTi − CTj  was calculated for the 40 samples (taking the mean CT 
between duplicates for each sample). The standard deviation σij of this ΔCTij among 
samples was then calculated. If the two genes were both ideal reference control genes, 
supposed to exhibit constant expression, this ΔCTij should be the same for all samples, 
and its standard deviation should be zero. The variation reflects that one (or both) 
gene(s) is (are) not constantly expressed. The calculation was repeated for the gene 
pair (i,k) and the average of σij and σik was used as the stability measure for control 
gene i. Same was done for control genes j and k. The gene with the lowest stability 
measure was selected as reference gene.  
For each assay and sample, ΔCT values were calculated as the difference 
between the target gene and the reference control gene. After checking the standard 
deviation of these ΔCT among replicate samples, the means of the two replicates were 
considered for the analysis.  
For each gender, the median CT of the 20 rats was calculated for each assay, 
and these medians were used to determine the genes showing sufficient expression for 
relative quantification to be valid. For these selected assays, normalised expressions 
were calculated with the formula 2−ΔCT and the ratios of individual rat expressions to the 
median expression in males or females were calculated and plotted for each assay.  
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PCA was performed on the normalised gene expressions using UV scaling to 
visualise the data and investigate gender differences. Univariate analysis of gender 
differences was also conducted, using the non-parametric Wilcoxon test. P-values 
were adjusted for multiple comparisons with dependencies using Benjamini-Yekutieli 
correction179.   
Ratios of gene expression between genders were first calculated based on 
gender median values, as medians are more robust to outliers than means. For 
comparison purposes, and because this is common practice in qPCR studies and 
allows calculation of a range for the ratios, they were also calculated based on gender 
means. The ratio ranges were calculated as follows: given one assay a, the mean CT 
was calculated for males (mCT(aM)) and for females (mCT(aF)), as well as the 
corresponding standard deviations σCT(aM) and σCT(aF). This was repeated for the Rplp2 
reference control gene, giving the mean mCT(rM) for males and mCT(rF) for females, with 
corresponding standard deviations σCT(rM) and σCT(rF). For both genders, the mean ΔCT 
values (mΔCT(M) and mΔCT(F)) were then calculated, by subtracting the mCT(r) from the 
mCT(a). The standard deviations of the ΔCT values (σΔCT(M) and σΔCT(F)) were 
calculated for each gender as (σCT(a) 
2
 + σCT(r) 
2)1/2. The ΔΔCT (section II.2.3) was 
calculated using either the mΔCT(M) or the mΔCT(F) as a calibrator. For instance, taking 
males as calibrator, ΔΔCT(F) = mΔCT(F) − mΔCT(M) and ΔΔCT(M) = mΔCT(M) − mΔCT(M) = 0.  
Standard deviation of ΔΔCT(F) (σΔΔCT(F)) was equal to σΔCT(F) and standard deviation of 
ΔΔCT(M) (σΔΔCT(M)) was equal to σΔCT(M), as calculation of ΔΔCT involved subtraction of 
an arbitrary constant. Gender ratios were calculated with 2−ΔΔCT, and the ranges for the 
ratios were calculated using 2−ΔΔCT+σΔΔCT and 2−ΔΔCT−σΔΔCT. 
 
 
V.2.3. Evaluation of CYP-related activities  
Although it was not possible to assess the expression of all CYPs by activity 
assays, it was nevertheless decided to measure activities for a few CYPs usually 
evaluated in drug development studies to examine their consistency with the mRNA 
results. The selected CYPs were 1a1/2, 2b1, 2d1, 2e1 and 3a1/2.  
Table V-3 lists the specific substrates employed for each CYP isoform. For 
subfamily 1a, both 1a1 and 1a2 isoforms catalysed the O-deethylation of phenacetin. 
Similarly, for subfamily 3a, both 3a1 and 3a2 isoforms catalysed the hydroxylation of 
midazolam.  
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Table V-3. Specific substrates employed to measure related activity of 5 CYP isoforms 
Cytochrome P450 Specific substrate Related activity 
1a1/2 Phenacetin Phenacetin O-deethylation 
2b1 Bupropion Bupropion hydroxylation 
2d1 Dextromethorphan Dextromethorphan O-demethylation 
2e1 Chlorzoxazone Chlorzoxazone hydroxylation 
3a1/2 Midazolam Midazolam hydroxylation 
 
 
The measurement of CYP activities was conducted by one of TES’s 
subcontractors (Xenoblis, Saint-Gregoire, France). Briefly, microsomes were prepared 
from the liver samples collected during the in-life phase. CYP activities were measured 
in triplicate on each microsome preparation. Phenacetin, bupropion, dextromethorphan 
and midazolam were incubated as a cocktail in presence of the microsomes to assess 
CYP 1a1/2, 2b1, 2d1 and 3a1/2-related activities respectively. Chlorzoxazone was 
incubated alone with the microsomes to assess Cyp2e1-related activity. Metabolites 
specific to each CYP isoform were quantified by LC-MS/MS. The measured enzyme 
activities were expressed as pmol/min/mg of protein.  
Mean and standard deviation for male and female groups were calculated for 
each CYP isoform. Comparison between genders was performed using a Student’s t-
test for unequal variance with adjustment of p-values for multiple comparisons using 
Holm-Bonferroni correction178. For each gender, differences between deliveries were 
investigated using a Kruskal-Wallis test with adjustment of p-values for multiple 
comparisons using Holm-Bonferroni correction. 
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V.3. Results 
V.3.1. CYP mRNA expression 
Assessment of liver CYP mRNA expression was performed on 20 male (M) and 
20 female (F) Wistar rats, corresponding to four delivery batches of 5 males and 5 
females (G1 to G4). Evaluation of RNA quality after total RNA extraction showed that 
all the 40 samples satisfied the quality control parameters (correct RNA profiles, RNA 
Integrity Number (RIN) range: 7.9-9.5, OD260nm/OD280nm range: 2.13-2.14, 
OD260nm/OD230nm range: 2.17-2.25, ratio 28S/18S close to 1.5) and were therefore of 
acceptable quality for qRT-PCR. 
 
V.3.1.1. Pre-study results 
A pre-study was performed in order to check the absence of genomic DNA 
contamination and qCPR inhibitors, and to assess the optimal RNA quantity for the 
qPCR. This pre-study was performed on five dilutions of four arbitrarily selected cDNA 
samples, corresponding to rats 1 (M-G1), 19 (M-G4), 24 (F-G1) and 38 (F-G4), and on 
their corresponding RT-negative controls (RNA “reverse transcribed” with no reverse 
transcription enzyme) and RT-minus controls (RNA non reverse transcribed). 
Amplification was also performed on water (NTC: no template control) and on human 
positive controls: cDNA control (reverse transcribed RNA) and commercial cDNA.  
The CT (Threshold Cycle) obtained for the NTC control was reported as 
“Undetermined” for Gapdh and Rplp2 (meaning that the fluorescence curve did not 
reach the threshold within the 40 cycles) and was > 36 for 18S, indicating the absence 
of non-specific fluorescence and DNA contamination of the PCR mix.  
CT values obtained for the positive controls with the 18S gene (10.9 for cDNA 
control and 13.2 for commercial cDNA) were consistent with those usually obtained by 
the laboratory and validated the RT and qPCR steps. As expected, these human 
positive controls were not amplified by the Rplp2 and Gapdh assays, which were rat-
specific.  
CT values obtained for the serial dilutions of the samples and the RT-negative 
and RT-minus controls are listed in Table V-4. CT values of negative controls were 
close to or above the limit of quantification (=35) for Rplp2 and Gapdh, and very high 
compared with the respective samples for 18S. Such high differences indicated the 
absence of genomic contamination in the samples.  
The serial dilutions of the samples were used to check the absence of qPCR 
inhibitors and the amplification efficiency for each assay. CT differences (ΔCT) between 
consecutive dilutions (1/10) are displayed in Table V-4. For Gapdh, ΔCT values of the 
first dilution were slightly higher than that of the second, indicative of a potential 
Assessment of cytochrome P450 expression in male and female Wistar rats 
152 
 
inhibition during the amplification for the non-diluted samples (C0). When compared to 
the theoretical value for a 1/10 dilution (ΔCT = 3.32), ΔCT between C2 and C1 were in 
the range, except for 18S. ΔCT between C3 and C2 were high for Gapdh, as values 
were close to the quantification limit. Therefore, it was decided to dilute the study 
samples at 1/10 (C1).  
Amplification efficiency (Table V-4) was clearly better for Rplp2 (~100%) 
compared with 18S (~84%) and Gapdh (~83%). The coefficient of determination R² 
was good for all genes (>0.995). Thus, Rplp2 appeared as the best choice for the 
reference control gene in the study.  
 
 
Table V-4. CT values of samples and negative controls in the pre-study, together with 
amplification efficiency 
Assay ID Rplp2 Gapdh 18S 
Sample  1 19 24 38 1 19 24 38 1 19 24 38 
C0 23.8 24.4 24.0 24.5 22.3 22.4 22.5 22.3 9.6 9.3 9.8 9.8 
C1 27.6 27.2 27.2 27.4 25.8 25.9 26.2 25.8 13.4 13.1 13.9 13.6 
C2 30.6 30.6 30.7 30.9 29.3 29.4 29.8 29.2 17.2 16.8 18.2 17.6 
C3 34.2 33.9 33.9 34.3 33.9 34.0 34.3 33.6 20.9 20.5 21.8 21.5 
C4 Out Out Out Out Out Out Out Out 24.4 23.8 25.1 25.2 
RT-negative Out Out Out Out 32.5 Out Out Out 30.7 31.6 30.8 32.1 
RT-minus Out Out Out Out 33.1 Out 34.9 Out 29.7 30.0 30.5 30.8 
                          
C1-C0 3.9 2.8 3.2 3.0 3.6 3.5 3.8 3.5 3.8 3.8 4.1 3.8 
C2-C1 3.0 3.4 3.5 3.5 3.4 3.5 3.6 3.4 3.9 3.7 4.2 4.0 
C3-C2 3.5 3.3 3.3 3.3 4.6 4.6 4.5 4.4 3.7 3.7 3.6 3.9 
C4-C3 NA NA NA NA NA NA NA NA 3.4 3.3 3.3 3.7 
                          
R
2
 0.998 0.998 1.000 0.999 0.995 0.995 0.998 0.996 1.000 0.999 0.997 1.000 
Amplification 
efficiency 
0.96 1.06 1.00 1.01 0.83 0.82 0.81 0.85 0.86 0.89 0.82 0.81 
C0 corresponds to the non-diluted samples, C1 to C4 are serial 1/10 dilutions.  
CT > 35 are reported as “Out” (out of the quantification range following the supplier’s recommendations) 
ΔCT values > 4 are shown in bold. 
 
 
V.3.1.2. Study results 
The study was performed on the 40 samples in duplicate and on 4 RT-negative 
controls. The individual CT values obtained for all assays are reported in Appendix IV. 
For amplification in TLDA cards, the supplier recommends to consider the genes with 
CT values higher than 32 as out of the quantification range.  
 
V.3.1.2.1. RT-negative controls 
For the 93 target assays, almost all the RT-negative CT values for the 4 samples 
were undetermined, meaning that the fluorescence curve had not reached the 
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threshold after 40 cycles. Only 7 CT values (corresponding to 5 different assays) were 
determined (out of 372), all out of the range of quantification and therefore not reliable 
(>34.4). Four of these CT values corresponded to two unexpressed or weakly 
expressed assays in the real samples, which would not be considered for 
quantification. For the other three values, the differences between the RT-negative 
value and the maximum CT value obtained for the real samples were 8.5, 10 and 13 
cycles, which was considered acceptable (expression at least 360 times higher in the 
samples compared to the negative control).  
For the 3 reference control genes, high CT values were obtained as well for the 
RT-negative controls: ~27 for 18s (18 cycle difference with the lowest expressed 
sample), ~34 for Gapdh (9 cycle difference with the lowest expressed sample) and ~37 
for Rplp2 (11 cycle difference with the lowest expressed sample). This was indicative of 
the absence of transcripts and/or genomic DNA contamination and validated the use of 
the CT values obtained for the samples.  
 
V.3.1.2.2. Choice of reference control gene 
Calculation of the mean standard deviation between duplicates for each 
reference control gene present in the TLDA cards produced values of 0.17 for 18S, 
0.16 for Gapdh and 0.12 for Rplp2. After calculating the duplicate mean CT value for 
each sample, the coefficient of variation among the 40 samples was calculated: 1.74% 
for 18S, 1.29% for Gapdh and 1.19% for Rplp2. These results demonstrated low 
variation of the three genes among replicates and among samples, whatever the 
gender of the rat and the delivery group.  
Control stability measures, calculated as described in the experimental section 
of this chapter (section V.2.2.4), were very similar for the three genes: 0.26 for 18S, 
0.27 for Gapdh and 0.25 for Rplp2. Genes with the lowest stability measure are 
considered as having the most stable expression. Rplp2, which had been suggested as 
reference control gene by the pre-study, showed lowest variation between replicates 
and between samples and lowest control stability measure. It was therefore used for 
normalisation of the target genes in the study.  
 
V.3.1.2.3. Analysis of technical replicates 
ΔCT (=CTassay − CTRplp2) standard deviations of technical replicates calculated for 
each rat and each assay were generally lower than 0.5, indicative of acceptable 
reproducibility. Warning on replicate reproducibility was mainly observed for CT values 
close or above the limit of quantification of 32 cycles. For these warnings, when 
replicate mean ΔCT values were compared to other replicate mean ΔCT values within 
the group, no salient differences were observed. Therefore no replicates were excluded 
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from the analysis. From this point, CT and ΔCT are considered the mean of both 
replicate values.  
 
V.3.1.2.4. Assay expression 
For each gender, the median CT of the 20 rats was calculated for each assay. 
Based on these values, the 93 assays were separated as follows: 
- median CT for both males and females above 37 (with most of them equal to 40): 
genes considered as unexpressed or at levels too low to be detected (19 assays, pink-
coloured in Table V-5) 
- one gender median CT between 32 and 35, and the other one above 31: genes 
considered as expressed but at too low levels for quantification and to draw any 
reliable conclusion (12 assays, orange-coloured in Table V-5) 
- at least one gender median below 31: genes considered as expressed and valid for 
relative quantification (62 assays, blue-coloured in Table V-5, corresponding to 55 
different CYPs (56 if including Cyp4f37, which was not specifically targeted))  
 
As expected, no mRNA expression was observed for the pseudo-gene Cyp2j5-
ps. For genes amplified with 2 or 3 different primers, CT values were generally 
consistent, except for Cyp27b1, for which no values were obtained for any sample with 
the _m1 primer, whereas all values were between 32 and 36 (except 4/80) for _g1 
primer. This difference might be due to amplification of genomic DNA with the _g1 
primer (while _m1 primers do not amplify genomic DNA), but this was unlikely as the 
RT-negative controls were all negative (no CT values). Although the reference 
sequence (RefSeq) was the same for both primers, the _m1 primer was designed to 
amplify only one GenBank mRNA transcript, while the _g1 primer amplified this 
transcript plus a second one. A possible explanation was that only the second 
transcript was present in the samples. Another explanation was that the efficiency was 
better for the _g1 assay. As none of these two assays was valid for quantification 
(median CT > 33), they were both excluded, therefore this difference did not have an 
impact on the subsequent data analysis. 
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Table V-5. Median CT values for males and females and classification of gene 
expression 
Cytochrome 
P450s 
Assay ID 
Med. 
CT 
M 
Med. 
CT 
F  
Cytochrome 
P450s 
Assay ID 
Med. 
CT 
M 
Med. 
CT 
F 
Cyp1a1 Rn00487218_m1 29.0 29.6  Cyp4a1 Rn00598510_m1 22.1 21.9 
Cyp1a2 Rn00561082_m1 19.4 19.3  Cyp4a2 Rn01417066_m1 18.0 20.5 
Cyp1b1 Rn00564055_m1 35.1 34.8  Cyp4a3 Rn00598411_m1 19.4 20.4 
Cyp2a1 Rn00562200_m1 22.4 20.9  Cyp4a8 Rn00581081_m1 27.6 32.4 
Cyp2a2 Rn00562207_m1 22.5 29.6  Cyp4b1 Rn00566515_m1 26.9 27.2 
Cyp2a3 Rn00561086_m1 40.0 37.3  Cyp4f1 Rn00571492_m1 22.8 22.9 
Cyp2b1 Rn01457875_m1 24.0 27.9  Cyp4f4 Rn00597513_m1 22.8 23.1 
Cyp2b2 Rn02786833_m1 26.0 28.2  Cyp4f5 Rn00687553_m1 28.2 29.8 
Cyp2b3 Rn01476085_m1 21.7 21.9  Cyp4f5;Cyp4f37 Rn00687557_gH 27.9 29.3 
Cyp2b3 Rn02786829_sH 24.7 25.0  Cyp4f6 Rn00686847_m1 24.8 24.8 
Cyp2b12 Rn00755182_g1 40.0 40.0  Cyp4f17 Rn01408612_m1 29.6 29.9 
Cyp2b21 Rn01475826_m1 40.0 40.0  Cyp4f18 Rn01420067_m1 33.8 33.1 
Cyp2c6 Rn02786821_m1 40.0 40.0  Cyp4f39 Rn01408191_m1 27.4 27.3 
Cyp2c7 Rn01529602_mH 18.1 16.6  Cyp4f40 Rn01408132_m1 40.0 40.0 
Cyp2c11 Rn00569868_m1 20.4 31.4  Cyp4v3 Rn01488162_m1 23.1 22.8 
Cyp2c12 Rn00755856_m1 24.9 17.5  Cyp4x1 Rn00595521_m1 39.1 37.5 
Cyp2c13 Rn00593388_g1 20.0 32.2  Cyp5a1(Tbxas1) Rn00562160_m1 29.8 29.3 
Cyp2c22 Rn00593377_m1 22.7 23.1  Cyp7a1 Rn00564065_m1 26.5 26.3 
Cyp2c23 Rn00582954_m1 21.3 21.2  Cyp7b1 Rn01461859_m1 28.2 28.3 
Cyp2c37 Rn02786817_m1 26.7 38.4  Cyp7b1 Rn01461862_m1 29.0 29.0 
Cyp2c79 Rn02047662_s1 33.2 31.7  Cyp8a1(Ptgis) Rn00580687_m1 28.6 26.8 
Cyp2c80 Rn01454089_m1 32.0 33.6  Cyp8b1 Rn00579921_s1 19.9 19.6 
Cyp2d1 Rn01775090_mH 22.0 22.6  Cyp11a1 Rn00568733_m1 40.0 40.0 
Cyp2d2 Rn00562419_m1 20.2 19.9  Cyp11a1 Rn01421674_m1 40.0 40.0 
Cyp2d3 Rn00597330_m1 21.3 22.3  Cyp11a1 Rn01421681_g1 40.0 40.0 
Cyp2d4 Rn01504629_m1 25.6 26.3  Cyp11b1 Rn02607234_g1 40.0 40.0 
Cyp2d4 Rn00696505_g1 26.1 26.9  Cyp11b2 Rn01767818_g1 35.0 36.8 
Cyp2d5 Rn01790051_s1 22.1 21.8  Cyp11b3 Rn00822066_g1 40.0 40.0 
Cyp2e1 Rn00580624_m1 18.8 18.7  Cyp17a1 Rn01444704_g1 24.8 23.9 
Cyp2f4 Rn00570779_m1 32.3 32.7  Cyp17a1 Rn00664858_m1 25.3 24.4 
Cyp2g1 Rn01454738_m1 40.0 40.0  Cyp17a1 Rn00562601_m1 26.2 25.4 
Cyp2j3 Rn00598500_m1 24.6 25.3  Cyp19a1 Rn00567222_m1 40.0 40.0 
Cyp2j4 Rn00576482_m1 23.6 24.0  Cyp19a1 Rn01422547_m1 40.0 40.0 
Cyp2j5-ps Rn01771422_m1 40.0 40.0  Cyp20a1 Rn01644438_g1 25.5 25.6 
Cyp2j10 Rn01433143_m1 30.7 31.7  Cyp21a1 Rn00588996_g1 31.1 30.4 
Cyp2j13 Rn01763811_g1 32.7 32.9  Cyp24a1 Rn01423143_m1 40.0 40.0 
Cyp2j16 Rn01433366_m1 40.0 40.0  Cyp26a1 Rn00590308_m1 31.1 28.1 
Cyp2r1 Rn01754616_m1 28.7 27.9  Cyp26b1 Rn00710376_m1 31.2 32.6 
Cyp2s1 Rn01476074_s1 32.2 32.8  Cyp27a1 Rn00710297_m1 21.8 21.8 
Cyp2s1 Rn01475871_m1 32.8 31.7  Cyp27b1 Rn01647147_g1 34.8 33.2 
Cyp2t1 Rn00592635_m1 24.6 23.8  Cyp27b1 Rn00587137_m1 40.0 40.0 
Cyp2u1 Rn01522408_m1 28.3 28.8  Cyp39a1 Rn01757120_m1 24.7 24.4 
Cyp2w1 Rn01412757_m1 40.0 40.0  Cyp46a1 Rn01430188_m1 33.4 33.6 
Cyp3a2 Rn01412889_mH 19.0 33.1  Cyp51 Rn01526553_m1 24.3 22.8 
Cyp3a2 Rn00756461_m1 19.3 33.2      
Cyp3a9 Rn00595977_m1 24.8 21.9      
Cyp3a18 Rn00595752_m1 22.0 26.1      
Cyp3a23(3a1) Rn01412959_g1 21.4 22.3      
Cyp3a62 Rn01409583_m1 28.1 29.5      
Med.: median; M: males; F: females. 
Colour code: pink=genes considered as unexpressed or at undetectable levels; orange=genes considered as 
weakly expressed, not quantifiable; blue=genes considered as expressed and quantifiable. 
CYP names in bold correspond to cases with multiple assays for the same gene.  
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 For the CYPs for which information on expression had been found in the 
literature (Table V-1), the expression levels obtained here were mostly consistent with 
the collected information. Four CYPs (2u1, 3a62, 2j13 and 1b1), previously reported as 
undetected in rat liver, were detected here, although only Cyp2u1 and Cyp3a62 were 
expressed at a sufficient level to pursue relative quantification. This could be explained 
by the higher sensitivity of the qPCR technique employed here compared with the 
methods employed in the papers mentioning their non detection: northern blot (2u1247), 
microarray (2j13242) and PCR followed by gel electrophoresis (1b1212 and 3a62219). 
Only one major discrepancy between our results and the literature was obtained: we 
did not detect any amplification for Cyp2c6 whereas this isoform is known to be 
expressed in rat liver213,229,262,266. It is likely that there was a problem with our Cyp2c6 
assay, which is supported by the fact that this assay has now been removed from the 
Applied Biosystems website for Cyp2c6. 
  
V.3.1.2.5. Principal Components Analysis of the 62 selected assays 
For the 62 assays selected for relative quantification, expression intensities 
relative to Rplp2 (2−ΔCT) were calculated for all samples, and principal components 
analysis (PCA) was performed with UV scaling (Figure V-1). The PC1 vs. PC2 scores 
plot (Figure V-1A), showed a clear separation between males and females along the 
first PC (explaining 47% of the total variance). No separation was seen between 
delivery groups, even when looking at subsequent PCs.   
The corresponding PC1 vs. PC2 loadings plots (Figure V-1B) was examined to 
identify variables responsible for gender separation. CYPs that appeared to be higher 
in females (circled with red) were: 2c12, 3a9, 26a1, 2a1, 2c7, 2t1, 51 and 2r1. There 
were many CYPs that appeared to be higher in males (boxed with blue). The most 
extreme of these in the loadings plot were: 2a2, 2c11, 3a18, 2c13, 2c37, 3a2, 2d3, 2d4 
and 3a62. These two lists included all the CYPs listed as differentially expressed in 
Table V-1 (plus others), showing good consistency of our results with the literature. 
Some CYPs, such as 2d5, 4a1, 4v3, 8b1, 7a1, Tbxas, 2e1, 2d2 and 39a1 had a weak 
p1 loading value and did not seem to be differentially expressed between males and 
females. In the loadings plot, variable correlation was good between assays targeting 
the same gene, such as the three assays for Cyp17a1 and the two assays for Cyp3a2. 
Individual rat expression values for some of the CYPs quoted above are plotted in 
Figure V-2 to illustrate the results obtained by PCA. For brevity, only 2 CYPs from 
each category (higher in females / higher in males / similar expression in both genders) 
are plotted here, the plots for all the 62 assays being presented in Appendix V. As 
expected from the loadings plot, CYPs 2c12 (Figure V-2A) and 3a9 (Figure V-2B) 
showed a higher expression in females compared to males, while CYPs 3a2 (Figure 
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V-2C) and 2d3 (Figure V-2D) showed a higher expression in males. CYPs 2d5 (Figure 
V-2E) and 4a1 (Figure V-2F) had similar levels of expression in males and females.  
 
 
 
Figure V-1. PCA of the 62 assays selected for quantification 
(A) Scores plot; (B) Loadings plot. 
There is a clear separation between males and females along the first PC, while no separation 
is seen between delivery groups. CYPs circled with red in the loadings plot have higher 
expression in females and CYPs boxed with blue have higher expression in males. 
Abbreviations: M=males; F=females; Gx=delivery group x. 
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Figure V-2. Ratios of individual rat gene expressions compared to the median 
expression in males or females for different CYPs 
(A) Cyp2c12; (B) Cyp3a9; (C) Cyp3a2; (D) Cyp2d3; (E) Cyp2d5; (F) Cyp4a1. 
Error bars represent the values of the two replicates. The blue bars correspond to the males, 
the red bars to the females. The blue dash line corresponds to the male median, the orange line 
to the female median.  
CYPs 2c12 and 3a9 are more expressed in females, CYPs 3a2 and 2d3 in males, and CYPs 
2d5 and 4a1 have a similar level of expression in both genders.  
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V.3.1.2.6. Univariate analysis of gender differences in CYP expression 
Some of the CYPs selected as expressed were highly expressed in males but 
showed CT values ~ 32 for females. As explained previously, reproducibility is not as 
good for values around the limit of quantification and exact values are less reliable. For 
this reason, it was decided to work on median values for further investigation of gender 
differences, as medians are more robust to outliers, and to apply a non-parametric test 
(Wilcoxon test). 
Assays were separated into three groups based on adjusted p-values  and 
ratios of median expressions between genders: CYPs with significantly higher 
expression in males (35 assays) (Table V-6), CYPs with significantly higher expression 
in females (11 assays) (Table V-7), and CYPs showing no significant difference at a 
0.05 threshold (16 assays, among which 11 showed no difference at all (adjusted p-
value = 1)) (Table V-8). Ratios of average expressions are also displayed in the tables, 
as they are a widely accepted way of presenting qPCR data and allow calculation of a 
range for the ratios, based on standard deviations for each group. Values obtained by 
two different assays for the same CYP were consistent.  
Looking at the 35 assays showing higher expression in males (Table V-6), 20 
assays exhibited a gender ratio higher than 2, which is a common threshold used in 
qPCR reports. For four CYPs (3a2, 2c13, 2c37 and 2c11), the gender ratio was higher 
than 2000. It should be noticed that the exact values of these particular ratios could not 
really be trusted, as female CT values were close to or over the limit of quantification 
and therefore not reliable, but they gave the order of magnitude of gender expression 
ratios. Four CYPs (2a2, 4a8, 3a18, 2b1) exhibited gender ratios between 15 and 200, 
and two (4a2, 2b2) between 5 and 10 
Among the 11 assays showing higher expression in females (Table V-7), 6 
exhibited a gender ratio higher than 2, with one equal to 140 (2c12) and two (26a1, 
3a9) between 5 and 10.  
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Table V-6. CYPs showing significantly higher expression in males (α=0.05) 
Cytochrome 
P450 
Assay 
adjusted 
p-values 
Ratio 
median 
expression 
in males / 
females 
Ratio 
average  
expression  
in males /  
females 
Ratio 
average 
expression 
in females / 
females 
Cyp3a2 Rn01412889_mH 0.000001 20000 10000   (6300-16000) 1   (0.3-3.4) 
Cyp3a2 Rn00756461_m1 0.000001 18000 11000   (6500-17000) 1   (0.3-4.0) 
Cyp2c13 Rn00593388_g1 0.000001 5900 4800   (3600-6300) 1   (0.4-2.3) 
Cyp2c37 Rn02786817_m1 0.000001 4000 4100   (2500-6700) 1   (0.4-2.3) 
Cyp2c11 Rn00569868_m1 0.000001 2400 4300   (3300-5700) 1   (0.2-4.5) 
Cyp2a2 Rn00562207_m1 0.000001 180 300   (230-380) 1   (0.2-4.4) 
Cyp4a8 Rn00581081_m1 0.000001 34 31   (14-67) 1   (0.2-4.6) 
Cyp3a18 Rn00595752_m1 0.000001 23 22   (16-30) 1   (0.8-1.3) 
Cyp2b1 Rn01457875_m1 0.000001 17 18   (10-31) 1   (0.5-1.9) 
Cyp4a2 Rn01417066_m1 0.000001 6.6 7.8   (5.0-12.2) 1   (0.6-1.6) 
Cyp2b2 Rn02786833_m1 0.000013 5.1 5.0   (2.6-9.3) 1   (0.5-2.0) 
Cyp4f5 Rn00687553_m1 0.000001 3.4 3.3   (2.1-5.2) 1   (0.7-1.4) 
Cyp4f5;Cyp4f37 Rn00687557_gH 0.000001 2.9 3.0   (2.0-4.7) 1   (0.7-1.3) 
Cyp3a62 Rn01409583_m1 0.000001 3.2 3.1   (2.3-4.1) 1   (0.7-1.4) 
Cyp4a3 Rn00598411_m1 0.000002 2.6 2.6   (1.7-4.0) 1   (0.7-1.4) 
Cyp3a23(3a1) Rn01412959_g1 0.000204 2.3 2.2   (1.5-3.2) 1   (0.6-1.7) 
Cyp2d3 Rn00597330_m1 0.000001 2.3 2.5   (1.8-3.4) 1   (0.7-1.3) 
Cyp2j10 Rn01433143_m1 0.000067 2.2 2.2   (1.5-3.2) 1   (0.6-1.7) 
Cyp2d4 Rn00696505_g1 0.000001 2.1 2.1   (1.6-2.9) 1   (0.8-1.2) 
Cyp2d4 Rn01504629_m1 0.000001 2.0 2.1   (1.4-3.0) 1   (0.8-1.2) 
      
Cyp2j3 Rn00598500_m1 0.000001 1.9 2.0   (1.5-2.6) 1   (0.7-1.4) 
Cyp2d1 Rn01775090_mH 0.000426 1.7 1.7   (1.2-2.5) 1   (0.7-1.5) 
Cyp2u1 Rn01522408_m1 0.002470 1.6 1.7   (1.1-2.9) 1   (0.7-1.5) 
Cyp2b3 Rn02786829_sH 0.001082 1.6 1.7   (1.2-2.4) 1   (0.5-1.8) 
Cyp2b3 Rn01476085_m1 0.000585 1.5 1.6   (1.3-2.1) 1   (0.6-1.7) 
Cyp2c22 Rn00593377_m1 0.000118 1.6 1.6   (1.1-2.1) 1   (0.8-1.2) 
Cyp4b1 Rn00566515_m1 0.000165 1.5 1.5   (1.1-2.1) 1   (0.8-1.2) 
Cyp4f17 Rn01408612_m1 0.000348 1.5 1.4   (1.1-1.9) 1   (0.7-1.4) 
Cyp2j4 Rn00576482_m1 0.000084 1.5 1.6   (1.2-2.1) 1   (0.7-1.4) 
Cyp4f4 Rn00597513_m1 0.000003 1.4 1.4   (1.1-1.9) 1   (0.9-1.2) 
Cyp4f1 Rn00571492_m1 0.007054 1.2 1.2   (1.0-1.6) 1   (0.8-1.2) 
Cyp20a1 Rn01644438_g1 0.000995 1.2 1.2   (0.9-1.6) 1   (0.9-1.2) 
Cyp7b1 Rn01461859_m1 0.003279 1.2 1.3   (1.0-1.6) 1   (0.8-1.2) 
Cyp4f6 Rn00686847_m1 0.000318 1.2 1.2   (1.0-1.6) 1   (0.9-1.1) 
Cyp27a1 Rn00710297_m1 0.020769 1.1 1.2   (0.9-1.6) 1   (0.8-1.2) 
Figures in ( ) correspond to the expression range, calculated as detailed in the experimental section of this 
chapter. 
The grey row separates median ratios above and below 2.  
CYP names in bold correspond to multiple assays for the same gene. 
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Table V-7. CYPs showing significantly higher expression in females (α=0.05) 
Cytochrome 
P450 
Assay 
adjusted  
p-values 
Ratio 
median 
expression 
in females / 
males 
Ratio 
average 
expression in 
females / 
males 
Ratio 
average 
expression 
in males / 
males 
Cyp2c12 Rn00755856_m1 0.000001 140 140   (110-180) 1   (0.5-1.9) 
Cyp26a1 Rn00590308_m1 0.000001 7.5 6.3   (4.8-8.5) 1   (0.6-1.5) 
Cyp3a9 Rn00595977_m1 0.000001 5.8 5.7   (4.1-7.9) 1   (0.6-1.6) 
Cyp51 Rn01526553_m1 0.000007 2.4 2.4   (1.8-3.2) 1   (0.6-1.6) 
Cyp2a1 Rn00562200_m1 0.000001 2.3 2.2   (1.9-2.7) 1   (0.7-1.4) 
Cyp2c7 Rn01529602_mH 0.000002 2.1 2.2   (1.7-2.7) 1   (0.7-1.4) 
      
Cyp2r1 Rn01754616_m1 0.000011 1.5 1.5   (1.3-1.7) 1   (0.8-1.3) 
Cyp2t1 Rn00592635_m1 0.000003 1.5 1.5   (1.3-1.8) 1   (0.7-1.3) 
Cyp17a1 Rn00664858_m1 0.028049 1.5 1.5   (0.9-2.7) 1   (0.7-1.4) 
Cyp17a1 Rn01444704_g1 0.028049 1.4 1.6   (0.9-2.8) 1   (0.7-1.5) 
Cyp17a1 Rn00562601_m1 0.038365 1.4 1.5   (0.8-2.8) 1   (0.7-1.5) 
Figures in ( ) correspond to the expression range, calculated as detailed in the experimental section of this 
chapter. 
The grey row separates median ratios above and below 2. 
CYP names in bold correspond to multiple assays for the same gene.  
 
 
Table V-8. CYPs showing no significant gender differences (α=0.05) 
Cytochrome 
P450 
Assay 
adjusted  
p-values 
Ratio 
median 
expression 
in males / 
females 
Ratio 
average 
expression in 
males / 
females 
Ratio 
average 
expression 
in females / 
females 
Cyp1a1 Rn00487218_m1 0.08 1.9 2.5   (1.2-5.2) 1   (0.2-4.1) 
Cyp4f39 Rn01408191_m1 0.26 1.3 1.2   (0.8-1.8) 1   (0.7-1.4) 
Cyp7b1 Rn01461862_m1 0.15 1.1 1.2   (1.0-1.6) 1   (0.8-1.3) 
Cyp1a2 Rn00561082_m1 1 1.1 1.1   (0.8-1.5) 1   (0.8-1.3) 
Cyp2c23 Rn00582954_m1 1 1.1 1.1   (0.8-1.4) 1   (0.8-1.2) 
Cyp2e1 Rn00580624_m1 1 1.1 1.0   (0.7-1.5) 1   (0.8-1.3) 
Cyp4v3 Rn01488162_m1 1 1.1 0.9   (0.5-1.6) 1   (0.7-1.5) 
 Cyp5a1 (Tbxas1) Rn00562160_m1 1 1.0 1.0   (0.7-1.5) 1   (0.7-1.5) 
Cyp2d5 Rn01790051_s1 1 1.0 1.0  (0.6-1.6) 1   (0.7-1.4) 
Cyp2d2 Rn00562419_m1 1 1.0 1.0   (0.8-1.3) 1   (0.9-1.2) 
Cyp8b1 Rn00579921_s1 1 1.0 1.0   (0.7-1.3) 1   (0.8-1.3) 
Cyp7a1 Rn00564065_m1 1 1.0 0.9   (0.5-1.7) 1   (0.5-2.2) 
Cyp4a1 Rn00598510_m1 1 1.0 1.0   (0.7-1.3) 1   (0.7-1.4) 
Cyp39a1 Rn01757120_m1 1 0.9 1.0   (0.8-1.3) 1   (0.8-1.2) 
Cyp21a1 Rn00588996_g1 0.37 0.7 0.7   (0.3-1.4) 1   (0.7-1.4) 
Cyp8a1 (Ptgis) Rn00580687_m1 0.14 0.4 0.7   (0.2-2.0) 1   (0.1-7.0) 
Figures in ( ) correspond to the expression range, calculated as detailed in the experimental section of this 
chapter. 
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A large proportion of the CYP isoforms showing significant differential 
expression between males and females are involved in steroid metabolism, with a 
higher degree of regiospecificity and stereoselectivity than for many exogenous 
compounds267. This is for instance the case for CYPs 3a2 (testosterone 2β- and 6β-
hydroxylation), 2c11 (testosterone 2α- and 16α-hydroxylation), 2a2 (testosterone 15α-
hydroxylation), 3a18 (testosterone 6β-, 16α-, 2β- and 15β-hydroxylation), 2c12 (15β-
hydroxylation of steroid sulfates), 3a9 (testosterone 6β-hydroxylation), 2a1 
(testosterone 7α-hydroxylation) and 2c7 (testosterone 16α-hydroxylation)24,267. The 
sex-dependent liver expression of these steroid hydroxylase CYPs is not surprising as 
the physiological requirements in terms of steroid hormone hydroxylation differ 
between males and females267. Experiments have demonstrated that plasma growth 
hormone (GH) profiles, which are sex-dependent in rats, are responsible for 
establishing and maintening the rat sex-dependent patterns of liver CYP expression267. 
GH is secreted by the pituitary gland in adult male rats in an intermittent (pulsatile) 
manner, such that high plasma peaks of hormone (~150-200 ng/ml) every ~3.5-4 hours 
are followed by a period of very low or undetectable circulating GH (< 1-2 ng/ml). 
Conversely, GH is secreted more frequently in adult female rats (several times per 
hour), so that the plasma GH pulses overlap and GH is continually present in 
circulation at significant levels (~15-40 ng/ml)267. This continuous plasma GH, 
characteristic of adult female rats, stimulates expression of CYPs 2c12, 2a1, 2c7 and 
3a9, which show higher expression in females267. Conversely, intermittent GH pulses, 
characteristic of adult male rats, induce expression of CYPs 2c11, 3a2 and 2a2, which 
show higher expression in males267. 
 
V.3.1.2.7. Inter-rat variability within each gender 
Within each gender, ratios of CYP mRNA expression between the highest and 
the lowest expression were calculated for each assay, to investigate variability between 
control rats of the same gender. The obtained values are given in Appendix VI. For 24 
assays, these ratios were below 3 for both males and females, which indicated low 
inter-rat variability; for 34 assays, theses ratios were below 5 for both males and 
females, and for 50 assays, below 10. Some very high values were obtained for a few 
assays (ratios up to 1000), which may partially result from the CT values being close to 
32 and therefore less accurate. However, high inter-rat variability was also observed for 
some assays with CT values below 30. This was for instance the case for Cyp8a1 
(Ptgis) (ratio of 220 for females and 78 for males) and for Cyp1a1 (ratio of 450 for 
females and 14 for males). The inter-rat variability for Cyp8a1 (Ptgis) can be observed 
in Figure V-3.  
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Figure V-3. Ratios of individual rat gene expression compared to the median 
expression in males for Cyp8a1 (Ptgis) 
Error bars represent the values of the two replicates. The blue bars correspond to the males, 
the red bars to the females. The blue dash line corresponds to the male median, the orange line 
to the female median.  
Within each gender, Cyp8a1 mRNA expression can vary considerably between rats, e.g. 
between males 10 and 11, or between females 21 and 36.  
 
 
V.3.1.2.8. Investigation of delivery group differences 
No obvious difference between delivery groups appeared when looking at plots 
of individual rat expression for each CYP (Appendix V). Moreover, using a multivariate 
approach, no separation between delivery groups was obtained with PCA (Figure V-1), 
as stated in paragraph V.3.1.2.5. In order to verify if there was really no difference 
between deliveries, males and females were separated and two PLS-DA models were 
constructed, one for each gender, using delivery groups for the Y dummy matrix. The 
obtained models were poor (Q2Y=15% for males and 12% for females) and were not 
validated neither by permutations, nor by CV-ANOVA (p = 0.7 for males and 0.9 for 
females). This confirmed that there were no major differences between delivery groups 
for the 62 selected assays.  
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V.3.2. CYP-related activities 
CYP-related activities were assessed for CYPs 1a1/2, 2b1, 2d1, 2e1 and 3a1/2 
to examine the consistency between mRNA expression and CYP activity. For CYP 
subfamilies 1a and 3a, the activity assays evaluated the combined activity of isoforms 1 
and 2.  
The mean activity values obtained for the different gender/delivery groups as 
well as for all males and all females are shown in Figure V-4. Cyp1a1/2-related activity 
was similar for males and females, whereas CYP 2b1-, 2d1-, 2e1- and 3a1/2-related 
activities were significantly higher in males. The ratios of male/female activities for 
these 4 CYPs ranged from 1.3 to 3.8 (Table V-9). For each gender, no significant 
differences between deliveries were found. 
 
 
 
Figure V-4. Measured activities for 5 CYPs 
(A) Cyp1a1/2; (B) Cyp2b1; (C) Cyp2d1; (D) Cyp2e1; (E) Cyp3a1/2. 
The first four bars show the mean of each male delivery group, the next four bars the mean of 
each female delivery group, and the last two bars the mean of all males and all females 
respectively. Error bars correspond to +/- standard deviation of the group. padj is the adjusted 
p-value corresponding to a Student’s t-test between males and females. 
CYP 2b1-, 2d1-, 2e1- and 3a1/2-related activities are significantly higher in males compared to 
females. There are no significant differences between deliveries for the measured activities. 
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Table V-9. Ratios of median value in males/females for both activities and mRNA 
expression 
CYP 
isoform 
1a1 1a2 2b1 2d1 2e1 3a1 3a2 
Activities 0.95 3.8* 1.7* 1.3* 3.3* 
mRNA 
expression 
1.9 1.1 17* 1.7* 1.1 2.3* 18000* 
* indicates a statistically significant difference between males and females. 
 
 
It is interesting to compare the activity findings with those obtained when 
assessing the mRNA expression (Table V-9). As a reminder, no significant gender 
differences were observed for CYPs 1a1 and 1a2 by qPCR, while higher expression in 
males was significant for 2b1, 2d1, 3a1 and 3a2. In terms of activity for these CYPs, no 
significant gender differences were obtained for Cyp1a1/2-related activity, while CYP-
related activity was significantly higher in males for CYPs 2b1, 2d1 and 3a1/2, which 
was in agreement with the mRNA results. For Cyp2e1 only, no significant gender 
differences were found in mRNA expression, while the difference was significant for the 
activity. However, the male/female ratios were similar (1.3 for activity, 1.1 for mRNA 
expression) and very close to 1, showing that, even if statistically significant, gender 
difference in Cyp2e1 activity was minor (common practice in this type of study is to 
focus on ratios above 1.5 or 2). Thus, mRNA expression and activity data were in good 
agreement in terms of qualitative assessment of gender differences. 
Concerning the ratio values, there was a good consistency between mRNA 
expression ratios and related activity ratios for CYPs 2d1 and 2e1, while for Cyp2b1 
the male to female ratio was about 4 times lower for activity compared with mRNA 
expression. It was difficult to compare ratios for the other CYPs as the activity assays 
targeted two isoforms simultaneously (1a1/1a2 and 3a1/3a2), while the mRNA 
expressions were assessed separately for these isoforms. Cyp1a2 was highly 
expressed compared with Cyp1a1 at the mRNA level, and the male to female ratio of 
Cyp1a2 at the mRNA level was similar to the one obtained with the 1a1/2-related 
activity assay. The only notable divergence between ratios at the mRNA and activity 
levels was observed for Cyp3a1/2. At the mRNA level, a ratio of 2.3 had been obtained 
for 3a1 and ~18000 for 3a2. If the exact value of this last ratio could not be trusted as 
the female expression was below the limit of quantification by qPCR, there was still a 
clear male over-expression (>6000). However, when looking at the activity level, the 
male to female ratio was only 3.3. This could result from differences in post-
transcriptional, translational and post-translational regulation between genders and 
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illustrate the difficulty of predicting phenotype from the mRNA expression levels, which 
do not always faithfully represent protein abundances and even more so their 
activity268,269. This will be further discussed in Chapter VII. Finally, it would have been of 
interest to assess the protein expression for this CYP to gain insight in the gender 
regulation differences, but this could not be achieved in the framework of this project.  
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V.4. Conclusion 
This chapter focused on the assessment of CYP baselines levels in liver of male 
and female rats. Using qPCR, we managed to evaluate the mRNA expression of 81 rat 
CYP isoforms out of the 89 isoforms currently listed in the rat genome database210. 
Among these 81 isoforms, 51 were expressed at sufficient level for quantification in 
females and 55 in males (the same as in females + CYPs 2c37, 2c13, 3a2 and 4a8), of 
which 23 exhibited significant gender differences with a gender ratio > 2. The strongest 
gender differences were observed for CYPs 3a2, 2a2 and many isoforms belonging to 
the 2c subfamily: CYPs 2c11, 2c13 and 2c37 were markedly higher in males, whereas 
Cyp2c12 was more expressed in females. A large proportion of these differentially 
expressed CYPs are involved in steroid metabolism, and their sex-dependent liver 
expression reflects the different physiological requirements between males and 
females in terms of steroid hormone hydroxylation267. 
Activities measured for a few CYPs yielded results consistent with mRNA 
expression in terms of qualitative gender differences. Gender ratios were mostly of the 
same order of magnitude for mRNA and activity levels, with the notable exception of 
Cyp3a2, for which the strong over-expression in males at the mRNA level (>6000) 
resulted in a Cyp3a1/3a2-related activity only 3 times higher in males compared to 
females.  
Finally, no significant differences between rat deliveries were observed in CYP 
mRNA expression and CYP-related activities, indicating a good consistency in terms of 
CYP profiles between deliveries.  
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Chapter VI.  Determination of rat 
metabolic profiles by UPLC−MS 
and integration with 
cytochrome P450 profiles 
 
 
 
 
 
OBJECTIVES 
 
 
 To establish metabolic profiles in serum, urine and liver by UPLC-MS in the rats for 
which CYP profiles have been determined in Chapter V.  
 
 To examine differences between collection time points and between genders as 
well as the impact of rat delivery groups on these profiles 
 
 To assess the possibility of constructing models predicting the CYP profiles from  
the corresponding metabolic profiles  
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VI.1. Introduction 
In Chapter V, liver CYP profiles in male and female Wistar rats have been 
characterised. The purpose of this chapter is to establish metabolic profiles in serum, 
urine and liver in the same rats, with the aim of predicting the CYP profiles from the 
corresponding metabolic profiles. The objective sought in further studies is to observe 
early biomarkers of CYP profile modification following the administration of a drug, 
through metabolic profiling of urine and serum, which can be obtained non- or 
minimally-invasively. This would avoid collecting and analysing livers, which 
necessitates animal termination, and would therefore facilitate the assessment of time 
effect after repeated administration of a drug. For this particular project, as livers were 
collected for CYP profiling, it was decided to also characterise their metabolic profiles, 
as these were likely to be easier to link with liver CYP profiles, which could therefore 
constitute an intermediate step before examining relationships between CYP profiles 
and serum/urine metabolic profiles. After dedicating the first part of my PhD to the 
development of a protocol to assess metabolic profiles in liver samples by UPLC-MS 
(Chapters III and IV), everything was set up to determine the urine, serum and liver 
metabolic profiles for the rats of this project, as methods for urine69 and serum76 were 
already in place in our laboratory.  
Although urine, serum and liver metabolic profiles were mainly established here 
to assess the possibility of predicting the CYP profiles, differences between collection 
time points and between genders were still investigated. Sex differences in the 
metabolism of bile acids, steroids and lipids in the rat have been studied for many 
years270-274. Marked differences between male and female rats in the proportions of 
various bile acids in liver271 and small intestine270, as well as significant differences in 
steroid excretory profiles (particularly for corticosterone metabolites)272, have been 
observed. Regarding lipid metabolism, Reaven reported that plasma triglyceride levels 
of 3-month old female rats were lower than those of comparably aged male rats, 
although the triglyceride production was similar for both genders, suggesting that 3-
month old female rats removed triglycerides from plasma more efficiently than similar 
aged males273. More recently, NMR-based metabonomic investigations on Wistar rat 
urine revealed higher levels of trimethylamine-N-oxide, dimethylglycine, 
hydroxyphenylpropionic acid, N-acetylglycoprotein, cholate, as well as progesterone 
and oestrogen metabolites in female urine samples compared to male samples46. 
Regarding plasma, NMR investigations showed lower concentrations of lipoproteins in 
female rats compared to male rats (reduced triglyceride resonances)42. The use of 
UPLC-MS to establish metabolic profiles in this work is likely to provide additional 
information on gender differences in rat urine, serum and liver. Concerning differences 
between collection time points, two effects were overlaid in our experiment: diurnal 
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variation and fasting. Indeed, rats were fasted from time point 8 h until termination 
(food available ad libitum before), with serum collection at time points 8 h (fed rats, 
mid-afternoon) and 24 h (fasted rats, early morning), and urine collection over the 
periods 0-8 h (fed rats, day time) and 8-24h (fasted rats, overnight) (section V.2.1). 
Rats are nocturnal and the difference in their activity between day and night is reflected 
in their urine metabolic profiles42. Serum metabolic profiles can also be affected by 
diurnal changes related to hormonal action42. NMR analysis of female Sprague-Dawley 
rat urine revealed lower levels of taurine, hippurate and creatinine, and higher levels of 
glucose, succinate, dimethylglycine, glycine, creatine and betaine in daytime samples 
compared with those collected overnight47. Regarding food deprivation, Sprague-
Dawley rats fasted for one day showed decreased level of tricarboxylic acid cycle 
intermediates and trans-aconitate and increased levels of creatinine, taurine and 
phenylacetylglycine in urine42. For another rat strain, obese Zucker rats, Williams et 
al.275 found that both NMR and HPLC-MS metabolic profiling analyses allowed for 
discrimination between urine samples collected in the morning and in the evening. With 
NMR, they observed lower levels of taurine, creatinine, allantoin and α-ketoglutarate 
and increased levels of citrate and formate in urine samples collected in the morning 
compared to the evening. For HPLC-MS results, they provided m/z values of some ions 
responsible for discrimination between time points and proposed a putative elemental 
composition, but metabolite identification was not further pursued.  
Indeed, as mentioned previously (section I.2.3), metabolite identification 
remains the bottleneck of LC-MS based metabolic profiling studies. Depending on the 
study aim, chemical identification of discriminating metabolites is not always pursued, 
these often only listed as m/z_RT pairs (RT=retention time), sometimes (not always 
though) with proposed elemental compositions. To aid metabolite identification for my 
project as well as other UPLC-MS projects in our laboratory, I constructed a standard 
compound database reporting m/z and RT of 163 standard compounds (section II.1.5). 
In this chapter, when a metabolite discriminating between two experimental groups 
matched with a compound in the constructed database (m/z and RT), comparative 
MS/MS between a study sample and the corresponding standard compound was 
performed to confirm identification. For the other discriminating metabolites, I chose to 
provide putative identity obtained by metabolite database searching, without pursuing 
further the identification. This would indeed have necessitated extensive work (section 
I.2.3) that could not be accomplished in the timeframe of this project, such as orbitrap 
or FT-ICR analyses  to obtain accurate mass and MSn fragmentations (not available in 
our laboratory), and/or NMR analyses to gain structural information. It was furthermore 
not one of the main project aims, as the main reason of establishing sample metabolic 
profiles here was to assess the possibility of predicting the CYP distribution from these 
metabolic profiles. 
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Combination of data obtained at mutiple cellular levels, such as DNA, RNA, 
protein and metabolites, is a key challenge in the current “omics” era.  Integration of 
information from the different biomolecular levels is likely to improve the understanding 
of complex organism systems as a whole, facilitating the reconstruction of biological 
networks. This can be highly helpful to gain insight into disease mechanisms and 
organism responses to perturbations, to validate and confirm findings obtained at one 
biomolecular level, and to increase the possibility of finding specific and reliable 
biomarkers of a biological condition by incorporating data from multiple “omics” 
levels157,276. There are two main approaches to combine datasets from two (or more) 
“omics” investigations performed on the same samples: datasets can first be analysed 
separately for each study with subsequent integration of the results, or they can be 
analysed together at the same time (data fusion). Performing separate analyses of the 
multiple “omics” data followed by combination of the different results is an approach 
often employed as it results in less data to integrate and facilitated interpretation. It has 
for instance been applied to obtain insights into toxicity mechanisms of methapyrilene 
(combination of transcriptomic, proteomic and metabonomic data)276 and paracetamol 
(transcriptomic and metabonomic data)277 and to investigate differences between 
obesity-prone and obesity-resistant phenotypes in rats under high-fat diet 
(transcriptomic and metabonomic data)278. The data fusion approach is more complex 
but more informative, providing better insights into relationships between elements 
from the different biomolecular levels, and therefore enhancing the opportunity of better 
understanding complex organism systems. This approach requires powerful tools to 
combine information from the multiple datasets generated at the different “omics” levels 
and enable its interpretation. One way of doing so is to employ the O2PLS method 
developed by Trygg155,156. This method has been successfully applied by Rantalainen 
et al.157 to integrate proteomic and metabonomic data in a model of prostate cancer. It 
allows separating the variation shared between the two datasets (predictive variation) 
from the variation unique to each dataset as well as the residual variation. The O2PLS 
method was applied here to assess the possibility of predicting CYP profiles from 
corresponding metabolic profiles. 
The first part of this chapter is dedicated to UPLC-MS metabolic profiling 
analyses of the serum, urine and liver samples collected as part of the rat CYP study 
described in Chapter V. Untargeted profiling methods were employed for all types of 
samples, and targeted analyses were also performed on triglycerides in serum and 
liver samples, and on free fatty acids in liver samples. In the second part of this 
chapter, statistical models are constructed to try to predict the CYP profiles obtained in 
Chapter V from the established metabolic profiles. 
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VI.2. Experimental section 
VI.2.1. Animal handling 
The animal handling has already been described in section V.2.1 (unique in-life 
study for both CYP profiling and metabolic profiling analyses). 
 
 
VI.2.2. Physiological and biochemical parameters 
VI.2.2.1. Measurements  
Body weights were recorded at the start of the experiment and liver weights at 
termination time (24 h). The following serum chemistry parameters were measured for 
each rat at 24 h at Biologie Servier (BS) (Gidy, France): albumin, total bile acids, total 
cholesterol, triglycerides, glucose, creatinine, total proteins, total bilirubin, alkaline 
phosphatase, alanine aminotransferase, aspartate aminotransferase and glutamate 
dehydrogenase (Cobas C501 analyser, Roche). Urine weights were recorded at the 
end of the collection periods and specific gravity was immediately measured (Atago 
refractometer). After urine centrifugation, glucose and creatinine were measured 
(Cobas C501 analyser, Roche). 
 
VI.2.2.2. Data analysis 
For each parameter, comparisons between genders were performed using 
Student’s t-test for unequal variances. For serum and urine parameters, as multiple 
testing was performed on the same samples, p-values were adjusted for multiple 
comparisons using the Holm-Bonferroni correction176,178 (section II.2.3.3).  
For each parameter, differences between deliveries were then investigated 
separately for each gender. Due to the small number of animals in each delivery group 
(n = 5), a Kruskal-Wallis test was employed (non-parametric one-way analysis of 
variance). As with Student’s test, p-values obtained for urine and serum were adjusted 
for multiple comparisons using the Holm-Bonferroni correction. When the p-value from 
the Kruskal-Wallis test was less than 0.05, indicating significant differences between 
some deliveries, pairwise comparisons (Wilcoxon test) were performed between 
deliveries (with adjustment of p-values using the Holm-Bonferroni correction) to 
determine which delivery differences were significant. 
Multivariate analysis was also conducted on all these parameters using principal 
components analysis (PCA) with unit variance (UV) scaling. 
 
 
Determination of rat metabolic profiles by UPLC−MS and integration with cytochrome P450 profiles 
174 
 
VI.2.3. Metabolic profiling 
I performed the untargeted metabolic profiling analyses in our laboratory at 
Imperial College London (ICL) on serum, urine and liver samples, using UPLC-MS with 
in-house developed protocols. In particular, the liver protocol was the one developed as 
part of this thesis, as detailed in Chapters III and IV. Selected targeted analyses were 
also performed by Technologie Servier (TES) (Orleans, France) on serum and liver 
samples with UPLC-MS (free fatty acids and triglycerides). As untargeted metabolic 
profiling was performed in both electrospray ionisation (ESI) modes, these analyses 
resulted in 11 datasets, as summarised in Table VI-1.  
 
 
Table VI-1. Summary table of metabolic profiling analyses 
Sample type 
Untargeted 
analysis 
Targeted analysis 
of triglycerides 
Targeted analysis 
of free fatty acids 
Urine ICL (ESI+ / ESI−) - - 
Serum ICL (ESI+ / ESI−) TES (ESI+) - 
Liver 
Aqueous 
extracts 
ICL (ESI+ / ESI−) - - 
Organic 
extracts 
ICL (ESI+ / ESI−) TES (ESI+) TES (ESI−) 
ICL: sample analysis performed at Imperial College London; TES: sample analysis performed at Technologie 
Servier; -: analysis not performed. ESI modes employed for each analysis are shown into brackets.  
 
 
VI.2.3.1. Sample preparation 
VI.2.3.1.1. Serum samples 
  Untargeted metabolic profiling at ICL  
The 80 serum samples (40 animals × 2 time points) were prepared in 4 batches 
of 20. Samples were distributed in the batches with the aim of minimising the effect of a 
potential batch influence during sample preparation on study results.  
After thawing the samples, 150 µl of cold methanol was added to 50 µl of serum. 
Samples were vortexed for 20 s, placed in freezer for 20 min and centrifuged (10 min, 
16 000g). 160 µl of supernatant was transferred to a clean tube. The supernatants 
were dried down in a Savant Speedvac and frozen at −40°C until UPLC-MS analysis.  
Before analysis, the samples were reconstituted in 120 µl of water, vortexed for 
20 s, sonicated for 5 min, and 90 µl transferred into a 96-well plate. 20 µl from all 
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samples was collected and pooled to obtain a quality control (QC) sample. Dilutions 1/2 
and 1/4 of this QC sample were also prepared.  
  
  Targeted analysis of triglycerides at TES 
50 µl of serum were diluted with 50 µl of water. The mixture was loaded on 1 ml 
Extrelut cartridges (Merck). After 10 min on the cartridge, lipids were extracted with 6 
ml of cold chloroform/methanol (2:1). The organic phase was evaporated under 
nitrogen with a Turbovap (30 min, 30°C) and resuspended in 200 µl 
acetonitrile/isopropanol (1:1). Dilutions 1/2 and 1/20 of these samples in 
acetonitrile/isopropanol (1:1) were prepared and transferred in MS vials.  
 
VI.2.3.1.2. Urine samples 
  Untargeted metabolic profiling at ICL  
150 µl of water was added to 50 µl of urine. Samples were vortexed, centrifuged 
(16 000g, 10 min) and 140 µl of supernatant transferred into MS 96-well plates. A QC 
sample was prepared with 40 µl of each sample. Dilutions 1/2, 1/4 and 1/8 of this QC 
sample were also prepared.  
 
VI.2.3.1.3. Liver samples 
  Untargeted metabolic profiling at ICL 
The 40 liver samples were prepared in 2 batches of 20. The first batch consisted 
of: 3 males + 2 females from deliveries 1 and 4, and 2 males + 3 females from 
deliveries 2 and 3. The second batch consisted of the remaining animals: 3 males + 2 
females from deliveries 2 and 3, and 2 males + 3 females from deliveries 1 and 4. 
Liver samples (50 mg) were homogenised in 1.5 ml of cold methanol/water (1:1) 
in a TissueLyser (25 Hz, 5 min) and centrifuged (16 000g, 10 min). Supernatants were 
collected and 650 µl transferred to eppendorf tubes, dried down in a Savant Speedvac 
and stored at −40°C until UPLC-MS analysis. The remaining pellets were homogenised 
in 1.5 ml of cold dichloromethane/methanol (3:1) in the TissueLyser (25 Hz, 5 min), 
transferred to clean eppendorf tubes and centrifuged (16 000g, 10 min). Supernatants 
were collected and 650 µl transferred to MS vials, dried overnight in a fume cupboard 
and stored at −40°C until UPLC-MS analysis.  
Before UPLC-MS analysis, aqueous extracts were resuspended in 200 µl of 
methanol/water (1:1), vortexed for 20 s, sonicated for 5 min and centrifuged (16 000g, 
3 min). 120 µl were transferred into MS well plate. A QC sample was prepared with 50 
µl of each sample. Dilutions corresponding to 1/2 and 1/4 of this QC sample were also 
prepared. Organic extracts were resuspended in 500 µl of methanol/water (1:1), 
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vortexed for 20 s, and sonicated for 5 min. A QC sample was prepared with 110 µl of 
each sample. Dilutions 1/2 and 1/4 of this QC sample were also prepared. 
 
  Targeted analysis of triglycerides and free fatty acids (FFA) at TES 
335 µl of cold methanol was added to 50 mg of liver samples and homogenised 
with a Precellys® system (Bertin Technologies) (5000 rpm, 1×30 s). Homogenates were 
transferred into glass conical tubes. Precellys tubes were rinsed with 335 µl of cold 
methanol, which was then added to the homogenates. After addition of 1340 µl of 
chloroform, samples were vortexed for 2 minutes and centrifuged (5 min, 770g, 4°C). 
The organic phase was transferred in a glass conical tube and washed with 400 µl 
NaCl 0.9% (v/v) (2 min vortex). After centrifugation (5 min, 770g, 4°C), the organic 
phase was collected, evaporated under nitrogen (30°C, 30 min) and resuspended in 
200 µl acetonitrile/isopropanol (1:1).  
For triglyceride analysis, dilutions 1/5, 1/20 and 1/100 of these samples in 
acetonitrile/isopropanol (1:1) were analysed.  
For FFA analysis, non-diluted samples and dilutions 1/5 and 1/100 in 
acetonitrile/isopropanol (1:1) were analysed.  
  
VI.2.3.2. UPLC-MS analysis 
For all the UPLC-MS analyses, the run order was set so as to minimise its 
correlation with the different factors of the experimental design (gender, delivery group, 
and collection time points when applicable). Thus, the effect of the run order on the 
data analysis was not overlaid with the biological variations of interest. Termination 
time and preparation batches were taken into account as well in the determination of 
the run order, to avoid amplifying any unwanted effects through addition of these 
factors. 
 
  Untargeted metabolic profiling at ICL 
Analyses were performed on an Acquity UPLC® System (Waters, Elstree) 
coupled to a LCT Premier time-of-flight mass spectrometer (Waters, Manchester), 
operated in the positive (ESI+) and negative (ESI−) electrospray ionisation modes.  
Chromatography conditions were specific to each type of sample and are 
summarised in Table VI-2 and Figure VI-1 (exact details of the gradients are provided 
in Appendix VII). The gradients employed for liver samples were the ones developed 
as part of this thesis (Chapters III and IV).  As mentioned in Chapter III, the gradients 
developed for aqueous liver extracts were also used for serum samples as they 
produced good peak separation across the entire gradient length. Concerning the urine 
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gradient, it was the one typically employed in our laboratory for urine metabolic 
profiling, which had been optimised previously by a PhD student.  
 
 
Table VI-2. Summary of the chromatographic conditions for the different types of 
samples 
 Urine 
Serum / Aqueous 
liver extracts 
Organic liver 
extracts 
Mobile phase A Water + 0.1% formic acid 
Mobile phase B 
Acetonitrile 
+ 0.1% formic acid 
Methanol 
+ 0.1% formic acid 
15% Isopropanol in 
methanol 
+ 0.1% formic acid 
Column 
Waters Acquity UPLC HSS T3  
(1.8 μm, 2.1x100 mm) 
Waters Acquity UPLC 
BEH C8  
(1.7 μm, 2.1x100 mm) 
Column 
Temperature 
40°C 50°C 50°C 
Flow rate 0.5 ml/min 0.4 ml/min 0.4 ml/min 
Gradient length 
ESI+ / ESI− 
10 min / 10 min 
(same gradient) 
23 min / 21 min 32 min / 20 min 
Re-equilibration 
period 
2 min 3 min 3 min 
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Figure VI-1. Time evolution of the percentage of mobile phase B for the different 
gradients 
(A) Urine; (B) Serum and aqueous liver extracts; (C) Organic liver extracts. 
The urine gradient is identical in both ESI modes, while gradients optimised for serum and liver 
organic extracts differ between ESI modes.  
Abbreviations: FA=formic acid. 
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A pre-filter (Waters Acquity UPLC Col-In-Line Filter kit) was used before the LC 
column to prevent particulate build-up on the column and thereby improve its lifetime. 
Samples were kept at 4°C in the autosampler during the analyses. The injection 
volume was 5 µl.  
ESI conditions were as follows: source temperature 120°C, desolvation 
temperature 350°C, cone gas flow 25 L/h, desolvation gas flow 900 L/h, capillary 
voltage for ESI− 2400 V, for ESI+ 3200 V, cone voltage 35 V. The instrument was 
operated in V optics mode and set to acquire over the m/z range 50-1000 with scan 
time of 0.2 s and an interscan delay of 0.01 s. Data were collected in centroid mode. 
Leucine Enkephalin (MW=555.62 Da) (200 pg/μl in acetonitrile/water (1:1)) was used 
as a lock mass for accurate mass measurements and the instrument was calibrated 
before analyses using 0.5 mM sodium formate solution (resolution ~8 000 and mass 
accuracy ~10 ppm). 
To monitor the stability of the analytical platform, a QC sample was injected 
regularly throughout each run (after every 10 samples for urine and serum, after every 
6 samples for liver extracts)69,133,134 (section II.1.2). This QC sample was also used to 
condition the column at the beginning of each run69,75,134,135. 
 
  Targeted analysis of triglycerides at TES 
Analyses were performed on an Acquity UPLC® System (Waters) coupled to a 
LCT Premier time-of-flight mass spectrometer (Waters).  
Chromatography was carried out at 50°C with a 0.5 ml/min flow rate on an 
Acquity UPLC BEH C18 column (1.7 μm, 2.1x100 mm). The injection volume was 1 µl. 
Mobile phase A was isopropanol and mobile phase B was acetonitrile. LC gradient was 
as follows: starting condition 0% solvent A, gradual increase to 75% over the first 15 
min, back to starting conditions at 15.1 min, then hold at starting condition (0% A) until 
17 min. A post-column pump was used, infusing 50 µL/min of 100mM ammonium 
formate in water. 
ESI conditions were: ionisation mode ESI+, source temperature 150°C, 
desolvation temperature 400°C, cone gas flow 50 L/h, desolvation gas flow 750 L/h, 
capillary voltage 2700 V, cone voltage 50 V. The instrument was operated in W optics 
mode and set to acquire over the m/z range 200-1200 with scan time of 0.1 s and an 
interscan delay of 0.01 s. Data were collected in centroid mode. Leucine Enkephalin 
(300 pg/μl) was used as a lock mass.  
Liver samples were analysed in two batches (dilutions 1/5, 1/20 and 1/100 of 
livers from 20 animals in each batch). The first batch consisted of: 3 males + 2 females 
from deliveries 1 and 3, and 2 males + 3 females from deliveries 2 and 4. The second 
batch consisted of the remaining animals: 2 males + 3 females from deliveries 1 and 3, 
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and 3 males + 2 females from deliveries 2 and 4. Serum samples were also analysed 
in two batches, corresponding to the two collection time points.  
A mixture of 7 triglycerides (glyceryl trimyristate, tripalmitoleate, tripalmitate, 
trilinoleate, trioleate, tristearate and triarachinate) at a concentration 1.5 µg/ml was 
injected periodically throughout the UPLC-MS runs as a reference mix.   
 
  Targeted analysis of FFAs at TES 
Analyses were performed on an Acquity UPLC® System (Waters) coupled to a 
4000 Q-TRAP mass spectrometer (AB SCIEX).  
Chromatography was carried out at 50°C with a 0.5 ml/min flow rate on an 
Acquity UPLC BEH C18 column (1.7 μm, 2.1x100 mm) equipped with pre-filter. The 
injection volume was 5 µl. Mobile phase A was water/acetonitrile (2:1) + 0.1% formic 
acid and mobile phase B was acetonitrile/isopropanol (1:1) + 0.1% formic acid. The LC 
gradient was as follows: starting condition 50% solvent B, gradual increase to 100% 
over the first 6 min, hold at 100% for one minute, then hold at starting conditions (50% 
B) for 1 min.  
Mass spectrometry conditions were: ESI (turbo Spray) in negative mode, 
acquisition mode Q1 multiple ions, source voltage –4500 V, source temperature 550°C, 
curtain gas 20 psi, nebuliser gas 40 psi, desolvation gas 60 psi, entrance potential –10 
V and declustering potential –60 V. Twelve m/z values were monitored, corresponding 
to the following FFAs: decanoic acid, dodecanoic acid, myristic acid, palmitoleic acid, 
palmitic acid, linolenic acid, linoleic acid, oleic acid, stearic acid, eicosapentaenoic acid, 
arachidonic acid and docosahexaenoic acid. A mixture of these FFAs at a 
concentration of 50 µg/ml in acetonitrile/isopropanol (1:1) was run periodically 
throughout the run as a reference mix.   
Liver samples were analysed in two batches (non-diluted samples and dilutions 
1/5 and 1/100 of 20 animals in each batch). The first batch consisted of: 3 males + 2 
females from deliveries 1 and 3, and 2 males + 3 females from deliveries 2 and 4. The 
second batch consisted of the remaining animals: 2 males + 3 females from deliveries 
1 and 3, and 3 males + 2 females from deliveries 2 and 4. 
 
VI.2.3.3. Data pre-processing 
  UPLC-MS analyses at ICL 
UPLC-MS raw data files of samples analysed at ICL were converted to netCDF 
format using the DataBridge tool implemented in MassLynx4.1TM software (Waters). 
They were then pre-processed using XCMS software138. The CentWave algorithm139 
was used for peak picking with a peak width window of 3-15 s for urine data and 3-20 s 
for serum and liver data, the m/z width for the grouping step was changed to 0.1 Da, 
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the bandwidth parameter was kept to default (30 s) for the first grouping, then 
determined from the retention time deviation profile after retention time correction. 
Isotope peaks, fragments, adducts and in-source dimers were treated as separate 
metabolite features. 
Eight output tables were obtained (corresponding to serum, urine, aqueous liver 
extracts, organic liver extracts, all in both ESI modes), listing m/z and retention time of 
the detected features with their intensities in each sample. Each dataset was 
normalised in R with an in-house script based on loess normalisation142,143 
(section II.1.4.1.2). For organic liver extracts, containing a large number of lipids, 
features with a coefficient of variation (CV=standard deviation/mean) higher than 30% 
in replicate injections of the QC samples were removed, as performed in the technical 
variation study exposed in Chapter IV. For serum and aqueous liver extracts, usually 
showing less issue of reproducibility and producing more reliable data, this threshold 
was set up at 100%. No features were removed for urine as we generally obtain good 
data reproducibility for this biofluid. Following the results obtained in Chapter IV, started 
log transformation was used for all datasets to stabilise the variance throughout the 
intensity range before centring the variables. 
 
  UPLC-MS analyses at TES 
Data were pre-processed by Vincent Croixmarie at TES using Refiner MS 
software (Genedata). As with XCMS software, this resulted in a table listing observed 
metabolite features with their m/z value, retention time and intensities in each sample.  
For triglyceride analysis, a table of theoretical triglyceride masses was 
generated in Matlab (The MathWorks, Natick, Massachusetts), allowing for each fatty 
acid chain an even number of carbons ranging from 8 to 26, with 0 to 4 unsaturations. 
The masses of the features detected by Refiner MS (after de-isotoping) were matched 
with the ammonium adducts in the generated triglyceride table. The closest match was 
kept for each feature and, when the mass difference was below 20 ppm, the feature 
was identified as the corresponding triglyceride and retained for data analysis.  
For FFA analysis, targeted FFAs were identified from the monitored m/z values 
by matching retention times with those of the corresponding authentic FFA standards 
run as a mix throughout the analysis.  
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VI.2.3.4. Data analysis 
PCA and OPLS-DA analyses were performed with Simca-P+ 12.0 software 
(Umetrics, Umeå, Sweden). 
 
  Datasets from untargeted UPLC-MS analyses at ICL 
PCA was performed first on the datasets, to visualise the data. OPLS-DA was 
then used to identify the main metabolite features responsible for separation between 
genders (all datasets) and time points (serum and urine datasets).  
The number of orthogonal components for each OPLS-DA model was optimised 
based on both R2Y and Q2Y values, in a recursive manner, with the aims of minimising 
the overfit of the model (difference R²Y−Q²Y), maximising its predictivity (Q²Y) and 
keeping the model as simple as possible (no necessity of adding one extra component 
if this does not result in a notable improvement of the model). This was done as 
follows: when adding an orthogonal component, if the difference between R2Y and Q2Y 
decreased and the increase in R2Y value was more than 1%, the component was kept. 
If the difference between R2Y and Q2Y increased, but the increase in R2Y value was 
more than 2% and the ratio of Q2Y increase to R2Y increase was higher than 0.8, the 
component was also kept. In all other cases, the component was rejected and the 
model was considered as optimal. When a component was kept, another one was 
added and the process was repeated until a component was rejected.  
The quality of the models was assessed looking at R2Y and Q2Y values, and 
their significance were tested based on analysis of variance of the cross-validated 
predicted residuals (CV-ANOVA)158 as implemented in Simca-P+ 12.0.1 software. CV-
ANOVA produced a p-value for each model, and when this p-value was lower than 
0.05, the model was considered as significant.  
S-plots148 (plots of modelled correlation (p(corr)) vs. modelled covariance (p) 
between metabolite features (X matrix) and predictive scores (tp)) were used for 
interpretation of OPLS-DA models (section II.1.4.2.4). Variables at both ends of the “S” 
in the S-plots were investigated for each model, as they combined high covariance and 
correlation with the predictive component. Chromatograms corresponding to the m/z 
values of these variables were extracted in MassLynxTM and the mass spectra of the 
extracted peaks were checked, to ensure that the selected feature corresponded to 
one of the main ions eluting at that retention time. Extracted ion chromatograms (EICs) 
were also plotted from XCMS for these variables for all samples in the dataset. 
Intensity plots, plotting the normalised integrated intensity of the discriminating features 
in each sample were realised to visualise intensity differences between groups.  
Differences between profiles were also investigated for the features matching 
with standard compounds present in the in-house database constructed as part of this 
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project (section II.1.5). The choice of the mass and retention time windows for 
matching each dataset with the database was based on the shift observed for a few 
peaks identified in the chromatograms. The S-plots previously obtained were 
investigated again, displaying only the features matching with the database. As 
performed with the unknown discriminating features, mass spectra from the EICs in 
MassLynxTM, EICs in XCMS and integrated intensity plots were checked for the most 
discriminating features (those closest to the ends of the “S”). Identity of these features 
was confirmed by comparative MS/MS analysis of the QC sample and the 
corresponding authentic standard compounds. 
 
  Targeted analysis of triglycerides and FFAs at TES 
PCA was performed on the table of features identified as triglycerides (resp. 
FFAs) to visualise the data. OPLS-DA was then conducted to investigate gender 
differences. The models were optimised and validated as detailed above for untargeted 
metabolic profiling at ICL, and S-plots were examined to determine which metabolites 
exhibited gender-differentiated expression.  
For the 12 FFAs, univariate comparison between genders was also performed 
using a Wilcoxon test. P-values were adjusted for multiple testing with the Holm-
Bonferroni correction178. 
 
 
VI.2.4. Integration of CYP profiles and metabolic 
profiles 
O2PLS was applied to link metabolic profiles (X-matrix) and CYP mRNA profiles 
(Y-matrix) for each biological sample. This was done for both untargeted and targeted 
metabolic profiles. For the untargeted metabolic profiles, both ESI modes were 
combined in one X-matrix to simplify the analyses. PCA was performed first on each 
metabolic profile matrix and on the CYP mRNA profiles using UV scaling to give equal 
weight to all variables, then O2PLS was applied between PCA scores from the X matrix 
and PCA scores from the Y matrix. This PCA step was performed to remove noise in 
the data before applying O2PLS, as O2PLS is sensitive to noise. No scaling was used 
for the O2PLS models, which were optimised based on the Q²Y value. For the targeted 
analysis of liver FFAs, the X matrix was used directly for O2PLS without performing 
PCA first, as it contained only 12 variables. 
For each O2PLS model, R²Y and Q²Y values were checked for every single y 
variable, and that showing negative Q²Y values were excluded before fitting a new 
O2PLS model. Loadings plots were then investigated and when the loading for the last 
x variable was close to zero with a confidence interval largely overlapping with zero, 
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this variable was excluded. When O2PLS model were judged of acceptable quality, 
they were validated in Matlab using one million random permutations of the Y matrix 
(response permutation validation). For each random permutation, an O2PLS model 
was fitted with the same number of components as the real model, and the Q²Y value 
of this model was calculated. This resulted in 1 000 000 randomly generated Q²Y 
values, which were then sorted in descending order. The p-value for the real model 
was calculated as the rank of the real Q²Y value in this sorted list, divided by 
1 000 000.  
If validation of the model was successful, model interpretation was performed, in 
terms of profiles. The metabolic and CYP profiles linked by a predictive component in 
the O2PLS model were reconstructed from the O2PLS and PCA loadings using Matlab. 
The strategy was exactly the same for the X and Y data and is therefore detailed here 
only for the X data. Let popls be the O2PLS loadings on the predictive component 
(vector of dimension A x 1, where A is the number of PCs from the PCA of the X 
matrix) and pX the PCA loadings (matrix of dimension K × A, where K is the number of 
metabolite features in the initial X matrix). The combined loadings p for the metabolite 
features were calculated as the product px × popls (vector of dimension K × 1). A 
confidence interval for each combined loading was calculated from the popls obtained in 
the seven O2PLS cross-validation rounds, with the same jack-knife approach as 
implemented in Simca-P+ software to produce confidence intervals for loadings. The 
calculation of these confidence intervals was done by propagating the error on the 
OPLS loadings to the combined loadings.  
When no valid O2PLS models were obtained with this approach, individual 
OPLS models were constructed between the PCA scores of the X matrix and mRNA 
expression of each CYP isoform. Models with a Q²Y value higher than 30% were 
validated in Matlab using one million random permutations of the y vector, exactly as 
with the O2PLS models. As several parallel OPLS models were constructed (one for 
each CYP), the p-value significance threshold was corrected for multiple testing using 
the Bonferroni correction176. The Holm-Bonferroni correction could not be applied here 
as p-values were calculated only for the models with Q²Y value higher than 30%. 
Indeed, permutation validation is computationally intensive and it was not deemed 
useful to validate models with negative or low Q2Y values.  
The strategy described in the paragraph above was also applied to link 
metabolic profiles and CYP activities. As activities were available only for 5 CYPs, 
individual OPLS models were constructed between the PCA scores of the metabolic 
profile matrices and the activity of each CYP. Models with a Q²Y value higher than 20% 
were validated in Matlab and the p-value significance threshold was corrected for 
multiple testing using the Bonferroni correction.  
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VI.3. Results and discussion 
VI.3.1. Physiological and biochemical parameters 
Individual values for all the physiological and biochemical parameters measured 
as part of the in-life phase are provided in Appendix VIII. 
 
VI.3.1.1. Body weights 
Body weights recorded at the start of the experiment resulted in a mean value ± 
standard deviation of 272.8 ± 13.7 g for males and 182.9 ± 11.7 g for females, which 
were significantly different (p = 5e−23).  
For each gender, body weight differences between deliveries were investigated 
using a Kruskal-Wallis test. This resulted in a p-value of 0.0045 for males and 0.010 for 
females, showing that there were differences in terms of body weights between the 
different deliveries. These differences can be observed in Figure VI-2, where the 
individual body weights are plotted for each delivery. To determine which differences 
were significant, pairwise comparisons were performed between deliveries within each 
gender. For males, delivery 1 was significantly different from deliveries 3 and 4 (both 
p = 0.048), and there seemed to be also a difference between delivery 2 compared to 3 
and 4, although this was not significant at a 0.05 threshold (p = 0.095). For females, 
delivery 4 was significantly different from delivery 1 (p = 0.048), the difference between 
delivery 4 compared to 2 and 3 being not significant at a 0.05 threshold (p = 0.095, 
resp. p = 0.079). All other pairwise comparison p-values were above 0.6, except 
comparison between female deliveries 1 and 3 (p = 0.310). 
 
 
 
Figure VI-2. Individual rat body weights for the different delivery groups 
Each cross represents one rat. Male body weights are lower in deliveries 1 and 2 compared to 3 
and 4. Female body weights are lower in delivery 1 than in delivery 4.  
Abbreviations: M=males; F=females; Gx=delivery group x.  
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VI.3.1.2. Liver weights 
Liver weights recorded at termination time resulted in a mean value ± standard 
deviation of 7.0 ± 0.5 g for males and 4.9 ± 0.3 g for females, which were significantly 
different (p = 9e-16).  
For females, no significant differences were found between deliveries. For 
males, the Kruskal-Wallis test revealed significant differences between deliveries 
(p = 0.013). Pairwise comparisons between deliveries for males confirmed that liver 
weight was significantly higher in delivery 3 compared to 1 (p = 0.048). Looking at the 
individual values, it also seemed to be higher in delivery 3 compared to 2, and in 
delivery 4 compared to 1 and 2, but this was not significant at a 0.05 threshold (p = 
0.222, resp. p = 0.079 and 0.333). These findings were not surprising as body weights 
were higher in male deliveries 3&4 compared to 1&2, and body and liver weights were 
well correlated (coefficient of correlation = 0.91 for males, 0.72 for females).  
 
VI.3.1.3. Serum biochemistry  
Student’s t-test revealed significant differences between males and females 
(adjusted p-value < 0.05) for the following serum biochemistry parameters, all higher in 
males: alkaline phosphatase (p = 1e−6), triglycerides (p = 4e−6), alanine 
aminotransferase (p = 3e−5), aspartate aminotransferase (p = 0.002) and total 
cholesterol (p = 0.02). 
Differences were not significant at a 0.05 threshold for glucose (p = 0.17), 
albumin (p = 0.21), creatinine (p = 0.29), total protein (p = 0.36), glutamate 
dehydrogenase (p = 0.36), total bile acids (p = 0.36) and total bilirubin (p = 0.78). 
For each gender, no significant differences between deliveries were found for 
any parameter. 
 
VI.3.1.4. Urine parameters 
Student’s t-test revealed significant differences between males and females for 
urine weights (higher in males) over the periods 0-8 h (p = 0.01). This difference was 
not statistically significant over the periods 8-24 h (p = 0.29). No significant differences 
were observed for glucose, creatinine and specific gravity.  
For males, no significant differences were found between deliveries. For 
females, no differences were significant over the period 0-8 h but significant differences 
were found over the period 8-24 h for the four parameters (all p = 0.038). Differences 
between deliveries were therefore further investigated for these parameters over the 
period 8-24 h for females by pairwise comparisons. No difference was significant at a 
0.05 threshold. Nevertheless, specific gravity, creatinine and glucose seemed to be 
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lower in deliveries 1 & 4 compared to 2 & 3 (all p = 0.095, except for glucose delivery 2 
compared to deliveries 1&4: p = 0.222), while weight seemed to be higher in delivery 4 
compared to 2 & 3 (p = 0.095). Specific gravity, creatinine and glucose were positively 
correlated with each other (pairwise coefficients of correlation > 0.92), and negatively 
correlated with weight (pairwise coefficients of correlation between −0.87 and −0.83) 
 
VI.3.1.5. Discussion 
Differences between deliveries were mainly found for body (and liver) weight, 
which may be due to the age of the animals being slightly different between the 
experiments. Indeed, although animals were specified to be 9 week old at experiment 
initiation, this age could vary slightly (one or two days) between deliveries for practical 
reasons. While no significant delivery differences were observed for serum, some were 
seen for urine. This highlights the importance of using animals from the same delivery 
in toxicology studies (whenever possible). As the in-life experiments were conducted 
separately on each delivery, at several week intervals, it was difficult to know if the 
observed differences were actually resulting from differences between deliveries or if 
they were linked with the experiment period. Moreover, as there were only 5 animals 
from each delivery here, further investigation with more animals should be conducted 
to confirm these results, some of which might have happened by chance.  
 
VI.3.1.6. Multivariate analysis 
Multivariate analysis was also conducted on all these parameters (body weight, 
liver weight, serum biochemistry and urine biochemistry) using PCA, to investigate 
correlation between them (Figure VI-3). A clear separation between males and 
females was observed on PC1 vs. PC2 scores plots (Figure VI-3A). The main 
parameters responsible for this separation were identified using the corresponding 
loadings plot (Figure VI-3B), on which they are circled with blue: body weight, liver 
weight and serum alkaline phosphatase, alanine aminotransferase, triglycerides, 
aspartate aminotransferase and cholesterol were higher in males than in females. This 
was consistent with the results obtained by univariate analysis. Unsurprisingly, liver 
and body weight appeared highly correlated. Urine parameters at 24 h (glucose, 
creatinine and specific gravity) were also correlated together and anti-correlated with 
urine weight. For each gender, animals from different deliveries overlapped and this 
was also true in the 3D PC1 vs. PC2 vs. PC3 scores plot, emphasizing that there was 
no major differences between deliveries.  
 
 
Determination of rat metabolic profiles by UPLC−MS and integration with cytochrome P450 profiles 
188 
 
 
Figure VI-3. PCA of the biochemical and physiological parameters 
(A) PC1 vs. PC2 scores plot; (B) PC1 vs. PC2 loadings plot.  
Males and females are clearly separated in the PC1 vs. PC2 scores plot, while animals from the 
different deliveries overlap within each gender. The main parameters responsible for gender 
separation, circled with blue in the loadings plot, are all higher in males. 
Abbreviations: M=males; F=females; Gx=delivery group x; BW=body weight; LW=liver weight; S_=Serum; 
Ur=Urine; Glu=glucose; Creat=creatinine; Alb=albumin; Prot=total protein; Chol=total cholesterol; 
Trig=triglycerides; ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate 
aminotransferase; GLDH=glutamate dehydrogenase; Bili=total bilirubin; BA=total bile acids; Sg=specific 
gravity; W=weight.  
 
 
VI.3.2. Metabolic profiling 
For serum and urine samples, 80 samples were analysed for each biofluid, 
corresponding to the 20 males and 20 females at two different time points (8 and 24 
hours). The four groups were labelled as follows: F08H = Female−Time point 8 hours, 
F24H = Female−Time point 24 hours, M08H = Male−Time point 8 hours, 
M24H = Male−Time point 24 hours. For liver samples, 40 samples were analysed, 
20 males (M) and 20 females (F).  
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VI.3.2.1. Serum samples 
VI.3.2.1.1. Serum untargeted metabolic profiling 
PCA was performed on the serum datasets analysed at ICL to visualise the 
data. PC1 vs. PC2 scores plots for ESI+ and ESI− modes are displayed in Figure VI-4. 
QC samples (black crosses) were located in the centre of the plot, as expected 
considering they had been prepared by mixing equal volumes of all the samples, and 
so represented an “average” of the samples. These QCs were well clustered, indicating 
good analytical stability over the run. The four groups of samples were perfectly 
separated, illustrating differences in metabolic profiles between the groups. PC1 
(explaining respectively 30 and 33% of the total variance for ESI+ and ESI− mode) 
approximately separated the time points, while PC2 approximately separated the 
genders (respectively 12 and 13% for ESI+ and ESI- mode), although the separation 
axes were actually slightly rotated. Within each group, no separation was seen 
between delivery batches, even when looking at subsequent PCs.  
 
 
 
Figure VI-4. PCA scores plots for the serum samples analysed by UPLC-MS  
(A) ESI+ mode; (B) ESI− mode. 
Replicate QC injections cluster tightly and the four groups of samples are perfectly separated. 
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To identify the main metabolite features responsible for separation between 
groups, OPLS-DA was performed, first assigning classes corresponding to time point to 
the samples, then corresponding to gender. Resulting cross-validated scores plots are 
displayed in Figure VI-5, with details of the optimised OPLS-DA models. As expected 
considering the perfect separation observed with PCA, OPLS-DA models were 
excellent, with Q2Y values higher than 96% and CV-ANOVA p-values rounded to zero 
by Simca-P+. With sample classes corresponding to time points (Figure VI-5A-B), the 
predictive component discriminated perfectly samples corresponding to 8 and 24 
hours, while the orthogonal component separated the genders. Similarly, with sample 
classes corresponding to genders (Figure VI-5C-D), the predictive component 
discriminated perfectly between males and females, and the first orthogonal 
component separated time points.  
 
 
 
Figure VI-5. Cross-validated scores plot from OPLS-DA of serum samples 
(A) Classes = Time point, ESI+ mode; (B) Classes = Time point, ESI− mode; (C) 
Classes =  Gender, ESI+ mode; (D) Classes = Gender, ESI− mode. 
OPLS-DA models are excellent and the predictive component perfectly discriminates between 
either time points or genders, depending on the sample classes selected for each model.   
 
 
The main metabolite features responsible for separation between classes were 
investigated using corresponding S-plots. Variables at both ends of the “S” were 
examined, as they combined high covariance and high correlation with the predictive 
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component. For these variables, mass spectra of the chromatographic peaks were 
extracted in MassLynxTM from the raw data to assess the importance of the features. 
Features corresponding to isotopes or co-eluting with many other more intense 
features were discarded. Extracted ion chromatograms (EICs) were then plotted from 
XCMS, and those showing reasonable intensities (peak heights in one group 
approximately > 500) were retained. These features are listed in Table VI-3 (time point 
differences) and Table VI-4 (gender differences), and corresponding EICs and 
integrated intensity plots are displayed for some of them in Figure VI-6 and Figure 
VI-7. For most of these features, features with m/z + 1 and the same retention time 
(due to 13C isotope) were also selected as important features but are not listed here. 
For some features with putative formulae suggesting both glycerophosphatidylcholines 
(PC) and glycerophosphatidylethanolamines (PE), MS/MS fragmentation was 
performed in ESI+ mode to determine the specific phospholipid family. 
Regarding differences between time points (Table VI-3 and Figure VI-6), one of 
the key discriminating metabolites, more elevated at time point 8 h than 24 h, was 
identified as hippurate. Hippurate was part of the constructed in-house standard 
database and identification was therefore based on m/z and retention time and 
confirmed by MS/MS fragmentation. The difference in hippurate concentration between 
the two time points could reflect diurnal effects (one sample collected in the afternoon 
(time point 8 h) and one in the early morning (time point 24 h)) and/or dietary effects 
(animals fasted between 8 and 24 h). Diurnal variations of hippurate concentration 
have been previously evidenced in female rat urine, attributed to the fact that rats are 
nocturnal and therefore more active metabolically during the night47. 
Concerning differences between genders (Table VI-4 and Figure VI-7), many of 
the main discriminating features, forming the top right end of the “S” (i.e. higher in 
females), corresponded to the same molecule, with two isomers showing up in both 
ESI modes (UPLC-MS gradients were slightly different for ESI+ and ESI− modes 
(Figure VI-1B), explaining the difference in retention times between modes). The 
compound mass was likely to be 350.2, producing discriminating ions at 351.25 
([M+H]+), 368.28 ([M+NH4]
+), 373.24 ([M+Na]+), 383.28 ([M+CH3OH+H]
+) and 333.24 
([M−H2O+H]+) in ESI+ mode, 349.24 ([M−H]−), 395.24 ([M+HCOO]−) and 417.23 
([M+HCOO+Na−H]−) in ESI− mode. With these hypotheses, calculated exact mass was 
~350.245. Searching METLIN database, the most likely formula was C21H34O4, with 
mass of 350.2457. This formula could correspond to a monoacylglyceride (MG(18:4)) 
or to steroids such as tetrahydrocorticosterone and tetrahydrodeoxycortisol. This was 
not surprising considering the fact that the compound eluted in the bile acid and steroid 
region. Moreover, males and females are known to exhibit different steroid profiles279. 
Further analyses would be necessary to determine the exact identity of the compound 
from the formula, such as comparative MS/MS analysis with authentic standards. 
Determination of rat metabolic profiles by UPLC−MS and integration with cytochrome P450 profiles 
192 
 
Table VI-3. Top metabolite features discriminating between time points in serum 
samples 
Observed 
RT in min 
(ESI 
mode) 
Observed 
m/z (ESI 
mode) 
Putative Ion 
Calculated 
mono-
isotopic 
mass 
(Da) 
ID  
or  
Putative ID 
Group 
differences 
6.43 (+/−) 
180.06 (+) [M+H]
+
 
179.06 Hippurate
a
   T08 
202.05 (+) [M+Na]
+
 
178.05 (−) [M−H]
−
 
224.05 (−) [M+HCOO]
−
 
246.04 (−)  [M+HCOO+Na-H]
−
 
357.11 (−) [2*M−H]
−
 
12.70 (+) 
11.47 (−) 
546.36 (+) [M+H]
+
 
545.35 C28H52NO7P = LPC 20:3
b
  T08 
568.35 (+) [M+Na]
+
 
590.35 (−) [M+HCOO]
−
 
658.34 (−) [M+2*HCOO+Na]
−
 
18.27 (+) 
16.83 (−) 
780.56 (+) [M+H]
+
 
779.55 C44H78NO8P = PC with 36:5
b
  T08 
802.54 (+) [M+Na]
+
 
824.55 (−) [M+HCOO]
−
 
892.54 (−) [M+2*HCOO+Na]
−
 
18.72 (+) 
17.08 (−) 
770.57 (+) [M+H]
+
 
769.57 C43H80NO8P = PC with 35:3
b
  T08 
814.57 (−) [M−H]
−
 
6.32 (−) 326.09 (−) [M−H]
−
 ? 327.09 ? No match within ± 0.02 Da  T08 
2.07 (−) 188.00 (−) [M−H]
−
 ? 189.01 ? C6H7NO4S = Lanthionine ketimine  T08 
7.43 (−) 
283.08 (−) [M−H]
−
 
284.09 
C13H16O7 = p-cresol glucuronide 
C19H12N2O = 6-formylindolo 
carbazole 
C12H16N2O4S1 = Tyr-Cys  
 T24 329.09 (−) [M+HCOO]− 
567.17 (−) [2*M−H]
−
 
6.77 (−) 
187.01 (−) [M−H]
−
 
188.01 
C7H8O6
c
 = 
2-methylaconitate 
Homoaconitate 
 T24 
255.00 (−) [M+HCOO+Na-H]
−
 
2.20 (−) 
103.04 (−) [M−H]
−
 
104.05 
C4H8O3 = 
hydroxy-butyric acid 
hydroxy-isobutyric acid  
hydroxy-butanoic acid  
 T24 
149.04 (−) [M+HCOO]
−
 
207.08 (−) [2*M−H]
−
 
229.07 (−) [2*M+Na−2*H]
−
 
2.20 (+) 
263.02 (+) ? 
   T24 
281.03 (+) ? 
304.05 (+) ? 
337.11 (+) ? 
367.07 (+) ? 
Putative IDs obtained from METLIN or HMDB online databases, based on exact mass with a tolerance mass 
window of ± 0.01 Da.  
UPLC gradients were slightly different for the two ESI modes, explaining the difference in retention times for 
some features. 
LPC=lysophosphatidylcholine; PC=phosphatidylcholine 
PC and LPC notation x:y =  x: total number of carbons in the fatty acid chain(s), y: total number of 
unsaturations in the fatty acid chain(s) 
a
 m/z and RT matching with in-house standard database + comparative MS/MS with authentic standard 
b
 Glycerophosphocholine nature checked by MS/MS fragmentation in ESI+ (fragment ions at 184.1, 125.0, 104.1, 
86.1)  
c 
Tolerance mass window: ± 0.02 Da (no match within ± 0.01 Da) 
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Figure VI-6. S-plots for OPLS-DA models of time point differences in untargeted 
UPLC-MS serum metabolic profiles, with extracted ion chromatograms and normalised 
intensity plots for some of the top discriminating features 
(A) ESI+ mode; (B) ESI− mode. 
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Table VI-4. Top metabolite features discriminating between genders in serum samples 
Observed RT in 
min 
(ESI mode) 
Observed 
m/z (ESI 
mode) 
Putative Ion 
Calculated 
mono-
isotopic 
mass 
(Da) 
ID  
or  
Putative ID 
Group 
differences 
10.60 / 10.92 (+) 
9.02 / 9.23 (−) 
351.25 (+) [M+H]
+
 
350.25 
C21H34O4 = 
Tetrahydrodeoxycortisol 
Tetrahydrocorticosterone 
MG(18:4) 
 Females 
333.24 (+) [M−H2O+H]
+
 
368.28 (+) [M+NH4]
+
 
373.24 (+) [M+Na]
+
 
383.28 (+) [M+CH3OH+H]
+
 
395.24 (−) [M+HCOO]
−
 
349.24 (−) [M−H]
−
 
417.23 (−) [M+HCOO+Na-H]
−
 
10.83 (+) 
9.18 (−) 
347.22 (+) [M+H]
+
 
346.21 
C21H30O4 = 
Corticosterone 
Cortexolone 
Deoxycortisol 
 Females 
391.21 (−) [M+HCOO]
−
 
12.27 (+) 
482.33 (+) [M+H]
+
 
481.32 
C23H48NO7P = 
LPC (15:0) 
LPE (18:0) 
 Males 
504.31 (+) [M+Na]
+
 
15.32 (−) 
15.67 (+) 
579.39 (−) [M−H]
−
 
580.40 
C40H52O3 = Hydroxy-
alloxanthin 
 Males 
625.40 (−) [M+HCOO]
−
 
647.38 (−) [M+HCOO+Na-H]
−
 
581.41 (+) [M+H]
+
 
603.39 (+) [M+Na]
+
 
14.85  (−) 
621.41 (−) [M−H]
−
 
622.41 No match within ± 0.02 Da   Males 667.41 (−) [M+HCOO]− 
689.39 (−) [M+HCOO+Na-H]
−
 
18.33 (+) 
16.87 (−) 
768.56 (+) [M+H]
+
 
767.55 C43H78NO8P = PC with 35:4
a
  Males 
812.55 (−) [M+HCOO]
−
 
Putative IDs obtained from METLIN or HMDB online databases, based on exact mass with a tolerance mass 
window of ± 0.01 Da.  
UPLC gradients were slightly different for the two ESI modes, explaining the difference in retention times for 
some features. 
MG=monoacylglyceride; LPC=lysophosphatidylcholine; LPE=lysophosphatidylethanolamine; PC= 
phosphatidylcholine 
PC, LPC and LPE notation x:y =  x: total number of carbons in the fatty acid chain(s), y: total number of 
unsaturations in the fatty acid chain(s) 
a 
Glycerophosphocholine nature checked by MS/MS fragmentation in ESI+ (fragment ions at 184.1, 125.0, 104.1, 
86.1) 
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Figure VI-7. S-plots for OPLS-DA models of gender differences in untargeted UPLC-
MS serum metabolic profiles, with extracted ion chromatograms and normalised 
intensity plots for some of the top discriminating features  
(A) ESI+ mode; (B) ESI− mode. 
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When multiple putative formulae corresponding to slightly different masses were 
possible for a metabolite, further analyses with high resolution mass spectrometers 
(e.g. orbitrap or FT-ICR) could be performed to determine accurately the metabolite 
mass and its isotopic pattern. Furthermore, fragmentation patterns obtained by high-
accurate MS/MS or MSn could provide useful information. NMR spectroscopy could 
also be employed to provide structural information (after isolation and concentration of 
the metabolite). However, the main objective of this project being the investigation of 
relationships between cytochrome P450 profiles and metabolic profiles, it was decided 
not to further pursue the metabolite identification at this stage, as this was beyond the 
scope of the thesis. Nevertheless, metabolite features that were matching with the 
constructed standard database and could therefore be identified (section II.1.5) were 
further investigated.  
Observation of UPLC-MS serum chromatograms in both ESI modes (Figure 
VI-8) allowed quick identification of a few peaks, based on masses, retention time and 
experience of metabolites present in this type of sample, which had already been 
profiled extensively in our laboratory. It was observed that, in these particular UPLC-
MS runs, these identified compounds tended to elute ~0.2-0.3 minutes later than the 
retention time reported in the constructed database. Mass accuracy was generally < 
0.01 Da, but a shift up to 0.03 Da was observed for a few lysophosphatidylcholine 
peaks. It was therefore decided to use the following window for matching features with 
our in-house database: mass accuracy of ± 0.05 Da and retention time accuracy of ± 
0.5 min.  
This slight difference in retention times compared with the database was not 
surprising, as retention times usually show some (minor) shift between UPLC runs. 
This can arise from between-run differences in column stationary phase (between two 
different columns, but also with the same column due to column ageing), column 
pressure, solvent composition and sample matrix effects. Temperature and flow rates 
were closely monitored by the UPLC instrument and were set to be exactly the same 
between runs, so they should not have an impact on the retention times.  
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Figure VI-8. BPI chromatograms of a serum QC sample  
(A) ESI+ mode; (B) ESI− mode; (C to F) zooms on two retention time zones in ESI+ 
and ESI− mode, showing polar and less polar metabolites. 
Some of the chromatographic peaks identified based on masses, retention time and previous 
experience, are annotated. It is reminded that UPLC gradients are slightly different for the two 
ESI modes, explaining the difference in retention times for the lysophosphatidylcholines (LPCs). 
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For serum samples, 190 features (of 5203, i.e. 4%) yielded at least one potential 
match in the database in ESI+ mode and 165 features (of 5561, i.e. 3%) in ESI− mode. 
The previously obtained S-plots were investigated again, displaying only the matched 
features to determine which “known” compounds were more differentially expressed 
between groups.  
As already mentioned, hippurate was higher at time point 8 hours compared 
with time point 24 hours. This was also the case for LPC 18:2 (observed ions: [M+H]+ in 
ESI+ mode, [M+HCOO]− in ESI− mode) and hydroxyphenylpropionic acid (not 
observed in ESI+ mode, [M−H]− and [M+HCOO]− in ESI− mode). Conversely, creatine 
was higher at time point 24 hours ([M+H]+ and [2*M+H]+ in ESI+ mode, [M−H]− and 
[M+HCOO]− in ESI− mode). As already mentioned for hippurate, diurnal variations 
have been previously reported for creatine in female rat urine samples47.  
Regarding gender differences, pantothenic acid was higher in males ([M+H]+ 
and [M+Na]+ in ESI+ mode, [M−H]−, [2*M−H]− and [M+HCOO]− in ESI− mode), while 
taurochenodeoxycholic acid ([M+H]+, [M+Na]+, [M+NH4]+, [M−H2O+H]
+ and 
[M−2*H2O+H]
+ in ESI+ mode, [M−H]− and [M+HCOO+Na−H]− in ESI− mode) and 
thymidine ([M+H]+, [M+Na]+ and protonated thymine in ESI+ mode, [M+HCOO]− in 
ESI− mode) were higher in females. Tyrosine  was found to be low in females at time 
point 8 hours compared with the three other groups ([M+H]+, [M−NH2]+ and 
[M−COOH]+ in ESI+ mode, [M−H]−, [M+HCOO]−, [2*M−H]− and [2*M+Na−2*H]− in ESI− 
mode).  
 
VI.3.2.1.2. Targeted analysis of serum triglycerides 
 Targeted analysis of triglycerides was conducted at TES on serum samples. 
The two time points were analysed into two separate UPLC-MS runs, with two dilutions 
for each sample to maximise the range of detectable triglycerides. After manual 
investigation of intensities for a few triglycerides covering the whole range of intensity 
for both dilutions, it was decided to focus the data analysis on the 1/2 dilution, for which 
more peaks could be seen without major detector saturation issues. Around 150 
triglycerides were identified for each time point based on exact mass (after de-
isotoping), as detailed in the experimental section of this chapter (section VI.2.3.3). 
Figure VI-9 shows the results obtained by PCA and gender OPLS-DA for the two time 
points. On PCA scores plots (Figure VI-9A-B), separation between genders could be 
seen, but there was some overlap. Performing OPLS-DA on gender produced good 
models, with Q2Y higher than 83% and CV-ANOVA p-values less than 2e-8. The cross-
validated scores plot perfectly separated the genders for the 8 h time point (Figure 
VI-9C), while male rat 1 was close to the females for the 24 h time point (Figure VI-9D) 
(the separation was perfect on the classical scores plot (not using cross-validated 
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predictive scores)). From the S-plots, which were similar for both time points (Figure 
VI-9E-F), it was obvious that triglycerides discriminating between genders were all 
higher in males, with almost no triglycerides located in the bottom left quadrant. This 
was consistent with what had been observed from the serum biochemistry parameters 
(section VI.3.1.3), showing higher triglyceride levels in males, as well as with results 
previously obtained by NMR by Bollard et al.42. The top discriminating triglycerides for 
each time point, circled with blue in the S-plots, are listed in Table VI-5.  
 
 
 
Figure VI-9. PCA and gender OPLS-DA for triglycerides in serum samples 
(A) PCA scores plot for time point 8 h; (B) PCA scores plot for time point 24 h; (C) 
gender OPLS-DA cross-validated scores plot for time point 8 h; (D) gender OPLS-DA 
cross-validated scores plot for time point 24 h; (E) gender OPLS-DA S-plot for time 
point 8 h; (F) gender OPLS-DA S-plot for time point 24 h. 
Separation between genders can be seen in PC1 vs. PC2 scores plots, but with some overlap. 
With OPLS-DA, good models are obtained to discriminate between genders for each time point. 
The top discriminating triglycerides, circled with blue in the S-plots, are all higher in males. 
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Table VI-5. Top discriminating serum triglycerides between genders (higher in males) 
for both time points 
A)     Time point 8 h 
Triglyceride 
Observed m/z of 
NH4
+
 adduct 
Retention time (min) 
ppm 
accuracy 
p[1] p(corr)[1] 
C56:8 920.77 4.7 4 0.18 0.85 
C58:9 946.79 4.7 5 0.17 0.79 
C56:9 918.76 4.4 7 0.17 0.79 
C58:8 948.81 5.4 5 0.16 0.79 
C52:6 868.74 5.1 1 0.16 0.74 
C56:7 922.79 5.5 5 0.15 0.78 
C54:8 892.74 4.5 4 0.14 0.68 
C60:7 978.85 5.5 4 0.14 0.72 
C54:8 892.74 4.3 2 0.14 0.76 
C58:7 950.82 5.0 3 0.14 0.73 
C58:9 946.79 5.1 3 0.14 0.75 
C54:6 896.77 5.5 1 0.14 0.70 
C54:7 894.76 5.2 7 0.13 0.66 
C54:7 894.76 5.0 4 0.13 0.73 
C58:11 942.76 3.9 4 0.13 0.74 
C58:10 944.78 4.4 6 0.13 0.79 
C56:8 920.78 5.2 7 0.13 0.70 
C52:7 866.73 4.4 4 0.12 0.81 
C60:10 972.81 5.0 5 0.12 0.68 
  
B)     Time point 24 h 
Triglyceride 
Observed m/z of 
NH4
+
 adduct 
Retention time (min) 
ppm 
accuracy 
p[1] p(corr)[1] 
C54:6 896.79 5.5 19 0.18 0.81 
C54:7 894.76 4.9 7 0.16 0.78 
C50:3 846.77 6.4 13 0.15 0.71 
C54:6 896.78 5.6 10 0.15 0.73 
C52:5 870.76 5.5 7 0.15 0.75 
C52:3 874.80 7.1 18 0.14 0.71 
C54:4 900.82 7.0 18 0.14 0.71 
C52:5 870.77 5.7 17 0.14 0.74 
C54:7 894.77 5.4 16 0.14 0.78 
C56:6 924.81 6.4 4 0.13 0.76 
C50:2 848.78 7.2 16 0.13 0.68 
C56:7 922.79 6.1 4 0.13 0.76 
C56:4 928.84 6.3 12 0.12 0.76 
C56:5 926.82 6.8 5 0.12 0.76 
C58:9 946.79 5.0 5 0.12 0.85 
C56:9 918.76 4.6 6 0.12 0.84 
C58:7 950.83 6.3 13 0.12 0.81 
C58:8 948.81 5.7 7 0.12 0.82 
Notation Cx:y = x:total number of carbons in the fatty acid chains, y: total number of unsaturations in the fatty 
acid chains.   
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No differences between deliveries were observed from the PCA scores plot. 
This delivery homogeneity was confirmed by failure in producing valid OPLS-DA 
models for delivery groups.  
 
VI.3.2.2. Urine samples 
PCA scores plot resulting from the untargeted UPLC-MS analysis of the 80 
urine samples are displayed in Figure VI-10. The QCs were closely clustered, 
indicating good analytical stability over the run. A clear separation between the four 
classes was obtained in both ESI modes in the PC1 vs. PC2 scores plots (Figure 
VI-10A-B): PC1 (explaining respectively 37% and 34% of the total variance for ESI+ 
and ESI− mode) separated the time points and PC2 (respectively 29% and 27% for 
ESI+ and ESI− mode) separated the gender. Figure VI-10C-D displays the PC1 vs. 
PC3 scores plots, with a colour code allowing for visualisation of delivery groups. 
Although there was no obvious separation between deliveries, the 5 females from 
delivery G2 all clustered together for the 8 h time point in ESI+ mode (circled with 
blue). In ESI− mode, these 5 females clustered together as well but also with the rest 
of the animals. This separation was not observed for the 24 h time point. As this 
clustering was observed only for the females of one delivery at one time point and as 
PC3 explained only 5% of the variance, it was considered as negligible.  
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Figure VI-10. PCA scores plot for the urine samples analysed by UPLC-MS 
(A) ESI+ mode, PC1 vs. PC2; (B) ESI− mode, PC1 vs. PC2; (C) ESI+ mode, PC1 vs. 
PC3; (D) ESI− mode, PC1 vs. PC3. 
Shapes and colours of observations in plots (A) and (B) correspond to time points and genders. 
Replicate QC injections cluster tightly and the four groups of samples are perfectly separated. 
For plots (C) and (D), showing PC3, shapes are the same as in plots (A) and (B), while colours 
of observations correspond to delivery groups. There is no obvious separation between 
deliveries except that the 5 females from delivery G2 all cluster together for the 8 h time point in 
ESI+ mode. 
 
 
Two OPLS-DA models were then constructed for each ESI mode, the first one 
with classes corresponding to time points and the second one to genders. 
Corresponding cross-validated scores plots, as well as details of the OPLS-DA models 
can be observed in Figure VI-11. OPLS-DA models were excellent, with Q2Y values 
higher than 97%, CV-ANOVA p-values rounded to zero by Simca-P+ and perfect 
separation between observations on cross-validated scores plot. This was not 
surprising as clear separation had been observed by unsupervised PCA.  
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Figure VI-11. Cross-validated scores plot from OPLS-DA of urine samples 
(A) Classes = time point, ESI+ mode; (B) Classes = time point, ESI− mode; 
(C) Classes = gender, ESI+ mode; (D) Classes = gender, ESI− mode. 
OPLS-DA models are excellent and the predictive component perfectly discriminates between 
either time points or genders, depending on the sample classes selected for each model.   
 
 
Following the same approach as with serum samples, variables at both ends of 
the “S” in S-plots were investigated. The main features responsible for separation 
between classes are listed in Table VI-6 (time point differences) and Table VI-7 
(gender differences), and corresponding EICs and integrated intensity plots are 
displayed for some of them in Figure VI-12 and Figure VI-13. Regarding time point 
differences, many features elevated in urine at time point 8 h could correspond to 
flavonoids from food, which was consistent with the animals having access to food for 
the first eight hours. Some other features elevated at time point 8 h compared to 24 h 
were identified collectively as pantothenic acid. This could be attributed to the fasting of 
the rats between 8 and 24 h, reducing the excretion of pantothenic acid in the urine, 
consistent with findings from Reibel et al.280. Reibel investigated the effect of fasting on 
pantothenic acid in rats and showed that fasting resulted in reduced urinary 
pantothenic acid excretion. He suggested this could be explained by regulatory 
mechanisms in the organism to maintain whole-body pantothenic acid despite 
fasting280. Regarding gender differences, several discriminating features were likely to 
correspond to steroids, which was not really surprising as males and females are 
known to exhibit differences in steroid metabolism and excretion46,279,281. 
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Table VI-6. Top metabolite features discriminating between time points in urine 
samples 
Observed 
RT in min 
Observed 
m/z (ESI 
mode) 
Putative Ion 
Calculated 
mono-
isotopic 
mass 
(Da) 
ID  
or  
Putative ID 
Group 
differences 
2.48 
271.14 (+) [M+H]
+
 
270.13 C17H18O3 = Flavonoid from food?  T08 
269.13 (−) [M−H]
−
 
3.07 
220.12 (+) [M+H]
+
 
219.11 Pantothenic acid
a
  T08 
242.10 (+) [M+Na]
+
 
461.21 (+) [2*M+Na]
+
 
218.10 (−) [M−H]
−
 
437.22 (−) [2*M−H]
−
 
4.27 
431.10 (+) [M+H]
+
 
430.09 
C21H18O10 = Flavonoid from 
food? 
 T08 
861.20 (+) [2*M+H]
−
 
429.08 (−) [M−H]
−
 
859.19 (−) [2*M−H]
−
 
2.77 347.10 (−) [M−H]
−
 348.11 C21H16O5 = Flavonoid from food?  T08 
3.88 
273.01 (−) [M−H]
−
 
274.02 
C6H11O10P =  
Glucuronic acid 1-phosphate 
 T08 547.03 (−) [2*M−H]− 
569.01 (−) [2*M+Na−2*H]
−
 
4.67 
174.11 (+) [M+H]
+
 
173.11 
C8H15NO3 = 
Hexanoylglycine 
Isovalerylalanine 
Isovalerylsarcosine 
 T24 
172.10 (−) [M−H]
−
 
240.09 (−) [M+HCOO+Na−H]
−
 
218.11 (−) [M+HCOO]
−
 
4.12 
276.12 (+) [M+H]
+
 
275.12 
C10H17N3O6 =  
Glu-Gly-Ala 
Ala-Asp-Ala 
Gln-Glu 
C14H17N3O3 = Trp-Ala 
 T24 
274.11 (−) [M−H]
−
 
4.77 
304.16 (+) [M+H]
+
 
303.15 
C11H21N5O5 = Arg-Glu 
C16H21N3O3 = Trp-Val 
C12H21N3O6 = tripeptide
b
 
 T24 
302.15 (−) [M−H]
−
 
5.15 
243.12 (−) [M−H]
−
 
244.13 
C9H16N4O4 = 
Guanidinoproclavaminic acid
c
  
 T24 
245.14 (+) [M+H]
+
 
227.13 (+) [M−H2O+H]
+
 
267.12 (+) [M+Na]
+
 
5.30 
199.10 (−) [M−H]
−
 
200.10 
C10H16O4 = 
Decenedioic acid 
Dioxodecanoic acid 
 T24 
245.12 (−) [M+HCOO]
−
 
399.20 (−) [2*M−H]
−
 
421.19 (−) [2*M+Na−2*H]
−
 
201.11 (+) [M+H]
+
 
4.85 
197.08 (−) [M−H]
−
 
198.09 
 C10H14O4 = 
5-tert-butyl-4-
hydroxymethylfuran-2-carboxylic 
acid 
 T24 
219.07 (−) [M+Na−2*H]
−
 
395.17 (−) [2*M−H]
−
 
199.10 (+) [M+H]
+
 
181.09 (+) [M−H2O+H]
+
 
Putative IDs obtained from METLIN or HMDB online databases, based on exact mass with a tolerance mass 
window of ± 0.01 Da. 
Ala=alanine; Arg=arginine; Asp=aspartic acid; Gln=glutamine; Glu=glutamic acid; Gly=glycine; Ile=isoleucine; 
Leu=leucine; Pro=proline; Ser=serine; Thr=threonine; Trp=tryptophan; Val=valine. 
a
 m/z and RT matching with in-house standard database + comparative MS/MS with authentic standard 
b
 tripeptide: Pro-Thr-Ser or Val-Glu-Gly or Ile-Asp-Gly or Leu-Asp-Gly or Asp-Val-Ala 
c 
Tolerance mass window: ± 0.015 Da (no match within ± 0.01 Da) 
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Figure VI-12. S-plots for OPLS-DA models of time point differences in UPLC-MS urine 
metabolic profiles, with extracted ion chromatograms and normalised intensity plots for 
some of the top discriminating features 
 (A) ESI+ mode; (B) ESI− mode. 
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Table VI-7. Top metabolite features discriminating between genders in urine samples 
Observed 
RT in min 
Observed 
m/z (ESI 
mode) 
Putative Ion 
Calculated 
mono-
isotopic 
mass 
(Da) 
ID  
or  
Putative ID 
Group 
differences 
6.23 
367.25 (+) [M+H]
+
 
366.24 
C21H34O5 = 
Tetrahydrocortisol 
Cortolone 
 Females 
408.27 (+) [M+ACN+H]
+
 
733.49 (+) [2*M+H]
+
 
365.23 (−) [M−H]
−
 
411.24 (−) [M+HCOO]
−
 
731.48 (−) [2*M−H]
−
 
4.47 
445.19 (+) [M−H2O+H]
+
 
462.19 C21H26N4O8 = Trp-Glu-Glu
a
  Females 
463.20 (+) [M+H]
+
 
461.18 (−) [M−H]
−
 
945.38 (−) [2*M+Na−2*H]
−
 
5.85 
345.21 (+) [M−H2O+H]
+
 
362.21 
C21H30O5 = 
Cortisol 
Dihydrocortisone 
Hydroxycorticosterone 
 Females 363.22 (+) [M+H]+ 
407.21 (−) [M+HCOO]
−
 
2.80 
321.04 (−) [M−H]
−
 
322.05 
C10H15N2O8P = 
Deoxythymidine monophosphate 
 Females 
323.05 (+) [M+H]
+
 
6.13 
367.21 (−) [M+HCOO]
−
 
322.21 No match within ± 0.02 Da  Females 
321.21 (−) [M−H]
−
 
323.22 (+) [M+H]
+
 
364.25 (+) [M+ACN+H]
+
 
3.37 
206.04 (+) [M+H]
+
 
205.04 Xanthurenic acid
b
  Males 
204.03 (−) [M−H]
−
 
4.70 
185.12 (+) [M−H2O+H]
+
   
202.12  
C9H18N2O3
c
 =  
Leu-Ala 
Ile-Ala 
 Males 
167.11 (+) [M−2*H2O+H]
+
   
203.13 (+) [M+H]
+
   
220.15 (+) [M+NH4]
+
   
4.88 
363.17 (−) [M−H]
−
 
364.17 
C17H24N4O5 = Phe-Ala-Gln 
C14H28N4O5S = Met-Lys-Ser 
 Males 
727.35 (−) [2*M−H]
−
 
365.18 (+) [M+H]
+
 
382.21 (+) [M+NH4]
+
 
387.16 (+) [M+Na]
+
 
4.15 
349.12 (−) [M−H]
−
 
350.12 
C18H22O5S = Estrone 3-sulfate 
C12H22N4O6S = 
Gln-Cys-Thr  
 Met-Ser-Asn 
 Males 
699.24 (−) [2*M−H]
−
 
368.16 (+) [M+NH4]
+
 
373.11 (+) [M+Na]
+
 
Putative IDs obtained from METLIN or HMDB online databases, based on exact mass with a tolerance mass 
window of ± 0.01 Da.  
Ala=alanine; Asn=asparagine; Cys=cysteine; Gln=glutamine; Glu=glutamic acid; Ile=isoleucine; Leu=leucine; 
Lys=lysine; Met=methionine; Phe=phenylalanine; Ser=serine; Thr=threonine; Trp=tryptophan. 
a 
Tolerance mass window: ± 0.02 Da (no match within ± 0.01 Da)
 
b
 Only possibility in online databases based on exact mass, and ESI+ MS/MS fragmentation identical to Metlin 
database 
c 
Tolerance mass window: ± 0.015 Da (one match within ± 0.01 Da: C10H18O4 = sebacic acid but RT not matching 
with in-house standard database (RT of sebacic acid = 5.52 min)) 
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Figure VI-13. S-plots for OPLS-DA models of gender differences in UPLC-MS urine 
metabolic profiles, with extracted ion chromatograms and normalised intensity plots for 
some of the top discriminating features 
(A) ESI+ mode; (B) ESI− mode. 
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As with serum samples, UPLC-MS chromatograms were investigated to decide 
which retention time window should be used for the matching with the in-house 
database (Figure VI-14). It was observed that all the identified peaks had exactly the 
same retention time and mass as in the database. It was therefore decided to use a 
smaller window compared with serum for the matching: mass accuracy of ± 0.02 Da 
and retention time accuracy of ± 0.3 minutes.  
For ESI+ mode, 153 features (of 5261, i.e. 3%) yielded at least one potential 
match in the database, and this number was 134 (of 6676, i.e. 2%) for ESI− mode. The 
S-plots were investigated again, displaying only the matched features. 
Regarding time point differences, as already mentioned, pantothenic acid was 
higher at time point 8 h for both genders. This was also the case for α-ketoglutaric acid 
(not detected in ESI+ mode, [M−H]− and [2*M+Na−2*H]− in ESI− mode) and glutaric 
acid ([M−H2O+H]
+ in ESI+ mode, [M−H]− in ESI− mode). Diurnal variation for 
α-ketoglutaric acid in urine had been previously observed by Williams et al.275 in obese 
Zucker rats, with an increase in the evening samples. The increase observed here at 
time point 8 h (end of the afternoon) compared to time point 24 h (early morning) was 
consistent with Williams’ findings. Conversely, sebacic acid ([M+H]+ in ESI+ mode, 
[M−H]−, [M+Na−2*H]−, [M+HCOO]− and [M+HCOO+Na−H]− in ESI− mode) and suberic 
acid ([M+H]+ in ESI+ mode, [M−H]− and [2*M+Na−2*H]− in ESI− mode) were higher at 
time point 24 h (fasted rats) for each gender, which was in agreement with previous 
reports of increased amounts of sebacic acid and suberic acid observed in urine under 
fasting conditions282. 
Concerning gender differences, deoxycytidine was found to be higher in males 
([M+H]+ and [2*M+H]+ in ESI+ mode, [M+HCOO]− in ESI− mode). Many features 
showing up as higher in females corresponded to bile acids (most of them being 
detected only in female samples): glycocholic acid ([M+H]+, [M+Na]+, [M−H2O+H]
+ and 
[M−2*H2O+H]
+  in ESI+ mode, [M−H]− in ESI− mode), cholic acid ([M+NH4]
+, 
[M−H2O+H]
+, [M−2*H2O+H]
+ and [M−3*H2O+H]
+  in ESI+ mode, [M−H]− and 
[M+HCOO]− in ESI− mode), taurocholic acid ([M+H]+, [M+Na]+, [M+NH4]
+ and 
[M−H2O+H]
+  in ESI+ mode, [M−H]− and [M+Na+HCOO-H]− in ESI− mode) and 
tauromuricholic acid ([M+H]+, [M+NH4]
+ and [M−2*H2O+H]
+  in ESI+ mode, [M−H]− and 
[M+Na+HCOO-H]− in ESI− mode). These findings were consistent with previous 
reports which showed that female rats exhibited elevated urinary bile acids compared 
to males, reflecting the increased rate of cholesterol and bile acid synthesis and 
metabolism in females42. Among females, cholic acid levels were generally higher at 
time point 8 h compared with 24 h, with notable variability between females at time 
point 8 h. In particular, the 5 females of the second delivery showed elevated values for 
this time point compared with the rest of the females. For the other bile acids cited 
above (glycocholic acid, taurocholic acid and tauromuricholic acid), levels at both time 
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points were similar, but one female from the second delivery exhibited notably high 
values at 24 h for these three bile acids compared to the other females.  
 
 
 
Figure VI-14. BPI chromatograms of a urine QC sample 
(A) ESI+ mode; (B) ESI- mode. 
Some of the chromatographic peaks identified based on masses, retention time and previous 
experience, are annotated.  
 
 
VI.3.2.3. Liver samples 
VI.3.2.3.1. Liver untargeted metabolic profiling 
Untargeted UPLC-MS profiling of the liver samples resulted into four datasets, 
corresponding to aqueous and organic extracts in both ESI modes. PCA was 
performed on these four datasets and PC1 vs. PC2 scores plots are displayed in 
Figure VI-15. For all datasets, the QC samples were tightly clustered, ensuring that 
analytical platform variability was lower than biological variability. For aqueous extracts 
(Figure VI-15A-B), separation was seen between genders, but two subgroups 
appeared within each gender. Further examination of the samples revealed that this 
within-gender clustering corresponded to the different sample preparation batches. 
Although the samples had been run all together in one UPLC-MS batch, they had been 
prepared in two separate batches for practical reasons, on the same day, one after the 
other, with the same solvent solutions. This clearly had an impact on the metabolic 
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profiles and highlighted the importance of preparing all the samples together whenever 
possible, or otherwise dividing the samples equally from the different groups into the 
preparation batches (which had been done here). Looking at the scores plot and R² 
values for the corresponding PCs, the variability coming from batch preparation 
seemed to have similar importance as gender variability. This batch separation was not 
obvious for the organic extracts, showing that polar metabolites were more affected by 
the preparation batches than non-polar metabolites such as lipids. This variability for 
aqueous extracts could also come from the evaporation step in the Speedvac, which 
was performed separately for both batches, although with exactly the same conditions. 
Conversely, the organic extracts were evaporated all together. Regarding differences 
between animal deliveries, no separation was observed in the PCA models, indicating 
that there were no major differences in liver metabolic profiles resulting from the 
delivery groups. 
 
 
 
Figure VI-15. PCA scores plots for the untargeted UPLC-MS analysis of liver samples 
(A) Aqueous extracts, ESI+ mode; (B) Aqueous extracts, ESI− mode; (C) Organic 
extracts, ESI+ mode; (D) Organic extracts, ESI− mode. 
For the four datasets, replicate QC injections cluster tightly and separation is seen between 
males and females. For aqueous extracts, two subgroups can be identified within each gender, 
corresponding to the two sample preparation batches. 
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OPLS-DA was then performed with classes corresponding to genders, to filter 
the batch preparation variation and allow for identification of main metabolite features 
responsible for gender separation. Corresponding cross-validated scores plots with 
details of the optimised models can be observed in Figure VI-16. The models were 
excellent (perfect separation between genders along the predictive component, Q2Y 
values higher than 96%, CV-ANOVA p-values less than 7e-25). For the aqueous 
extracts, the first orthogonal component corresponded to preparation batches, which 
was expected considering the PCA results.  
 
 
 
Figure VI-16. Cross-validated scores plot from OPLS-DA of liver samples 
(A) Aqueous extracts, ESI+ mode; (B) Aqueous extracts, ESI− mode; (C) Organic 
extracts, ESI+ mode; (D) Organic extracts, ESI− mode.  
OPLS-DA models are excellent and the predictive component perfectly discriminates between 
males and females for each dataset. For aqueous extracts, the first orthogonal component 
separates the sample preparation batches. 
 
 
Figure VI-17 and Figure VI-18 display the S-plots corresponding to the 
predictive component, with some of the main features responsible for gender 
separation. These features are also listed in Table VI-8 and Table VI-9. 
For the aqueous extracts (Figure VI-17 and Table VI-8), many features at the 
upper right of the S-plot (higher in females) corresponded to the same compound as 
observed for gender separation in serum samples, with two isomers eluting 21 seconds 
apart in ESI+ mode and 14 seconds apart in ESI− mode. As mentioned for serum, it 
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was likely to be a metabolite with formula C21H34O4, with mass of 350.2457, and could 
be a monoacylglyceride (MG(18:4)) or steroids such as tetrahydrocorticosterone and 
tetrahydrodeoxycortisol. 
For the organic extracts (Figure VI-18 and Table VI-9), most discriminating 
features belonged to high mass compounds eluting at high organic mobile phase, with 
putative identities corresponding to lipids. 
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Table VI-8. Top metabolite features discriminating between genders in aqueous 
extracts of liver samples 
Observed RT in 
min 
(ESI mode) 
Observed 
m/z (ESI 
mode) 
Putative Ion 
Calculated 
mono-
isotopic 
mass 
(Da) 
ID  
or  
Putative ID 
Group 
differences 
10.60 / 10.92 (+) 
9.01 / 9.23 (-) 
351.27 (+) [M+H]
+
 
350.25 
C21H34O4 = 
Tetrahydrodeoxycortisol 
Tetrahydrocorticosterone 
MG(18:4) 
 Females 
333.26 (+) [M−H2O+H]
+
 
368.29 (+) [M+NH4]
+
 
373.25 (+) [M+Na]
+
 
383.29 (+) [M+CH3OH+H]
+
 
701.49 (+) [2*M+H]
+
 
723.47 (+) [2*M+Na]
+
 
395.24 (−) [M+HCOO]
−
 
349.24 (−) [M−H]
−
 
699.49 (−) [2*M−H]
−
 
10.55 (+) 
353.28 (+) [M+H]
+
 
352.27 
C21H36O4
a
 = 
MG(18:3) 
Methane-epoxy prostaglandin F1α 
 Females 335.27 (+) [M−H2O+H]+ 
375.26 (+) [M+Na]
+
 
6.59 (+/−) 
646.35 (+) [M+H]
+
 
645.35 No match within ± 0.02 Da  Females 
644.34 (−) [M−H]
−
 
690.35 (−) [M+HCOO]
−
 
758.34 (−) [M+2*HCOO+Na]
−
 
7.40 (−) 445.19 (−) [M−H]
− 
? 446.20 ? 
C24H30O8 = Estrone glucuronide 
C20H26N6O6 = 
His-Gln-Tyr or Asn-Gln-Trp 
 Females 
10.26 (−) 493.26 (−) [M−H]
−
 ? 494.27 ? 
 C30H38O6
b
= 
Pentahydroxy-3'-geranyl-5-
prenyldihydrochalcone 
 Females 
6.68 (+) 
6.63 (−) 
305.18 (+) [M+H]
+
 
304.17 
C12H24N4O5
a
 = 
Lys-Thr-Gly or Ala-Ser-Lys 
 Males 
303.15 (−) [M−H]
−
 
18.03 (+) 
780.54 (+) [M+H]
+
 
779.54 
C44H78NO8P
a 
= PC with 36:5 
C40H77NO11S
a
 = C16 sulfatide 
 Males 
802.52 (+) [M+Na]
+
 
1.05 (−) 224.02 (−) [M−H]
− 
? 225.03 ? No match within ± 0.02 Da  Males 
8.07 (−) 318.14 (−) [M−H]
− 
? 319.15 ? 
C14H25NO5S =  
4-hydroxy nonenal mercapturic acid 
C16H21N3O4 = Phe-Pro-Gly 
C13H25N3O4S1 = tripeptide
c 
C12H21N3O7 = tripeptide
d
 
 Males 
Putative IDs obtained from METLIN or HMDB online databases, based on exact mass with a tolerance mass 
window of ± 0.01 Da.  
UPLC gradients were slightly different for the two ESI modes, explaining the difference in retention times for 
some features. 
MG=monoacylglyceride; PC=phosphatidylcholine 
Ala=alanine; Asn=asparagine; Asp=aspartic acid; Cys=cysteine; Gln=glutamine; Glu=glutamic acid; 
Gly=glycine; His=histidine; Ile=isoleucine; Leu=leucine; Lys=lysine; Met=methionine; Phe=phenylalanine; 
Pro=proline; Ser=serine; Thr=threonine; Trp=tryptophan; Tyr=tyrosine; Val=valine. 
a
 Tolerance mass window: ± 0.015 Da (no match with ± 0.01 Da) 
b
 Tolerance mass window: ± 0.02 Da (no match with ± 0.015 Da) 
c
 Tripeptide: Val-Ala-Met or Ile-Met-Gly or Leu-Met-Gly or Cys-Val-Val 
d
 Tripeptide: Ala-Thr-Glu or Val-Ser-Asp 
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Figure VI-17. S-plots for OPLS-DA models of gender differences in untargeted UPLC-
MS metabolic profiles of aqueous liver extracts, with extracted ion chromatograms 
(EICs) and normalised intensity plots for some of the top discriminating features 
 (A) ESI+ mode; (B) ESI− mode. 
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Table VI-9. Top metabolite features discriminating between genders in organic extracts 
of liver samples 
Observed RT 
in min 
(ESI mode) 
Observed 
m/z (ESI 
mode) 
Putative Ion 
Calculate
d mono-
isotopic 
mass 
(Da) 
ID  
or  
Putative ID 
Group 
differences 
8.85 (+) 
10.46 (−) 
808.59 (+) [M+H]
+
 
807.60 C46H82NO8P = PC with 38:5
a
  Males 852.63 (−) [M+HCOO]− 
920.59 (−) [M+2*HCOO+Na]
−
 
5.63/5.78 (+) 
7.53/7.63 (−) 
790.57 (+) [M+H]
+
 
789.57 
C46H80NO7P = 
Plasmalogen PC with 38:6
a   Males 834.57 (−) [M+HCOO]
−
 
902.56 (−) [M+2*HCOO+Na]
−
 
2.59 (+) 
4.36 (−) 
660.43 (+) [M+H]
+
 
659.42 C35H66NO8P = PE with 30:2  Males 704.42 (−) [M+HCOO]
−
 
772.40 (−) [M+2*HCOO+Na]
−
 
3.29 (+) 
5.33 (−) 
700.46 (+) [M+H]
+
 
699.46 C38H70NO8P = PE with 33:3  Males 744.45 (−) [M+HCOO]
−
 
812.44 (−) [M+2*HCOO+Na]
−
 
7.86 (−) 683.45 (−) 
[M-H]
−
 or  
[M+HCOO]
− 
? 
684.45? 
638.45? 
684.45: No match within ± 0.06 Da 
638.45: C41H66O5 = DG with 38:7
b
 
 Males 
9.87 (+) 
11.43 (−) 
834.61 (+) [M+H]
+
 
833.62 C48H84NO8P = PC with 40:6
a
  Females 878.65 (−) [M+HCOO]− 
946.60 (−) [M+2*HCOO+Na]
−
 
5.26 (+) 367.34 (+) [M+H]
+
 366.33 C24H46O2 = Nervonic acid   Females 
13.75 (−) 
12.48 (+) 
828.67 (−) [M+HCOO]
−
 
783.67 
C46H89NO8 =  
Glucosylceramide (d18:1/22:0) 
Galactosylceramide (d18:1/22:0) 
C46H90NO6P = 
CerP(d18:1/26:1(17Z)) 
 Females 
896.66 (−) [M+2*HCOO+Na]
−
 
784.68 (+) [M+H]
+
 
806.66 (+) [M+Na]
+
 
14.49 (−) 
13.38 (+) 
842.69 (−) [M+HCOO]
−
 
797.69 No match within ± 0.06 Da  Females 
910.68 (−) [M+2*HCOO+Na]
−
 
798.70 (+) [M+H]
+
 
820.68 (+) [M+Na]
+
 
Putative IDs obtained from METLIN or HMDB online databases, based on exact mass with a tolerance mass 
window of ± 0.03 Da.  
UPLC gradients were different for the two ESI modes, explaining the difference in retention times between 
modes. 
PC=phosphatidylcholine; PE=phosphatidylethanolamine; DG=diglyceride; CerP=ceramide 1-phosphate 
a
 Glycerophosphocholine nature checked by MS/MS fragmentation in ESI+ (fragment ions at 184.1, 125.0, 104.1, 
86.1) 
b
 Tolerance mass window: ± 0.045 Da (no match with ± 0.03 Da) 
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Figure VI-18. S-plots for OPLS-DA model of gender differences in UPLC-MS 
untargeted metabolic profiles of organic liver extracts, with extracted ion 
chromatograms (EICs) and normalised intensity plots for some of the top discriminating 
features  
(A) ESI+ mode; (B) ESI− mode. 
Determination of rat metabolic profiles by UPLC−MS and integration with cytochrome P450 profiles 
217 
 
As previously, chromatograms were investigated to determinate the time and 
mass windows to use for matching with our in-house database (Figure VI-19).  
For aqueous extracts (Figure VI-19A-B), it was observed that identified peaks 
tended to elute 0.2-0.3 seconds later than the time reported in the database. Mass 
accuracy was generally good, but a shift up to 0.02 Da was observed for a few peaks. 
It was therefore decided to use the same window as serum for matching features with 
the database: mass accuracy of ± 0.05 Da and retention time accuracy of ± 0.5 
minutes. For ESI+ mode, 228 features (of 4375, i.e. 5%) yielded at least one potential 
match in the database, and this number was 226 (of 5445, i.e. 4%) for ESI− mode. The 
S-plots were investigated again, displaying only the matched features. Although no 
compounds in the database exhibited strong differences between genders, it was 
observed that taurocholic acid ([M+H]+, [M+NH4]
+, [M+Na]+ and [M−H2O+H]
+ in ESI+ 
mode, [M−H]– and [M+HCOO+Na−H]– in ESI− mode) and LPC 18:0 ([M+H]+ and 
[M+Na]+ in ESI+ mode, [M+HCOO]– and [M+2*HCOO+NA]– in ESI− mode) were higher 
in females, while pantothenic acid tended to be higher in males ([M+H]+ and [M+Na]+ in 
ESI+ mode, [M−H]−, [2*M−H]− and [M+HCOO]− in ESI− mode). 
For organic extracts (Figure VI-19C-D), most identified peaks eluted exactly at 
the same time as reported in our in-house database, while a mass shift up to 0.06 Da 
was observed for a few lipid peaks. It was thus decided to use the following window for 
matching features with the database: mass accuracy of ± 0.07 Da and retention time 
accuracy of ± 0.2 minutes. Organic liver extracts contained mostly lipids and there were 
few lipid standard compounds in the database, so only a few peaks could be matched. 
The database should be extended by running more lipid standard compounds to help 
with peak identification in organic extracts. Looking at the features that matched with 
the database, it was observed that LPC 18:0 ([M+H]+ and [M+Na]+ in ESI+ mode, 
[M+HCOO]– in ESI− mode)  was higher in females.  
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Figure VI-19. BPI chromatograms of liver QC samples 
(A) Aqueous extract, ESI+; (B) Aqueous extract, ESI−; (C) Organic extract, ESI+; 
(D) Organic extract, ESI−. 
Some of the chromatographic peaks identified based on masses, retention time and 
fragmentation pattern (for PCs), are annotated.  
Abbreviations: LPC=lysophosphatidylcholine; PC=phosphatidylcholine; TCA=Taurocholic acid; TCDCA= 
Taurochenodeoxycholic acid; TDCA=Taurodeoxycholic acid. 
Determination of rat metabolic profiles by UPLC−MS and integration with cytochrome P450 profiles 
219 
 
VI.3.2.3.2. Targeted analysis of liver triglycerides 
For the triglyceride analysis performed at TES, three dilutions were run for each 
sample to maximise the range of detectable triglycerides. After investigation of the 
intensities of the identified triglycerides in the three dilutions, it was decided to base the 
analysis on the intermediate dilution (1/20), as many peaks did not appear in the 1/100 
diluted samples and a few peaks were saturated in the 1/5 dilution. The 120 samples 
(40 animals × 3 dilutions) had been analysed by UPLC-MS in two separate batches 
(with the 3 dilutions of 10 male and 10 female samples in each batch) to avoid source 
contamination effects observed when running a large batch of liver extracts without 
cleaning the MS source. Looking at the intensities obtained for the test mixture of 
seven triglycerides regularly injected within each batch, it appeared that intensities in 
run 2 were lower than in run 1. Approximately half of the 344 peaks identified as 
triglycerides exhibited low intensities in run 2 and were discarded before multivariate 
analysis. Two strong outliers (corresponding to two male samples from run 1) showed 
up when first applying PCA to the 40 samples with the 155 remaining identified 
triglycerides. Investigation of these samples revealed that one had not been injected 
properly and the other one exhibited really low intensities for all peaks compared to the 
other samples, which might be due to a dilution issue or an injection problem. These 
two samples were excluded from the analysis and PCA was performed again (Figure 
VI-20). The PC1 vs. PC2 scores plot (Figure VI-20A), explaining 87% of the variation 
in the dataset, showed a strong separation between the two UPLC-MS runs. Only the 
third PC (6%) (Figure VI-20B) was discriminating between genders. Following these 
results, PCA was applied separately on each run (Figure VI-20C-D). For both runs, 
PC2 (14% for run 1, 9% for run 2) separated gender. Variation observed along PC1 
could not be explained by the UPLC-MS run order or the delivery group.  
  
Determination of rat metabolic profiles by UPLC−MS and integration with cytochrome P450 profiles 
220 
 
 
Figure VI-20. PCA scores plot for the targeted analysis of triglycerides in liver samples 
(A) Both UPLC-MS runs, PC1 vs. PC2 scores plot; (B) Both UPLC-MS runs, PC1 vs. 
PC3 scores plot; (C) UPLC-MS run 1, PC1 vs. PC2 scores plot; (D) UPLC-MS run 2, 
PC1 vs. PC2 scores plot. 
Clear separation between UPLC-MS runs is observed in PC1 vs. PC2 scores plot, while PC3 
separates genders. When investigating runs separately, gender separation is seen along PC2. 
 
 
OPLS-DA was then applied to the dataset combining both runs to investigate 
gender differences (Figure VI-21). The resulting model was of good quality, with Q2Y 
higher than 88%, CV-ANOVA p-value lower than 9e-12, and perfect separation between 
genders on cross-validated scores plots (Figure VI-21A). The corresponding S-plot 
(Figure VI-21B) did not exhibit any feature strongly correlated with gender separation 
(the highest p(corr) value was 0.68). On the male side, only one triglyceride had a 
p(corr) value less than −0.5. When looking at individual intensities for this triglyceride 
(Figure VI-21C1), it appeared that it was clearly higher in male samples compared to 
female samples in run 1, but this difference was not as obvious for run 2. The individual 
intensity plots for the triglycerides at the other extremity of the S-plot (Figure VI-21C2-
C8) showed that these triglycerides tended indeed to be higher in females, but with 
noticeable variability between females, even within a single run.  
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Figure VI-21. OPLS-DA of triglycerides in liver samples 
(A) Cross-validated scores plot; (B) S-plot; (C) Intensity plots for metabolites circled in 
the S-plot. 
In the intensity plots, dash lines correspond to the median of the subset.  
Combining data from both UPLC-MS runs, a good OPLS-DA model is obtained to discriminate 
between genders. The triglyceride circled with blue in the S-plot is clearly higher in males than 
in females in run 1, while gender difference is not obvious in run 2. The triglycerides circled with 
red are higher in females than in males, but with noticeable variability between females, even 
within a single run. 
Abbreviations: Cx:y = x:total number of carbons in the fatty acid chains, y: total number of unsaturations in the 
fatty acid chains; M-R1=males in UPLC-MS run 1; F-R1= females in UPLC-MS run 1; M-R2=males in UPLC-MS 
run 2; F-R2=females in UPLC-MS run 2. 
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VI.3.2.3.3. Targeted analysis of liver free fatty acids (FFAs) 
For targeted analysis of FFAs, 12 FFAs were monitored in the samples, namely 
decanoic acid, dodecanoic acid, myristic acid, palmitoleic acid, palmitic acid, linolenic 
acid, linoleic acid, oleic acid, stearic acid, eicosapentaenoic acid, arachidonic acid and 
docosahexaenoic acid. Three dilutions were run for each sample and the 120 samples 
(40 animals × 3 dilutions) were analysed by UPLC-MS in two separate runs, with the 3 
dilutions of 10 male and 10 female samples in each run.  
When performing PCA of the combined runs for each dilution (Figure 
VI-22A-C), clear separation between runs was seen on PC1 vs. PC2 scores plot. No 
separation between genders was observed, even when looking at subsequent PCs, 
and this was also true when investigating each run separately (Figure VI-22D-I).  
Individual OPLS-DA of each run-dilution pair to discriminate between genders 
failed to produce valid models, except for dilution 1/5 in run 2 (Q2Y=77.1%, CV-ANOVA 
p-value = 0.004) (Figure VI-23A). Observation of the corresponding S-plot (Figure 
VI-23B) revealed that the only FFA exhibiting high p and p(corr) value was the stearic 
acid, for which the intensity plot indeed revealed a higher expression in females 
compared to males (Figure VI-23C3). The other two FFAs showing up on the S-plot, 
eicosapentaenoic acid and oleic acid, had low p(corr) values, and intensity plots 
showed notable overlap between intensity ranges for males and females (Figure 
VI-23, C1−C2). The difference between males and females observed for stearic acid at 
dilution 1/5 for the 20 samples in run 2 was not observed for the other 20 samples at 
the same dilution in run 1, nor in any run for the other dilutions (Figure VI-23, C4−C6). 
Univariate comparison between genders conducted for each FFA in every run-
dilution pair yielded to the same result: the only significant difference between genders 
at a 0.05 threshold was observed for stearic acid between male and female samples at 
dilution 1/5 in run 2 (p=0.005). The p-value corresponding to the same sample dilution 
for run 1 was 0.45, and the p-values for the other dilutions were all equal to 1. As the 
gender difference for stearic acid was observed only for one dilution in one of the runs, 
it was considered as not reliable. It was therefore concluded that there was no 
significant difference between genders for the 12 monitored FFAs.  
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Figure VI-22. PC1 vs. PC2 scores plot for the targeted analysis of FFAs in liver 
samples 
(A) Undiluted samples, both UPLC-MS runs; (B) Samples diluted 1/5, both UPLC-MS 
runs; (C) Samples diluted 1/100, both UPLC-MS runs; (D) Undiluted samples, run 1; 
(E) Samples diluted 1/5, run 1; (F) Samples diluted 1/100, run 1; (G) Undiluted 
samples, run 2; (H) Samples diluted 1/5, run 2; (I) Samples diluted 1/100, run 2. 
Clear separation between UPLC-MS runs is observed for each dilution. When investigating 
each run separately, no separation between genders is seen.  
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Figure VI-23. OPLS-DA of FFAs in liver samples and intensity plots 
(A) Cross-validated scores plot for gender OPLS-DA for dilutions 1/5 in run 2; (B) 
Corresponding S-plot; (C1-C3) Intensity plots for FFAs circled in the S-plot; (C4-C6) 
Intensity plots for stearic acid at each dilution. 
In the intensity plots, dash lines correspond to the median of the subset.  
Only the samples at dilution 1/5 in run 2 produce a valid OPLS-DA model to discriminate 
between genders, due mainly to stearic acid being higher in females than in males. This gender 
difference for stearic acid is observed only for this run-dilution pair.  
Abbreviations:  M-R1=males in UPLC-MS run 1; F-R1=females in UPLC-MS run 1; M-R2=males in UPLC-MS run 
2; F-R2=females in UPLC-MS run 2; pWadj=adjusted p-value for Wilcoxon test.  
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VI.3.3. Integration of CYP profiles and metabolic 
profiles 
After separate analysis of CYP profiles and metabolic profiles of urine, serum 
and liver samples, the next step was to investigate the relationships between these 
profiles. Indeed, the main objective of this thesis was to determine if a link could be 
observed between the CYP profiles and the metabolic profiles. O2PLS was used to 
integrate both types of datasets. To simplify the analysis, both UPLC-MS ionisation 
modes were combined together in the matrix X for each biological sample. As O2PLS 
is sensitive to noise, PCA was performed first on the metabolic profiles (matrix X) and 
on the CYP profiles (matrix Y) and O2PLS was then applied to link scores from both 
PCA models. It was decided to start the integration with the liver metabolic profiles as 
they were most likely to show correlation with the liver CYP profiles.  
 
VI.3.3.1. Metabolic profiles of aqueous liver extracts and CYP 
mRNA profiles 
A PCA model was constructed for the X matrix containing the aqueous liver 
extract metabolic profiles. Based on cross-validation, six PCs were extracted, 
explaining 58% of the variation in the matrix. For the Y matrix containing the CYP 
mRNA profiles for the 62 expressed assays, three PCs were obtained using cross-
validation (explained variation = 63%). An O2PLS model was then created to link the 
PCA scores of the X and Y matrices. The optimised model, comprising 2 predictive 
components, 2 orthogonal components for X and 0 orthogonal component for Y, was 
considered of good quality, with a Q2Y value of 72.6% and a R2Y value of 78.3%.  
When looking at the individual values obtained for each y vector, it appeared that the 
model was essentially good for predicting the first column of the Y matrix (R2Y = 95% 
and Q2Y = 93% for the 1st column, R2Y = 36% and Q2Y = 19% for the 2nd column, R2Y 
= 19% and Q2Y = 6% for the 3rd column). This first column contained the scores on 
PC1 obtained from the PCA of the CYP mRNA profiles. As shown in Chapter V (Figure 
V-1), this PC corresponded to gender differences. The loadings plot revealed that the 
first predictive component was predicting exclusively this first y variable and that the 
most important x variable to explain this first y variable was the 2nd one, corresponding 
to the scores on PC2 for the liver metabolic profiles. Investigation of PCA scores plot 
for these metabolic profiles showed that this component was discriminating between 
genders. It was not surprising to obtain a good O2PLS model as the latent variable 
“gender” was present in both datasets. As clear separation between genders had been 
obtained by PCA for both metabolic profiles and CYP mRNA profiles, it could be 
expected that this latent variable would be detected when looking at the X-Y correlated 
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variation. In this particular study, the aim was not to get a better understanding of 
gender differences by combining CYP and metabolic profiles, but to determine if these 
two types of profiles could be linked in control animals. It was therefore decided to 
investigate each gender separately. PCA was thus performed again for both X and Y 
matrices, first on the 20 male samples, then on the 20 female samples.  
 
VI.3.3.1.1. Linking profiles from male rats 
For the male samples, an O2PLS model was first constructed between the first 
four PCs of the liver metabolic profiles and the first two PCs of the CYP mRNA profiles. 
Looking at the R2Y and Q2Y values for each y variable, it appeared that only the first 
one could be predicted by the model, the second one having a negative Q2Y value. A 
new model was therefore constructed and optimised, keeping only the first y variable. 
This resulted in an OPLS model with one predictive component and zero orthogonal 
component (equivalent to a one-component PLS model), with R2Y = 69%, Q2Y = 51% 
and R2X = 29%. In this model, the loadings corresponding to the 3rd and 4th variables 
were low and their confidence intervals were largely overlapping with 0. A new OPLS 
model was therefore constructed, with the first two PCs of the metabolic profiles and 
the first PC of the CYP mRNA profiles. This resulted in a model with one predictive 
component and zero orthogonal component (equivalent to a one-component PLS 
model), with R2Y = 65%, Q2Y = 60% and R2X = 41%. Observation of the cross-
validated scores versus the model scores (Figure VI-24A) confirmed that the model 
was not overfitted. The correlation between u and t was good (Figure VI-24B), 
although rats 11, 13 and 17 were slightly far from the identity line. Validation of the 
model in Matlab using one million random permutations of the y vector (response 
permutation validation) resulted in a p-value of 4.2e−5. This ensured that the model was 
significant and valid for interpretation.  
Examination of the loadings of the OPLS model revealed that a combination of 
both x variables was responsible for the prediction of y, this combination being 
dominated by the second variable (loading three times higher for the 2nd variable 
compared with the 1st one). It was concluded that the first PC of the CYP mRNA 
profiles (R2X = 26%) was related with the first two PCs of the aqueous liver metabolic 
profiles (R2X = 35%). To investigate the signification of these findings in terms of 
profiles, the loadings of these PCs in the corresponding PCA models had to be 
examined.  
For the CYP mRNA profiles, there was only one PC from the CYP mRNA PCA 
implicated in the OPLS model, which facilitated the interpretation. The loadings 
corresponding to this PC, displayed in Figure VI-24C, are representative of the CYP 
mNRA profile that was linked with the liver metabolic profile. Looking at the CYPs 
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having the most importance in this profile (boxed with blue in Figure VI-24C), it is 
interesting to note the presence of many isoforms of the subfamilies 2c (5 of the 7 
expressed isoforms of this subfamily), 3a (3 of the 5 expressed isoforms of this 
subfamily) and 4f (3 of the 6 expressed isoforms of this subfamily). Another interesting 
observation is that most of these CYPs (12 of 15) were significantly more expressed in 
males compared to females. Although only the CYPs with the highest loadings are 
mentioned here, it is essential to highlight that this is a multivariate approach: the CYP 
profile linked with the metabolic profile is a combination of all CYPs as shown in Figure 
VI-24C, and cannot be restrained to the top 15 loadings. Moreover, it does not 
necessarily mean that each CYP with a high loading taken individually would exhibit 
high correlation with the metabolic profile. This multivariate approach allows us to 
consider a profile formed by all CYPs, which is more powerful than analysing them 
individually.  
Interpretation of the metabolic profile linked with the CYP profile was far more 
complicated for two reasons. First, the OPLS loadings showed that this profile was a 
weighted combination of the first two PCs from the PCA of liver metabolic profiles. So 
the first step was to calculate this combined profile from the OPLS loadings and the 
PCA loadings. Secondly, this combined profile contained 9819 metabolite features 
(4375 from ESI+ mode and 5444 from ESI− mode), which made it impossible to 
visualise in its entirety as done for the CYP profiles in Figure VI-24C. The combined 
loading values ranged from −0.025 to 0.023, and among the 9819 features, 3628 had a 
combined loading value whose confidence interval was not overlapping with zero. 
Considering as the most significant the loadings for which the absolute value was 
above 0.01 and more than twice the half length of their confidence interval, the number 
of significant features was narrowed down to 755 from ESI+ mode and 537 from ESI− 
mode. Among those, for the ESI+ mode, 406 had a negative loading value and 349 
had a positive loading value, these numbers being respectively 309 and 228 for ESI− 
mode. These features, corresponding to m/z_RT pairs, are mapped in Figure 
VI-24D-E, with a colour relative to their loading value in the profile. They covered a 
large range of m/z ratios and retention times. For both ESI modes, there was an 
important concentration of metabolite features with negative loading values at the 
upper right corner of the plot (blue dots), corresponding to the phospholipid/lipid zone 
of the chromatograms. In ESI+ mode, there were also some features with positive 
loading values in this area (red dots). This showed that liver phospholipid/lipid profiles 
and CYP mRNA profiles were somehow related, which could be expected as CYPs act 
on fatty acid metabolism and are regulated by receptors involved in lipid homeostasis. 
In particular, among the CYPs having the most importance in the CYP profile linked 
with the liver profile (boxed with blue in Figure VI-24C), subfamily 2c is involved in 
arachidonic acid and linoleic acid metabolism283,284, CYPs 7b1 and 39a1 are involved in 
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cholesterol catabolism to bile acids210,283,285, CYPs of subfamily 4f are key enzymes of 
arachidonic metabolism210,227,228,283 and CYPs of subfamily 3a are involved in linoleic 
acid metabolism and steroid hormone biosynthesis210,283. It was therefore not surprising 
to find a relationship between these CYPs and lipid profiles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend of next page figure: 
Figure VI-24. OPLS model linking PCA scores of male aqueous liver metabolic profiles 
(PC1&2) and PCA scores of male CYP mRNA profiles (PC1)  
(A) Cross-validated scores vs. model scores for the predictive component;  
(B) y-scores u vs. x-scores t for the predictive component;  
(C) CYP loadings with confidence intervals for the first PC in PCA of CYP mRNA 
profiles;  
(D) and (E) m/z vs. retention time for the metabolite features with highest significant 
combined loadings in the aqueous liver metabolic profiles, using a colour-scale 
corresponding to loading values.  
On subplots A and B, the blue line corresponds to the identity line (y = x) and the labels are the 
rat numbers. Subplot A confirms that the model is not overfitted and subplot B shows a good 
correlation between u and t (although rats 11, 13 and 17 are slightly far from the identity line). 
CYPs boxed with blue in subplot C are those having the most importance in the CYP profile 
linked with the liver metabolic profile. The liver metabolite features plotted on subplots D and E, 
covering a large range of m/z ratios and retention times, are those with a combined loading 
value p such that abs(p) ≥ 0.01 and having a half confidence interval less than half of the 
loading value. There is an important concentration of metabolite features with negative loading 
values at the upper right corner, corresponding to the phospholipid/lipid zone of the 
chromatograms (the time-shift of the zone between the two subplots can be explained by the 
difference between ESI+ and ESI- gradients). 
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VI.3.3.1.2. Linking profiles from female rats 
For the females, an O2PLS model was first constructed between the first four 
PCs of the aqueous liver metabolic profiles and the first two PCs of the CYP mRNA 
profiles. Looking at the R2Y and Q2Y values for each y variable, it appeared that only 
the first one could be predicted by the model, the second one having a negative Q2Y 
value. A new model was therefore constructed and optimised, keeping only the first y 
variable. In this model, the loading value corresponding to the 4th variable was low and 
its confidence interval was largely overlapping with 0. A new model was then 
constructed, with the first three PCs of the metabolic profiles and the first PC of the 
CYP mRNA profiles. This resulted in an OPLS model with one predictive component 
and one orthogonal component for the X matrix, with R2Y = 38%, Q2Y = 18%, R2Xpred 
= 29%, R2Xcum = 78%. Considering the relatively low value of Q2Y, the model was 
considered as not significant enough for interpretation. As mentioned previously, most 
of the most important CYPs in the male CYP mRNA profile linked with the male liver 
metabolic profile were significantly more expressed in males compared to females. 
This may partially explain why the link between CYP mRNA and aqueous liver 
metabolic profiles observed for males was not significantly observed for females.  
As no significant model could be constructed to link aqueous liver metabolic 
profiles and CYP mRNA profiles for the females, it was decided to investigate each 
CYP separately to determine if some of them could still be linked with the liver 
metabolic profiles. This was a less global and therefore less powerful approach, as it 
did not take into account correlation between the different CYPs, contrary to the 
O2PLS approach with the PCA of the CYPs. However, if the expression of one CYP 
only was linked with the metabolic profiles, this information might have been lost when 
applying PCA to the CYP matrix and using the scores on the PCs as the Y matrix for 
the O2PLS model. It was therefore decided to construct 62 OPLS models, each with 
one y variable only, corresponding to one of the 62 CYP assays. For the X matrix, the 
scores on the first four PCs of the PCA of the female aqueous liver metabolic profiles 
were used as with the O2PLS models. This was done to remove noise in the MS matrix 
before applying OPLS.  
Of the 62 optimised models, two CYPs produced models with a Q2Y value 
higher than 30%, namely Cyp39a1 and Cyp2a1. When investigating loadings for these 
two models, it appeared that the loading for the 4th x variable was negligible. This 
variable was therefore excluded from the two models, which improved their quality. The 
optimal model for Cyp39a1 had two orthogonal components, with Q2Y = 46% and R2Y 
= 56%, and validation of this model by response permutation resulted in a p-value of 
0.0016. The optimal model for Cyp2a1 had one orthogonal component, with Q2Y = 
37% and R2Y = 45%, and validation of this model by response permutation resulted in 
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a p-value of 0.0049. One of the drawbacks of modelling the CYPs one by one was that 
62 models were constructed, as opposed to only one model when applying O2PLS 
after PCA of the CYP matrix. Therefore, this multiple testing should be taken into 
consideration when assessing the p-values obtained for the OPLS models, to control 
the probability of obtaining false positives. Setting the significance level at 0.05 for the 
entire set of the 62 tests, a significant level of 0.0008 (= 0.05 / 62) should be used for 
each individual test if applying the Bonferroni correction176. With this correction, none of 
the two models was statistically significant. However, considering the Q²Y value of 46% 
and the reasonably low p-value for the first model, it was concluded that a link might 
exist between Cyp39a1 mRNA expression and female aqueous liver metabolic profiles, 
although this link was not significant when applying multiple testing correction.  
 
VI.3.3.2. Metabolic profiles of organic liver extracts and CYP 
mRNA profiles 
The O2PLS approach was then applied to the organic liver extracts. When 
analysing all animals together, a good O2PLS model  was obtained between scores 
from PCA of metabolic profiles and scores from PCA of CYP mRNA profiles (Q²Y = 
68%, R²Y = 75%). As with the aqueous extracts, this model was mainly reflecting the 
latent variable “gender”, linking the first PC of CYP profiles (gender differences) (Q²Y = 
89%, R²Y = 90%) with the first PC of organic liver metabolic profiles (gender 
differences). Males and females were therefore investigated separately.  
For each gender, O2PLS analysis between scores from PCA of organic liver 
metabolic profiles and scores from PCA of CYP mRNA profiles failed to produce valid 
models (Q²Y < 0 for males, < 9% for females), indicating that there was no obvious link 
between organic liver metabolic profiles and CYP mRNA profiles among control 
animals from the same gender. As previously, separate OPLS models for each CYP 
were then constructed to investigate possible relationships between metabolic profiles 
and individual CYPs.  
 
VI.3.3.2.1. Linking profiles from male rats 
For males, Cyp4a1 was the only CYP for which a Q²Y value higher than 30% 
was obtained. Only the first two PCs from PCA of the metabolic profiles had significant 
loadings in this model and were kept to optimise the model. This resulted in a model 
with 1 orthogonal component, Q²Y = 38%, R²Y = 42%, and a p-value of 0.0035 when 
validating the model by response permutation. As explained previously, the 
significance threshold for the p-values was 0.0008 when correcting for multiple testing, 
so the model was considered as not significant.  
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VI.3.3.2.2. Linking profiles from female rats 
For females, only CYPs 2c7 and 7b1 produced models with a Q²Y value higher 
than 30%. For the optimal model for Cyp2c7, values of 35% for Q²Y and 45% for R²Y 
were obtained, and the response permutation p-value was 0.0103, which was too 
elevated to judge the model as reliable. The model for Cyp7b1 was considerably better, 
with a Q²Y value of 65%, a R²Y value of 72% and a p-value of 5.9e-5. Considering the 
quality of this model, it was concluded that the existence of a relationship between 
organic liver metabolic profiles and cytochrome 7b1 for females was likely. This could 
be related to the fact that Cyp7b1, also known as oxysterol 7α-hydroxylase, can 
mediate the 7α-hydroxylation of lipids such as 27-hydroxycholesterol and 25-
hydroxycholesterol234.  Surprisingly, although no significant gender differences were 
found for this cytochrome, this relationship was not found with the male profiles 
(Q²Y < 0).  
 
VI.3.3.3. Serum metabolic profiles and CYP mRNA profiles 
For the integration of serum metabolic profiles and CYP mRNA profiles, only the 
metabolic profiles at the 24 h time point were kept. As with the liver metabolic profiles, 
a good O2PLS model (Q²Y = 65%, R²Y = 73%) was obtained between scores from 
PCA of serum metabolic profiles and scores from PCA of CYP mRNA profiles when 
analysing all the animals together, due to the presence of the latent variable “gender” 
(Q²Y = 88%, R²Y = 90% for the first y variable (discriminating genders in the CYP 
mRNA PCA), almost exclusively predicted by the first x variable (discriminating 
genders in the serum PCA). Each gender was therefore investigated separately as 
previously.  
O2PLS analysis between scores from PCA of serum profiles and scores from 
PCA of CYP mRNA profiles failed to produce valid models for both genders (Q²Y < 0 
for males and Q²Y = 0% for females), indicating that no relationship between serum 
metabolic profiles and CYP mRNA profiles could be detected for control animals within 
each gender. As previously, separate OPLS models for each CYP were then 
constructed to investigate possible relationships between metabolic profiles and 
individual CYPs.  
 
VI.3.3.3.1. Linking profiles from male rats 
For males, only CYPs 2a1 and 2a2 produced OPLS models with a Q²Y higher 
than 30%. The optimal model for Cyp2a1 resulted in Q²Y value of 31% and a R²Y value 
of 47%, with a p-value of 0.0142. Considering the low value of Q²Y and the p-value, the 
model was not considered as reliable enough to draw any conclusions. The obtained 
model was better for Cyp2a2, with a Q²Y value of 53%, a R²Y value of 68% and a p-
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value of 0.0018, showing that there might be a relationship between male serum 
metabolic profiles and Cyp2a2 expression profiles, although the model was not 
statistically significant when correcting the significance threshold for multiple testing.  
 
VI.3.3.3.2. Linking Profiles from female rats 
 For females, 5 CYPs produced OPLS models with a Q²Y value higher than 
30%: 2c22, 2t1, 51, 3a9 and 7a1. Parameters for these 5 models are shown in Table 
VI-10. The five models were of similar quality, with Q²Y values between 30 and 40% 
and p-values between 0.005 and 0.02. After correction for multiple testing, none of 
these models was statistically significant.  
 
 
Table VI-10. Parameters for OPLS models linking female serum metabolic profiles and 
five individual CYPs 
CYP isoform 2c22 2t1 51 3a9 7a1 
Orthogonal components 0 0 1 0 0 
Q²Y (%) 30 34 35 34 37 
R²Y (%) 47 58 57 59 54 
p-value (response 
permutations) 
0.0174 0.0056 0.0097 0.0106 0.0076 
 
 
VI.3.3.4. Urine metabolic profiles and CYP mRNA profiles 
For the integration of urine metabolic profiles with CYP mRNA profiles, only the 
metabolic profiles at the 24 h time point were kept. As with all the other metabolic 
profiles, a good O2PLS model was obtained when relating scores from PCA of urine 
profiles with scores from PCA of CYP mRNA profiles for all animals together (Q²Y = 
67%, R²Y = 69%), due to the presence of the latent variable “gender” in both datasets 
(Q²Y = 91.7%, R²Y=92.4% for the first y variable (discriminating genders in the CYP 
mRNA PCA), almost exclusively predicted by the first x variable (discriminating 
genders in the urine PCA). Males and females were therefore investigated separately 
as previously. 
 
VI.3.3.4.1. Linking profiles from male rats 
O2PLS analysis between scores from PCA of urine profiles and scores from 
PCA of CYP mRNA profiles failed to produce a valid model for males (Q²Y < 0). 
Individual OPLS models were therefore constructed for each CYP. Only Cyp21a1 
resulted in a model with a Q²Y value higher than 30%. The optimal model for this CYP 
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exhibited a Q²Y value of 33%, a R²Y value of 49% and a response permutation p-value 
of 0.0127. Considering the low Q²Y value and the p-value, the model was not 
considered as reliable enough to draw conclusions.  
 
VI.3.3.4.2. Linking profiles from female rats 
An acceptable O2PLS model between scores from PCA of urine profiles and 
scores from PCA of CYP mRNA profiles was obtained for females (Q²Y = 36%). In this 
model, only the first two x variables (of 4) had loadings significantly different from 0. A 
new model was therefore constructed, between the scores on the first two PCs for 
urine profiles and the scores on the first two PCs for CYP mRNA profiles. The optimal 
model had 2 predictive components and 0 orthogonal component and exhibited a Q²Y 
value of 42% and a R²Y value of 55%. Closer examination revealed that these values 
were low for the first predictive component (Q²Y = 4%, R²Y = 18%). Investigation of the 
y variable loadings for each predictive component showed that the first predictive 
component was mainly predicting the second y variable, while the second one was 
predicting the first y variable. As this second predictive component was the one mainly 
responsible for the good quality of the model, it was decided to construct an OPLS 
model between the first two PCs for urine profiles and the first PC for CYP mRNA 
profiles. This model, with 1 orthogonal component, was good, with a Q²Y value of 56%, 
a R²Y value of 71% and a response permutation p-value of 1.5e−4, indicating that it was 
valid for interpretation. The absence of overfitting was supported by the consistency 
between the model scores and the cross-validated scores (Figure VI-25A). The u vs. t 
plot (Figure VI-25B) showed a good correlation between X and Y, except for rat 25, 
which was slightly far from the identity line.  
Examining the loadings plots, it appeared that a combination of both x variables 
was responsible for the prediction of the y variable, although the second x variable was 
largely dominating the combination (loading 4 times higher for the 2nd variable 
compared with the 1st one). In terms of profiles, it meant that the first PC of the female 
CYP mRNA profiles (R2X = 18%) was related with the first two PCs of the female urine 
metabolic profiles (R2X = 41%).  
The loadings corresponding to the first PC of the CYP mRNA profiles, 
representative of the CYP mRNA profile linked with the female urine metabolic profile, 
are displayed in Figure VI-25C. Five of the nine CYPs having the most importance in 
this profile (boxed in red in Figure VI-25C) had been found to show significantly higher 
expression in females compared to males (section V.3.1.2.6), and four of these nine 
CYPs (2r1, 4f1, 4f6 and 39a1) were part of the male CYP profiles linked with the 
aqueous liver extract profiles. Once again, although I highlight here the CYPs exhibiting 
the highest loadings in the profile, the CYP mRNA profile linked with the female urine 
Determination of rat metabolic profiles by UPLC−MS and integration with cytochrome P450 profiles 
235 
 
metabolic profile was in reality a combination of all CYPs and could not be restrained to 
the top 9 loadings.  
The metabolic profile linked with the CYP mRNA profile was calculated from the 
OPLS loadings and the PCA loadings as done previously with the aqueous liver 
metabolic profile. The combined loadings obtained for the 11884 metabolite features 
(5253 from ESI+ mode and 6631 from ESI− mode) ranged from −0.025 to 0.026. 
Among these features, 7937 had a confidence interval not overlapping with zero. 
Considering as the most significant the loadings for which the absolute value was 
above 0.015 and more than twice the half length of their confidence interval, the 
number of significant features was narrowed down to 543 for ESI+ mode and 786 for 
ESI− mode. Among those, for the ESI+ mode, 206 had a negative loading value and 
337 had a positive loading value, these numbers being respectively 338 and 448 for 
ESI− mode. These features, corresponding to m/z_RT pairs, are mapped in Figure 
VI-25D-E, with a colour relative to their loading value in the profile. They covered the 
whole range of retention times. For both ESI modes, the more polar compounds, 
eluting during the first few minutes of the LC run, tended to be negatively correlated 
with the CYP profile displayed in Figure VI-25C (blue dots), while the less polar 
compounds, eluting in the second part of the LC-run (after 4 min), tended to be 
positively correlated with the CYP profile (red dots).  
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Legend of next page figure: 
Figure VI-25. OPLS model linking PCA scores of female urine metabolic profiles 
(PC1&2) and PCA scores of female CYP mRNA profiles (PC1)  
(A) Cross-validated scores vs. model scores for the predictive component; (B) y-scores 
u vs. x-scores t for the predictive component; (C) CYP loadings with confidence 
intervals for the first PC in PCA of CYP mRNA profiles; (D) and (E) m/z vs. retention 
time for the metabolite features with highest significant combined loadings in the urine 
metabolic profiles, using a colour-scale corresponding to loading values.  
On subplots A and B, the red line corresponds to the identity line (y = x) and the labels are the 
rat numbers. Subplot A confirms that the model is not overfitted and subplot B shows a good 
correlation between u and t (although rat 25 is slightly far from the identity line). CYPs boxed 
with red in subplot C are those having the most importance in the CYP profile linked with the 
urine metabolic profile. The urine metabolite features plotted on subplots D and E are those with 
a combined loading value p such that abs(p) ≥ 0.015 and having a half confidence interval less 
than half of the loading value. Compounds eluting during the first few minutes of the LC run tend 
to be negatively correlated with the CYP profile, while compounds eluting after 4 minutes tend 
to be positively correlated with the CYP profile.  
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VI.3.3.5. Targeted metabolic profiles and CYP mRNA profiles 
VI.3.3.5.1. Liver samples 
As significant UPLC-MS run effects had been observed during the targeted 
analysis of triglycerides and FFAs for the liver samples, it was decided to perform 
O2PLS analysis between the targeted metabolic profiles and the CYP mRNA profiles 
separately for each run. 
When doing so for the triglyceride profiles with all animals, good O2PLS models 
were obtained, which was expected as gender separation had been observed for both 
triglyceride profiles and CYP mRNA profiles. The latent variable “gender” was clearly 
identified when investigating these models, as detailed previously for the untargeted 
metabolic profiles. Investigation of each gender separately would have resulted in only 
ten animals per model due to the UPLC-MS run issue. This was considered to be too 
small a number to construct reliable O2PLS models. It was therefore decided not to 
pursue investigations on these triglyceride targeted profiles.  
For the FFA analysis, it was decided to keep only the data from the intermediate 
dilution. As there were only 12 x variables (corresponding to the 12 FFAs), the X matrix 
was used directly, without first performing PCA. O2PLS models were therefore 
constructed for each run between the FFA matrix and the scores from PCA of CYP 
mRNA profiles. The model for run 1 was not valid (Q²Y = 6%), indicating that no 
relationship between FFA metabolic profiles and CYP mRNA profiles could be 
detected. The model was better for run 2 (Q²Y = 37%), but investigation of the obtained 
predictive component showed that this was due to the latent variable gender. Indeed, 
for the intermediate dilution, gender separation had been observed by OPLS-DA for 
run 2 (Figure VI-21). It was not desirable to perform the analysis separately for each 
gender for this run, as this would have resulted in only 10 animals per model. So it was 
decided to pursue the analysis only for the 20 animals of run 1, for which no gender 
differences had been observed.  
Separate OPLS models for each CYP were constructed for this run to 
investigate possible relationships between FFA profiles and individual CYPs. Only 
Cyp2b3 resulted in a model with a Q²Y value higher than 30% (0 orthogonal 
component, R²Y = 45%, Q²Y = 31%). Validation of this model by response permutation 
produced a p-value of 0.0055. Considering the low value of Q²Y and the p-value higher 
than 0.0008 (0.05 threshold adjusted for multiple testing), the model was considered as 
not significant.  
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VI.3.3.5.2. Serum samples 
For the targeted analysis of triglycerides in serum samples, all the samples from 
the 24 h time point had been run in the same UPLC-MS batch, so there was no run 
issue. O2PLS analysis was conducted between scores from PCA of serum triglyceride 
profiles at 24 h time point and scores from PCA of CYP mRNA profiles. As previously, 
the latent variable “gender” was clearly dominating the obtained model.  
The two models obtained when analysing each gender separately were not valid 
(Q²Y < 0), showing that no link could be detected between the serum triglyceride 
profiles and the CYP profiles for control animals within each gender.  
When constructing individual OPLS models for each CYP, no valid models were 
obtained for females. For males, only Cyp2c13 resulted in an acceptable model with 
Q²Y = 44% and R²Y = 55%. Validation of the model by response permutations resulted 
in a p-value of 0.0057, so the model was considered to be not significant. 
 
VI.3.3.6. Metabolic profiles and CYP-related activities 
After investigating relationships between metabolic profiles and CYP mRNA 
profiles, a similar approach was pursued between metabolic profiles and CYP-related 
activities. CYP-related activities are closer to metabolic profiles than CYP mRNA, 
making more likely the possibility of finding relationships between profiles. As detailed 
previously, activity data were available only for 5 CYPs. Considering this small number, 
it was decided to create individual OPLS models for each CYP-related activity. Scores 
from PCA of metabolic profiles were used as the X matrix, except for the liver FFAs as 
with the CYP mRNA profiles. Similarly to what had been observed with CYP mRNA, 
the latent variable “gender” was dominating all the models for the 4 CYPs that were 
differentially expressed between males and females. Separate models were therefore 
created for males and females. As with CYP mRNA profiles, the analysis was not 
conducted for the liver triglyceride profiles, due to the low number of samples after run 
and gender splitting, and was conducted only for the first UPLC-MS run for the liver 
FFA profiles (without separating the genders).  
Table VI-11 lists the Q2Y value obtained for each model and the corresponding 
p-value for models with a Q2Y value higher than 20%. As 5 models were constructed 
from each metabolic profile, the significance threshold for each individual test was set 
at 0.01 to take into account the multiple testing. Several models resulted in a Q²Y value 
between 20% and 40% and a p-value between 0.01 and 0.05, showing that a 
relationship might exist but making difficult to draw any conclusion due to the weak 
quality of the models. Reproducing the experiment with more animals could help to 
confirm or invalidate these results.  
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Table VI-11. Q²Y values and p-values for OPLS models of CYP activities 
Metabolic 
profiles 
Gender Cyp1a1/2 Cyp2b1 Cyp2d1 Cyp2e1 Cyp3a1/2 
Liver 
(aqueous) 
Male <0 <0 3% <0 <0 
Female 16% <0 
25% 
(p=0.036) 
<0 <0 
Liver 
(organic) 
Male <0 <0 
23% 
(p=0.032) 
<0 <0 
Female 
25% 
(p=0.049) 
<0 15% <0 <0 
Serum 
Male 
39% 
(p=0.010) 
20% 
(p=0.047) 
<0 
30% 
(p=0.024) 
47% 
(p=0.003) 
Female <0 <0 <0 <0 <0 
Urine 
Male <0 <0 <0 3% <0 
Female 6% 
33% 
(p=0.028) 
41% 
(p=0.013) 
32% 
(p=0.026) 
3% 
Serum 
triglycerides 
Male 
48% 
(p=0.00093) 
38% 
(p=0.0028) 
<0 
59% 
(p=0.00075) 
10% 
Female 2% 8% 17% 2% 10% 
Liver FFAs 
(Run 1) 
Both 3% 13% 3% 10% 
20% 
(p=0.054) 
 
 
While a good model had been constructed between male aqueous liver 
metabolic profiles and CYP mRNA profiles, no model could be constructed for the 
individual activities, although activities were expected to be more related to metabolic 
profiles. This might be explained by the more complete picture given by the 62 mRNA 
profiles compared to individual CYP activities. For the female urine profiles, for which a 
link with the mRNA CYP profile had also been found, three of the five CYP-related 
activities resulted in OPLS models with a Q²Y higher than 30% and p-value less than 
0.03. These three CYPs had relatively high loading values in the mRNA profile linked 
with the urine profile, but this was also the case for CYPs 1a1 and 1a2, for which 
activity could not be successfully linked with the urine profile. Conversely, CYPs 3a1 
and 3a2, which activity could not be predicted either, had low loading values in the 
mRNA profile linked with the urine profile, which was more consistent.  
The best models were obtained with the male serum metabolic profiles, both 
untargeted and targeted on triglycerides.  
Of the 5 models constructed from male untargeted serum profiles, 4 had a Q²Y 
value higher than 20%, Cyp2d1 being the only one resulting in a negative Q²Y value 
(Table VI-11). Among these 4 models, the ones for CYPs 1a1/2 and 3a1/2 were 
statistically significant (p ≤ 0.01), showing that the existence of a relationship between 
male serum profiles and activities of these cytochromes was likely. In the same way of 
what had been done for CYP mRNA profiles, serum metabolic profiles corresponding 
to each of these 2 CYPs were reconstructed from the OPLS loadings of each model 
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and the serum PCA loadings. Metabolite features with the most significant combined 
loadings (absolute value higher than 0.01 and more than twice the half length of their 
confidence interval) are mapped in Figure VI-26 for each CYP, with a colour relative to 
their loading value in the profile. These features covered a large range of m/z ratios 
and retention times. Among these features, the highly polar ones, poorly retained on 
the LC column and eluting within the first minute, had mostly negative loadings, 
illustrating a global negative correlation with CYPs 1a1/2 and 3a1/2 activities. There 
was a series of features eluting around 8.5 minutes (510 seconds) in ESI+ mode 
showing positive correlation with the activities. Some areas in the second part of the 
UPLC-MS run (after 10 minutes), corresponding to bile acids, phospholipids and lipids, 
showed high concentration of features with significant loadings (both negative and 
positive), illustrating the strong relationship between these categories of molecules and 
the two CYPs. This was not surprising as CYPs 1a1 and 1a2 are active arachidonic 
acid oxygenases284, which are also involved, as well as CYPs 3a1 and 3a2, in steroid 
hormone biosynthesis and linoleic acid metabolism283. 
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Figure VI-26. m/z vs. retention time for the metabolite features with highest significant 
combined loadings in the male serum untargeted metabolic profiles corresponding to 
CYPs 1a1/2 and 3a1/2  
(A) Cyp1a1/2, ESI+ mode; (B) Cyp1a1/2, ESI− mode; (C) Cyp3a1/2, ESI+ mode; (D) 
Cyp3a1/2, ESI− mode. 
The colour-scale corresponds to loading values. The serum metabolite features plotted are 
those with a combined loading value p such that abs(p) ≥ 0.01 and having a half confidence 
interval less than half of the loading value. They cover a large range of m/z ratios and retention 
times. Features eluting within the first minute mostly show negative loadings. A series of 
features eluting around 510 seconds in ESI+ mode show positive loadings. Some areas after 
600 seconds, corresponding to bile acids, phospholipids and lipids, exhibit high concentration of 
features with significant loadings (both negative and positive). 
 
 
Three of the models constructed from male serum triglyceride profiles were 
significant (for CYP 1a1/2-, 2b1- and 2e1-related activity), the one for Cyp2e1 
exhibiting a particularly good Q²Y value (59%) (Table VI-11). This revealed a probable 
relationship between male serum triglyceride profiles and activities of cytochromes 
1a1/2, 2b1 and 2e1, which could be linked with the involvement of these isoforms in the 
metabolism of fatty acids, including arachidonic, linoleic and decanoic acids223,283,284,286. 
The OPLS loadings plots were similar for these three models: the first variable, 
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corresponding to the first PC of the male triglyceride serum PCA, was clearly 
dominating the model, and it had a negative loading. In the loadings plot of this first PC 
in the PCA model, almost all triglycerides had a positive loading. These results 
expressed that the activity of CYPs 1a1/2, 2b1 and 2e1 seemed to be negatively 
correlated with the global triglyceride profile.  
The triglyceride concentration had been measured in serum at 24 h as part of 
the clinical chemistry analysis (sections VI.2.2 and VI.3.1.3). This concentration is 
plotted versus the activity of each cytochrome for both males and females in Figure 
VI-27, and the linear correlation coefficient (R) is displayed on each subplot. The trends 
observed on these plots were consistent with the results from the OPLS analysis. 
Triglyceride concentration tended to be negatively correlated with activity of CYPs 
1a1/2, 2b1 and 2e1 in males. This negative correlation tendency was not observed for 
females, which may explain the difference in quality of OPLS models observed 
between males and females for the serum triglyceride profiles. From the clinical 
chemistry analysis, it was possible to see that the global concentration of triglycerides 
was negatively correlated with the activities of cytochromes 1a1/2, 2b1 and 2e1 in 
males; the OPLS models from the triglyceride profiles revealed that this trend was 
common to most of the observed individual triglycerides.  
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Figure VI-27. Triglyceride concentration vs. activity of each cytochrome 
 (A) Cyp1a1/2, males; (B) Cyp2b1, males; (C) Cyp2d1, males; (D) Cyp2e1, males; (E) 
Cyp3a1/2, males; (F) Cyp1a1/2, females; (G) Cyp2b1, females; (H) Cyp2d1, females; 
(I) Cyp2e1, females; (J) Cyp3a1/2, females.  
The linear regression line is displayed for each subplot, with the corresponding correlation 
coefficient R. Triglyceride concentration tends to be negatively correlated with activity of CYPs 
1a1/2, 2b1 and 2e1 in males. This tendency is not observed for females. 
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VI.4. Conclusion 
The first part of this chapter illustrated the great power of UPLC-MS to 
distinguish between rat metabolic profiles obtained in males and females and at two 
different collection time points. The excellent quality of the statistical models 
constructed to discriminate between experimental groups in each biological sample 
type (urine, serum and liver) indicated that there were clear differences in their 
UPLC-MS metabolic profiles. Metabolites showing different levels between the two 
collection time points included hippurate, creatine and some PCs/LPCs in serum 
samples, and pantothenic acid, α-ketoglutaric acid, sebacic acid and suberic acid in 
urine samples. Metabolites exhibiting sex-dependent levels included several steroids 
and bile acids in serum, urine and liver samples, as well as thymidine and pantothenic 
acid in serum samples, xanthurenic acid and deoxycytidine in urine samples, and some 
PCs and PEs in liver samples. Some metabolites discriminating between experimental 
groups were part of the standard compound database constructed as part of this work 
and could be confirmed by comparison of both retention time and MS/MS 
fragmentation data with authentic standards. Identification of other discriminating 
metabolites, not performed in the timeframe of this thesis, could be pursued by 
performing MS/MS analysis on a Q-TOF instrument to obtain fragmentation 
information, and/or analysing samples with high resolution mass spectrometers (e.g. 
orbitrap or FT-ICR), which may allow unambiguous assignment of a single molecular 
formula to each of these metabolites, based on their accurate mass and isotopic 
pattern. MSn fragmentation capabilities offered by this type of instrument may also 
provide useful information. NMR spectroscopy could also be employed to provide 
structural information (after isolation and concentration of the metabolite). The clear 
differences observed between genders and between collection time points in serum, 
urine and liver metabolic profiles should be kept in mind when designing metabonomic 
studies in the preclinical development stage of drug candidates. Importantly, within 
each gender, there was no obvious difference between the metabolic profiles of the 
four rat delivery groups. 
In the second part of the chapter, the possibility of integrating these metabolic 
profiles with corresponding liver CYP profiles was assessed. When including all 
animals, the constructed O2PLS models, allowing for extraction of the shared variation 
between two datasets, mainly highlighted the presence of the latent variable “gender” 
in both CYP and metabolic profiles. Further analyses were therefore performed 
separately for males and females. A good statistical model was obtained linking liver 
aqueous metabolic profiles and CYP mRNA profiles in male control rats. Interpretation 
of this model indicated that liver phospholipid/lipid profiles were somehow related with 
the mRNA expression of some CYPs, including isoforms from subfamilies 2c, 4f and 
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3a, as well as CYPs 7b1 and 39a1. This could be related to the involvement of these 
isoforms in the metabolism of arachidonic and linoleic acids, the catabolism of 
cholesterol to bile acids and the biosynthesis of steroid hormones210,227,228,283,284,285. The 
good statistical model obtained for males could not be reproduced for females, possibly 
because a large part of the most important CYPs in CYP profiles linked with male liver 
metabolic profiles were significantly more expressed in males compared to females. 
Similarly, a good O2PLS model linking urine metabolic profiles and CYP mRNA profiles 
was obtained for female control rats, but not for male rats.  
While CYP-related activities were expected to be easier to link with metabolic 
profiles than CYP mRNA as they are closer to the phenotype, the valid model obtained 
between male liver aqueous extracts and CYP mRNA could not be reproduced with 
CYP activities. This could be attributed to the fact that the picture given by the 
combined 62 mRNA profiles was more complete compared to the individual activities of 
the 5 selected CYPs. Differences observed between assessment of CYP expression at 
mRNA and activity levels will be further discussed in Chapter VII. The best series of 
models linking CYP activities and metabolic profiles were obtained from serum 
metabolic profiling analyses, both untargeted and targeted on triglycerides, in males. 
The retention time/mass zone corresponding to bile acids, phospholipids and lipids had 
a strong influence in the untargeted serum metabolic profiles found to be associated 
with activities of CYPs 1a1/2 and 3a1/2. This could be related to the arachidonic acid 
oxygenase activity of CYPs 1a1 and 1a2 and the involvement of CYPs 1a1, 1a2, 3a1 
and 3a2 in steroid hormone biosynthesis and linoleic acid metabolism283,284. Similarly, 
the significant models that were obtained associating serum triglyceride profiles and 
activities of cytochromes 1a1/2, 2b1 and 2e1 could be linked with the involvement of 
these isoforms in the metabolism of fatty acids, including arachidonic, linoleic and 
decanoic acids223,283,284,286. The fact that the best series of models linking CYP activities 
and metabolic profiles were obtained from serum metabolic profiles, both untargeted 
and targeted, is particularly interesting, as serum can be easily obtained during 
preclinical studies. Special attention should therefore be given to the analysis of this 
biofluid in the subsequent studies performed in the overall pharmaceutical research 
project this work is part of. 
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Chapter VII.  General discussion and 
future work 
 
The involvement of cytochrome P450s (CYPs) in the metabolism of many 
endogenous substrates and the regulation of their expression by nuclear receptors 
involved in endogenous pathways make the fingerprint of CYP activity likely to be 
linked with endogenous metabolic profiles. In this context, the overall goal of this work 
was to characterise liver CYP distribution in control rats and investigate potential 
relationships between these CYP profiles and corresponding serum, urine and liver 
UPLC-MS metabolic profiles. Perturbations of these profiles by known CYP inducers 
could then be investigated in subsequent projects with the aim of identifying early 
metabolic biomarkers of CYP induction, which is of great interest for the 
pharmaceutical industry. 
In the first part of this thesis, an efficient and reproducible protocol was 
developed for untargeted metabolic profiling of liver samples by UPLC-MS, and the 
ability of this protocol to distinguish between biological and technical variation was 
evaluated in a toxicology study on the hepatotoxin galactosamine. This evaluation 
study also enabled the establishment of strategies for metabolic profiling analyses by 
UPLC-MS and processing of the resulting data, which were then employed for the 
subsequent control rat study. These strategies included: 
 Design of the sample list so that the sample run order is orthogonal to the 
experimental design, to avoid bias in data analysis and interpretation  
 Monitoring of the analytical platform stability with regular injections of a pooled 
quality control (QC) sample, representative of the sample batch  
 Design of an XCMS workflow with parameters adapted to our UPLC-MS platform 
to pre-process the data 
 Evaluation of data normalisation effectiveness to remove irrelevant sources of 
systematic variation between samples and thus observe more clearly biological 
variation of interest 
 Determination of appropriate data transformation/scaling in order to produce 
adequate multivariate models of UPLC-MS data (assessed through the 
investigation of the measurement error on replicate injections of the QC sample)  
 Selection of most relevant metabolite features to discriminate between 
experimental groups from combined investigation of OPLS-DA S-plots, XCMS 
extracted ion chromatograms (EICs) and intensity plots 
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In the second part, an in vivo study was designed to fulfil both aims of this thesis 
project: characterisation of CYP profiles in control rats and assessment of their 
relationship with urine, serum and liver metabolic profiles. The characterisation of CYP 
distribution was performed at the mRNA level for almost all CYPs currently known in 
the rat, as well as at the activity level for a small number of these CYPs. When these 
CYP profiles were linked with corresponding metabolic profiles, the strong difference 
existing between males and females in each type of profiles made it difficult to highlight 
anything other than the latent variable “gender” in the constructed statistical models. 
Separate investigations were therefore performed for males and females, resulting in 
models built from 20 control rats of the same gender. When integrating metabolic 
profiles and CYP profiles for each gender separately, notable differences were 
observed between the prediction of CYP mRNA profiles and the prediction of CYP 
activities: overall, good prediction of CYP mRNA profiles was obtained from male liver 
aqueous extract metabolic profiles and female urine metabolic profiles, while prediction 
of CYP activities was better from male serum metabolic profiles, both untargeted and 
targeted on triglycerides.  
 
 
VII.1. Correlation between mRNA levels and 
enzyme activities  
A schematic diagram representing the different organisational levels within a 
cell, with associated “omics” technologies, is shown in Figure VII-1. DNA sequences of 
protein-coding genes are transcribed into messenger RNAs (mRNAs), which are then 
translated into linear proteins. These proteins fold into three dimensional structures and 
undergo a series of posttranslational modifications to form active proteins. These active 
proteins can then catalyse reactions that act on and produce metabolites. Technologies 
termed as “omics” are technologies capable of measuring in a comprehensive way the 
various cell components, be it genes (genomics), transcripts (transcriptomics), proteins 
(proteomics) or metabolites (metabolomics/metabonomics). All of these approaches 
provide complementary information in the study of complex living systems. 
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Figure VII-1. Schematic diagram of the different organisational levels within a cell with 
associated “omics” technologies 
Protein-coding genes are transcribed into messenger mRNAs, which are then translated into 
proteins. After undergoing posttranslational modifications to become active, these proteins can 
catalyse reactions that act on and produce metabolites. “Omics” technologies can measure 
genes (genomics), mRNA (transcriptomics), proteins (proteomics) or metabolites 
(metabolomics/metabonomics). 
Adapted from Joyce et al.
287
  
 
 
Many publications mention that the correlation between RNA transcripts, 
proteins and metabolites is often weak157,259,268,269,288-290. It is worth noticing that 
correlation assessment can have two different meanings depending on papers: overall 
correlation between mRNA and protein abundance for a set of proteins268,269 or 
correlation between mRNA and protein changes when comparing two experimental 
groups of samples (e.g. hydrazine-treated vs. untreated rats291, or non-invasive vs. 
invasive human bladder tumours292).  
As examples of the first case, Anderson and Seilhamer269 showed that the 
distribution of protein abundances was different from that of mRNAs in human liver, 
and Gigy et al.268 found that correlation between mRNA and protein levels in yeast was 
insufficient to predict protein levels from mRNA levels: comparable mRNA levels could 
yield to protein expression varying by 30-fold, and conversely proteins with comparable 
expression levels could result from mRNA levels varying by 20-fold. This can be 
attributed to posttranscriptional, translational and posttranslational mechanisms, such 
as regulation of mRNA translation to proteins and control of mRNA and protein half-
life268.  
However, this low correlation between mRNA and protein abundance for a set 
of proteins does not necessarily imply that when introducing a perturbation (e.g. a drug 
treatment) into a biological system, changes observed at the mRNA level will not be 
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detected at the protein level. In a study combining transcriptomics, proteomics and 
metabonomics to investigate the effect of hydrazine in rat, Kleno et al.291 found a 
perfect qualitatively correspondence between the protein and transcript data for most 
identified proteins with identified transcript counterparts. Quantitatively, they observed 
that the transcripts tended to exhibit factors of up- or down-regulation at least 2 fold 
higher than those for the corresponding proteins. Another study, comparing non-
invasive and invasive human bladder tumours292, found significant correlation between 
mRNA and protein alterations for most of the abundant known proteins identified. 
Conversely, discordant protein and mRNA expression has been reported in an 
investigation on 76 lung adenocarcinomas and 9 non-neoplastic lung tissues293: only 
17% (28/165) of the protein spots showed a statistically significant correlation between 
expression of their protein and mRNA. However, these 165 protein spots included all 
spots examined by the researchers, differentially expressed or not between the two 
groups.  
In summary, according to all these publications, it can be difficult to correlate 
overall mRNA and protein abundance. However, when a perturbation is introduced in a 
system, changes at the mRNA and protein levels are generally well correlated, with 
differences in regulation factor values though.  
 
The major part of the CYP distribution assessment in this project was carried 
out at the mRNA level. Although protein expression was not measured, protein 
activities were assessed for five CYPs, using specific probes. There was no 
perturbation introduced in this study as it aimed to characterise control animals, but the 
differences observed in CYP expression between males and females at mRNA and 
activity levels were compared. As detailed in section V.3.2, mRNA expression and 
activity data were qualitatively in very good agreement in terms of gender difference 
assessment. Quantitatively, there was a good consistency between male/female 
expression ratios obtained at the mRNA and activity levels for 3 CYPs out of the 5 
evaluated (Cyp2d1, Cyp2e1 and Cyp1a2, with consideration that liver expression of 
Cyp1a1 was negligible compared to Cyp1a2). For the fourth CYP (Cyp2b1), the 
male/female expression ratio was ~4 times higher at the RNA level compared with 
related activity. For the last CYP, it was difficult to reach a definite conclusion as the 
probe employed for activity assessment was specific for both Cyp3a1 and Cyp3a2 
(male/female expression ratio = 3.3), while mRNA expression was evaluated 
separately for each isoform (male/female expression ratio = 2.3 for Cyp3a1 and >6000 
for Cyp3a2). The value of 3.3 obtained for Cyp3a1/3a2 at the activity level was small 
compared to the ratio of 6000 observed for Cyp3a2 at the mRNA level. The substrate 
employed to assess the activity of Cyp3a1/3a2 might be predominantly metabolised by 
Cyp3a1. This difference could also result from translation mechanisms and/or post-
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transcriptional and post-translational modifications. Evaluating corresponding protein 
expression for Cyp3a1 and Cyp3a2 would be of interest to obtain insight regarding the 
levels of the mechanisms responsible for this discrepancy between ratios at the mRNA 
and activity level. From a combined metabolomic and proteomic study of a β-cell line 
culture at two levels of glucose, Fernandez et al.289 observed that the correlation 
between increases in metabolite levels and expression of the regulatory enzymes was 
weak, and concluded that substrate availability, allosteric regulation, and/or post-
translational modifications, could have a more important role in the determination of 
metabolite levels than enzyme expression at the protein level.  
In summary, except for Cyp3a1/3a2, there was a good consistency in gender 
differences at the mRNA and activity levels, with higher ratios observed at the mRNA 
level compared with the activity level for some CYPs, which was in harmony with the 
observations of Kleno cited above291. 
 
When investigating each gender separately, the correlation between mRNA 
levels and activities for each CYP was not very good. This probably explains the 
discrepancy in model qualities observed when integrating metabolic profiles of urine, 
serum or liver with CYP mRNA levels or with CYP-related activity after separating 
genders. These differences could also be due to the more complete picture given by 
the mRNA profiles of the 62 CYP isoforms compared to the individual activities of a few 
CYPs.  
It should not be forgotten that the models were constructed from 20 control rats, 
of the same gender, housed in an identical environment under strictly controlled 
conditions. Although experiments were conducted by batches of 5 rats from each 
gender (4 batches, corresponding to 4 rat deliveries), with intervals of 2 to 6 weeks 
between each batch, no differences between batches were observed for both CYP and 
metabolic profiles. Differences between genders were obvious, and excellent models 
were constructed when integrating CYP and metabolic profiles for male and female 
animals together, highlighting the latent variable “gender”. When separating males and 
females, it is likely that there was not enough inter-rat variability within the 20 control 
rats from a same gender to be able to consider individually each rat profile (either CYP 
or metabolic) and to link metabolic levels of these control rats taken individually with 
their corresponding CYP profiles. This is rather positive, as homogenous control 
groups facilitate the identification of any perturbations introduced by a drug treatment in 
preclinical studies. Following the characterisation of control animals and the 
development of a strategy to integrate CYP profiles and metabolic profiles in this 
control rat study, it is now possible to introduce perturbations via administration of 
reference inducers of CYPs.  
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VII.2. Measuring CYP mRNA levels or CYP-
related activities? 
The difference observed between models of CYP mRNA profiles and CYP-
related activities from metabolic profiles raises the question of the biological level at 
which CYPs should be assessed in subsequent studies carried out in this research 
project with reference inducers of CYPs. 
When investigating the impact of a new drug candidate on CYPs to assess 
possible drug-drug interactions, the information sought is whether this drug modifies 
the activity of the different CYP isoforms and will therefore have an impact on the 
metabolism of other drugs. If the mRNA abundance, or even the protein abundance, of 
a particular CYP is increased or decreased without this resulting in a modification of the 
activity of this CYP, this induction/inhibition is of minor importance as it is not reflected 
at the activity level and will therefore not impact upon the metabolism of other drugs. 
Consequently, it seems more relevant to assess CYP-related activity than CYP mRNA.  
However, due to the broad and overlapping substrate specificity of CYP 
isoforms, there is a risk that a substrate employed to assess the activity of a CYP 
isoform may also be metabolised by another isoform, resulting in activity assays 
producing inaccurate results. The specificity of commonly-used human CYP probe 
substrates for rat CYP enzymes has been examined by Kobayashi et al.294 (2002) and 
Chovan et al.295 (2007). They both found that most investigated probes were 
metabolised by multiple rat CYP isoforms, with none clearly dominant. For instance, 
chlorzoxazone hydroxylation, frequently used as a substrate-specific reaction for 
human CYP2E1 and employed here to assess rat Cyp2e1-related activity, was found to 
be catalysed by rat Cyp2e1 but also by rat Cyp1a1295, Cyp1a2294, Cyp3a1294,295 and 
Cyp2c11294,295. Surprisingly, Cyp1a2 was found to catalyse chlorzoxazone 
hydroxylation in Kobayashi’s study, but not in Chovan’s study (Cyp1a1 was not studied 
by Kobayashi). These differences between both studies may be explained by 
differences in substrate and/or CYP concentrations. Indeed, when multiple isoforms are 
involved in a reaction, enzyme-selectivity may differ depending on substrate 
concentration294. Concerning dextromethorphan O-demethylation, used as a specific 
reaction for human CYP2D6 and employed here to assess rat Cyp2d1-related activity, 
it was found to be catalysed in the rat by Cyp2c6 and Cyp2c11 in Chovan’s study and 
by Cyp2d2 in Kobayashi’s study (with no metabolism by Cyp2c6 and Cyp2c11). 
Midazolam 1’-hydroxylation, specific reaction for human CYP3A4 and employed here 
for Cyp3a1/3a2-related activity, was found to be preferentially catalysed by Cyp3a1 
and Cyp3a2 in both studies but could also be catalysed by Cyp2c11 (both studies) and 
2c13 (Chovan’s only). Phenacetin O-deethylation, a marker metabolism reaction for 
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human CYP1A1/1A2 and employed here to assess rat Cyp1a1/1a2-related activity, 
was found by Kobayashi to be indeed catalysed by rat Cyp1a1, but also by Cyp2c6 
(Cyp1a2 metabolism was not evaluated by Kobayashi and this reaction was not studied 
in Chovan’s study). Regarding Cyp2b1, the probe substrate employed in our study was 
not investigated in either study.  
These results illustrate the difficulty of finding substrate-specific reactions for 
CYP isoforms. However, they must be interpreted with care as metabolism 
investigations were carried out on systems expressing recombinant rat CYP isoforms 
individually (i.e. separate investigation of each isoform), with the same concentration 
for all isoforms. Therefore, these results take into account neither expression level 
differences between CYP isoforms in rat liver nor the competition between them. Thus, 
an enzyme may catalyse a substrate-specific reaction when this enzyme is alone in the 
presence of the substrate, but play a minor role in the metabolism of this substrate in 
vivo due to the presence of other CYP isoforms, more abundant and/or having more 
affinity for the substrate.  
The implication of multiple isoforms in metabolic reactions and the differences 
observed between the two studies in terms of isoform implication show the difficulty of 
finding substrate-specific reactions to evaluate activities of CYP isoforms separately. 
Moreover, if substrate-specific reactions are found in the literature for CYPs commonly 
assessed in drug metabolism studies (with the specificity issue raised above though), 
this is not the case for all the rat CYP isoforms, especially for those in families 5 to 51. 
Therefore, although assessment of CYP activities would seem a good choice for the 
induction studies we want to conduct as they are closer to the phenotype than CYP 
mRNA or protein levels, it cannot be used as the unique approach as it would 
considerably reduce the number of investigated CYPs.  
For most CYPs, CYP induction occurs via activation of transcription factors 
mediating gene transcription, and changes in CYP activity are therefore preceded by 
changes in mRNA levels296,297. Thus, mRNA expression profiling should provide 
valuable information on the induction of the multiple CYP isoforms by exogenous 
compounds. A good correlation between mRNA expression and CYP activities has 
previously been observed in hepatocytes treated with inducers296. Consequently, it 
seems a valid approach to investigate the CYPs at the mRNA level with qRT-PCR in 
the induction studies as performed in the control rat study. This approach offers the 
advantage of producing quantitative data for all the CYP isoforms known in the rat in a 
relatively high throughput manner. Investigations at the protein level would provide 
more reliable data in terms of expression as they would be closer to phenotype, but it 
would be much more complicated to evaluate all CYP isoforms.  
Therefore, the strategy employed for the subsequent induction studies will be to 
calculate ratios of expression between dosed and control animals at the mRNA level 
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for all CYP isoforms, as well as activity ratios for a few of these CYP isoforms. The 
consistency of the results obtained between mRNA and activity levels will then be 
checked. In the control rat study detailed in this work, overall good consistency of inter-
group ratios (i.e. male vs. female) was observed between mRNA and activity levels, 
and it will be of interest to see if this is also the case in the induction studies (dosed vs. 
control rats).  
In addition to post-transcriptional, translational and post-translational 
modifications, another factor may complicate the linking of mRNA and activity results: 
the time shift between events at the multiple levels157. This was less of a problem in the 
control rat study as there was no perturbation and the system was assumedly 
equilibrated. Conversely, in induction studies, the induction of CYP mRNA levels, 
proteins and activities will not be simultaneous. Moreover, the cellular processes do not 
go from genes to proteins in a unidirectional way as displayed in Figure VII-1. There 
are many feedback loops between genes, mRNAs, proteins and metabolites, regulating 
the multiple levels and forming intricate dynamic networks298, e.g. the quantity of 
metabolites formed by a protein can impact on the transcription/translation processes 
producing this protein to maintain homeostasis. Therefore, it could be of interest to 
produce transcriptomic and metabonomic data at multiple time points, as mRNA and 
metabolite levels from simultaneous samplings may not necessarily be the most 
biologically related. 
 
 
VII.3. Future work 
As explained in the general introduction of this thesis, this work was carried out 
as part of a pharmaceutical research project aiming to discover early biomarkers of 
CYP induction through metabolic profiling approaches. CYP induction or inhibition can 
alter the plasma concentration of a drug and lead to inefficiency of a drug treatment or 
conversely toxic effects due to an overdose (either of the inducer itself or of a co-
administered compound). It is therefore desirable for pharmaceutical companies to 
avoid developing new drugs that strongly induce or inhibit CYPs. Initial assessment of 
CYP induction/inhibition by a drug candidate is generally performed in vitro, using 
microsomes or hepatocytes. Induction is further evaluated later in the drug 
development process on laboratory animals, such as rat, mouse or dog. This 
evaluation is performed through analysis of the livers and therefore necessitates 
sacrificing animals. Study of the inhibition time course following repeated drug 
administration thus requires a large number of animals. Identification of early metabolic 
biomarkers of induction in urine or serum metabolic profiles would reduce the number 
of animals employed in induction studies, as metabolic profiling approaches offer the 
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great benefit of being non- or minimally-invasive, therefore enabling time course 
studies without multiplying the number of animals required. This is in accordance with 
the “Three Rs” guiding principles for the use of animals in research: Replacement (use 
of non-animal models whenever possible), Reduction (minimisation of the number of 
animals used) and Refinement (minimisation of animal pain and distress)299.  
 
Subsequent to the results obtained in the control rat study described in this 
thesis and as part of the induction project detailed above, I designed a protocol in 
collaboration with Catherine Spire (Biologie Servier, Gidy, France) and Vincent 
Croixmarie (Technologie Servier, Orleans, France) to investigate the effect of 
phenobarbital on CYP and metabolic profiles. Phenobarbital was chosen as it is a well 
known CYP inducer27 and the characterisation of its impact on CYP and metabolic 
profiles is of interest for future drug development studies.  
Phenobarbital was administered intraperitoneally to male and female Wistar rats 
at 80 mg/kg/day for one or four days. The study design is shown in Figure VII-2A. Half 
of the animals were terminated at Day 2, 16 hours after the first dosing (SG1), and the 
other half at Day 5, 16 hours after the fourth dosing (SG2). Livers were collected at 
study termination for CYP quantification and metabolic profiling (48 samples: 24 
collected at Day 2 and 24 at Day 5). Urine and serum were collected at three time 
points for metabolic profiling as shown in Figure VII-2B (120 samples: 48 pre-dose, 48 
at Day 2 and 24 at Day 5). 
Sample analyses were conducted in the same manner as in the control rat 
study. Quantification of mRNA was performed for 81 rat CYP isoforms with the TLDA 
cards designed for the control rat study, and CYP-related activities were assessed for 
isoforms 1a1/2, 2b1, 2d1, 2e1 and 3a1/2. Untargeted UPLC-MS metabolic profiles 
were established in urine, serum and liver samples, and targeted analyses of 
triglycerides and free fatty acids were carried out in serum and liver samples. Further 
work needs to be carried out to analyse and interpret the large amount of generated 
data. Integration of CYP profiles and metabolic profiles will be performed with the aim 
of identifying metabolic biomarkers of phenobarbital induction. If biomarkers are 
discovered, a new study will be designed to confirm these biomarkers, including 
multiple phenobarbital doses and collection time points to evaluate dose and time 
effects.  
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Figure VII-2. Phenobarbital study design 
(A) Schematic design of the study; (B) Sampling times. 
Abbreviations: PB=phenobarbital; G=group; SG=subgroup. 
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VII.4. Conclusion 
This work has globally improved our knowledge of basal CYP profiles and 
metabolic profiles in control male and female Wistar rats. Strategies have been 
established to evaluate expression of a large number of rat CYP isoforms, to recover 
reliable metabolic information from metabolic profiling analyses of urine, serum and 
liver by UPLC-MS, and to integrate CYP and metabonomic data. If interesting results 
are obtained from the phenobarbital study whose data are currently being analysed, 
the same type of study will be performed with other reference CYP inducers (such as 
TCPOBOP, β-naphthoflavone, 3-methylcholanthrene, isoniazid, pregnenolone 16 α-
carbonitrile) to identify serum or urine endogenous metabolite biomarkers specific of 
these reference CYP inducers. Urine and serum metabolic profiles obtained following 
administration of a new drug candidate could then be compared with those obtained 
with the reference inducers to determine if the drug candidate resembles to a reference 
CYP inducer. 
Importantly, the study design, data pre-processing workflow and statistical tools 
developed through this work have applications in many areas of metabolic profiling and 
are now employed in a large range of UPLC-MS studies performed in our laboratory. 
Moreover, the constructed standard compound database proved very useful to identify 
discriminating metabolites in other UPLC-MS metabolic profiling studies. 
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Appendix I: Standard compounds included in the 
constructed standard database (Chapter II) 
1 5(S)-Hydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoic acid 
 
56 Fumarate 
2 (5S,6S)-Dihydroxy-(7E,9E,11Z,14Z)-eicosatetraenoic acid 
 
57 Galacturonic acid 
3 1,2-diacyl-glycero-3-phosphoethanolamine 
 
58 GD1a 
4 1,2-dioleoyl-glycero-3-phosphocholine 
 
59 Glucosamine 6-phosphate 
5 14(R),15(S)-Epoxy-(5Z,8Z,11Z)-eicosatrienoic acid 
 
60 Glucose 6-phosphate 
6 1-oleoyl-glycero-3-phosphocholine (LPC 18:1) 
 
61 Glucuronic acid 
7 1-palmitoyl-glycero-3-phosphocholine (LPC 16:0) 
 
62 Glutamic acid 
8 1-stearoyl-glycero-3-phosphocholine (LPC 18:0) 
 
63 Glutamine 
9 3-hydroxyanthranilic acid 
 
64 Glutaric acid 
10 3-hydroxycinnamic acid 
 
65 Glutaryl Coenzyme A 
11 3-hydroxyphenylpropionic acid 
 
66 Gluthatione 
12 3-methylglutaric acid 
 
67 Glycerol 
13 Acetyl α-D-glucosamine-1-Phosphate 
 
68 Glycerophosphocholine 
14 Acetylcysteine 
 
69 Glycine 
15 Acetylglutamic acid 
 
70 Glycocholic acid (GCA) 
16 Acetylmuramic acid 
 
71 Glycogen 
17 Acetylneuraminic acid 
 
72 Glycolic acid 
18 Adenosine 
 
73 Glycolithocholic acid (GLCA) 
19 Adenosine 5'-diphosphate (ADP) 
 
74 Guanidine 
20 Adenosine 5'-monophosphate (AMP) 
 
75 Guanidoacetic acid 
21 Adenosine 5'-triphosphate (ATP) 
 
76 Hippuric acid 
22 Adipate 
 
77 Histidine 
23 Alanine 
 
78 Homocysteine 
24 Arginine 
 
79 Hydroxyproline 
25 Ascorbic acid 
 
80 Hyocholic acid (HCA) 
26 Asparagine 
 
81 Hyodeoxycholic acid (HDCA) 
27 Aspartic acid 
 
82 Hypoxanthine 
28 Betaine 
 
83 Indoxyl sulphate 
29 Bilirubin 
 
84 Inosine 
30 Carnitine 
 
85 Isoleucine 
31 Carnosine 
 
86 Leucine 
32 Chenodeoxycholic acid (CDCA) 
 
87 Leukotrien E4 
33 Cholic acid (CA) 
 
88 Lipoic acid 
34 Choline 
 
89 Lithocholic acid (LCA) 
35 Cinnamic acid 
 
90 Lysine 
36 cis_aconitic acid 
 
91 Malate 
37 Citrate 
 
92 Mannitol 
38 Citrulline 
 
93 Methionine 
39 Creatine 
 
94 Methylhistidine 
40 Creatinine 
 
95 Methylmalonic acid 
41 Cysteine Dimer 
 
96 Myoinositol 
42 Cytidine 
 
97 Nicotinamide adenine dinucleotide (NAD) 
43 Cytidine 5'-monophosphate (CMP) 
 
98 Nicotinic acid 
44 Deoxyadenosine diphosphate (dADP) 
 
99 Ornithine 
45 Deoxyadenosine monophosphate (dAMP) 
 
100 Orotic acid 
46 Deoxycholic acid (DCA) 
 
101 O-succinylhomoserine 
47 Deoxycytidine 
 
102 Oxalic acid 
48 Dihydroorotic acid 
 
103 Oxaloacetic acid 
49 Dihydrothymine 
 
104 Palmitic acid 
50 Dihydrouracil 
 
105 Pantothenic acid 
51 Epinephrine 
 
106 p-cresol 
52 Erythrodihydrosphingosine 
 
107 Phenylalanine 
53 Folic acid 
 
108 Phosphatidylserine 
54 Fructose 
 
109 Phosphoarginine 
55 Fructose-6-Phosphate 
 
110 Phosphocholine 
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111 Phosphorylethanolamine 
112 Phthalic acid 
113 Pimelic acid 
114 Pipecolic acid 
115 Porphobilinogen 
116 Proline 
117 Putrescine 
118 Pyridoxal-5-phosphate 
119 Pyridoxine 
120 Pyroglutamate 
121 Pyruvic acid 
122 Riboflavin 
123 Salicylic acid 
124 Sebacic acid 
125 Serine 
126 Spermidine 
127 Spermine 
128 Suberic acid 
129 Succinic acid 
130 Taurine 
131 Taurochenodeoxycholic acid (TCDCA) 
132 Taurocholic Acid (TCA) 
133 Taurodehydrocholic acid (T-dehydroCA) 
134 Taurodeoxycholic acid (TDCA) 
135 Taurohyocholic acid (THCA) 
136 Taurohyodeoxycholic acid (THDCA) 
137 Taurolithocholic acid (TLCA) 
138 Tauroursocholic acid (TUCA) 
139 Tauroursodeoxycholic acid (TUDCA) 
140 Tauro-α-muricholic acid (T-α-MCA) 
141 Tauro-ω-muricholic acid (T-ω-MCA) 
142 Threonine 
143 Thymidine 
144 Tryptophan 
145 Tyramine 
146 Tyrosine 
147 UDP 
148 UDP glucose 
149 UDP glucuronic acid 
150 Uracil 
151 Urea 
152 Uric acid 
153 Uridine 
154 Uridine monophosphate (UMP) 
155 Uridine triphosphate (UTP) 
156 Urocanic acid 
157 Ursodeoxycholic acid (UDCA) 
158 Valine 
159 Xylose 
160 α-ketoglutaric acid (Oxoglutaric acid) 
161 α-muricholic acid (α-MCA) 
162 α-phosphatidylcholine (mix) 
163 β-muricholic acid (β-MCA) 
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Appendix II: Materials and suppliers for ICL UPLC-MS 
metabolic profiling analysis (Chapters III, IV and VI) 
 
 
HPLC grade water, acetronitrile, methanol, chloroform, dichloromethane, 
isopropanol, formic acid, leucine enkephalin and sodium formate were obtained from 
Sigma (Gillingham, UK), except for acetonitrile mobile phase employed in the method 
development study (Chapter III), which was from VWR (hypergrade for LC/MS 
LiChrosolv®). 
96-well plates and vials were from Waters (Hertfordshire, UK); well plate cap 
mats were from VWR (Leicestershire, UK). 
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Appendix III: Supplementary data for chapter III 
 
 Consecutive extraction protocol, organic extracts 
- Summary table for the numbers and percentages of consistently detected 
peaks and of reproducible peaks (CV≤20% and CV≤40%) for the analysis of 
the CE organic extracts  
ESI+ mode 
Protocols 
Number 
of peaks 
(N) 
Number 
of peaks 
present in 
at least 
60% 
samples 
(N60) 
% of 
N 
Number of 
peaks 
present in 
at least 
60% 
samples 
and with 
CV<=20% 
(N6020%) 
% of 
N 
% of 
N60 
Number of 
peaks 
present in 
at least 
60% 
samples 
and with 
CV<=40% 
(N6040%) 
% of 
N 
% of 
N60 
aA-oC-sA 1747 1364 78.1% 137 7.8% 10.0% 634 36.3% 46.5% 
aM-oC-sA 2134 1621 76.0% 114 5.3% 7.0% 603 28.3% 37.2% 
aA-oD-sA 1804 1354 75.1% 65 3.6% 4.8% 530 29.4% 39.1% 
aM-oD-sA 2684 2126 79.2% 427 15.9% 20.1% 1296 48.3% 61.0% 
aA-oC-sM 1141 855 74.9% 11 1.0% 1.3% 184 16.1% 21.5% 
aM-oC-sM 1582 1265 80.0% 58 3.7% 4.6% 377 23.8% 29.8% 
aA-oD-sM 1600 1199 74.9% 91 5.7% 7.6% 597 37.3% 49.8% 
aM-oD-sM 2348 1866 79.5% 204 8.7% 10.9% 1007 42.9% 54.0% 
ESI− mode 
Protocols 
Number 
of peaks 
(N) 
Number 
of peaks 
present in 
at least 
60% 
samples 
(N60) 
% of 
N 
Number of 
peaks 
present in 
at least 
60% 
samples 
and with 
CV<=20% 
(N6020%) 
% of 
N 
% of 
N60 
Number of 
peaks 
present in 
at least 
60% 
samples 
and with 
CV<=40% 
(N6040%) 
% of 
N 
% of 
N60 
aA-oC-sA 2161 1777 82.2% 334 15.5% 18.8% 987 45.7% 55.5% 
aM-oC-sA 2261 1912 84.6% 538 23.8% 28.1% 1358 60.1% 71.0% 
aA-oD-sA 1797 1390 77.4% 15 0.8% 1.1% 441 24.5% 31.7% 
aM-oD-sA 2386 1986 83.2% 328 13.7% 16.5% 1077 45.1% 54.2% 
aA-oC-sM 1446 1164 80.5% 119 8.2% 10.2% 526 36.4% 45.2% 
aM-oC-sM 1827 1517 83.0% 301 16.5% 19.8% 997 54.6% 65.7% 
aA-oD-sM 1890 1538 81.4% 363 19.2% 23.6% 1054 55.8% 68.5% 
aM-oD-sM 2507 2056 82.0% 529 21.1% 25.7% 1402 55.9% 68.2% 
Abbreviations: aqueous extraction with acetonitrile/water (aA) or methanol/water (aM); organic extraction with 
chloroform/methanol (oC) or dichloromethane/methanol (oD); organic extract resuspension in acetonitrile/water 
(sA) or methanol/water (sM). 
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 Two-layer extraction protocol TLEa, aqueous extracts 
- Box plots comparing the distribution of metabolite feature intensity CVs 
among replicates for the 8 conditions tested for the aqueous extracts of 
protocol TLEa 
 
(A) ESI+ mode, complete distribution; (B) ESI+ mode, zoom in on distribution 
between 25th and 75th percentile; (C) ESI− mode, complete distribution; (D) 
ESI− mode, zoom in on distribution between 25th and 75th percentile. 
 
 
- Assessment of peak reproducibility (y-axis) and number of consistently 
detected peaks (x-axis) for the 8 conditions tested for the aqueous extracts of 
protocol TLEa 
 
(A) ESI+ mode, 20% CV threshold; (B) ESI+ mode, 40% CV threshold; (C) ESI− 
mode, 20% CV threshold; (D) ESI− mode, 40% CV threshold. 
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- Summary table for the numbers and percentages of consistently detected 
peaks and of reproducible peaks (CV≤20% and CV≤40%) for the 8 conditions 
tested for the aqueous extracts of protocol TLEa 
ESI+ mode 
   
Number 
of peaks 
(N) 
Number 
of peaks 
present 
in at 
least 
60% 
samples 
(N60) 
% of 
N 
Number 
of peaks 
present 
in at 
least 60% 
samples 
and with 
CV<=20% 
(N6020%) 
% of 
N 
% of 
N60 
Number 
of peaks 
present 
in at 
least 60% 
samples 
and with 
CV<=40% 
(N6040%) 
% of 
N 
% of 
N60 
TLEa-0C1 2722 1473 54.1% 76 2.8% 5.2% 369 13.6% 25.1% 
TLEa-0C2 2470 1602 64.9% 205 8.3% 12.8% 683 27.7% 42.6% 
TLEa-0D1 1705 1006 59.0% 15 0.9% 1.5% 114 6.7% 11.3% 
TLEa-0D2 2484 1478 59.5% 68 2.7% 4.6% 211 8.5% 14.3% 
TLEa-10C1 1770 1098 62.0% 72 4.1% 6.6% 254 14.4% 23.1% 
TLEa-10C2 2955 2058 69.6% 132 4.5% 6.4% 450 15.2% 21.9% 
TLEa-10D1 3101 2081 67.1% 347 11.2% 16.7% 1308 42.2% 62.9% 
TLEa-10D2 2843 1963 69.0% 18 0.6% 0.9% 165 5.8% 8.4% 
ESI− mode 
  
Number 
of peaks 
(N) 
Number 
of peaks 
present 
in at least 
60% 
samples 
(N60) 
% of N 
Number of 
peaks 
present in 
at least 
60% 
samples 
and with 
CV<=20% 
(N6020%) 
% of N 
% of 
N60 
Number of 
peaks 
present in 
at least 
60% 
samples 
and with 
CV<=40% 
(N6040%) 
% of N 
% of 
N60 
TLEa-0C1 2739 1246 45.5% 77 2.8% 6.2% 337 12.3% 27.0% 
TLEa-0C2 2457 1567 63.8% 404 16.4% 25.8% 865 35.2% 55.2% 
TLEa-0D1 1686 1024 60.7% 36 2.1% 3.5% 234 13.9% 22.9% 
TLEa-0D2 2413 1477 61.2% 69 2.9% 4.7% 299 12.4% 20.2% 
TLEa-10C1 1797 1084 60.3% 108 6.0% 10.0% 411 22.9% 37.9% 
TLEa-10C2 2557 1706 66.7% 46 1.8% 2.7% 276 10.8% 16.2% 
TLEa-10D1 2659 1742 65.5% 150 5.6% 8.6% 688 25.9% 39.5% 
TLEa-10D2 2602 1507 57.9% 9 0.3% 0.6% 58 2.2% 3.8% 
 
- Global variances obtained from PCA scores of the aqueous extracts of 
protocol TLEa 
 ESI+ mode ESI− mode 
TLEa-0C1 1962 2835 
TLEa-0C2 2532 2854 
TLEa-0D1 1712 1611 
TLEa-0D2 1350 1424 
TLEa-10C1 1191 878 
TLEa-10C2 3000 1932 
TLEa-10D1 1672 1612 
TLEa-10D2 2850 2564 
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 Two-layer extraction protocols TLEb TLEc TLEd, aqueous 
extracts 
- Box plots comparing the distribution of metabolite feature intensity CVs 
among replicates for the conditions tested for the aqueous extracts of 
protocols TLEb, TLEc and TLEd 
 
(A) ESI+ mode, complete distribution; (B) ESI+ mode, zoom in on distribution 
between 25th and 75th percentile; (C) ESI− mode, complete distribution; (D) 
ESI− mode, zoom in on distribution between 25th and 75th percentile.  
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- Assessment of peak reproducibility (y-axis) and number of consistently 
detected peaks (x-axis) for the conditions tested for the aqueous extracts of 
protocols TLEb, TLEc and TLEd 
 
(A) ESI+ mode, 20% CV threshold; (B) ESI+ mode, 40% CV threshold; (C) ESI− 
mode, 20% CV threshold; (D) ESI− mode, 40% CV threshold. 
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- Summary table for the numbers and percentages of consistently detected 
peaks and of reproducible peaks (CV≤20% and CV≤40%) for the  conditions 
tested for the aqueous extracts of protocols TLEb, TLEc and TLEd 
ESI+ mode 
 
Number 
of peaks 
(N) 
Number 
of peaks 
present 
in at 
least 
60% 
samples 
(N60) 
% of N 
Number 
of peaks 
present 
in at least 
60% 
samples 
and with 
CV<=20% 
(N6020%) 
% of N 
% of 
N60 
Number 
of peaks 
present in 
at least 
60% 
samples 
and with 
CV<=40% 
(N6040%) 
% of N 
% of 
N60 
TLEb-0C1 2348 1119 47.7% 69 2.9% 6.2% 228 9.7% 20.4% 
TLEb-0C2 3085 2018 65.4% 138 4.5% 6.8% 655 21.2% 32.5% 
TLEb-0D1 1120 682 60.9% 82 7.3% 12.0% 315 28.1% 46.2% 
TLEb-0D2 1817 983 54.1% 23 1.3% 2.3% 92 5.1% 9.4% 
TLEb-
10C1 
1387 862 62.1% 59 4.3% 6.8% 185 13.3% 21.5% 
TLEb-
10C2 
2752 1011 36.7% 9 0.3% 0.9% 41 1.5% 4.1% 
TLEb-
10D1 
2663 1541 57.9% 188 7.1% 12.2% 595 22.3% 38.6% 
TLEb-
10D2 
1529 1167 76.3% 136 8.9% 11.7% 395 25.8% 33.8% 
TLEc-0C1 1911 1298 67.9% 69 3.6% 5.3% 269 14.1% 20.7% 
TLEc-0C2 2638 1573 59.6% 42 1.6% 2.7% 215 8.2% 13.7% 
TLEc-0D1 3080 2312 75.1% 159 5.2% 6.9% 733 23.8% 31.7% 
TLEc-0D2 2514 892 35.5% 27 1.1% 3.0% 105 4.2% 11.8% 
TLEd-0C1 2783 1773 63.7% 45 1.6% 2.5% 221 7.9% 12.5% 
TLEd-0C2 3386 2378 70.2% 192 5.7% 8.1% 579 17.1% 24.3% 
TLEd-0D1 2137 1457 68.2% 248 11.6% 17.0% 522 24.4% 35.8% 
TLEd-0D2 1915 1271 66.4% 74 3.9% 5.8% 314 16.4% 24.7% 
ESI− mode 
 
Number 
of peaks 
(N) 
Number 
of peaks 
present 
in at 
least 
60% 
samples 
(N60) 
% of N 
Number 
of peaks 
present 
in at least 
60% 
samples 
and with 
CV<=20% 
(N6020%) 
% of N 
% of 
N60 
Number 
of peaks 
present in 
at least 
60% 
samples 
and with 
CV<=40% 
(N6040%) 
% of N 
% of 
N60 
TLEb-0C1 2812 1571 55.9% 92 3.3% 5.9% 480 17.1% 30.6% 
TLEb-0C2 3413 2529 74.1% 242 7.1% 9.6% 1090 31.9% 43.1% 
TLEb-0D1 1748 1221 69.9% 187 10.7% 15.3% 618 35.4% 50.6% 
TLEb-0D2 2202 1304 59.2% 4 0.2% 0.3% 64 2.9% 4.9% 
TLEb-
10C1 
1949 1390 71.3% 121 6.2% 8.7% 427 21.9% 30.7% 
TLEb-
10C2 
2646 1324 50.0% 6 0.2% 0.5% 96 3.6% 7.3% 
TLEb-
10D1 
3017 2001 66.3% 236 7.8% 11.8% 791 26.2% 39.5% 
TLEb-
10D2 
2167 1702 78.5% 310 14.3% 18.2% 870 40.1% 51.1% 
TLEc-0C1 2524 1833 72.6% 107 4.2% 5.8% 497 19.7% 27.1% 
TLEc-0C2 3202 2038 63.6% 148 4.6% 7.3% 510 15.9% 25.0% 
TLEc-0D1 3594 2755 76.7% 336 9.3% 12.2% 1291 35.9% 46.9% 
TLEc-0D2 3027 1342 44.3% 73 2.4% 5.4% 279 9.2% 20.8% 
TLEd-0C1 2926 2125 72.6% 58 2.0% 2.7% 357 12.2% 16.8% 
TLEd-0C2 3552 2543 71.6% 147 4.1% 5.8% 636 17.9% 25.0% 
TLEd-0D1 2030 1421 70.0% 165 8.1% 11.6% 505 24.9% 35.5% 
TLEd-0D2 2321 1651 71.1% 6 0.3% 0.4% 82 3.5% 5.0% 
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- Global variances obtained from PCA scores of the aqueous extracts of 
protocols TLEb, TLEc and TLEd 
 ESI+ mode ESI− mode 
TLEb-0C1 2010 1802 
TLEb-0C2 3252 2023 
TLEb-0D1 334 161 
TLEb-0D2 5367 3708 
TLEb-10C1 2321 2261 
TLEb-10C2 6133 2914 
TLEb-10D1 1698 1647 
TLEb-10D2 642 405 
TLEc-0C1 1832 2415 
TLEc-0C2 2469 3088 
TLEc-0D1 1855 1994 
TLEc-0D2 4338 3644 
TLEd-0C1 3524 1475 
TLEd-0C2 4219 3108 
TLEd-0D1 2279 1887 
TLEd-0D2 269 448 
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Appendix IV: Individual CT values obtained in the CYP 
mRNA expression study (Chapter V) 
Rats 1-10 
 
Rat01 Rat01 Rat02 Rat02 Rat03 Rat03 Rat04 Rat04 Rat05 Rat05 Rat06 Rat06 Rat07 Rat07 Rat08 Rat08 Rat09 Rat09 Rat10 Rat10 
Cyp1a1-Rn00487218_m1 31.5 31.7 28.8 27.8 28.4 28.7 28.9 29.1 30.1 30.3 30.0 31.1 30.3 26.0 28.3 28.5 29.1 28.8 28.7 28.6 
Cyp1a2-Rn00561082_m1 19.9 19.6 19.1 19.0 19.2 19.0 19.3 19.3 19.8 20.0 19.5 19.6 20.1 19.9 19.2 19.2 19.3 19.4 18.9 19.7 
Cyp1b1-Rn00564055_m1 34.6 33.2 34.0 34.3 40.0 34.6 34.1 40.0 31.9 33.8 32.6 34.3 33.2 33.4 33.3 33.4 34.4 40.0 35.7 35.3 
Cyp2a1-Rn00562200_m1 23.0 22.5 22.4 22.4 22.5 22.4 22.1 22.4 21.9 22.0 23.1 23.0 22.1 22.2 22.4 22.2 22.2 22.1 22.5 22.9 
Cyp2a2-Rn00562207_m1 22.9 22.7 22.5 22.4 22.6 22.6 22.3 22.2 22.2 22.3 22.9 22.8 22.2 22.2 22.3 22.1 22.4 22.5 22.2 22.8 
Cyp2a3-Rn00561086_m1 40.0 40.0 40.0 34.7 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2b1-Rn01457875_m1 25.1 25.6 23.3 23.1 23.5 23.3 23.3 23.3 22.6 22.9 24.0 23.8 24.1 24.1 23.9 23.7 24.1 24.1 23.5 23.8 
Cyp2b2-Rn02786833_m1 27.9 27.7 27.6 27.5 25.4 25.1 25.8 25.9 24.5 24.5 25.3 25.4 26.4 26.0 25.7 25.4 24.8 25.2 26.9 27.5 
Cyp2b3-Rn01476085_m1 21.3 21.2 21.8 21.5 22.0 21.7 21.7 21.5 21.4 21.5 21.7 21.5 21.4 21.1 21.8 21.5 22.1 22.3 21.4 22.0 
Cyp2b3-Rn02786829_sH 24.0 24.0 24.8 24.5 24.9 24.9 24.3 24.4 24.6 24.8 24.9 24.6 24.4 24.4 24.9 24.8 25.7 25.7 24.4 25.0 
Cyp2b12-Rn00755182_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2b21-Rn01475826_m1 35.1 40.0 40.0 40.0 40.0 35.5 34.7 40.0 34.4 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2c6-Rn02786821_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2c7-Rn01529602_mH 17.8 17.8 18.5 18.2 18.5 18.2 18.1 18.2 17.2 17.7 18.2 18.0 17.5 17.2 18.2 17.9 18.0 17.8 18.0 18.4 
Cyp2c11-Rn00569868_m1 20.2 20.1 20.7 20.4 20.3 20.3 20.3 20.3 20.4 20.5 20.8 20.7 20.8 20.9 20.3 20.3 20.3 20.3 20.6 20.9 
Cyp2c12-Rn00755856_m1 24.0 24.0 25.0 24.6 24.9 24.5 25.5 25.6 24.6 25.1 23.4 23.1 25.8 25.7 25.7 25.4 24.1 24.6 24.4 24.9 
Cyp2c13-Rn00593388_g1 20.3 20.3 20.7 20.2 20.3 20.0 20.0 19.9 19.6 19.7 20.5 20.2 20.0 19.9 20.0 19.7 20.1 20.1 20.2 20.8 
Cyp2c22-Rn00593377_m1 22.3 22.4 22.7 22.5 22.3 22.1 22.9 22.8 22.0 22.2 23.5 23.2 23.0 22.9 22.7 22.7 22.9 22.9 23.2 23.5 
Cyp2c23-Rn00582954_m1 21.6 21.0 21.5 20.9 21.8 21.5 21.3 21.4 21.3 21.3 21.7 21.1 21.3 21.1 21.6 21.2 21.1 21.2 21.0 21.5 
Cyp2c37-Rn02786817_m1 27.0 26.8 26.8 26.7 26.5 26.3 27.0 26.9 26.6 26.7 27.1 27.0 27.5 27.5 26.8 26.6 27.0 26.7 28.5 29.3 
Cyp2c79-Rn02047662_s1 32.0 32.0 30.9 30.6 32.8 33.0 34.8 35.5 33.2 32.9 32.4 32.3 34.9 33.1 35.2 38.1 40.0 40.0 31.7 31.6 
Cyp2c80-Rn01454089_m1 31.8 31.5 31.8 31.6 32.0 32.2 31.6 31.6 31.4 31.7 32.8 33.8 32.0 32.0 33.3 32.8 31.2 31.6 30.2 31.0 
Cyp2d1-Rn01775090_mH 21.7 22.1 22.0 21.4 22.2 22.5 22.0 22.6 21.5 22.2 22.4 22.1 21.8 22.0 21.7 21.8 22.3 22.2 22.0 22.9 
Cyp2d2-Rn00562419_m1 20.4 20.0 20.5 20.1 20.3 20.1 20.3 20.4 20.0 20.0 20.1 20.1 20.3 20.2 20.0 20.0 20.2 20.2 20.0 20.7 
Cyp2d3-Rn00597330_m1 21.3 21.2 21.4 21.0 21.3 21.1 21.3 21.4 21.0 21.1 21.2 21.0 21.1 21.2 21.2 21.1 21.3 21.3 21.0 21.5 
Cyp2d4-Rn01504629_m1 25.8 25.8 26.0 25.6 25.6 25.4 24.9 25.2 25.1 25.1 25.8 25.2 25.9 25.8 26.0 25.7 25.9 26.1 25.1 25.8 
Cyp2d4-Rn00696505_g1 26.2 26.0 26.5 26.0 26.1 25.9 25.6 25.6 25.8 25.8 26.1 26.0 26.1 26.2 26.4 26.1 26.4 26.3 26.0 26.5 
Cyp2d5-Rn01790051_s1 22.0 21.9 21.5 21.2 21.6 21.6 22.8 22.9 21.7 21.7 21.8 21.8 21.3 21.2 21.9 21.8 22.1 22.1 21.9 22.3 
Cyp2e1-Rn00580624_m1 19.2 19.2 18.5 18.0 19.1 18.8 18.8 18.6 18.1 18.5 19.3 18.9 18.6 18.3 18.9 18.5 18.8 18.7 18.3 19.0 
Cyp2f4-Rn00570779_m1 31.8 33.4 32.2 32.0 32.0 32.5 31.3 31.9 32.1 31.9 34.8 32.8 32.7 31.8 31.9 33.1 34.4 34.6 34.6 32.8 
Cyp2g1-Rn01454738_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2j3-Rn00598500_m1 24.7 24.7 24.7 24.1 24.5 24.3 24.7 24.8 24.0 24.1 24.6 24.7 24.8 24.7 24.7 24.6 24.6 24.6 24.0 24.5 
Cyp2j4-Rn00576482_m1 23.8 23.9 23.6 23.2 23.6 23.4 23.6 23.4 23.4 23.8 23.7 23.1 23.7 23.6 24.0 24.0 23.8 23.6 22.9 23.2 
Cyp2j5-ps-Rn01771422_m1 36.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2j10-Rn01433143_m1 30.6 30.2 30.2 29.8 30.9 30.4 29.5 29.9 31.1 30.7 31.7 30.5 30.9 30.7 30.7 30.6 31.1 30.7 29.7 30.4 
Cyp2j13-Rn01763811_g1 33.9 34.1 33.2 32.3 32.9 32.3 33.0 32.8 32.2 30.9 33.7 33.5 32.9 32.7 33.0 32.0 33.1 32.5 30.2 32.3 
Cyp2j16-Rn01433366_m1 26.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 37.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2r1-Rn01754616_m1 28.5 28.2 29.0 28.8 28.9 28.9 28.8 28.6 28.9 28.8 28.8 28.5 28.5 28.7 28.5 28.4 28.4 28.3 28.6 29.0 
Cyp2s1-Rn01476074_s1 31.7 32.9 30.4 30.8 32.4 31.4 31.3 30.8 33.1 33.4 32.4 31.9 31.1 31.9 33.3 34.2 33.7 34.2 32.4 33.5 
Cyp2s1-Rn01475871_m1 31.8 30.8 32.3 33.3 33.0 33.5 31.9 33.1 31.9 32.5 33.4 32.2 33.2 32.6 32.2 32.7 34.9 31.5 32.3 31.8 
Cyp2t1-Rn00592635_m1 24.0 24.3 24.8 24.4 24.8 25.4 24.6 24.9 24.2 24.5 25.0 24.8 24.8 24.8 24.7 24.5 25.0 24.9 24.5 24.7 
Cyp2u1-Rn01522408_m1 28.9 29.0 27.9 27.4 27.8 27.6 28.6 28.8 27.7 27.6 28.8 28.8 28.8 29.0 28.7 28.1 28.5 28.5 27.4 28.5 
Cyp2w1-Rn01412757_m1 40.0 40.0 40.0 40.0 40.0 36.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp3a2-Rn01412889_mH 18.9 19.0 18.9 18.3 18.7 18.6 20.2 20.3 19.8 19.9 20.7 20.3 19.0 19.0 18.9 18.7 19.0 19.0 19.6 20.0 
Cyp3a2-Rn00756461_m1 19.0 19.2 19.2 18.8 19.1 18.7 20.5 20.8 19.9 20.2 21.0 20.7 19.2 19.4 19.1 19.1 19.3 19.3 19.8 20.3 
Cyp3a9-Rn00595977_m1 23.8 23.6 25.1 24.6 24.8 24.7 23.9 24.0 23.9 24.2 25.3 25.0 24.8 24.8 26.4 25.9 24.2 24.2 24.4 24.8 
Cyp3a18-Rn00595752_m1 22.0 22.2 22.3 21.7 21.7 21.5 22.1 22.1 21.8 22.0 22.3 22.2 22.4 22.5 22.2 22.1 22.1 22.1 21.8 22.4 
Cyp3a23(3a1)-Rn01412959_g1 20.9 21.2 21.5 21.1 21.7 21.7 22.1 22.0 21.0 21.4 22.4 22.2 21.0 20.9 21.7 21.6 21.5 21.4 22.3 22.8 
Cyp3a62-Rn01409583_m1 28.7 28.6 28.0 27.6 27.8 27.5 27.8 28.3 28.4 28.2 28.3 27.8 28.6 28.2 28.4 28.3 28.1 28.0 27.4 28.2 
Cyp4a1-Rn00598510_m1 21.9 21.9 22.6 22.1 22.3 22.2 21.9 21.9 21.8 22.0 21.8 21.7 22.0 22.0 22.0 21.9 21.5 21.5 21.1 21.8 
Cyp4a2-Rn01417066_m1 17.7 18.0 18.8 18.3 18.3 18.0 17.0 17.6 18.0 18.0 17.4 17.0 18.0 17.7 18.0 18.1 17.6 17.3 16.9 17.4 
Cyp4a3-Rn00598411_m1 19.5 19.3 19.9 19.6 19.5 19.4 18.8 18.9 19.4 19.4 18.7 18.4 19.0 19.2 19.5 19.2 18.6 18.6 18.3 18.8 
Cyp4a8-Rn00581081_m1 26.2 26.7 27.5 26.7 27.4 27.1 28.0 28.5 26.3 27.6 30.7 30.5 28.4 29.0 28.0 27.3 29.0 29.0 28.8 29.3 
Cyp4b1-Rn00566515_m1 26.9 26.8 27.1 26.9 26.8 27.0 26.6 26.8 27.1 27.1 26.7 26.4 27.1 27.0 27.2 27.0 26.8 26.9 26.0 26.5 
Cyp4f1-Rn00571492_m1 23.0 22.6 22.9 22.6 22.9 22.7 23.2 23.2 22.7 22.5 22.9 22.7 22.9 22.8 22.7 22.5 22.7 22.7 22.8 23.1 
Cyp4f4-Rn00597513_m1 22.8 22.8 22.9 22.5 22.8 22.8 22.5 22.6 22.3 22.5 23.1 22.9 22.7 22.7 23.0 22.9 22.9 23.0 22.6 22.9 
Cyp4f5-Rn00687553_m1 28.0 28.0 28.1 28.0 27.8 27.5 27.1 27.3 28.6 28.6 29.0 28.5 28.4 28.0 28.2 28.2 28.1 28.0 27.4 27.7 
Cyp4f5;4f37-Rn00687557_gH 27.6 27.6 28.0 27.5 27.4 27.2 26.9 26.9 27.6 28.0 28.6 28.1 28.1 27.9 28.1 27.9 27.8 28.0 27.6 27.5 
Cyp4f6-Rn00686847_m1 24.8 24.9 25.0 24.7 25.0 24.8 24.7 24.6 24.3 24.6 25.0 24.4 24.9 25.0 24.8 24.7 25.1 25.0 24.4 25.0 
Cyp4f17-Rn01408612_m1 29.6 29.5 30.0 29.7 29.6 29.8 29.6 30.0 29.3 29.2 29.6 29.8 29.6 29.5 29.7 29.2 29.6 29.4 29.5 30.0 
Cyp4f18-Rn01420067_m1 33.8 33.0 32.9 34.1 35.3 31.9 32.9 32.1 34.6 32.7 32.3 40.0 32.1 32.5 33.8 35.0 34.9 32.7 34.1 32.8 
Cyp4f39-Rn01408191_m1 27.7 27.8 27.3 26.9 27.1 27.0 27.9 28.1 26.5 26.8 26.9 26.7 27.1 27.4 27.5 27.9 27.6 27.8 26.4 27.2 
Cyp4f40-Rn01408132_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 36.0 40.0 40.0 40.0 35.0 40.0 40.0 40.0 40.0 40.0 40.0 34.8 40.0 
Cyp4v3-Rn01488162_m1 22.6 22.7 23.0 22.6 24.8 24.8 23.0 23.0 23.1 23.3 22.4 22.2 22.9 23.0 22.9 22.7 24.6 24.6 22.6 23.1 
Cyp4x1-Rn00595521_m1 34.8 40.0 40.0 40.0 35.5 34.8 40.0 34.9 40.0 40.0 40.0 40.0 40.0 40.0 35.3 33.4 40.0 40.0 40.0 40.0 
Tbxas1-Rn00562160_m1 28.9 28.8 30.7 30.1 30.4 30.0 29.3 29.0 29.1 29.5 31.2 30.8 29.9 29.7 29.1 29.1 29.5 29.4 29.5 30.2 
Cyp7a1-Rn00564065_m1 26.4 26.4 26.7 26.2 27.6 27.5 25.6 25.9 25.9 26.1 27.8 27.5 26.7 26.4 26.4 26.3 26.0 25.9 27.0 27.5 
Cyp7b1-Rn01461859_m1 28.2 28.0 29.0 28.3 28.1 28.0 28.5 28.1 28.2 27.9 28.4 28.5 28.3 28.1 28.2 28.1 28.1 28.4 28.1 28.6 
Cyp7b1-Rn01461862_m1 28.9 28.6 29.6 29.0 29.0 29.0 28.7 28.9 28.7 28.9 29.4 29.0 29.0 29.0 29.0 28.9 29.4 29.3 29.1 29.5 
Ptgis-Rn00580687_m1 28.6 29.3 28.7 28.6 27.4 27.4 32.8 31.3 28.5 28.4 28.1 28.0 29.5 29.9 27.2 27.0 29.0 28.9 32.8 33.1 
Cyp8b1-Rn00579921_s1 20.0 20.0 20.5 20.2 20.3 20.1 19.7 19.8 19.9 20.0 19.1 19.1 19.8 19.8 19.9 19.7 19.7 19.7 19.5 19.9 
Cyp11a1-Rn00568733_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp11a1-Rn01421674_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 35.5 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp11a1-Rn01421681_g1 40.0 40.0 40.0 40.0 34.1 32.7 34.6 34.6 40.0 40.0 35.1 40.0 40.0 40.0 40.0 40.0 36.2 35.0 40.0 40.0 
Cyp11b1-Rn02607234_g1 40.0 40.0 40.0 40.0 40.0 37.0 40.0 40.0 40.0 40.0 33.9 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp11b2-Rn01767818_g1 33.2 34.4 32.0 30.9 33.2 32.5 40.0 40.0 35.6 40.0 33.4 33.6 40.0 40.0 40.0 40.0 40.0 33.9 21.7 33.9 
Cyp11b3-Rn00822066_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 23.3 40.0 40.0 40.0 40.0 40.0 40.0 27.3 
Cyp17a1-Rn01444704_g1 24.9 24.7 25.2 25.0 24.8 24.8 24.6 24.7 24.7 24.8 24.3 24.1 25.4 25.5 24.6 24.3 24.4 24.5 23.8 24.4 
Cyp17a1-Rn00664858_m1 25.2 25.3 25.6 25.2 25.4 25.2 25.1 25.1 25.1 25.2 24.9 24.7 25.8 25.8 25.2 24.9 25.0 24.9 24.4 24.9 
Cyp17a1-Rn00562601_m1 26.1 26.0 26.8 26.2 26.3 26.1 26.2 26.0 26.1 26.2 25.7 25.5 26.9 26.7 25.9 26.0 25.9 26.0 25.6 25.8 
Cyp19a1-Rn00567222_m1 40.0 40.0 40.0 39.0 40.0 40.0 34.4 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp19a1-Rn01422547_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp20a1-Rn01644438_g1 25.7 25.5 25.5 25.0 25.5 25.5 25.3 25.4 25.3 25.4 25.5 25.0 25.8 25.6 25.4 25.3 25.6 25.7 24.8 25.5 
Cyp21a1-Rn00588996_g1 30.3 29.7 30.5 30.0 29.8 30.4 29.8 30.5 29.9 30.5 31.6 31.8 29.7 29.9 31.6 31.8 31.6 32.2 30.4 30.6 
Cyp24a1-Rn01423143_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp26a1-Rn00590308_m1 31.5 31.2 30.9 30.3 32.1 31.2 31.4 31.2 31.0 31.0 31.2 30.4 31.2 31.0 30.8 30.6 32.0 31.0 31.0 31.7 
Cyp26b1-Rn00710376_m1 31.7 31.9 31.4 31.0 31.0 30.6 31.6 32.0 30.2 30.2 30.1 29.6 31.1 31.1 31.2 31.0 31.6 30.2 30.2 30.4 
Cyp27a1-Rn00710297_m1 21.5 21.6 21.7 21.3 22.0 21.8 21.2 21.5 21.2 21.4 21.8 21.7 21.4 21.6 21.7 21.7 21.9 22.0 21.5 22.0 
Cyp27b1-Rn01647147_g1 33.3 33.3 35.1 35.6 33.2 34.3 35.8 36.3 35.8 34.9 32.6 33.5 34.7 33.4 33.2 33.9 33.5 33.7 35.7 35.8 
Cyp27b1-Rn00587137_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp39a1-Rn01757120_m1 24.6 24.4 24.8 24.3 24.9 24.8 24.7 24.9 24.4 24.7 24.9 24.4 24.7 24.9 24.5 24.4 24.4 24.4 24.7 25.2 
Cyp46a1-Rn01430188_m1 33.9 32.7 33.1 32.4 32.0 34.2 33.0 35.1 33.0 33.8 32.1 34.9 32.2 35.8 31.2 33.1 33.4 34.0 32.1 32.8 
Cyp51-Rn01526553_m1 23.3 23.1 24.5 24.1 25.1 25.1 24.0 23.9 24.2 24.3 25.4 24.7 23.9 23.7 23.5 23.1 23.8 23.8 24.6 24.9 
18S-Hs99999901_s1 8.5 8.1 8.5 7.9 8.3 8.1 8.3 8.2 8.0 8.1 8.5 8.1 8.4 8.1 8.3 8.0 9.0 8.2 8.1 8.2 
Gapdh-Rn99999916_s1 20.1 20.3 20.8 20.3 20.5 20.3 20.0 20.3 20.2 20.3 20.1 20.0 20.3 20.3 20.1 20.0 20.0 20.0 20.3 20.6 
Rplp2-Rn01479927_g1 21.7 21.7 22.0 21.8 21.9 21.9 21.8 21.8 21.4 21.6 21.7 21.6 21.8 21.9 21.7 21.6 22.0 21.9 21.5 21.9 
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Rats 11-20 
 
Rat11 Rat11 Rat12 Rat12 Rat13 Rat13 Rat14 Rat14 Rat15 Rat15 Rat16 Rat16 Rat17 Rat17 Rat18 Rat18 Rat19 Rat19 Rat20 Rat20 
Cyp1a1-Rn00487218_m1 31.0 30.7 28.9 28.7 27.6 28.9 29.4 29.2 28.9 29.3 29.1 30.0 28.8 29.4 31.0 31.0 28.5 28.4 28.8 27.8 
Cyp1a2-Rn00561082_m1 19.4 19.6 19.4 19.2 19.2 19.5 19.8 19.3 19.5 19.7 19.4 19.8 19.0 19.2 20.4 20.3 19.0 18.7 20.1 19.7 
Cyp1b1-Rn00564055_m1 35.8 34.5 34.7 35.9 35.1 40.0 40.0 40.0 33.8 33.5 32.9 34.7 34.8 35.4 40.0 40.0 35.3 32.3 40.0 35.6 
Cyp2a1-Rn00562200_m1 22.7 22.5 22.6 22.5 22.5 22.6 23.0 22.6 22.3 22.7 22.1 22.5 21.9 22.2 23.7 23.1 22.2 22.3 22.6 22.1 
Cyp2a2-Rn00562207_m1 22.3 22.4 22.4 22.6 22.4 22.5 22.7 22.4 21.9 22.4 22.4 22.6 21.7 22.2 22.9 22.8 22.2 22.1 22.7 22.2 
Cyp2a3-Rn00561086_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2b1-Rn01457875_m1 24.2 24.4 23.1 23.2 24.2 24.2 23.9 23.8 24.0 24.4 24.2 24.3 24.4 24.5 26.1 26.0 23.2 23.1 24.2 23.8 
Cyp2b2-Rn02786833_m1 25.9 26.0 25.1 24.9 26.7 27.0 25.7 25.5 26.5 26.5 26.0 26.2 26.0 26.3 26.8 27.0 25.8 25.8 26.3 26.0 
Cyp2b3-Rn01476085_m1 22.0 22.0 21.7 21.7 21.7 21.9 21.8 21.6 21.3 21.7 21.2 21.3 21.5 21.6 21.8 21.6 21.5 21.3 21.9 21.5 
Cyp2b3-Rn02786829_sH 25.2 25.3 24.8 24.8 24.5 24.5 25.0 24.8 24.2 24.7 24.3 24.3 24.5 24.7 24.9 24.9 24.6 24.3 25.0 24.5 
Cyp2b12-Rn00755182_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 33.7 40.0 40.0 40.0 
Cyp2b21-Rn01475826_m1 40.0 40.0 40.0 40.0 35.9 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2c6-Rn02786821_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2c7-Rn01529602_mH 17.8 18.0 18.5 18.3 18.8 18.7 18.0 18.2 17.3 18.0 17.9 17.9 17.5 18.0 18.4 18.3 18.1 17.4 18.6 18.2 
Cyp2c11-Rn00569868_m1 20.5 20.4 19.7 19.8 20.3 20.5 20.4 20.2 20.2 20.5 20.3 20.4 19.7 20.0 20.9 20.5 20.3 20.1 20.9 20.5 
Cyp2c12-Rn00755856_m1 25.1 24.8 24.6 24.5 24.9 25.0 23.3 23.1 25.2 25.5 25.2 25.3 25.3 26.0 26.5 26.2 25.8 25.1 26.6 26.4 
Cyp2c13-Rn00593388_g1 20.5 20.5 19.7 19.6 20.1 20.2 19.9 19.8 19.3 19.8 19.7 19.7 19.6 19.7 20.0 19.8 20.0 19.6 20.1 19.8 
Cyp2c22-Rn00593377_m1 22.9 23.0 22.3 22.7 22.6 22.8 22.3 22.1 22.7 22.8 22.7 22.8 22.7 22.7 23.1 23.0 22.9 22.7 23.5 22.8 
Cyp2c23-Rn00582954_m1 21.5 21.1 22.0 21.5 22.0 21.7 21.4 21.0 21.2 21.5 21.3 21.2 20.8 21.2 22.2 21.9 21.3 21.0 22.0 21.3 
Cyp2c37-Rn02786817_m1 26.7 26.5 26.0 26.0 26.2 26.1 26.3 26.1 25.9 26.2 26.1 26.4 26.0 26.3 26.8 26.8 26.5 26.3 27.5 27.2 
Cyp2c79-Rn02047662_s1 34.5 36.6 34.0 32.5 33.8 34.3 34.1 32.2 33.3 32.1 40.0 40.0 29.9 30.1 31.6 31.5 35.1 40.0 36.8 33.5 
Cyp2c80-Rn01454089_m1 32.9 34.2 31.2 31.5 33.7 36.8 33.0 33.5 31.8 32.9 33.1 33.2 31.7 33.0 33.1 32.5 32.0 32.0 32.5 31.3 
Cyp2d1-Rn01775090_mH 21.3 22.6 22.3 22.8 22.9 22.8 21.8 22.2 21.2 22.1 22.2 22.0 20.4 21.5 23.1 23.0 22.3 21.6 22.5 22.2 
Cyp2d2-Rn00562419_m1 20.6 20.5 20.5 20.4 20.4 20.5 20.2 20.0 19.9 20.2 20.0 20.1 20.0 20.4 21.3 21.0 20.1 20.0 20.5 20.3 
Cyp2d3-Rn00597330_m1 22.1 22.0 21.8 21.7 21.5 21.5 21.5 21.3 21.2 21.5 21.1 21.2 21.1 21.6 22.7 22.4 21.3 21.0 21.7 21.4 
Cyp2d4-Rn01504629_m1 26.1 26.0 26.0 26.0 25.7 25.7 24.9 25.0 25.1 25.1 25.1 24.9 25.2 25.6 26.7 26.7 25.8 24.9 25.9 25.6 
Cyp2d4-Rn00696505_g1 26.7 26.5 26.4 26.2 25.9 25.9 26.0 25.7 25.6 25.7 26.4 25.6 25.8 26.1 27.2 26.9 26.0 25.7 26.4 25.9 
Cyp2d5-Rn01790051_s1 22.6 22.6 23.2 23.2 22.1 22.3 22.9 22.8 23.0 23.2 22.6 22.7 22.0 22.1 23.2 23.1 22.7 22.4 22.2 21.8 
Cyp2e1-Rn00580624_m1 19.3 19.5 19.0 18.8 19.1 19.2 18.9 18.7 18.4 18.9 18.9 19.0 18.6 18.9 20.6 20.3 19.0 18.6 19.8 19.2 
Cyp2f4-Rn00570779_m1 32.3 32.5 33.0 32.9 31.8 32.1 32.8 32.3 32.0 32.6 33.5 32.9 31.4 31.9 35.2 40.0 32.4 32.2 31.5 30.8 
Cyp2g1-Rn01454738_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2j3-Rn00598500_m1 24.7 24.6 24.7 24.8 24.9 24.9 24.8 24.5 24.5 24.9 24.5 24.6 24.5 24.6 25.5 25.4 24.8 24.4 25.2 24.9 
Cyp2j4-Rn00576482_m1 23.9 24.3 23.2 23.3 24.1 24.1 23.7 23.4 22.3 24.1 23.7 23.8 23.1 23.7 24.3 24.5 23.7 23.2 24.3 23.8 
Cyp2j5-ps-Rn01771422_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2j10-Rn01433143_m1 31.4 31.0 30.7 30.3 31.1 30.4 30.6 30.7 30.3 30.9 30.8 30.7 30.2 30.3 31.6 31.5 30.9 30.7 30.3 30.0 
Cyp2j13-Rn01763811_g1 32.8 32.6 32.1 31.7 33.0 34.6 33.5 33.8 34.2 34.4 32.2 32.2 32.1 32.4 33.3 33.0 32.4 32.8 35.3 33.3 
Cyp2j16-Rn01433366_m1 40.0 35.6 27.1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2r1-Rn01754616_m1 28.6 29.0 28.4 28.4 29.0 28.8 28.8 28.6 28.5 28.8 28.9 28.9 28.3 28.6 29.1 29.3 28.8 28.4 29.0 28.6 
Cyp2s1-Rn01476074_s1 32.4 32.0 32.2 33.9 32.4 31.9 32.4 31.8 31.3 33.2 31.9 31.9 31.1 31.6 32.4 32.6 32.1 31.2 32.2 32.5 
Cyp2s1-Rn01475871_m1 32.8 31.5 31.5 31.2 36.0 31.7 32.3 33.8 32.3 40.0 32.3 33.4 33.3 33.0 31.6 40.0 33.6 32.2 32.3 32.2 
Cyp2t1-Rn00592635_m1 24.8 25.0 25.0 25.1 24.8 24.4 24.7 24.5 24.0 24.7 24.6 24.7 24.0 24.4 25.4 25.4 24.3 24.2 25.2 24.8 
Cyp2u1-Rn01522408_m1 28.6 29.2 26.0 27.8 27.6 27.9 28.0 27.9 28.3 29.0 28.1 28.3 27.4 26.1 29.0 28.9 28.2 27.9 29.0 28.9 
Cyp2w1-Rn01412757_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp3a2-Rn01412889_mH 18.7 19.0 19.0 18.9 19.2 19.3 19.7 19.4 18.5 18.6 19.3 19.0 18.8 18.8 19.3 19.2 20.5 20.2 19.1 18.7 
Cyp3a2-Rn00756461_m1 19.1 19.4 19.3 19.3 19.6 19.8 20.0 19.9 18.5 19.0 19.4 19.6 18.8 19.0 19.6 19.6 20.9 20.4 19.5 19.1 
Cyp3a9-Rn00595977_m1 25.1 25.3 25.0 24.9 24.7 24.7 24.2 23.9 24.0 24.4 25.2 25.3 24.3 24.7 25.0 24.8 25.1 25.0 25.6 25.0 
Cyp3a18-Rn00595752_m1 22.1 22.5 21.7 22.0 21.7 21.9 21.7 21.6 20.8 21.5 21.6 21.5 21.0 21.6 22.3 22.2 22.3 21.9 22.0 21.6 
Cyp3a23(3a1)-Rn01412959_g1 21.3 21.4 21.6 21.5 21.7 21.8 21.2 21.2 21.0 21.1 21.0 20.9 21.1 21.4 22.0 21.9 22.3 22.0 21.3 21.0 
Cyp3a62-Rn01409583_m1 28.1 28.2 28.5 28.4 28.6 28.5 28.1 28.1 28.4 28.7 27.8 27.2 27.8 28.2 28.3 27.9 28.2 27.9 28.6 27.7 
Cyp4a1-Rn00598510_m1 22.0 22.1 22.0 22.2 22.1 22.3 22.7 22.4 22.0 22.3 21.9 22.0 22.3 22.6 22.8 22.8 22.2 22.0 23.0 22.4 
Cyp4a2-Rn01417066_m1 19.1 19.1 17.6 17.5 19.0 18.9 18.9 18.1 16.9 17.6 17.2 17.4 17.6 18.4 18.0 18.0 18.4 18.2 18.7 18.1 
Cyp4a3-Rn00598411_m1 20.3 20.4 18.8 18.9 20.4 20.5 19.7 19.5 18.8 19.0 18.9 18.9 19.4 19.6 19.4 19.2 19.6 19.5 19.9 19.4 
Cyp4a8-Rn00581081_m1 27.1 27.7 29.0 29.3 27.0 27.1 27.7 27.6 27.0 28.2 28.8 28.4 25.5 26.8 28.0 28.0 27.4 26.6 28.2 27.5 
Cyp4b1-Rn00566515_m1 26.9 27.1 26.3 26.5 27.1 27.3 27.8 27.5 26.6 27.1 27.2 27.1 26.7 27.0 27.3 27.3 26.7 26.2 27.8 27.5 
Cyp4f1-Rn00571492_m1 23.0 22.9 23.0 23.0 23.1 23.1 22.6 22.2 22.5 22.7 22.6 22.7 22.3 22.5 23.2 23.1 22.8 22.6 23.2 22.8 
Cyp4f4-Rn00597513_m1 23.1 23.1 23.1 23.2 22.9 23.0 22.7 22.5 22.8 23.1 22.6 22.8 22.8 22.9 23.8 23.7 22.7 22.4 23.0 22.6 
Cyp4f5-Rn00687553_m1 29.3 29.2 27.9 28.0 28.2 28.3 28.5 28.3 28.4 28.6 28.9 29.3 28.2 28.1 29.9 29.4 28.2 28.4 29.0 28.5 
Cyp4f5;4f37-Rn00687557_gH 28.3 29.0 27.4 27.6 27.7 27.6 28.4 28.1 27.6 28.0 28.6 28.9 27.8 28.2 29.7 29.3 28.3 27.6 28.9 28.2 
Cyp4f6-Rn00686847_m1 24.9 24.9 24.9 25.0 25.2 25.1 24.9 24.6 24.3 24.9 24.6 24.7 24.6 24.8 25.3 25.2 24.7 24.4 25.3 24.9 
Cyp4f17-Rn01408612_m1 29.6 30.1 30.1 29.7 29.9 29.9 29.9 29.3 29.6 29.5 29.4 29.3 29.5 29.2 30.2 29.8 29.3 29.2 29.7 29.2 
Cyp4f18-Rn01420067_m1 40.0 34.3 40.0 32.5 31.8 40.0 40.0 34.4 33.5 35.7 33.6 32.1 34.2 33.5 33.5 33.6 34.5 36.0 40.0 33.5 
Cyp4f39-Rn01408191_m1 27.4 27.5 28.0 28.3 28.1 27.9 27.1 26.9 27.1 27.8 26.8 26.8 27.3 27.3 28.7 28.5 27.1 27.0 27.7 27.3 
Cyp4f40-Rn01408132_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 34.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp4v3-Rn01488162_m1 23.0 23.0 23.7 23.7 23.4 23.5 25.0 24.9 22.6 23.0 23.1 23.2 22.5 22.9 24.3 24.4 23.7 23.6 23.4 22.9 
Cyp4x1-Rn00595521_m1 40.0 40.0 40.0 40.0 40.0 34.7 34.9 40.0 40.0 40.0 40.0 35.6 34.9 33.5 40.0 40.0 36.2 40.0 36.2 40.0 
Tbxas1-Rn00562160_m1 28.7 28.9 30.0 30.0 29.7 29.8 30.0 29.4 29.3 29.5 30.0 30.2 30.0 30.0 30.1 29.8 29.8 29.0 30.2 29.5 
Cyp7a1-Rn00564065_m1 28.1 28.2 25.9 26.0 27.2 27.1 25.7 25.6 27.2 27.4 28.3 28.5 26.2 26.6 27.1 27.1 26.7 26.3 27.4 27.0 
Cyp7b1-Rn01461859_m1 28.6 28.2 28.2 28.1 28.4 28.4 28.6 28.2 27.9 28.3 28.0 28.4 27.6 28.1 28.3 28.4 28.2 28.3 28.8 28.3 
Cyp7b1-Rn01461862_m1 29.1 29.0 28.7 28.6 29.2 29.0 29.5 29.0 29.0 29.3 28.9 29.0 28.8 28.8 29.6 29.2 29.1 28.6 29.6 28.9 
Ptgis-Rn00580687_m1 27.2 27.4 28.7 28.7 27.4 27.7 29.8 29.7 28.0 28.3 29.7 30.0 27.8 27.8 28.7 28.5 28.2 28.2 29.3 29.0 
Cyp8b1-Rn00579921_s1 20.2 20.2 20.1 20.1 20.0 20.1 20.0 19.9 20.0 20.2 19.4 19.4 19.6 19.7 20.8 20.8 19.9 19.7 20.0 19.7 
Cyp11a1-Rn00568733_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 33.1 33.2 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp11a1-Rn01421674_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 33.6 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp11a1-Rn01421681_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 33.2 32.4 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp11b1-Rn02607234_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 33.5 32.7 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp11b2-Rn01767818_g1 34.7 33.8 36.5 24.3 40.0 40.0 36.9 33.7 32.3 33.6 40.0 40.0 34.1 35.4 34.2 31.0 40.0 40.0 37.2 35.2 
Cyp11b3-Rn00822066_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 34.0 34.5 40.0 40.0 40.0 40.0 40.0 26.1 40.0 40.0 
Cyp17a1-Rn01444704_g1 24.1 24.3 25.1 25.0 25.2 25.3 24.9 24.7 25.3 25.4 25.1 25.3 25.4 25.7 25.5 25.5 24.2 24.0 24.8 24.3 
Cyp17a1-Rn00664858_m1 24.7 25.0 25.6 25.6 25.8 25.7 25.5 25.3 25.4 25.8 25.8 26.0 26.0 26.1 26.0 26.0 24.8 24.6 25.2 24.8 
Cyp17a1-Rn00562601_m1 25.6 25.7 26.3 26.4 26.7 26.6 26.3 26.1 26.7 27.1 26.8 26.9 26.9 27.3 27.1 27.0 25.6 25.4 26.2 25.7 
Cyp19a1-Rn00567222_m1 40.0 40.0 40.0 40.0 34.8 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 37.1 40.0 40.0 40.0 40.0 
Cyp19a1-Rn01422547_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp20a1-Rn01644438_g1 25.5 26.0 25.6 25.5 25.7 25.8 25.8 25.2 25.1 26.0 25.6 25.8 25.3 25.8 26.3 26.5 25.6 25.4 26.1 25.5 
Cyp21a1-Rn00588996_g1 31.4 31.6 33.0 32.8 30.3 30.5 31.9 31.5 31.2 32.0 30.1 30.8 31.3 31.6 33.2 33.7 31.1 30.9 31.2 31.4 
Cyp24a1-Rn01423143_m1 40.0 40.0 40.0 35.3 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 34.7 40.0 40.0 40.0 40.0 40.0 
Cyp26a1-Rn00590308_m1 31.6 30.5 27.4 31.2 31.0 31.4 31.5 30.7 30.5 30.6 29.9 30.0 31.2 30.6 30.7 30.5 31.3 31.5 31.3 31.6 
Cyp26b1-Rn00710376_m1 32.4 32.6 32.0 31.2 34.8 32.1 31.4 31.5 31.5 31.5 29.8 30.1 30.3 30.4 31.7 32.0 31.4 31.0 31.1 31.1 
Cyp27a1-Rn00710297_m1 22.0 22.3 21.8 21.9 22.1 22.2 21.7 21.4 21.9 22.2 21.9 22.0 21.7 22.1 22.8 22.9 21.7 21.6 21.9 21.8 
Cyp27b1-Rn01647147_g1 35.9 33.8 36.0 34.8 33.5 34.8 40.0 40.0 35.8 35.1 35.6 34.7 34.6 34.8 36.0 34.2 32.9 34.6 34.5 34.9 
Cyp27b1-Rn00587137_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp39a1-Rn01757120_m1 24.8 24.9 24.7 24.6 25.2 25.0 24.8 25.0 24.2 24.8 24.9 24.7 24.4 24.6 25.1 24.9 24.9 24.4 25.3 24.7 
Cyp46a1-Rn01430188_m1 31.4 34.0 32.7 32.2 32.9 33.5 40.0 32.0 33.0 35.1 33.0 33.8 34.5 32.7 40.0 33.0 32.2 32.4 34.7 33.9 
Cyp51-Rn01526553_m1 24.7 24.7 23.5 23.6 25.0 25.0 24.9 24.6 24.4 24.7 24.6 24.8 23.8 24.0 24.2 24.1 25.0 24.7 24.2 23.5 
18S-Hs99999901_s1 7.9 8.3 8.3 8.1 8.5 8.2 8.2 8.0 8.0 8.1 8.2 8.2 8.2 8.2 8.5 8.5 8.3 7.8 8.5 8.2 
Gapdh-Rn99999916_s1 20.0 20.5 20.2 20.3 20.6 20.5 20.7 20.6 19.7 20.4 20.3 20.2 20.1 20.6 20.4 20.4 20.6 20.0 20.7 20.2 
Rplp2-Rn01479927_g1 22.3 22.4 22.1 22.2 21.9 22.1 22.0 22.0 21.6 21.9 21.7 21.7 21.9 22.0 22.6 22.8 21.9 21.5 22.4 22.0 
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Rats 21-30 
 
Rat21 Rat21 Rat22 Rat22 Rat23 Rat23 Rat24 Rat24 Rat25 Rat25 Rat26 Rat26 Rat27 Rat27 Rat28 Rat28 Rat29 Rat29 Rat30 Rat30 
Cyp1a1-Rn00487218_m1 28.5 29.1 31.7 31.8 34.2 38.4 29.7 33.5 29.1 29.4 27.9 27.5 29.6 30.0 33.0 32.2 30.2 31.6 29.5 29.3 
Cyp1a2-Rn00561082_m1 18.9 19.0 19.8 19.5 19.8 19.6 20.0 19.6 19.0 19.1 19.3 19.2 19.3 19.5 20.0 19.9 19.3 19.8 19.2 19.4 
Cyp1b1-Rn00564055_m1 34.7 33.9 35.7 34.3 33.4 34.3 36.0 40.0 33.2 34.7 35.6 40.0 33.2 35.0 33.0 40.0 33.2 35.1 35.6 35.6 
Cyp2a1-Rn00562200_m1 20.9 20.9 21.5 21.8 20.8 20.9 21.0 20.7 20.9 21.1 20.9 20.8 21.1 21.2 20.9 20.7 20.6 21.0 20.9 21.2 
Cyp2a2-Rn00562207_m1 28.8 28.8 29.7 29.6 29.6 29.6 29.2 29.5 28.1 28.4 29.9 29.8 29.4 29.6 28.9 28.7 28.2 28.6 31.4 31.9 
Cyp2a3-Rn00561086_m1 34.1 40.0 34.8 40.0 34.7 40.0 34.0 33.9 40.0 40.0 40.0 32.6 40.0 38.5 40.0 34.7 40.0 40.0 40.0 34.9 
Cyp2b1-Rn01457875_m1 27.7 28.0 26.9 26.6 28.6 28.6 25.9 25.7 27.2 27.2 26.9 26.3 28.0 28.5 27.5 27.3 28.6 29.2 28.2 28.6 
Cyp2b2-Rn02786833_m1 29.2 28.7 26.9 26.9 28.8 29.1 26.7 26.3 28.4 28.6 26.6 26.9 28.3 28.6 27.5 27.1 28.9 29.1 28.0 28.4 
Cyp2b3-Rn01476085_m1 21.7 21.7 21.7 21.7 22.1 22.0 22.4 22.4 21.6 21.7 22.3 22.2 21.8 22.0 22.2 22.2 20.9 21.5 22.1 22.5 
Cyp2b3-Rn02786829_sH 24.6 24.6 24.8 24.6 25.1 25.2 25.9 25.8 24.7 24.8 25.6 25.4 24.9 25.0 25.3 25.1 24.0 24.5 25.3 25.6 
Cyp2b12-Rn00755182_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 22.6 40.0 40.0 40.0 40.0 40.0 40.0 40.0 34.4 40.0 40.0 36.3 40.0 
Cyp2b21-Rn01475826_m1 40.0 40.0 40.0 40.0 40.0 40.0 36.6 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2c6-Rn02786821_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2c7-Rn01529602_mH 16.8 16.9 17.0 16.6 16.6 16.5 16.9 16.9 16.4 17.0 16.6 16.7 17.5 17.1 17.0 16.9 16.7 16.8 16.3 16.7 
Cyp2c11-Rn00569868_m1 28.7 28.6 30.7 31.0 31.3 31.3 30.4 30.2 30.2 30.9 31.0 30.5 30.4 30.7 31.9 31.7 31.0 30.8 31.3 33.0 
Cyp2c12-Rn00755856_m1 17.7 17.7 18.0 17.6 17.5 17.4 18.1 17.5 17.9 18.0 17.9 17.8 18.0 17.9 17.8 17.6 17.1 17.7 17.3 17.5 
Cyp2c13-Rn00593388_g1 28.6 28.5 32.0 32.4 31.2 31.7 30.1 30.0 30.6 30.7 31.3 31.5 30.7 31.0 32.9 32.5 31.8 32.0 31.3 32.1 
Cyp2c22-Rn00593377_m1 23.2 23.3 22.8 22.5 23.3 23.2 23.2 23.1 23.5 23.5 23.3 23.0 23.1 23.3 23.0 22.9 23.3 23.6 23.4 23.7 
Cyp2c23-Rn00582954_m1 20.7 20.8 21.2 21.1 21.0 20.8 21.1 20.6 21.0 21.3 21.5 21.0 21.5 21.6 21.4 21.0 21.3 21.4 21.6 21.5 
Cyp2c37-Rn02786817_m1 36.3 34.4 40.0 39.2 38.4 38.5 34.6 40.0 39.6 40.0 37.6 37.6 35.8 40.0 40.0 40.0 40.0 36.4 35.6 39.0 
Cyp2c79-Rn02047662_s1 30.3 30.7 30.1 30.5 32.3 31.5 31.7 32.4 33.1 31.9 31.6 32.1 40.0 40.0 31.7 30.6 40.0 34.8 31.2 32.2 
Cyp2c80-Rn01454089_m1 33.1 33.1 32.7 32.3 34.0 33.4 32.6 31.5 32.7 34.1 33.4 33.4 32.1 32.2 33.9 34.6 32.4 33.3 35.5 40.0 
Cyp2d1-Rn01775090_mH 23.4 23.5 23.0 22.8 22.6 22.0 22.8 22.7 21.7 22.7 22.8 22.4 23.1 22.8 22.4 22.8 20.4 22.1 22.1 22.8 
Cyp2d2-Rn00562419_m1 20.0 20.0 20.0 19.9 19.8 19.7 20.1 19.8 19.8 20.0 20.2 19.9 20.2 20.4 19.9 19.9 20.0 20.3 20.0 20.3 
Cyp2d3-Rn00597330_m1 22.3 22.4 22.6 22.5 22.1 22.1 23.0 22.8 21.9 22.1 22.0 21.8 21.8 21.8 23.1 23.0 21.9 22.4 22.2 22.5 
Cyp2d4-Rn01504629_m1 26.2 26.4 26.9 26.4 26.2 26.0 26.5 26.3 26.1 26.7 26.3 25.9 26.5 26.4 26.2 26.0 25.6 26.3 25.6 26.2 
Cyp2d4-Rn00696505_g1 27.0 27.0 27.5 27.4 26.7 26.4 27.2 26.7 26.9 27.1 26.9 26.5 27.0 26.9 26.6 26.4 26.4 26.8 26.4 26.6 
Cyp2d5-Rn01790051_s1 22.9 22.8 21.7 21.7 21.8 21.7 22.5 22.4 21.8 21.9 21.9 21.8 21.8 22.1 21.6 21.6 21.1 21.3 21.6 21.9 
Cyp2e1-Rn00580624_m1 18.4 18.7 19.1 18.4 18.5 18.4 18.8 18.4 17.9 18.3 18.6 18.6 19.0 19.0 19.2 19.0 18.5 19.5 18.8 19.0 
Cyp2f4-Rn00570779_m1 33.0 32.3 33.6 33.0 32.4 32.3 32.0 31.1 33.3 33.2 33.0 31.7 32.6 32.4 32.6 31.6 33.6 31.8 33.6 33.4 
Cyp2g1-Rn01454738_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2j3-Rn00598500_m1 26.7 26.8 24.9 24.8 24.8 24.7 25.3 25.2 24.6 25.0 25.6 25.2 26.0 26.2 25.7 25.5 25.8 26.0 25.2 25.4 
Cyp2j4-Rn00576482_m1 23.6 23.9 23.5 23.2 23.9 23.9 23.8 23.5 23.0 23.4 23.9 23.7 24.1 24.3 23.7 23.5 23.8 24.5 24.0 24.6 
Cyp2j5-ps-Rn01771422_m1 40.0 40.0 40.0 40.0 35.9 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2j10-Rn01433143_m1 31.2 31.2 32.1 32.3 31.6 31.0 30.7 30.3 31.2 31.3 30.0 30.1 31.1 30.8 31.9 31.4 30.6 31.8 31.9 32.3 
Cyp2j13-Rn01763811_g1 34.7 33.0 32.2 33.6 32.6 32.1 34.0 32.0 32.2 32.6 40.0 40.0 33.5 34.0 33.3 33.0 32.6 33.4 32.4 35.1 
Cyp2j16-Rn01433366_m1 40.0 40.0 40.0 40.0 40.0 35.8 40.0 40.0 40.0 40.0 40.0 40.0 36.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2r1-Rn01754616_m1 28.0 27.8 28.2 27.7 28.0 27.7 28.2 28.1 27.9 28.0 27.7 27.8 28.0 27.9 28.0 27.8 27.5 27.9 27.8 28.0 
Cyp2s1-Rn01476074_s1 34.2 34.1 31.9 31.6 34.5 34.2 34.0 33.2 32.0 32.7 32.7 33.0 31.0 31.7 32.9 32.3 30.8 32.0 32.6 34.5 
Cyp2s1-Rn01475871_m1 31.9 33.3 33.8 28.4 33.0 40.0 31.7 31.3 33.3 31.2 31.6 31.3 32.3 30.6 31.7 32.1 31.9 33.2 31.5 40.0 
Cyp2t1-Rn00592635_m1 23.8 23.8 23.9 24.0 23.6 23.4 24.0 23.8 23.7 23.9 23.9 24.0 23.8 24.0 23.7 23.5 23.4 24.2 23.4 24.0 
Cyp2u1-Rn01522408_m1 28.6 28.8 28.9 28.8 28.8 29.0 28.4 28.4 28.2 29.1 27.3 27.4 28.5 28.7 29.8 28.7 27.7 28.4 28.3 28.9 
Cyp2w1-Rn01412757_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp3a2-Rn01412889_mH 27.6 27.7 32.7 34.1 30.7 31.0 31.0 30.0 30.2 30.2 31.9 31.8 29.8 30.0 33.2 33.3 32.9 30.6 31.2 31.3 
Cyp3a2-Rn00756461_m1 27.8 28.2 33.7 33.4 30.6 30.5 30.8 30.5 30.4 30.6 32.0 32.0 30.6 31.1 34.8 35.0 33.5 34.0 31.3 32.3 
Cyp3a9-Rn00595977_m1 21.5 21.6 22.7 22.6 22.5 22.3 22.0 21.9 22.0 22.2 21.8 21.7 22.4 22.4 22.2 22.1 21.2 21.4 22.5 23.0 
Cyp3a18-Rn00595752_m1 25.8 25.8 26.8 26.5 25.4 25.3 26.3 26.2 26.0 26.1 25.8 25.7 26.4 26.6 25.4 25.5 26.2 26.6 26.4 27.0 
Cyp3a23(3a1)-Rn01412959_g1 22.3 22.2 23.0 22.8 21.6 21.6 21.4 21.4 21.7 22.1 21.0 21.2 23.2 23.3 21.6 21.6 22.1 22.7 21.8 22.3 
Cyp3a62-Rn01409583_m1 29.6 29.9 29.0 28.1 29.3 29.5 28.3 28.2 29.0 29.2 29.5 29.4 29.7 29.7 29.6 29.3 29.8 30.2 29.9 30.0 
Cyp4a1-Rn00598510_m1 21.6 21.6 21.0 21.0 22.0 22.0 21.3 21.1 20.7 20.9 21.9 21.8 21.8 22.2 21.5 21.4 21.7 22.1 22.3 22.8 
Cyp4a2-Rn01417066_m1 19.7 19.7 20.3 19.9 21.5 21.7 21.4 21.4 21.0 21.5 21.6 21.8 20.6 20.5 20.0 19.5 19.7 20.0 20.3 20.5 
Cyp4a3-Rn00598411_m1 20.5 20.5 19.9 20.0 20.3 20.3 19.6 19.5 19.4 19.6 20.2 20.0 20.3 20.5 20.4 20.4 20.5 20.9 21.0 21.3 
Cyp4a8-Rn00581081_m1 32.5 32.2 33.7 33.1 40.0 40.0 35.8 30.5 32.8 33.6 35.9 35.9 32.8 32.6 30.3 30.6 30.0 32.0 30.2 30.3 
Cyp4b1-Rn00566515_m1 26.6 26.9 27.2 27.0 27.5 27.5 27.2 27.2 27.5 27.6 27.5 27.5 27.0 27.3 27.2 27.1 26.8 27.0 27.4 28.0 
Cyp4f1-Rn00571492_m1 22.9 22.9 23.0 22.9 22.8 22.7 23.1 22.8 23.0 23.0 23.4 23.0 22.9 23.0 22.9 22.7 22.5 22.8 22.8 23.0 
Cyp4f4-Rn00597513_m1 23.1 23.1 23.1 23.0 23.0 22.9 22.7 22.6 23.0 23.3 22.9 22.8 23.2 23.3 23.0 22.9 23.0 23.3 23.0 23.3 
Cyp4f5-Rn00687553_m1 29.6 29.2 30.2 29.4 30.0 29.5 29.6 29.0 28.7 29.6 29.2 29.4 29.6 29.9 30.4 29.8 29.5 30.3 30.5 30.9 
Cyp4f5;4f37-Rn00687557_gH 28.6 28.7 29.4 28.6 29.1 29.5 29.1 29.2 28.8 29.3 28.9 29.4 29.5 29.5 29.3 29.0 29.8 29.8 30.3 30.3 
Cyp4f6-Rn00686847_m1 24.9 24.9 25.0 24.9 24.7 24.8 24.9 24.6 24.6 24.9 24.9 24.8 25.0 25.0 25.0 24.7 24.3 24.9 24.6 24.9 
Cyp4f17-Rn01408612_m1 29.4 30.0 29.8 30.0 29.6 29.4 29.9 29.3 29.5 30.1 27.8 29.8 30.1 29.5 30.0 29.5 29.7 30.0 30.4 30.1 
Cyp4f18-Rn01420067_m1 31.9 33.0 32.7 31.4 33.5 32.4 33.2 32.4 34.3 31.9 40.0 40.0 40.0 32.8 31.3 32.2 34.1 32.3 33.6 32.2 
Cyp4f39-Rn01408191_m1 27.0 27.1 26.8 26.4 27.3 27.5 27.0 27.0 27.2 27.5 27.8 28.0 26.8 27.0 27.0 26.8 27.0 28.1 27.7 28.4 
Cyp4f40-Rn01408132_m1 40.0 40.0 40.0 40.0 40.0 40.0 28.4 40.0 40.0 40.0 40.0 40.0 40.0 40.0 35.4 40.0 40.0 40.0 40.0 40.0 
Cyp4v3-Rn01488162_m1 22.5 22.4 23.3 23.1 22.8 22.7 22.5 22.2 22.8 23.1 23.0 23.0 23.5 23.5 22.4 22.4 22.6 23.1 22.2 22.6 
Cyp4x1-Rn00595521_m1 40.0 35.9 40.0 33.9 40.0 35.0 40.0 40.0 36.2 40.0 33.9 34.9 34.2 40.0 34.2 40.0 40.0 40.0 33.5 40.0 
Tbxas1-Rn00562160_m1 28.9 28.9 29.1 29.0 29.2 28.9 30.1 29.5 29.1 29.3 29.6 29.6 29.3 29.3 30.0 29.9 29.2 29.4 30.1 30.8 
Cyp7a1-Rn00564065_m1 24.8 25.0 28.5 28.3 25.0 25.0 26.1 26.0 28.0 28.0 26.1 26.1 26.4 26.2 25.5 25.2 26.9 27.3 26.9 27.4 
Cyp7b1-Rn01461859_m1 28.3 28.3 28.0 27.8 28.6 28.3 28.5 28.0 28.3 28.4 28.7 28.4 28.0 28.2 28.7 28.2 28.1 28.5 28.8 29.3 
Cyp7b1-Rn01461862_m1 29.0 28.9 28.7 28.6 29.4 29.2 29.7 29.1 29.1 29.2 29.6 29.3 28.7 28.8 29.5 29.2 29.0 29.2 29.8 29.6 
Ptgis-Rn00580687_m1 25.6 25.6 25.9 25.6 27.0 27.0 31.7 32.5 32.3 32.6 27.4 27.1 32.2 32.5 25.9 25.8 27.8 28.0 26.2 26.6 
Cyp8b1-Rn00579921_s1 19.0 19.1 19.8 19.6 19.7 19.7 19.3 19.3 19.0 19.3 19.7 19.6 19.2 19.3 19.3 19.3 19.4 19.7 19.8 20.1 
Cyp11a1-Rn00568733_m1 40.0 40.0 40.0 40.0 35.9 34.5 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 31.2 40.0 40.0 40.0 33.5 
Cyp11a1-Rn01421674_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 35.4 40.0 40.0 40.0 35.4 
Cyp11a1-Rn01421681_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 36.6 40.0 40.0 40.0 40.0 33.7 40.0 40.0 40.0 40.0 
Cyp11b1-Rn02607234_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp11b2-Rn01767818_g1 40.0 38.2 32.8 31.2 26.4 35.7 40.0 32.9 35.6 33.6 36.9 23.6 40.0 40.0 34.2 32.8 33.0 32.5 40.0 35.1 
Cyp11b3-Rn00822066_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 36.9 37.1 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp17a1-Rn01444704_g1 23.1 23.2 23.3 23.3 24.2 24.1 22.7 22.6 23.1 23.5 23.7 23.7 22.9 23.1 22.8 22.6 23.5 23.8 24.5 24.8 
Cyp17a1-Rn00664858_m1 23.8 23.8 23.9 23.6 24.7 24.6 23.5 23.2 23.9 24.0 24.1 24.3 23.7 23.9 23.3 23.1 23.8 24.4 24.9 25.3 
Cyp17a1-Rn00562601_m1 24.6 24.7 24.7 24.9 25.7 25.7 24.2 24.0 24.5 25.0 25.3 25.2 24.6 24.8 24.2 23.9 25.1 25.0 26.1 26.2 
Cyp19a1-Rn00567222_m1 28.4 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp19a1-Rn01422547_m1 40.0 35.3 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp20a1-Rn01644438_g1 25.7 25.4 25.6 25.6 25.8 25.5 25.3 25.5 25.5 25.4 25.2 25.3 25.4 25.8 25.3 25.5 25.2 25.9 25.8 25.8 
Cyp21a1-Rn00588996_g1 30.0 29.9 31.2 31.0 30.5 30.8 29.9 29.5 30.8 31.7 30.1 29.8 31.2 30.4 29.7 29.7 30.4 30.3 30.0 30.8 
Cyp24a1-Rn01423143_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 32.5 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp26a1-Rn00590308_m1 27.5 27.4 28.2 28.1 28.8 29.2 27.8 27.8 28.3 28.4 27.9 27.8 27.4 27.7 28.3 28.2 27.4 27.9 27.8 28.3 
Cyp26b1-Rn00710376_m1 31.3 31.5 33.1 32.5 32.9 31.9 35.2 33.1 31.5 32.8 31.3 31.7 32.7 33.0 33.1 34.5 30.8 31.6 33.2 34.2 
Cyp27a1-Rn00710297_m1 21.6 21.5 21.9 21.8 21.6 21.4 21.6 21.3 21.8 21.9 21.4 21.6 21.7 21.9 21.6 21.5 22.2 22.3 21.6 22.1 
Cyp27b1-Rn01647147_g1 32.4 32.1 32.5 34.5 32.4 34.0 33.6 33.2 32.8 35.8 33.9 33.7 33.1 33.0 34.6 34.1 33.6 33.0 32.5 40.0 
Cyp27b1-Rn00587137_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp39a1-Rn01757120_m1 24.5 24.4 24.9 24.4 24.3 24.4 24.8 24.5 24.4 24.8 24.5 24.4 24.6 24.7 24.5 24.3 23.7 24.3 24.4 24.5 
Cyp46a1-Rn01430188_m1 34.7 34.0 33.9 34.7 33.9 33.2 37.0 31.8 32.9 40.0 31.9 31.8 31.3 33.7 34.3 33.7 32.9 33.5 40.0 35.3 
Cyp51-Rn01526553_m1 22.4 22.4 23.1 22.8 21.9 22.0 23.1 22.9 23.0 22.9 23.5 23.3 23.0 23.1 23.2 23.0 22.7 23.2 22.8 22.8 
18S-Hs99999901_s1 8.2 8.2 8.4 7.8 8.1 8.2 8.3 8.1 7.8 8.0 7.7 7.9 8.3 8.0 8.4 8.3 8.3 8.2 8.1 8.2 
Gapdh-Rn99999916_s1 20.1 20.1 20.3 20.2 20.4 20.3 20.4 20.2 19.6 20.2 19.7 19.8 19.7 19.8 19.7 19.7 19.7 20.1 19.3 20.0 
Rplp2-Rn01479927_g1 21.7 21.7 21.6 21.4 21.6 21.7 21.5 21.5 21.5 21.7 21.5 21.6 21.3 21.7 21.5 21.5 21.4 21.7 21.6 22.0 
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Rats 31-40 
 
Rat31 Rat31 Rat32 Rat32 Rat33 Rat33 Rat34 Rat34 Rat35 Rat35 Rat36 Rat36 Rat37 Rat37 Rat38 Rat38 Rat39 Rat39 Rat40 Rat40 
Cyp1a1-Rn00487218_m1 29.7 28.3 30.0 29.2 29.2 28.8 29.5 29.4 30.7 31.0 31.6 29.3 29.5 28.9 28.0 27.2 29.7 29.4 32.0 33.7 
Cyp1a2-Rn00561082_m1 19.3 19.2 19.4 19.1 19.2 19.1 19.3 18.9 19.1 19.0 19.5 19.2 19.1 19.2 18.8 18.9 19.1 18.9 19.9 19.7 
Cyp1b1-Rn00564055_m1 35.6 40.0 34.1 35.6 40.0 34.3 34.8 34.6 40.0 33.6 34.2 34.8 34.1 40.0 33.0 33.5 32.1 35.4 35.1 34.5 
Cyp2a1-Rn00562200_m1 21.0 20.7 21.4 21.1 21.3 21.2 20.8 20.9 21.0 21.0 21.1 20.8 21.4 21.4 20.7 20.8 21.0 20.8 21.4 21.2 
Cyp2a2-Rn00562207_m1 29.4 29.3 31.3 31.5 34.6 34.9 29.9 30.2 34.9 35.1 27.9 27.6 33.7 34.3 29.0 29.6 31.9 32.2 29.7 29.0 
Cyp2a3-Rn00561086_m1 40.0 34.4 40.0 40.0 33.7 40.0 38.0 34.6 40.0 33.5 40.0 29.1 35.5 33.9 40.0 40.0 36.4 34.4 34.9 40.0 
Cyp2b1-Rn01457875_m1 27.3 26.9 28.1 27.9 29.5 29.3 28.5 28.7 28.0 27.8 27.9 28.0 26.8 26.9 27.9 27.8 28.0 27.5 29.5 29.2 
Cyp2b2-Rn02786833_m1 26.7 27.0 28.5 28.1 29.8 29.9 28.7 28.8 27.5 27.9 29.9 29.7 27.1 27.1 27.6 27.9 27.2 27.2 29.2 29.1 
Cyp2b3-Rn01476085_m1 21.3 21.2 21.7 21.3 22.0 21.9 21.7 21.5 22.1 22.0 21.8 21.2 24.0 23.9 22.0 22.2 24.2 23.7 21.8 21.6 
Cyp2b3-Rn02786829_sH 24.3 24.5 24.7 24.5 25.0 25.0 24.5 24.3 25.4 25.4 24.8 24.5 27.2 27.0 25.5 25.5 27.6 27.7 24.9 24.7 
Cyp2b12-Rn00755182_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 25.1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2b21-Rn01475826_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 35.6 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2c6-Rn02786821_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2c7-Rn01529602_mH 16.9 16.4 17.1 16.6 16.4 16.1 16.5 16.3 16.5 16.5 16.9 16.3 16.5 16.5 16.0 16.2 16.3 16.2 16.6 16.6 
Cyp2c11-Rn00569868_m1 31.4 30.7 31.6 31.7 35.0 35.6 35.9 35.7 34.3 33.0 31.3 31.4 34.3 34.9 34.2 40.0 33.0 34.5 31.8 30.9 
Cyp2c12-Rn00755856_m1 17.4 16.0 18.0 17.5 17.5 17.5 17.5 17.3 17.3 17.3 17.6 17.0 17.6 17.7 17.1 17.2 17.6 16.8 17.6 17.5 
Cyp2c13-Rn00593388_g1 32.5 32.0 31.8 31.0 33.5 32.0 32.2 33.4 32.6 32.9 33.9 32.4 34.0 32.4 32.7 34.3 32.8 32.6 32.9 32.8 
Cyp2c22-Rn00593377_m1 23.2 23.0 23.0 22.5 22.9 22.7 23.0 22.8 22.9 22.8 23.5 23.2 22.9 22.7 23.3 23.2 23.1 22.9 23.0 22.8 
Cyp2c23-Rn00582954_m1 20.9 20.4 21.2 21.0 21.8 21.4 21.6 21.2 21.4 21.4 21.2 20.8 21.3 21.0 21.0 21.0 21.4 20.7 21.6 20.8 
Cyp2c37-Rn02786817_m1 35.5 40.0 40.0 40.0 39.6 40.0 40.0 36.8 40.0 38.8 38.1 38.7 38.7 35.9 40.0 38.3 40.0 36.3 38.3 40.0 
Cyp2c79-Rn02047662_s1 31.4 32.0 32.1 34.4 30.9 30.8 30.2 29.8 31.9 31.1 32.5 31.9 31.7 31.3 31.5 32.2 31.6 31.5 31.5 30.5 
Cyp2c80-Rn01454089_m1 33.2 33.4 33.3 33.7 36.9 40.0 35.2 34.8 34.2 33.8 33.2 32.8 34.8 34.4 35.3 40.0 40.0 40.0 34.7 34.8 
Cyp2d1-Rn01775090_mH 22.6 20.3 23.1 23.4 23.0 22.7 23.4 23.4 23.0 23.3 22.7 22.6 22.7 22.9 21.7 22.5 22.8 21.4 22.4 22.8 
Cyp2d2-Rn00562419_m1 19.9 19.6 20.0 19.9 20.6 20.5 20.1 20.1 19.9 20.0 20.1 19.8 19.9 19.8 19.8 19.9 20.0 19.5 19.9 19.8 
Cyp2d3-Rn00597330_m1 22.0 21.7 23.0 22.8 22.3 22.3 22.8 22.6 22.6 22.5 22.2 21.8 22.8 22.7 22.9 23.1 22.9 22.3 22.4 22.1 
Cyp2d4-Rn01504629_m1 26.5 26.0 26.2 26.4 26.9 26.7 26.4 26.1 26.1 26.0 26.9 26.5 26.4 26.5 26.3 26.1 27.0 26.7 26.8 26.5 
Cyp2d4-Rn00696505_g1 26.9 26.8 27.2 27.0 27.3 27.4 27.0 26.8 26.5 26.5 27.3 26.9 27.2 26.8 26.9 26.8 27.5 27.1 27.3 26.8 
Cyp2d5-Rn01790051_s1 21.6 21.6 22.7 22.6 21.6 21.8 22.8 22.8 22.8 22.8 22.0 21.7 22.0 21.9 21.8 21.9 21.8 21.7 21.9 21.7 
Cyp2e1-Rn00580624_m1 18.2 18.1 19.4 19.1 18.9 18.5 19.4 19.0 18.9 18.4 18.5 18.2 18.7 18.8 17.9 18.3 18.8 18.2 19.1 19.0 
Cyp2f4-Rn00570779_m1 32.4 34.4 33.2 32.5 34.6 32.3 32.0 32.8 32.4 32.6 32.1 32.7 34.0 32.2 32.4 32.2 32.5 34.2 33.5 32.6 
Cyp2g1-Rn01454738_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2j3-Rn00598500_m1 25.4 25.7 25.7 25.5 26.0 25.7 25.3 25.2 25.1 25.0 25.1 24.7 25.3 25.3 24.8 24.7 25.4 25.2 24.9 24.7 
Cyp2j4-Rn00576482_m1 23.7 23.4 24.1 24.0 24.8 24.6 24.7 24.5 24.6 24.7 24.3 23.9 24.3 24.3 23.9 24.2 24.7 24.0 24.0 23.9 
Cyp2j5-ps-Rn01771422_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2j10-Rn01433143_m1 30.9 30.5 32.4 31.6 32.4 31.6 31.9 31.7 31.9 32.6 31.8 31.6 32.9 31.8 29.9 30.3 31.9 31.9 32.9 31.7 
Cyp2j13-Rn01763811_g1 33.9 33.6 32.0 32.4 34.7 33.4 32.4 32.0 31.6 32.6 32.6 31.7 33.3 33.5 27.5 32.6 32.1 32.2 32.9 31.7 
Cyp2j16-Rn01433366_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp2r1-Rn01754616_m1 27.8 27.7 28.0 27.9 28.0 28.0 27.6 27.6 27.7 27.7 28.1 27.8 27.9 28.0 27.6 27.8 27.9 27.6 27.8 27.7 
Cyp2s1-Rn01476074_s1 33.0 32.7 32.8 32.7 32.2 32.7 32.5 31.1 32.6 34.5 31.0 33.0 32.6 35.9 34.6 33.6 35.0 40.0 33.4 31.4 
Cyp2s1-Rn01475871_m1 31.7 29.5 31.2 33.4 31.5 31.7 32.8 32.0 31.3 31.6 33.9 31.4 30.9 31.6 30.8 32.1 31.2 27.5 31.3 32.1 
Cyp2t1-Rn00592635_m1 23.9 23.7 23.9 23.7 24.4 24.1 23.8 23.5 24.0 23.8 24.2 23.9 24.0 24.0 23.0 23.7 23.9 23.5 23.9 23.7 
Cyp2u1-Rn01522408_m1 29.3 29.3 28.8 28.8 28.8 28.7 28.3 28.3 29.1 29.0 29.7 29.5 29.5 29.3 27.4 27.7 28.9 28.6 29.6 29.6 
Cyp2w1-Rn01412757_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp3a2-Rn01412889_mH 33.2 33.6 31.3 31.9 33.7 33.7 33.0 34.1 32.4 34.0 33.3 33.8 34.0 33.6 33.3 32.9 34.5 33.4 35.4 33.8 
Cyp3a2-Rn00756461_m1 26.9 33.5 32.8 31.8 35.1 32.9 35.2 33.8 34.0 35.9 33.9 36.0 33.5 33.5 34.4 33.7 33.7 32.3 35.3 34.1 
Cyp3a9-Rn00595977_m1 21.3 21.1 22.1 21.8 21.5 21.3 21.3 21.2 21.7 21.6 22.3 22.0 21.9 21.8 22.1 22.3 21.8 21.6 21.9 21.8 
Cyp3a18-Rn00595752_m1 26.5 26.4 26.4 26.4 26.1 26.1 26.0 26.0 25.9 25.8 26.0 25.6 26.3 26.0 26.3 26.5 26.3 25.7 26.5 26.4 
Cyp3a23(3a1)-Rn01412959_g1 21.9 21.9 23.7 23.6 22.7 22.6 21.7 21.7 22.4 22.5 22.9 22.5 23.0 22.8 22.0 22.5 22.5 22.1 24.3 24.2 
Cyp3a62-Rn01409583_m1 29.4 29.4 29.6 29.0 30.0 30.2 30.1 29.6 30.0 30.1 30.9 29.3 29.6 29.1 29.3 29.8 29.3 28.8 29.4 29.0 
Cyp4a1-Rn00598510_m1 21.7 21.7 21.6 21.4 22.1 22.0 22.0 22.0 22.6 22.5 22.3 22.0 21.6 21.4 22.1 22.3 22.4 22.2 21.8 21.5 
Cyp4a2-Rn01417066_m1 20.4 20.2 20.5 20.3 21.0 20.7 22.2 22.0 20.1 20.3 20.7 20.4 19.8 19.7 20.4 20.9 20.9 20.6 21.0 20.4 
Cyp4a3-Rn00598411_m1 20.2 20.3 20.3 20.2 20.7 20.6 20.4 20.4 21.2 21.2 20.6 20.2 20.8 20.5 20.6 20.8 20.8 20.6 20.5 20.2 
Cyp4a8-Rn00581081_m1 31.4 31.5 31.6 31.4 31.8 31.0 33.1 32.3 30.1 30.3 34.1 32.7 31.5 32.3 31.2 31.2 32.6 32.8 32.7 32.2 
Cyp4b1-Rn00566515_m1 27.4 27.7 27.2 27.1 27.0 26.9 27.4 27.5 27.3 27.4 27.3 26.9 27.4 27.1 27.1 27.5 27.6 27.1 26.8 27.1 
Cyp4f1-Rn00571492_m1 22.6 22.5 23.0 22.7 23.1 23.0 22.7 22.6 22.6 22.4 23.3 23.0 23.1 22.9 22.5 22.6 22.6 22.3 23.0 22.7 
Cyp4f4-Rn00597513_m1 22.8 22.8 23.3 23.2 23.3 23.2 23.4 23.3 23.2 23.2 23.3 23.0 23.0 23.0 23.0 23.2 23.1 23.0 23.1 23.0 
Cyp4f5-Rn00687553_m1 29.6 29.4 30.2 30.5 30.7 30.7 30.0 30.0 30.4 30.2 30.3 29.7 30.0 29.8 28.8 29.8 29.3 28.8 29.5 29.3 
Cyp4f5;4f37-Rn00687557_gH 29.3 29.0 29.0 29.7 29.8 29.7 30.3 29.3 29.1 29.4 29.4 29.1 29.2 29.5 28.9 29.6 29.3 29.3 28.5 28.6 
Cyp4f6-Rn00686847_m1 24.8 24.6 24.9 24.8 25.0 24.9 25.2 24.9 24.9 24.8 25.1 24.6 24.9 24.8 24.7 24.8 24.9 24.4 25.1 24.7 
Cyp4f17-Rn01408612_m1 30.1 29.9 30.4 30.1 30.3 30.3 30.3 30.2 30.1 30.7 30.2 30.6 30.2 30.2 29.0 29.1 29.7 29.6 30.0 29.9 
Cyp4f18-Rn01420067_m1 32.4 32.2 32.1 32.4 33.6 33.1 32.7 40.0 40.0 33.1 33.6 33.5 33.2 31.9 33.6 34.7 33.4 40.0 34.1 32.9 
Cyp4f39-Rn01408191_m1 27.2 27.0 27.5 27.3 28.4 28.3 27.7 27.3 28.0 28.0 27.6 26.9 27.4 27.0 26.9 27.3 27.5 27.5 27.4 27.3 
Cyp4f40-Rn01408132_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 35.4 40.0 
Cyp4v3-Rn01488162_m1 22.2 22.0 23.1 23.1 22.7 22.6 22.5 22.4 22.9 22.9 23.6 23.3 23.4 23.3 24.6 24.8 22.9 22.7 22.7 22.5 
Cyp4x1-Rn00595521_m1 35.1 40.0 35.0 40.0 40.0 40.0 35.0 34.2 40.0 40.0 35.0 40.0 40.0 40.0 40.0 33.5 40.0 40.0 40.0 40.0 
Tbxas1-Rn00562160_m1 30.0 29.8 28.8 28.4 30.0 29.7 29.9 29.8 29.0 28.5 29.5 28.9 30.1 30.0 29.0 28.7 28.9 28.7 30.5 29.4 
Cyp7a1-Rn00564065_m1 27.8 27.6 24.7 24.5 26.8 26.7 25.0 24.9 27.5 27.3 26.3 26.0 26.3 26.1 25.3 25.5 27.1 27.0 27.3 27.1 
Cyp7b1-Rn01461859_m1 28.2 28.2 28.5 27.9 28.0 28.0 28.9 28.7 28.3 28.5 28.5 27.9 28.3 28.1 28.3 28.4 28.4 28.2 28.3 28.1 
Cyp7b1-Rn01461862_m1 28.8 28.8 28.9 28.8 28.7 28.8 29.4 29.0 29.2 29.7 29.1 28.5 29.1 29.0 29.0 29.0 28.7 28.8 29.0 28.4 
Ptgis-Rn00580687_m1 32.1 34.5 25.9 25.7 26.4 26.4 26.6 26.5 26.9 26.7 33.7 32.7 26.4 26.3 27.1 27.7 26.9 26.8 26.0 25.6 
Cyp8b1-Rn00579921_s1 19.6 19.6 19.7 19.5 20.2 20.1 19.3 19.2 20.1 20.2 19.6 19.3 19.3 19.1 19.4 19.6 20.1 20.0 19.7 19.7 
Cyp11a1-Rn00568733_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 35.3 40.0 40.0 40.0 40.0 34.4 40.0 40.0 40.0 
Cyp11a1-Rn01421674_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 37.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp11a1-Rn01421681_g1 40.0 33.4 40.0 38.8 40.0 33.8 35.1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 33.3 
Cyp11b1-Rn02607234_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp11b2-Rn01767818_g1 40.0 32.2 40.0 38.7 40.0 34.4 33.5 31.2 40.0 40.0 40.0 40.0 40.0 34.1 40.0 40.0 40.0 40.0 34.8 33.9 
Cyp11b3-Rn00822066_g1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp17a1-Rn01444704_g1 24.2 24.3 23.7 23.6 24.5 24.3 25.7 25.5 24.7 24.7 23.1 22.8 24.3 24.2 24.1 24.3 25.5 25.1 24.1 23.9 
Cyp17a1-Rn00664858_m1 24.9 24.5 24.3 24.2 25.0 24.8 26.2 26.1 25.3 25.2 23.7 23.2 24.9 24.7 24.8 25.0 26.1 25.7 24.7 24.5 
Cyp17a1-Rn00562601_m1 25.6 25.5 25.2 25.0 25.9 25.9 27.2 27.0 26.4 26.2 24.6 24.2 25.9 25.6 25.6 25.8 27.0 26.9 25.8 25.2 
Cyp19a1-Rn00567222_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 34.7 40.0 40.0 
Cyp19a1-Rn01422547_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 34.9 40.0 
Cyp20a1-Rn01644438_g1 25.4 24.8 25.9 25.6 25.9 25.7 25.9 25.4 25.6 25.8 25.8 25.6 25.4 25.3 25.2 25.8 25.9 25.1 25.9 25.5 
Cyp21a1-Rn00588996_g1 30.2 30.8 30.6 30.2 31.0 31.1 30.0 29.9 30.1 30.5 30.3 30.9 30.2 29.8 30.0 30.7 29.5 29.6 29.9 29.9 
Cyp24a1-Rn01423143_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp26a1-Rn00590308_m1 27.4 27.6 28.3 28.1 28.2 27.9 27.6 27.6 28.1 28.3 28.2 27.9 28.7 28.3 28.0 28.2 27.6 27.4 28.5 27.9 
Cyp26b1-Rn00710376_m1 32.4 32.0 34.5 35.8 32.3 31.6 33.0 32.3 32.0 32.1 36.0 33.2 33.4 32.9 32.2 33.1 32.1 32.1 33.0 32.5 
Cyp27a1-Rn00710297_m1 21.7 21.6 22.0 21.8 22.0 22.0 22.0 21.9 22.1 22.0 22.0 21.7 21.7 21.6 21.6 21.9 22.1 22.0 21.9 21.9 
Cyp27b1-Rn01647147_g1 32.7 32.4 33.4 34.4 32.4 31.8 32.2 32.5 32.1 31.8 33.6 32.7 32.5 31.9 33.1 33.3 35.6 34.1 33.0 32.2 
Cyp27b1-Rn00587137_m1 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
Cyp39a1-Rn01757120_m1 24.3 24.3 24.6 24.4 24.4 24.2 24.6 24.3 24.2 24.4 24.7 24.2 24.8 24.7 24.0 24.3 24.4 24.0 24.9 24.4 
Cyp46a1-Rn01430188_m1 31.9 32.5 33.2 33.1 35.1 36.9 32.5 33.4 35.1 33.9 34.5 32.9 31.4 32.5 32.8 34.0 32.9 32.7 34.5 33.1 
Cyp51-Rn01526553_m1 22.9 22.8 22.4 22.2 22.6 22.5 22.3 22.1 22.4 22.5 23.4 23.0 22.7 22.5 21.9 22.2 22.6 22.4 23.2 22.9 
18S-Hs99999901_s1 8.3 8.1 8.3 8.1 8.3 8.1 8.5 8.2 8.1 8.2 8.4 8.0 8.1 8.1 7.8 8.1 8.1 7.9 8.6 8.1 
Gapdh-Rn99999916_s1 20.0 20.2 19.9 19.8 19.9 19.7 19.8 19.7 19.7 19.9 20.3 20.0 20.2 20.0 19.8 20.0 20.1 20.0 19.9 19.9 
Rplp2-Rn01479927_g1 21.5 21.7 21.7 21.7 21.9 21.7 21.4 21.4 21.6 21.7 22.1 21.7 21.8 21.6 21.6 21.9 21.6 21.6 21.5 21.6 
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RT-negative controls 
  RTneg_Rat01 RTneg_Rat19 RTneg_Rat24 RTneg_Rat38 
Cyp1a1-Rn00487218_m1  40.0 40.0 40.0 40.0 
Cyp1a2-Rn00561082_m1  40.0 40.0 40.0 40.0 
Cyp1b1-Rn00564055_m1  40.0 40.0 40.0 40.0 
Cyp2a1-Rn00562200_m1  40.0 40.0 40.0 40.0 
Cyp2a2-Rn00562207_m1  40.0 40.0 40.0 40.0 
Cyp2a3-Rn00561086_m1  40.0 40.0 40.0 40.0 
Cyp2b1-Rn01457875_m1  40.0 40.0 40.0 40.0 
Cyp2b2-Rn02786833_m1  40.0 40.0 40.0 40.0 
Cyp2b3-Rn01476085_m1  40.0 40.0 40.0 40.0 
Cyp2b3-Rn02786829_sH  36.1 40.0 40.0 40.0 
Cyp2b12-Rn00755182_g1  40.0 40.0 40.0 40.0 
Cyp2b21-Rn01475826_m1  40.0 40.0 40.0 40.0 
Cyp2c6-Rn02786821_m1  40.0 40.0 40.0 40.0 
Cyp2c7-Rn01529602_mH  40.0 40.0 40.0 40.0 
Cyp2c11-Rn00569868_m1  40.0 40.0 40.0 40.0 
Cyp2c12-Rn00755856_m1  40.0 40.0 40.0 40.0 
Cyp2c13-Rn00593388_g1  40.0 40.0 40.0 40.0 
Cyp2c22-Rn00593377_m1  40.0 40.0 40.0 40.0 
Cyp2c23-Rn00582954_m1  40.0 40.0 40.0 40.0 
Cyp2c37-Rn02786817_m1  40.0 40.0 40.0 40.0 
Cyp2c79-Rn02047662_s1  34.9 35.6 35.3 40.0 
Cyp2c80-Rn01454089_m1  40.0 40.0 40.0 40.0 
Cyp2d1-Rn01775090_mH  40.0 40.0 40.0 40.0 
Cyp2d2-Rn00562419_m1  40.0 40.0 40.0 40.0 
Cyp2d3-Rn00597330_m1  40.0 40.0 40.0 40.0 
Cyp2d4-Rn01504629_m1  40.0 40.0 40.0 40.0 
Cyp2d4-Rn00696505_g1  40.0 40.0 40.0 40.0 
Cyp2d5-Rn01790051_s1  37.0 40.0 40.0 40.0 
Cyp2e1-Rn00580624_m1  40.0 40.0 40.0 40.0 
Cyp2f4-Rn00570779_m1  40.0 40.0 40.0 40.0 
Cyp2g1-Rn01454738_m1  40.0 40.0 40.0 40.0 
Cyp2j3-Rn00598500_m1  40.0 40.0 40.0 40.0 
Cyp2j4-Rn00576482_m1  40.0 40.0 40.0 40.0 
Cyp2j5-ps-Rn01771422_m1  40.0 40.0 40.0 40.0 
Cyp2j10-Rn01433143_m1  40.0 40.0 40.0 40.0 
Cyp2j13-Rn01763811_g1  40.0 40.0 40.0 40.0 
Cyp2j16-Rn01433366_m1  40.0 40.0 40.0 40.0 
Cyp2r1-Rn01754616_m1  40.0 40.0 40.0 40.0 
Cyp2s1-Rn01476074_s1  40.0 40.0 40.0 40.0 
Cyp2s1-Rn01475871_m1  40.0 40.0 40.0 40.0 
Cyp2t1-Rn00592635_m1  40.0 40.0 40.0 40.0 
Cyp2u1-Rn01522408_m1  40.0 40.0 40.0 40.0 
Cyp2w1-Rn01412757_m1  40.0 40.0 40.0 40.0 
Cyp3a2-Rn01412889_mH  40.0 40.0 40.0 40.0 
Cyp3a2-Rn00756461_m1  40.0 40.0 40.0 40.0 
Cyp3a9-Rn00595977_m1  40.0 40.0 40.0 40.0 
Cyp3a18-Rn00595752_m1  40.0 40.0 40.0 40.0 
Cyp3a23(3a1)-Rn01412959_g1  40.0 40.0 40.0 40.0 
Cyp3a62-Rn01409583_m1  40.0 40.0 40.0 40.0 
Cyp4a1-Rn00598510_m1  40.0 40.0 40.0 40.0 
Cyp4a2-Rn01417066_m1  40.0 40.0 40.0 40.0 
Cyp4a3-Rn00598411_m1  40.0 40.0 40.0 40.0 
Cyp4a8-Rn00581081_m1  40.0 40.0 40.0 40.0 
Cyp4b1-Rn00566515_m1  40.0 40.0 40.0 40.0 
Cyp4f1-Rn00571492_m1  40.0 40.0 40.0 40.0 
Cyp4f4-Rn00597513_m1  40.0 40.0 40.0 40.0 
Cyp4f5-Rn00687553_m1  40.0 40.0 40.0 40.0 
Cyp4f5;4f37-Rn00687557_gH  40.0 40.0 40.0 40.0 
Cyp4f6-Rn00686847_m1  40.0 40.0 40.0 40.0 
Cyp4f17-Rn01408612_m1  40.0 40.0 40.0 40.0 
Cyp4f18-Rn01420067_m1  40.0 40.0 40.0 40.0 
Cyp4f39-Rn01408191_m1  40.0 40.0 40.0 40.0 
Cyp4f40-Rn01408132_m1  40.0 40.0 40.0 40.0 
Cyp4v3-Rn01488162_m1  40.0 40.0 40.0 40.0 
Cyp4x1-Rn00595521_m1  40.0 40.0 40.0 40.0 
Tbxas1-Rn00562160_m1  40.0 40.0 40.0 40.0 
Cyp7a1-Rn00564065_m1  40.0 40.0 40.0 40.0 
Cyp7b1-Rn01461859_m1  40.0 40.0 40.0 40.0 
Cyp7b1-Rn01461862_m1  40.0 40.0 40.0 40.0 
Ptgis-Rn00580687_m1  40.0 40.0 40.0 40.0 
Cyp8b1-Rn00579921_s1  40.0 40.0 40.0 40.0 
Cyp11a1-Rn00568733_m1  40.0 40.0 40.0 40.0 
Cyp11a1-Rn01421674_m1  40.0 40.0 40.0 40.0 
Cyp11a1-Rn01421681_g1  40.0 40.0 40.0 40.0 
Cyp11b1-Rn02607234_g1  40.0 40.0 40.0 40.0 
Cyp11b2-Rn01767818_g1  34.4 40.0 40.0 40.0 
Cyp11b3-Rn00822066_g1  40.0 40.0 40.0 40.0 
Cyp17a1-Rn01444704_g1  40.0 40.0 40.0 40.0 
Cyp17a1-Rn00664858_m1  40.0 40.0 40.0 40.0 
Cyp17a1-Rn00562601_m1  40.0 40.0 40.0 40.0 
Cyp19a1-Rn00567222_m1  40.0 40.0 40.0 40.0 
Cyp19a1-Rn01422547_m1  40.0 40.0 40.0 40.0 
Cyp20a1-Rn01644438_g1  40.0 40.0 40.0 40.0 
Cyp21a1-Rn00588996_g1  40.0 40.0 40.0 40.0 
Cyp24a1-Rn01423143_m1  40.0 40.0 40.0 40.0 
Cyp26a1-Rn00590308_m1  40.0 40.0 40.0 40.0 
Cyp26b1-Rn00710376_m1  40.0 40.0 40.0 40.0 
Cyp27a1-Rn00710297_m1  40.0 40.0 40.0 40.0 
Cyp27b1-Rn01647147_g1  40.0 40.0 40.0 40.0 
Cyp27b1-Rn00587137_m1  40.0 40.0 40.0 40.0 
Cyp39a1-Rn01757120_m1  40.0 40.0 40.0 40.0 
Cyp46a1-Rn01430188_m1  40.0 40.0 40.0 40.0 
Cyp51-Rn01526553_m1  36.0 40.0 40.0 40.0 
18S-Hs99999901_s1  27.4 27.2 27.6 27.3 
Gapdh-Rn99999916_s1  30.1 34.0 31.0 40.0 
Rplp2-Rn01479927_g1  33.6 40.0 35.9 40.0 
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Appendix V: Individual rat CYP mRNA expression 
(Chapter V) 
Cyp1a1-Rn00487218_m1 
 
 
Cyp1a2-Rn00561082_m1 
 
 
Cyp2a1-Rn00562200_m1 
 
 
Cyp2a2-Rn00562207_m1 
 
 
Cyp2b1-Rn01457875_m1 
 
 
Cyp2b2-Rn02786833_m1 
 
 
Cyp2b3-Rn01476085_m1 
 
 
Cyp2b3-Rn02786829_sH 
 
 
Cyp2c7-Rn01529602_mH 
 
 
Cyp2c11-Rn00569868_m1 
 
 
Cyp2c12-Rn00755856_m1 
 
 
Cyp2c13-Rn00593388_g1 
 
 
Cyp2c22-Rn00593377_m1 
 
 
Cyp2c23-Rn00582954_m1 
 
 
Cyp2c37-Rn02786817_m1 
 
 
Plots show the ratio of individual rat gene expression compared to the median expression in males or females 
for each CYP isoform. Error bars represent the values of the two replicates. The blue bars correspond to the 
males, the red bars to the females. The blue dash line corresponds to the male median, the orange line to the 
female median.  
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Cyp2d1-Rn01775090_mH 
 
 
Cyp2d2-Rn00562419_m1 
 
 
Cyp2d3-Rn00597330_m1 
 
 
Cyp2d4-Rn01504629_m1 
 
 
Cyp2d4-Rn00696505_g1 
 
 
Cyp2d5-Rn01790051_s1 
 
 
Cyp2e1-Rn00580624_m1 
 
 
Cyp2j3-Rn00598500_m1 
 
 
Cyp2j4-Rn00576482_m1 
 
 
Cyp2j10-Rn01433143_m1 
 
 
Cyp2r1-Rn01754616_m1 
 
 
Cyp2t1-Rn00592635_m1 
 
 
Cyp2u1-Rn01522408_m1 
 
 
Cyp3a2-Rn00756461_m1 
 
 
Cyp3a2-Rn01412889_mH 
 
 
Plots show the ratio of individual rat gene expression compared to the median expression in males or females 
for each CYP isoform. Error bars represent the values of the two replicates. The blue bars correspond to the 
males, the red bars to the females. The blue dash line corresponds to the male median, the orange line to the 
female median.  
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Cyp3a9-Rn00595977_m1 
 
 
Cyp3a18-Rn00595752_m1 
 
 
Cyp3a23(3a1)-Rn01412959_g1 
 
 
Cyp3a62-Rn01409583_m1 
 
 
Cyp4a1-Rn00598510_m1 
 
 
Cyp4a2-Rn01417066_m1 
 
 
Cyp4a3-Rn00598411_m1 
 
 
Cyp4a8-Rn00581081_m1 
 
 
Cyp4b1-Rn00566515_m1 
 
 
Cyp4f1-Rn00571492_m1 
 
 
Cyp4f4-Rn00597513_m1 
 
 
Cyp4f5-Rn00687553_m1 
 
 
Cyp4f5;4f37-Rn00687557_gH 
 
 
Cyp4f6-Rn00686847_m1 
 
 
Cyp4f17-Rn01408612_m1 
 
 
Plots show the ratio of individual rat gene expression compared to the median expression in males or females 
for each CYP isoform. Error bars represent the values of the two replicates. The blue bars correspond to the 
males, the red bars to the females. The blue dash line corresponds to the male median, the orange line to the 
female median.  
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Cyp4f39-Rn01408191_m1 
 
 
Cyp4v3-Rn01488162_m1 
 
 
Cyp5a1(Tbxas1)-Rn00562160_m1 
 
 
Cyp7a1-Rn00564065_m1 
 
 
Cyp7b1-Rn01461859_m1 
 
 
Cyp7b1-Rn01461862_m1 
 
 
Cyp8a1(Ptgis)-Rn00580687_m1 
 
 
Cyp8b1-Rn00579921_s1 
 
 
Cyp17a1-Rn01444704_g1 
 
 
Cyp17a1-Rn00664858_m1 
 
 
Cyp17a1-Rn00562601_m1 
 
 
Cyp20a1-Rn01644438_g1 
 
 
Cyp21a1-Rn00588996_g1 
 
 
Cyp26a1-Rn00590308_m1 
 
 
Cyp27a1-Rn00710297_m1 
 
 
Cyp39a1-Rn01757120_m1 
 
 
Cyp51-Rn01526553_m1 
 
 
Plots show the ratio of individual rat 
gene expression compared to the 
median expression in males or females 
for each CYP isoform. Error bars 
represent the values of the two 
replicates. The blue bars correspond to 
the males, the red bars to the females. 
The blue dash line corresponds to the 
male median, the orange line to the 
female median. 
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Appendix VI: Intra-gender variability in CYP mRNA 
expression (Chapter V) 
Ratios of CYP mRNA expression between the highest and the lowest 
expression within each gender: 
CYP Assay ID 
Median 
CT 
Males 
Median 
CT 
Females 
Ratio 
median expression 
in males / females 
Ratio Males 
Highest/Lowest 
expression 
Ratio Females 
Highest/Lowest 
expression 
Cyp1a1 Rn00487218_m1 29.0 29.6 1.9 14 450 
Cyp1a2 Rn00561082_m1 19.4 19.3 1.1 2.5 2.5 
Cyp2a1 Rn00562200_m1 22.4 20.9 0.43 2.5 2.3 
Cyp2a2 Rn00562207_m1 22.5 29.6 180 2.3 180 
Cyp2b1 Rn01457875_m1 24.0 27.9 17 6.7 12 
Cyp2b2 Rn02786833_m1 26.0 28.2 5.1 9.7 8.3 
Cyp2b3 Rn01476085_m1 21.7 21.9 1.5 2.4 6.5 
Cyp2b3 Rn02786829_sH 24.7 25.0 1.6 3.1 10 
Cyp2c7 Rn01529602_mH 18.1 16.6 0.48 2.5 2.7 
Cyp2c11 Rn00569868_m1 20.4 31.4 2400 2.8 340 
Cyp2c12 Rn00755856_m1 24.9 17.5 0.0069 8.6 2.5 
Cyp2c13 Rn00593388_g1 20.0 32.2 5900 3.0 30 
Cyp2c22 Rn00593377_m1 22.7 23.1 1.6 2.8 1.9 
Cyp2c23 Rn00582954_m1 21.3 21.2 1.1 1.9 2.0 
Cyp2c37 Rn02786817_m1 26.7 38.4 4000 10 29 
Cyp2d1 Rn01775090_mH 22.0 22.6 1.7 3.6 5.0 
Cyp2d2 Rn00562419_m1 20.2 19.9 0.98 1.4 1.7 
Cyp2d3 Rn00597330_m1 21.3 22.3 2.3 1.5 2.7 
Cyp2d4 Rn01504629_m1 25.6 26.3 2.0 2.3 2.2 
Cyp2d4 Rn00696505_g1 26.1 26.9 2.1 1.7 2.4 
Cyp2d5 Rn01790051_s1 22.1 21.8 0.99 3.8 3.4 
Cyp2e1 Rn00580624_m1 18.8 18.7 1.1 2.5 2.7 
Cyp2j3 Rn00598500_m1 24.6 25.3 1.9 1.7 4.0 
Cyp2j4 Rn00576482_m1 23.6 24.0 1.5 2.3 3.0 
Cyp2j10 Rn01433143_m1 30.7 31.7 2.2 2.9 5.2 
Cyp2r1 Rn01754616_m1 28.7 27.9 0.66 2.1 1.6 
Cyp2t1 Rn00592635_m1 24.6 23.8 0.67 2.0 1.8 
Cyp2u1 Rn01522408_m1 28.3 28.8 1.6 5.7 4.6 
Cyp3a2 Rn00756461_m1 19.3 33.2 18000 4.9 130 
Cyp3a2 Rn01412889_mH 19.0 33.1 20000 5.4 140 
Cyp3a9 Rn00595977_m1 24.8 21.9 0.17 5.3 3.0 
Cyp3a18 Rn00595752_m1 22.0 26.1 23 2.4 2.7 
Cyp3a23(3a1) Rn01412959_g1 21.4 22.3 2.3 3.8 8.7 
Cyp3a62 Rn01409583_m1 28.1 29.5 3.2 2.9 3.2 
Cyp4a1 Rn00598510_m1 22.1 21.9 0.97 2.0 3.2 
Cyp4a2 Rn01417066_m1 18.0 20.5 6.6 3.2 6.5 
Cyp4a3 Rn00598411_m1 19.4 20.4 2.6 3.7 3.0 
Cyp4a8 Rn00581081_m1 27.6 32.4 34 28 1000 
Cyp4b1 Rn00566515_m1 26.9 27.2 1.5 2.7 2.1 
Cyp4f1 Rn00571492_m1 22.8 22.9 1.2 1.9 1.9 
Cyp4f4 Rn00597513_m1 22.8 23.1 1.4 1.6 1.7 
Cyp4f5 Rn00687553_m1 28.2 29.8 3.4 3.8 2.7 
Cyp4f5;Cyp4f37 Rn00687557_gH 27.9 29.3 2.9 3.7 2.9 
Cyp4f6 Rn00686847_m1 24.8 24.8 1.2 1.5 1.7 
Cyp4f17 Rn01408612_m1 29.6 29.9 1.5 1.7 3.1 
Cyp4f39 Rn01408191_m1 27.4 27.3 1.3 2.3 2.7 
Cyp4v3 Rn01488162_m1 23.1 22.8 1.1 5.1 5.6 
Cyp5a1(Tbxas1) Rn00562160_m1 29.8 29.3 1.0 7.5 3.2 
Cyp7a1 Rn00564065_m1 26.5 26.3 0.97 8.0 16 
Cyp7b1 Rn01461859_m1 28.2 28.3 1.2 2.1 2.3 
Cyp7b1 Rn01461862_m1 29.0 29.0 1.1 2.1 2.0 
Cyp8a1(Ptgis) Rn00580687_m1 28.6 26.8 0.37 78 220 
Cyp8b1 Rn00579921_s1 19.9 19.6 0.98 1.9 2.2 
Cyp17a1 Rn00562601_m1 26.2 25.4 0.72 3.6 9.0 
Cyp17a1 Rn00664858_m1 25.3 24.4 0.68 3.3 9.2 
Cyp17a1 Rn01444704_g1 24.8 23.9 0.69 3.4 8.8 
Cyp20a1 Rn01644438_g1 25.5 25.6 1.2 1.6 1.7 
Cyp21a1 Rn00588996_g1 31.1 30.4 0.69 6.9 3.3 
Cyp26a1 Rn00590308_m1 31.1 28.1 0.13 5.8 3.1 
Cyp27a1 Rn00710297_m1 21.8 21.8 1.1 1.7 1.8 
Cyp39a1 Rn01757120_m1 24.7 24.4 0.94 1.9 1.7 
Cyp51 Rn01526553_m1 24.3 22.8 0.41 4.0 2.9 
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Appendix VII: UPLC-MS gradients employed in the control 
rat metabolic profiling study (Chapter VI) 
Detailed information on UPLC columns, flow rates and column temperatures is 
provided in Table VI-2 of Chapter VI.  
 
 Urine: 
ESI+ / ESI− 
t (min) %A %B 
0 100 0 
1 100 0 
3 85 15 
6 50 50 
9 5 95 
10 5 95 
10.1 100 0 
12 100 0 
A= Water + 0.1% formic acid; B = Acetonitrile + 0.1% formic acid 
 
 Serum/Aqueous liver extracts: 
ESI+ 
 
ESI− 
t (min) %A %B t (min) %A %B 
0 99.9 0.1 0 99.9 0.1 
2 99.9 0.1 2 99.9 0.1 
6 75 25 6 75 25 
10 20 80 8 20 80 
12 10 90 14 7 93 
21 0.1 99.9 15 3 97 
23 0.1 99.9 19 0.1 99.9 
24 99.9 0.1 21 0.1 99.9 
26 99.9 0.1 22 99.9 0.1 
   
24 99.9 0.1 
A= Water + 0.1% formic acid; B = Methanol + 0.1% formic acid 
 
 Organic liver extracts 
ESI+ 
 
ESI− 
t (min) %A %B 
 
t (min) %A %B 
0 25 75 
 
0 30 70 
1 25 75 
 
2 30 70 
6 15 85 
 
7 15 85 
10 15 85 
 
11 15 85 
15 10 90 
 
15 10 90 
17 10 90 
 
17 10 90 
18 9 91 
 
18 0.1 99.9 
21 9 91 
 
20 0.1 99.9 
22 8 92 
 
21 30 70 
27 8 92 
 
23 30 70 
29 0.1 99.9 
    
32 0.1 99.9 
    
33 25.0 75.0 
    
35 25.0 75.0 
    
A= Water + 0.1% formic acid; B = 15% Isopropanol in methanol + 0.1% formic acid  
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Appendix VIII: Individual values obtained for the 
physiological and biochemical parameters measured in the 
in-life phase (Chapter VI) 
Rat 
BW 
 
g 
LW 
 
g 
S_Glu 
 
mmol/L 
S_Creat 
 
μmol/L 
S_Alb 
 
g/L 
S_Prot 
 
g/L 
S_Chol 
 
mmol/L 
S_Trig 
 
mmol/L 
S_Bili 
 
μmol/L 
S_ALP 
 
U/L 
S_ALT 
 
U/L 
S_AST 
 
U/L 
S_GLDH 
 
U/L 
S_BA 
 
μmol/L 
Ur8h_
W 
g 
Ur8h_
Sg 
- 
Ur8h_ 
Creat 
mmol/L 
Ur8h_
Glu 
mmol/L 
Ur24h_
W 
g 
Ur24h_
Sg 
- 
Ur24h_
Creat 
mmol/L 
Ur24h_
Glu 
mmol/L 
1 257 6.38 6.17 44 44.2 59.9 1.1 0.4 1.5 144 27 153 6 12.3 0.987 1.044 9.0 1.28 3.604 1.029 8.6 0.86 
2 262 6.69 5.95 30 41.1 58.6 1.7 0.3 1.2 170 20 107 5 3.7 2.103 1.037 6.8 0.90 11.762 1.018 4.4 0.46 
3 258 6.32 5.33 35 39.0 59.1 1.9 1.0 0.9 131 29 121 19 4.3 2.488 1.031 5.7 0.73 7.185 1.018 4.3 0.39 
4 253 6.45 6.75 29 43.0 60.3 1.9 0.7 1.1 181 20 95 6 6.1 1.845 1.033 5.5 0.80 11.635 1.018 4.0 0.44 
5 262 6.51 5.50 46 44.5 63.7 1.7 0.5 1.1 133 22 127 6 24.6 2.018 1.019 2.6 0.35 9.505 1.017 3.6 0.35 
6 281 7.51 4.61 36 41.2 61.7 1.4 0.7 1.0 137 18 102 5 3.3 2.519 1.037 7.7 0.94 18.991 1.009 2.2 0.23 
7 262 6.62 6.06 27 45.2 62.6 2.3 0.7 1.3 128 20 109 6 16.9 2.258 1.035 7.3 0.93 5.712 1.027 7.8 0.77 
8 261 6.83 5.60 23 39.8 59.8 1.8 0.9 0.9 84 18 107 4 2.7 2.277 1.040 8.0 1.03 11.842 1.017 4.1 0.42 
9 262 6.50 5.52 32 40.9 57.9 1.3 0.6 1.0 118 21 105 5 4.9 2.075 1.036 6.6 0.84 24.660 1.011 2.9 0.28 
10 256 6.35 5.39 27 41.1 59.3 1.2 0.6 1.0 216 21 101 7 2.7 1.362 1.046 10.7 1.28 19.038 1.012 3.0 0.31 
11 282 7.34 5.44 34 42.4 63.0 2.0 0.6 1.1 125 20 113 5 6.5 3.551 1.033 6.0 0.82 5.619 1.028 7.4 0.74 
12 281 6.88 5.23 35 43.9 64.5 1.6 0.4 0.9 111 15 93 5 4.7 2.143 1.036 7.6 0.84 6.172 1.023 6.3 0.49 
13 278 6.97 5.61 32 40.6 60.0 1.3 0.8 0.9 149 19 84 5 6.0 2.806 1.033 7.0 0.81 2.512 1.034 10.0 0.89 
14 293 7.56 6.71 32 41.5 62.1 1.4 0.8 0.9 124 18 117 5 4.7 2.312 1.043 8.3 1.15 3.663 1.035 9.5 0.93 
15 297 8.11 6.05 43 43.0 61.1 1.1 1.1 1.1 125 21 83 5 12.5 2.541 1.031 5.8 0.80 10.314 1.018 4.9 0.44 
16 284 7.61 5.22 44 44.0 67.4 1.5 0.6 1.3 135 20 130 5 22.2 2.115 1.025 5.3 0.68 2.391 1.043 13.7 1.18 
17 274 7.28 5.59 25 44.6 62.7 1.9 0.6 1.7 119 17 125 7 4.3 3.241 1.032 6.6 0.82 12.837 1.016 4.1 0.40 
18 288 7.51 5.93 26 39.2 58.7 1.4 1.1 1.2 84 16 93 5 3.5 2.641 1.032 6.0 0.81 10.462 1.020 5.6 0.53 
19 278 6.61 6.35 28 38.7 59.2 1.3 0.8 1.1 89 16 93 5 4.7 1.472 1.039 7.7 0.95 11.372 1.018 4.3 0.36 
20 287 7.57 6.66 24 42.5 61.8 1.4 0.7 1.5 105 17 99 5 2.5 4.922 1.021 3.7 0.48 9.789 1.020 4.9 0.51 
21 173 4.50 5.55 39 42.4 58.7 1.3 0.3 0.9 84 16 89 6 6.6 2.083 1.038 6.4 1.11 7.633 1.016 3.4 0.49 
22 177 4.84 5.70 40 42.3 57.7 1.1 0.4 1.5 110 18 84 5 68.4 1.276 1.039 5.9 0.82 1.860 1.031 7.1 0.65 
23 172 4.94 6.00 32 41.7 58.6 1.5 0.5 0.9 69 16 75 3 5.0 1.686 1.039 6.2 1.26 9.146 1.014 2.8 0.45 
24 178 4.68 6.77 30 43.7 60.8 1.0 0.3 1.2 56 9 56 3 21.1 2.844 1.028 4.7 0.59 15.246 1.009 2.0 0.19 
25 170 4.59 5.50 30 44.9 58.0 1.2 0.3 1.3 48 12 78 4 5.9 1.019 1.034 5.8 0.79 8.960 1.013 2.7 0.26 
26 165 4.49 6.19 32 44.2 58.8 1.1 0.4 1.3 100 13 77 4 5.0 1.605 1.031 5.1 0.76 3.091 1.030 6.8 0.72 
27 186 4.68 5.73 33 44.5 59.6 1.3 0.4 1.9 56 17 73 4 103.9 2.296 1.033 5.8 0.84 8.083 1.018 3.7 0.41 
28 181 4.85 5.67 40 45.3 61.0 1.2 0.5 0.9 95 14 94 5 8.7 1.090 1.044 8.1 1.05 1.984 1.037 9.6 0.91 
29 176 4.73 7.43 37 47.8 63.6 0.7 0.2 0.9 62 15 74 4 9.7 0.480 1.031 5.4 0.77 2.024 1.043 10.8 1.20 
30 185 5.02 7.57 45 43.8 58.7 1.0 0.3 1.1 65 15 74 5 10.5 1.396 1.034 5.6 0.88 1.019 1.046 12.7 1.39 
31 172 5.09 5.09 31 44.1 61.5 1.2 0.2 0.9 57 14 112 5 6.9 1.942 1.035 5.8 0.95 6.884 1.019 4.2 0.53 
32 192 5.03 6.01 42 43.2 59.9 1.4 0.4 1.0 61 19 88 6 10.9 1.150 1.036 5.9 0.81 0.616 1.039 10.7 1.01 
33 178 4.68 6.54 39 48.3 62.6 1.5 0.2 0.9 52 14 93 5 6.7 1.745 1.036 6.6 0.95 2.369 1.031 8.3 0.97 
34 179 4.77 6.30 46 45.1 63.1 1.2 0.3 0.9 74 15 134 5 9.6 1.169 1.027 5.1 0.98 2.247 1.038 9.3 1.55 
35 182 4.73 6.97 34 46.5 62.8 1.5 0.3 0.9 91 13 101 4 5.4 0.614 1.032 4.9 0.75 3.758 1.033 7.5 0.94 
36 185 4.64 6.55 36 37.9 57.2 1.4 0.2 0.9 62 13 97 5 5.6 2.814 1.023 4.3 0.57 11.129 1.012 2.8 0.23 
37 210 5.37 6.35 40 40.5 58.1 1.7 0.3 0.9 84 15 86 5 4.9 2.523 1.036 6.1 0.79 22.453 1.008 1.8 0.19 
38 196 5.53 6.95 31 41.7 59.1 1.8 0.5 0.9 71 14 70 5 8.4 2.096 1.031 4.6 0.80 11.455 1.013 2.6 0.38 
39 202 5.58 5.63 42 43.8 62.4 1.2 0.4 1.1 105 17 86 5 7.8 0.209 1.019 2.6 0.39 8.506 1.016 3.6 0.44 
40 199 4.82 6.33 30 40.3 56.1 0.8 0.3 1.9 55 12 76 7 23.2 1.561 1.045 8.0 1.17 3.972 1.028 6.8 0.78 
                       
Mm 272.80 6.98 5.78 32.60 42.02 61.17 1.56 0.70 1.14 130.40 19.75 107.85 6.05 7.66 2.384 1.034 6.70 0.86 9.953 1.022 5.78 0.55 
Msd 13.72 0.54 0.56 7.05 2.00 2.36 0.33 0.22 0.23 32.03 3.43 17.25 3.14 6.57 0.841 0.007 1.79 0.22 5.859 0.009 2.90 0.26 
Fm  182.90 4.88 6.24 36.45 43.60 59.92 1.26 0.34 1.11 72.85 14.55 85.85 4.75 16.71 1.580 1.034 5.65 0.85 6.622 1.025 5.96 0.68 
Fsd 11.71 0.31 0.67 5.23 2.51 2.18 0.27 0.10 0.32 19.01 2.31 16.91 0.97 24.92 0.735 0.006 1.22 0.21 5.549 0.012 3.41 0.40 
Abbreviations:  
BW: body weight; LW: liver weight; S_: Serum; Ur: Urine; Glu: glucose; Creat: creatinine; Alb: albumin; Prot: 
total protein; Chol: total cholesterol; Trig: triglycerides; ALP: alkaline phosphatase; ALT: alanine 
aminotransferase; AST: aspartate aminotransferase; GLDH: glutamate dehydrogenase; Bili: total bilirubin; BA: 
total bile acids; Sg: specific gravity; W: weight. 
Mm: male mean; Msd: male standard deviation; Fm: female mean; Fsd: female standard deviation.  
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Optimization and evaluation of metabolite extraction 
protocols for untargeted metabolic profiling of liver 
samples by UPLC-MS 
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Analytical Chemistry 2010, 82(18), 7779-7786 
Optimization and Evaluation of Metabolite
Extraction Protocols for Untargeted Metabolic
Profiling of Liver Samples by UPLC-MS
Perrine Masson, Alexessander Couto Alves, Timothy M. D. Ebbels, Jeremy K. Nicholson, and
Elizabeth J. Want*
Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Sir Alexander Fleming Building,
Imperial College London, South Kensington, SW7 2AZ, U.K.
A series of six protocols were evaluated for UPLC-MS
based untargeted metabolic profiling of liver extracts in
terms of reproducibility and number of metabolite fea-
tures obtained. These protocols, designed to extract both
polar and nonpolar metabolites, were based on (i) a two
stage extraction approach or (ii) a simultaneous extraction
in a biphasic mixture, employing different volumes and
combinations of extraction and resuspension solvents. A
multivariate statistical strategy was developed to allow
comparison of the multidimensional variation between the
methods. The optimal protocol for profiling both polar and
nonpolar metabolites was found to be an aqueous extrac-
tion with methanol/water followed by an organic extraction
with dichloromethane/methanol, with resuspension of the
dried extracts in methanol/water before UPLC-MS analy-
sis. This protocol resulted in a median CV of feature
intensities among experimental replicates of <20% for
aqueous extracts and <30% for organic extracts. These
data demonstrate the robustness of the proposed protocol
for extracting metabolites from liver samples and make it
well suited for untargeted liver profiling in studies explor-
ing xenobiotic hepatotoxicity and clinical investigations of
liver disease. The generic nature of this protocol facilitates
its application to other tissues, for example, brain or lung,
enhancing its utility in clinical and toxicological studies.
Metabonomics is a top-down systems biology approach which
provides insights into the metabolic status of complex living
systems through the nontargeted analysis of metabolites in
biological samples.1,2 Levels of hundreds of metabolites can be
determined simultaneously, and metabolic changes caused by
stimuli such as diet, environment, disease processes, or pharma-
ceutical interventions can be monitored over time.1,2 Compared
with other -omics technologies, for example, genomics, transcrip-
tomics, and proteomics, metabonomics offers the advantage of
taking into account the dynamic metabolic status of the whole
organism and provides the ability to more accurately predict
phenotypical properties.1,3,4 Metabolic profiling approaches have
been used for numerous environmental, preclinical, and clinical
applications,5,6 including disease diagnosis and monitoring,7,8
understanding tumor development and progression,9 identifying
mechanisms and biomarkers of xenobiotic toxicity,10-12 and large-
scale epidemiological studies.13
Metabolic profiles of biological samples, such as urine, plasma
and tissue extracts, are typically obtained using nuclear magnetic
resonance (NMR) spectroscopy and/or mass spectrometry
(MS),14 providing information on thousands of metabolites in a
sample in a single analytical run. Chemometric and mathematical
modeling methods, for example, principal components analysis
(PCA) and partial least-squares discriminant analysis (PLS-DA),
are then used to interpret the complex resulting data sets.15,16
To address biological sample complexity, MS is generally coupled
with a prior separation stage, for example, gas chromatography
(GC), high performance liquid chromatography (HPLC) or, more
recently, ultra performance liquid chromatography (UPLC). This
latter technique employs smaller particles and higher pressure
than conventional HPLC, resulting in better resolution, increased
sensitivity and faster analysis times.14,15 If NMR has the advan-
* To whom correspondence should be addressed. Phone: +44 (0) 207 594
3023; Fax: +44 (0) 207 594 3226; E-mail: e.want@imperial.ac.uk.
(1) Nicholson, J. K.; Lindon, J. C.; Holmes, E. Xenobiotica 1999, 29, 1181–
1189.
(2) Lindon, J. C.; Holmes, E.; Nicholson, J. K. FEBS J 2007, 274, 1140–1151.
(3) Nicholson, J. K.; Wilson, I. D. Nat Rev Drug Discovery 2003, 2, 668–676.
(4) Goodacre, R.; Vaidyanathan, S.; Dunn, W. B.; Harrigan, G. G.; Kell, D. B.
Trends Biotechnol 2004, 22, 245–252.
(5) Robertson, D. G. Toxicol. Sci. 2005, 85, 809–822.
(6) Viant, M. R.; Rosenblum, E. S.; Tieerdema, R. S. Environ. Sci. Technol.
2003, 37, 4982–4989.
(7) Moolenaar, S. H.; Engelke, U. F.; Wevers, R. A. Ann. Clin. Biochem. 2003,
40, 16–24.
(8) Brindle, J. T.; Antti, H.; Holmes, E.; Tranter, G.; Nicholson, J. K.; Bethell,
H. W.; Clarke, S.; Schofield, P. M.; McKilligin, E.; Mosedale, D. E.; Grainger,
D. J. Nat. Med. 2002, 8, 1439–1444.
(9) Griffin, J. L.; Shockcor, J. P. Nat. Rev. Cancer 2004, 4, 551–561.
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(11) Mortishire-Smith, R. J.; Skiles, G. L.; Lawrence, J. W.; Spence, S.; Nicholls,
A. W.; Johnson, B. A.; Nicholson, J. K. Chem. Res. Toxicol. 2004, 17, 165–
173.
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tages of being nonselective and requiring minimal sample prepara-
tion, LC-MS is more sensitive and can aid in metabolite identifi-
cation,5,14,17 although the unequivocal identification of “unknown”
compounds remains a key challenge in metabonomic studies.
Therefore, using both NMR and LC-MS in these studies allows for
combining the strengths of the two techniques.14,18
Sample preparation procedures for metabonomic studies are
highly dependent on the sample type and the analytical tool being
employed.14,19-25 For LC-MS analyses, tissue preparation usually
requires a liquid metabolite extraction. An efficient and reproduc-
ible method is crucial in order to obtain reliable metabolic profile
data. Here, we focus on the optimization of metabolite extraction
from liver samples for metabolic profiling by UPLC-MS. Liver is
a lipid-rich tissue which also contains many polar metabolites (e.g.,
amino acids). Therefore, in order to perform untargeted metabo-
nomic analysis, both polar and nonpolar metabolites must be
extracted. Two different approaches are (1) simultaneous extrac-
tion of polar and nonpolar metabolites using a combination of
water, methanol and chloroform, resulting into two layers sepa-
rated by a protein pellet26-28 or (2) two consecutive extractions:
an aqueous extraction using perchloric acid or polar organic
solvents (e.g., methanol or acetonitrile) mixed with water, followed
by a lipid extraction of the remaining pellet, usually with
chloroform/methanol.29,30 This second approach avoids the dif-
ficult step of separating the two layers, but is more time-consuming
as two extractions are performed instead of one. For aqueous
extractions Lin et al.27 concluded that methanol/water (2:1),
acetonitrile/water (1:1 or 2:1) and methanol/chloroform/water
all produced good consistent yields for NMR metabolic profiling
of liver samples (assessed from normalized total spectral area),
although the acetonitrile-based extractions tended to also extract
some macromolecules and lipids into the aqueous layer. Using
PCA, they found methanol/water extraction to be more variable
than acetonitrile/water and methanol/chloroform/water extrac-
tions. Conversely, Want et al.23 showed that methanol/water
combination gave more effective and reproducible results than
acetonitrile/water for LC-MS based metabolic profiling of serum.
Although chloroform is most commonly used for organic extrac-
tions, often in combination with methanol or methanol/water,30-34
it presents health and environmental hazards. Carlson35 and
Cequier-Sanchez36 compared the efficiency of chloroform/
methanol and dichloromethane/methanol for lipid extraction and
concluded that dichloromethane (which seems to be less toxic
than chloroform) was a viable replacement.
Here, both consecutive and two-layer extraction strategies were
evaluated for UPLC-MS metabolic profiling of liver samples in
order to produce a robust and efficient protocol. Key consider-
ations were reproducibility, metabolite yield, and sample through-
put. A traditional statistical approach to investigate reproducibility
is to calculate the coefficient of variation (CV) of replicated
measurements. Here, the CV of the intensities measured among
replicates of a single protocol can be calculated for each metabolite
feature37 and the distribution of these CVs can then be compared
between the various methods to obtain an overview of differences
in reproducibility. However, when dealing with thousands of
features, it is essential to use a multivariate approach to combine
multiple features and enhance the statistical comparison of
methods. PCA scores plots can be used for this purpose, often
by comparing the areas or volumes occupied by replicates of
different experimental methods.27 However, this approach is a
projection of the multidimensional variation in few dimensions and
variation among replicates in the remaining dimensions is not
taken into account. For this reason, a statistical strategy based
on the variation in the whole multidimensional space was
developed for this study.
When performing untargeted metabolic profiling of samples
by UPLC-MS, analyzing a large number of samples in one
analytical run can lead to instrumental drift, arising from column
degradation or contamination of the MS source.38 However, the
comparison of data acquired within different batches of samples
is nontrivial. Hence, to enable the investigation of many protocols,
a preliminary study was performed, in which the consecutive
extraction approach (8 protocols) and the two-layer extraction
approach (24 protocols) were examined separately (Supporting
Information (SI)). The most promising conditions in terms of
number of features extracted and reproducibility were selected
for each approach to be further investigated in the study reported
here. Interestingly, all six selected conditions used dichlo-
romethane as an organic solvent (rather than chloroform). This
study aimed to thoroughly compare these six conditions in order
to determine the optimal protocol for UPLC-MS metabolic profiling
of liver samples.
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EXPERIMENTAL SECTION
Materials. All solvents for liver metabolite extraction (water,
acetonitrile, methanol, chloroform, dichloromethane) were ob-
tained from Sigma (Gillingham, UK) and chilled before use.
Homogenization of the liver samples was performed using a
TissueLyser with 5 mm stainless steel beads from Qiagen (West
Sussex, UK). For UPLC-MS analyses, 96-well plates and vials were
from Waters (Hertfordshire, UK); well plate cap mats were from
VWR (Leicestershire, UK); water was LC-MS Chromasolv grade
from Sigma; acetonitrile was hypergrade for LC-MS LiChrosolv
from VWR; formic acid, leucine enkephalin and sodium formate
were from Sigma. Standard compounds used for metabolite
identification were obtained from Sigma.
Liver Sample. A portion (total weight ∼5 g) of a chicken liver
from a single animal (standard commercially available fresh food
product) was used to evaluate the different protocols. It was stored
at -80 °C until use. 1H NMR spectra were acquired to assess
sample integrity and to confirm that global metabolite patterns
were similar to those of previously acquired liver data, which
ensured that the samples were fit for purpose for method
development.
Liver Metabolite Extraction. Six liver sample preparation
protocols were compared, each using fifteen replicates and five
experimental blanks (containing no liver). TissueLyser parameters
were set at 25 Hz, 5 min, and centrifugations were performed at
16 000g for 10 min.
Consecutive Extraction Protocols (CE1, CE2, CE3). Protocols
were adapted from Coen et al.30 Liver samples (50 mg) were
homogenized in 1.5 mL of methanol/water (1:1) (CE1 and CE3)
or acetonitrile/water (1:1) (CE2) in the TissueLyser. Supernatants
were collected in Eppendorf tubes after centrifugation and dried
in a Savant Speedvac (aqueous extracts). The remaining pellets
were homogenized in 1.5 mL of dichloromethane/methanol (3:
1) in the TissueLyser. Homogenates were transferred to clean
Eppendorf tubes and centrifuged. Supernatants were collected in
glass vials and dried overnight in a fume cupboard (organic
extracts). Dried aqueous and organic extracts were stored at -40
°C until UPLC-MS analysis. Before analysis, aqueous extracts were
resuspended in 200 µL of methanol/water (1:1) (CE1) or water
(CE2 and CE3) and organic extracts in 200 µL of acetonitrile/
water (1:1) (CE1) or methanol/water (1:1) (CE2 and CE3).
Two-Layer Extraction Protocols (TLE1, TLE2, TLE3). TLE1 was
an internally developed protocol, TLE2 was adapted from Wu et
al.39 and TLE3 was similar to TLE1, but using TLE2 volumes of
solvents. For TLE1, 500 µL of dichloromethane/methanol (2:1)
was added to 50 mg of liver. Samples were homogenized in the
TissueLyser before adding 500 µL of water. Samples were then
vortexed, left on ice for 10 min and centrifuged. For TLE2, 400
µL of methanol and 125 µL of water were added to 50 mg of liver.
Samples were homogenized in the TissueLyser before adding 200
µL of water and 400 µL of dichloromethane. Samples were
vortexed and centrifuged. For TLE3, 800 µL of dichloromethane/
methanol (1:1) were added to 50 mg of liver. Samples were
homogenized in the TissueLyser before adding 325 µL of water,
then vortexed and centrifuged. For these three protocols, cen-
trifugation produced a biphasic mixture and upper (aqueous) and
lower (organic) layers were collected separately and dried as
before. Before analysis, aqueous extracts were resuspended in
200 µL of water and organic extracts were resuspended in 200
µL of methanol/water (1:1). Table 1 summarizes the different
protocols. The choice of these six protocols arose from a
preliminary study, details of which can be found in the SI (Tables
S-1 and S-2 for a list of investigated protocols and Tables S-3 to
S-5 for a summary of the results).
UPLC-MS Analysis. Analyses were performed separately for
aqueous and organic extracts using an Acquity UPLC System
(Waters, Elstree) coupled to a Q-Tof Premier mass spectrometer
(Waters, Manchester), operated in the positive (ESI+) and
negative (ESI-) electrospray ionization modes. Chromatography
was carried out at 40 °C on a Waters Acquity UPLC HSS T3
column (1.8 µm, 2.1 × 100 mm) with the following solvent system:
A ) 0.1% formic acid in water, B ) 0.1% formic acid in acetonitrile.
A gradient was used from 100% A to 100% B at a flow rate of 0.5
mL/min (21 min for aqueous extracts, 25 min for organic extracts,
followed by a 5-min re-equilibration phase). The injection volume
was 5 µL. ESI conditions were source temperature 120 °C,
(39) Wu, H.; Southam, A. D.; Hines, A.; Viant, M. R. Anal. Biochem. 2008, 372,
204–212.
Table 1. Protocols Compared for the Preparation of Liver Samples (Selected from Preliminary Study Detailed in
Supporting Information)a
consecutive extractions (CE)
resuspension of dried extracts
name aqueous extraction organic extraction aqueous organic
CE1 1.5 mL M/W (1:1) 1.5 mL D/M (3:1) 200 µL M/W (1:1) 200 µL A/W (1:1)
CE2 1.5 mL A/W (1:1) 1.5 mL D/M (3:1) 200 µL W 200 µL M/W (1:1)
CE3 1.5 mL M/W (1:1) 1.5 mL D/M (3:1) 200 µL W 200 µL M/W (1:1)
two-layer extraction (TLE)
resuspension of dried extracts
name
solvents for
homogenization
after homogenization,
before centrifugation aqueous organic
TLE1 500 µL D/M (2:1) 500 µL W. Samples left on ice 10 min 200 µL W 200 µL M/W (1:1)
TLE2 400 µL M + 125 µL W 200 µL W + 400 µL D 200 µL W 200 µL M/W (1:1)
TLE3 800 µL D/M (1:1) 325 µL W 200 µL W 200 µL M/W (1:1)
a Abbreviations: A: acetonitrile; D: dichloromethane; M: methanol; W: water.
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desolvation temperature 350 °C, cone gas flow 25 L/h, desolvation
gas flow 900 L/h, capillary voltage for ESI- 2400 V, for ESI+ 3000
V (aqueous extracts) or 3200 V (organic extracts), cone voltage
35 V. The instrument was set to acquire over the m/z range
50-1000 with scan time of 0.1 s and an interscan delay of 0.01 s.
Data were collected in centroid mode. Leucine Enkephalin (MW
) 555.62 Da) (200 pg/µL in acetonitrile/water 50:50) was used
as a lock mass with an analyte-to-reference scan ratio of 10:1. The
instrument was calibrated before analyses using 0.5 mM sodium
formate solution. For each analysis, a quality control sample (QC),
prepared by combining equal aliquots of replicates from each
method, was injected regularly throughout the run to monitor the
stability of the UPLC-MS platform.40 This QC sample was also
used to condition the column at the beginning of each analysis
(eight injections). The order of injection was set by “supervised”
randomization, using the criterion that each of the sequences 1-6,
7-12, 13-18... should contain one replicate from each method.
Data Preprocessing. UPLC-MS analyses resulted in two data
sets for the aqueous extracts and two data sets for the organic
extracts (ESI- and ESI+ modes). Each data set was preprocessed
using the freely available XCMS software41 (version 1.14.0) in
order to convert the three-dimensional LC-MS raw data (retention
time, m/z, intensity) into a table of time-aligned detected features,
with their retention time, m/z ratio and intensity in each sample.
Isotope peaks, fragments and adducts were treated as separate
features. For each data set, samples were grouped by protocol,
separating liver samples and corresponding experimental blanks,
and QC samples were treated as a separate group, resulting in 13
classes. Default settings were employed in XCMS with the
exception of the minimum fraction of samples for grouping
(minfrac ) 0.6) and the bandwidth for the grouping performed
after retention time correction (bw ) 10 s). Four output tables
were thereby obtained (one for each data set), summarizing the
intensities of the detected features in each sample (liver, experi-
mental blanks and QC samples).
Data Visualization. The XCMS output tables were used as
an input for Simca P+11.5 (Umetrics) to visualize each data set
with principal components analysis (PCA). Data were scaled using
level scaling, which consists of centering the variables and dividing
them by their mean; this focuses on changes relative to the mean
concentration of the metabolite features. Scores plots were
examined to assess the degree of similarity between methods and
identify potential outliers or trends in the data.
Metabolite Feature Selection. For each data set, statistical
tests were performed in Matlab (version 7.4, The MathWorks,
Natick, Massachusetts) to remove features arising from the
extraction solvents and mobile phases. Due to the number of
experimental blanks for each protocol and the very low breakdown
point of the mean statistics, a nonparametric approach was
followed. For each method, the features statistically significantly
different from the corresponding experimental blanks were
selected using a test of differences in medians42 based on the two-
sided bootstrap confidence interval inversion (R ) 0.05) with
correction of the false discovery rate (FDR ) 0.05) for multicom-
parison with dependencies.43 These metabolite features were then
used for investigation of reproducibility and efficiency.
Evaluation of Method Reproducibility. Univariate statistics
were used initially to visualize differences in reproducibility
between methods. As several thousand metabolite features were
obtained for each data set, a multivariate strategy was subse-
quently developed to enhance the statistical comparison of the
methods.
Univariate Statistics. The CV distribution of feature intensities
among the 15 replicates was compared between the different
methods using box plots. Each box shows the degree of dispersion
of CVs of metabolite features for one condition by displaying the
25th percentile (bottom of box), the median, the mean and the
75th percentile (top of box). For each method, all features selected
as different from the corresponding experimental blanks were
used.
Multivariate Statistics. Only the metabolite features common
to all methods were retained in order to make methods compa-
rable. To combine information from these multiple features, and
since there is no standard method for computing multivariate
variation, a multivariate statistical test was developed, based on a
dimensionless statistic representative of the multivariate relative
variation within the replicates of each method. Let xij be the
intensity of the feature j in sample i. The statistic æi was based
on the overall l1 norm of each sample’s relative deviation
vector Zi. The elements Zij of the relative deviation vector were
the absolute differences between the sample’s feature intensi-
ties xij and the replicates’ medians x˜j, divided by the replicates’
medians, that is, Zij ) |xij - x˜j|/x˜j. The l1 norm of the vector
was normalized by the number of common metabolites K,
resulting in æi ) (1)/(K)|Zi|1. The median of the statistic among
replicates æ˜ was then calculated for each method with its 95%
confidence interval computed using the Studentized bootstrap
percentile T with double bootstrap variance estimate.42 The
statistic was plugged-in to the Conover’s nonparametric test
of differences in medians44 to perform pairwise comparisons
of the multivariate relative variation between methods.
RESULTS AND DISCUSSION
Due to the high sensitivity of UPLC-MS, highly reproducible
techniques are essential for sample preparation, since variation
introduced during the preparation step is likely to be seen in the
resulting data. Many reported approaches for metabolite extraction
from tissues focus on a small subset of metabolites, often from
the same class of compounds, and optimization of sample
preparation frequently reflects this. As our aim was to perform
untargeted metabolic profiling of liver samples and therefore
extract thousands of metabolites encompassing a wide range of
chemical structures, it was essential to try to optimize the
reproducibility of all features arising from both aqueous and
organic extracts simultaneously. Six protocols were compared
(each performed on 15 liver samples and 5 experimental blanks),
resulting in 120 aqueous extracts and 120 organic extracts
analyzed in both ESI+ and ESI- modes, producing four data sets.
(40) Sangster, T.; Major, H.; Plumb, R.; Wilson, A. J.; Wilson, I. D. Analyst 2006,
131, 1075–1078.
(41) Smith, C. A.; Want, E. J.; O’Maille, G.; Abagyan, R.; Siuzdak, G. Anal. Chem.
2006, 78, 779–787.
(42) Manly, B. F. J. Randomization, Bootstrap and Monte Carlo Methods in Biology;
Chapman & Hall/CRC: Boca Raton, FL, 2006.
(43) Benjamini, Y.; Yekutieli, D. Ann. Stat. 2001, 29, 1165–1188.
(44) Conover, W. J. Practical Nonparametric Statistics; John Wiley & Sons: New
York, 1998.
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Each data set was initially visualized using PCA plots. Efficiency
and reproducibility were investigated using univariate and mul-
tivariate statistics to select the optimal protocol.
Data Visualization using PCA. Of particular interest was the
clustering of the multiple injections of the QC sample, injected at
regular intervals throughout the UPLC-MS run in order to assess
analytical platform reproducibility.22,38,40,45,46 QC sample chro-
matograms can be examined to detect any trends in the run (e.g.,
decrease/increase in signal intensity, changes in peak shapes,
retention time shift). In PCA scores plots, multiple injections of
the QC samples should cluster tightly together and ideally show
no drift over time.
For each data set, PCA scores plots (PC1 vs PC2) showed a
tight clustering of the experimental blanks and some separation
between the different protocols, indicating differences in metabolic
profiles.
Aqueous Extracts. Using ESI- mode, a drift was observed for
the last three QCs (Figure 1a). Therefore, for this data set, the
last third of the analytical run was discarded for the analysis of
reproducibility and efficiency (10 replicates and 3 experimental
blanks remained for each protocol) (Figure 1b). This highlights
the importance of QC samples for assessing the consistency of
the analytical run over time. For the aqueous extracts analyzed
in ESI+ mode, the first and last QC samples did not cluster with
the other QC samples, therefore the beginning and the end of
the run were removed (12 replicates and 4 experimental blanks
remained for each protocol; SI Figure S-1). Lack of clustering of
the first QC sample with the others could indicate that the column
had not been sufficiently conditioned before starting the run. After
removal of these samples, the scores plots were similar for both
modes. A clear separation was seen between the different
protocols, except for TLE2 and TLE3, which overlapped. These
two protocols were highly similar and used the same volume of
each solvent, the only differences being the order of addition of
these solvents (and therefore the solvents in which homogeniza-
tion was performed). The PCA scores plots indicated that these
differences did not seem to have an impact on the metabolite
extraction.
Organic Extracts. A clear separation was seen between the
consecutive extraction approach and the two-layer extraction
approach, whereas replicates from the different protocols over-
lapped within each approach (SI Figure S-2). CE1 replicates, the
only samples to be resuspended in acetonitrile/water (methanol/
water for all other extracts), showed more spread than the
replicates of other protocols. In positive mode, TLE1 clustered
very close to the experimental blanks, which may indicate that
the organic extraction was less efficient with this protocol.
Evaluation of Method Reproducibility Using Univariate
Statistics. Box plots were used to visualize the distribution of
metabolite feature intensity CVs among replicates for each method
(Figure 2), as well as among multiple injections of the QC sample
(far right box). QC variability was lower than experimental
variability, and higher for the organic extracts than the aqueous
extracts (median CV ∼ 20% and ∼10% respectively). This could
be explained by the high lipid content in the organic extracts,
which can induce carryover between samples and saturation of
the MS detector, affecting reproducibility.
For the aqueous extracts (Figure 2a and b), taking into account
both ESI- and ESI+ modes, the most reproducible protocols were
CE1 and TLE2, showing a median CV of 16.9% and 17.3%
respectively for ESI– mode, and 19.2% and 19.8% for ESI+ mode.
For the organic extracts (Figure 2c and d), the two-layer
extractions showed a higher variability than the consecutive
extractions. The most reproducible protocols were CE3 and CE2,
with median CVs of 29.0% and 32.1%, respectively, for ESI- mode
and 26.1% and 31.6%, respectively, for ESI+ mode. These involved
an organic extraction with dichloromethane/methanol (3:1) with
resuspension of extracts in methanol/water (1:1) (following an
aqueous extraction with methanol/water for CE3 and with
acetonitrile/water for CE2).
Evaluation of Method Reproducibility Using Multivariate
Statistics. The box plots (Figure 2) allowed visualization of the
CV distribution for each method and provided an overview of
differences in reproducibility. In order to statistically compare
these differences, a dimensionless statistic representative of the
multidimensional variation was calculated for each method, as well
as its confidence interval (Figure 3). Pairwise comparisons of this
statistic were performed so as to determine whether differences
in variability observed between two methods were significant.
Aqueous Extracts. In ESI- mode, TLE1 and TLE3 showed the
highest variation (Figure 3a), consistent with observations from the CV
box plots (Figure 2a). Pairwise comparisons confirmed these differences
(p < 0.008 for comparisons with CE1, CE2, and TLE2, p < 0.08 with
CE3). The difference between TLE2, which showed the lowest variation,
and the CE methods was not significant in ESI- mode. In ESI+ mode
(45) Gika, H. G.; Theodoridis, G. A.; Wingate, J. E.; Wilson, I. D. J. Proteome
Res. 2007, 6, 3291–3303.
(46) Gika, H. G.; Macpherson, E.; Theodoridis, G. A.; Wilson, I. D. J. Chromatogr.,
B 2008, 871, 299–305.
Figure 1. (a) PCA scores plot for the aqueous extracts analyzed in ESI-
mode (PC1: 42% of total variance, PC2: 18% of total variance). There is
an observable time drift in the final part of the run, containing the last three
QCs. (b) PCA scores plots of the same analysis after removing the last
third of the analytical run (PC1: 42% of total variance, PC2: 20% of total
variance). CE: consecutive extractions, TLE: two-layer extraction, QC: quality
control sample. Protocol details are given in Table 1.
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(Figure 3b), TLE2 also produced the lowest variation, with larger
differences than in ESI- mode (p < 0.015 for comparison with TLE1, p
< 0.103 for comparisons with all other conditions).
Organic Extracts. The relative variations and their confidence
intervals were smaller for CE3 and CE2, which made the methods
more reliable (Figure 3c and d), and confirmed the observations
from the CV box plots (Figure 2c and d). In ESI+ mode (Figure
3d), CE3 clearly appeared to be the most reproducible condition.
Pairwise comparisons with the other conditions confirmed this
result to be significant (p < 0.011 with all conditions except with
CE2 (p < 0.068)). In ESI- mode (Figure 3c), the difference was
still obvious compared with TLE1 and TLE3 (p < 0.068), not
significant but still important for CE1 and TLE2 (p < 0.274), and
negligible compared with CE2 (p > 0.715). Therefore, CE3
(organic extraction with dichloromethane/methanol (3:1) with
resuspension of extracts in methanol/water (1:1), following an
aqueous extraction with methanol/water) appeared to be the
optimal choice for organic extracts, followed by CE2 (same as
CE3 except aqueous extraction with acetonitrile/water).
Effect of Resuspension Solvent. It is interesting to note that CE1
and CE3 were the same extraction protocols, only the resuspen-
sion solvents were different. For the aqueous extracts, resuspen-
sion in methanol/water (CE1) rather than in water (CE3) seemed
slightly more reproducible in ESI- mode but not significantly so
(p ) 0.371). No difference was detected in ESI+ mode (p ) 1).
Conversely, for the organic extracts, choice of resuspension
solvent had a noticeable impact on the reproducibility, especially
in ESI+ mode: resuspension in methanol/water (CE3) gave more
reproducible results compared to acetonitrile/water (CE1).
Selection of Optimal Protocol. As the selected method will
be applied for untargeted metabolic profiling of liver, it must give
reproducible results for both aqueous and organic extracts. Among
the two-layer extraction protocols, TLE1 and TLE3 showed high
variation for both aqueous and organic extracts and could therefore
be eliminated. TLE2, which gave good results in terms of reproduc-
ibility for aqueous extracts, did not give satisfactory results for organic
extracts and was also excluded. To obtain reproducible results for
organic extracts, the optimal protocol was to perform two consecutive
extractions, with organic extraction using dichloromethane/methanol
and resuspension of organic extracts in methanol/water (protocols
CE3 (aqueous extraction with methanol/water) and CE2 (aqueous
extraction with acetonitrile/water)). These two protocols gave similar
results for ESI- mode, whereas, in ESI+ mode, CE3 was more
reproducible than CE2. For the aqueous extracts, the optimal protocol
among consecutive extractions was CE1 (aqueous extraction with
methanol/water and resuspension in methanol/water), which was
compatible with protocol CE3 for organic extracts. In summary,
combining the results from both extract types in ESI- and ESI+
modes, the most reproducible protocol was to perform two consecu-
tive extractions: an aqueous extraction with methanol/water (1:1)
followed by an organic extraction with dichloromethane/methanol
(3:1), with resuspension of both extracts in methanol/water (1:1).
This resulted in a median CV of feature intensities among experi-
mental replicates of <20% for aqueous extracts and <30% for organic
extracts.
A recent study investigating sample preparation for metabolic
profiling of rat liver samples reported an overall mean CV (mean of
CVs of all ions calculated separately for each ESI mode and then
Figure 2. Box plots comparing the distribution of metabolite feature intensity CVs among replicates for the different methods for (a) aqueous
extracts in ESI- mode, (b) aqueous extracts in ESI+ mode, (c) organic extracts in ESI- mode, (d) organic extracts in ESI+ mode. For each
box, bottom ) 25th percentile, middle band ) median, red dot ) mean, top ) 75th percentile. The far right box on each subplot represents the
variability in QC injections (UPLC-MS platform variability). CE: consecutive extractions, TLE: two-layer extraction, QC: quality control sample,
aq: aqueous extracts, org: organic extracts. Protocol details are given in Table 1.
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mean of both means) of 57% for the most reproducible method.47
The investigated preparation methods differed from ours, consisting
of a homogenization step in a buffer followed by acidification and
solid-phase extraction using cartridges. The optimal protocol de-
scribed in our study seems more reproducible, with overall mean
CVs of 23.0% for aqueous extracts and 33.1% for organic extracts.
This notable difference in mean CV may arise from the sample
preparation or from the difference in analytical platform (direct
injection MS). Comparing the reproducibility of our liver preparation
approach with data published for urine or serum is not straightfor-
ward, as CVs of feature intensities among sample preparation
replicates are often reported for only a small subset (∼10) of
metabolites or labeled internal standards.24,48 For serum samples
profiled via LC-MS in ESI+ mode, a mean CV for all detected features
ranging from 19% to 36% was reported, depending on the extraction
solvent.23 More detailed information concerning CV distribution of
feature intensities has been published for replicate injections of a
QC sample during urine46 and plasma49 UPLC-MS analyses (assess-
ing only analytical platform variability, not sample preparation). For
both biofluids, the median CV of feature intensities among replicate
QC injections was between 15 and 20%. Similar values were found
for QCs in our liver study (∼10% for aqueous extracts and ∼20% for
organic extracts).
Number of Extracted Features. The number of metabolite
features statistically significantly different from the experimental
blanks of each protocol is shown in SI Figure S-3, together with
the number of metabolite features common to all conditions.
Aqueous Extracts. The efficiency was similar between protocols
(∼3000 features per mode) and >75% of features extracted by each
protocol were common to all conditions. Focusing on the optimal
method for reproducibility (CE1aq), the number of metabolite
features common to CE1aq and each of the other protocols was
calculated to examine the difference in terms of extracted
metabolites. For all protocols, at least 90% of the metabolite
features found in the aqueous extracts were also extracted using
CE1aq.
Organic Extracts. The efficiency was similar between protocols
(∼2000 features per mode), except for TLE1, which extracted
substantially fewer metabolites (∼1000 features per mode),
resulting in a low number of common features. This lower
efficiency of TLE1 could explain its clustering close to the
experimental blanks in the PCA scores plot (SI Figure S-2a). The
number of metabolites common to the optimal method for
reproducibility (CE3org) and every other protocol was calculated;
for all protocols, at least 85% of the metabolite features found in
the organic extracts were also extracted using CE3org.
(47) Parab, G. S.; Rao, R.; Lakshminarayanan, S.; Bing, Y. V.; Moochhala, S. M.;
Swarup, S. Anal. Chem. 2009, 81, 1315–1323.
(48) Wong, M. C.; Lee, W. T.; Wong, J. S.; Frost, G.; Lodge, J. J. Chromatogr.,
B 2008, 871, 341–348.
(49) Michopoulos, F.; Lai, L.; Gika, H.; Theodoridis, G.; Wilson, I. J. Proteome
Res. 2009, 8, 2114–2121.
Figure 3. Multivariate relative variation calculated for each condition with its 95% confidence interval for (a) aqueous extracts in ESI- mode, (b)
aqueous extracts in ESI+ mode, (c) organic extracts in ESI- mode, (d) organic extracts in ESI+ mode. The calculation of this multivariate relative
variation, representative of the spread of the replicates in the multidimensional space formed by the metabolite features, is detailed in the Experimental
Section. CE: consecutive extractions, TLE: two-layer extraction, aq: aqueous extracts, org: organic extracts. Protocol details are given in Table 1.
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Thus, comparing the optimal method (in terms of reproduc-
ibility) to the other tested protocols did not show major differences
in the extracted metabolites.
As a consequence, on the basis of this study, we conclude that
the preferred method is aqueous extraction with methanol/water
(1:1) followed by organic extraction with dichloromethane/
methanol (3:1), with resuspension of both extracts in methanol/
water (1:1) (protocol CE1aq followed by CE3org).
Reproducibility of Known Metabolites. Once the optimal
method for untargeted metabolic profiling had been chosen, analyti-
cal and extraction reproducibility were further investigated using
selected compounds. Metabolites were identified based on matching
their m/z and retention time with those of authentic standards
injected within the batches of samples. Table 2A lists the metabolites
identified in the aqueous extracts, with their measured m/z values,
retention times, CV among replicates of the selected extraction
method and among QC injections (UPLC-MS platform variability)
(see SI Table S-6 for CVs obtained for all the investigated methods).
All CV values for the selected method were <15% and most were
close to the platform variability, indicating good extraction reproduc-
ibility for the targeted compounds. In the organic extracts, four
lysophosphatidylcholines (LPCs) were examined (Table 2B). CVs
among replicates of the selected extraction method were around 20%
for these LPCs (see SI Table S-7 for CVs obtained for all the
investigated methods). Many lipids and phospholipids were also
observed but could not be unambiguously identified in the absence
of appropriate standards.
CONCLUSION
We have established that performing an aqueous extraction
with methanol/water followed by an organic extraction with
dichloromethane/methanol and resuspension of both dried ex-
tracts in methanol/water is an efficient and reproducible technique
for the untargeted metabolic profiling of liver samples by UPLC-
MS. Moreover, this method avoids the difficult step of separation
and transfer of the two layers of the biphasic mixture obtained in
the two-layer approach, which likely contributed to the variability
observed for the organic extracts in this study.
The multivariate statistical strategy developed here allowed the
variation in each dimension of the multidimensional space formed
by the metabolite features to be taken into account for the
investigation of reproducibility. Calculation of confidence intervals
for the multivariate variation and pairwise comparison tests
enabled the most reproducible method to be identified.
The developed extraction protocol can be applied to a wide range
of studies involving tissue metabolic profiling by UPLC-MS, such as
toxicological and pharmacological studies as well as investigations
of liver or brain diseases. Further, the developed multivariate
statistical approach can be employed for a range of studies involving
comparison of protocol reproducibility in a multivariate space, for
other sample types as well as other analytical platforms.
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Table 2. Metabolites Identified in (A) Aqueous Extracts and (B) Organic Extracts, with their Observed Retention Time, m/z
Values in ESI+ and ESI- Modes and CVs Obtained among Replicates of the Selected Protocol and among QC Injectionsa
(A) aqueous extracts
metabolite ID
retention
time (seconds)
m/z
ESI+
m/z
ESI-
CV CE1aq (%)
ESI+
CV CE1aq (%)
ESI-
CV QCaq (%)
ESI+
CV QCaq (%)
ESI-
arginine 30.7 175.12 12.0 6.2
aspartic acid 30.9 132.03 4.6 3.7
glutamic acid 32.8 148.06 146.05 8.0 3.7 5.0 2.0
betaine 33.5 118.09 6.0 8.0
L-carnitine 33.5 162.11 12.3 4.3
alanine 33.7 90.05 88.04 9.4 4.9 5.9 3.5
proline 38.1 116.07 7.7 7.6
succinic acid 100.1 117.02 11.1 7.0
tyrosine 116.1 182.08 180.07 14.8 5.7 5.0 3.6
phenylalanine 231.6 166.09 164.07 11.3 8.0 8.4 8.6
pantothenic acid 258.6 220.12 218.10 9.2 7.4 8.9 8.1
taurocholic acid (TCA) 593.3 480.28 514.28 7.8 10.0 4.1 3.3
taurochenodeoxycholic
acid (TCDCA)
657.1 464.28 498.29 10.0 12.9 2.8 3.7
cholic acid (CA) 723.8 355.26 407.28 8.9 9.7 8.7 6.3
(B) organic extracts
metabolite
ID
retention
time (seconds)
m/z
ESI+
m/z
ESI-
CV CE3org (%)
ESI+
CV CE3org (%)
ESI-
CV QCorg (%)
ESI+
CV QCorg (%)
ESI-
LPC 16:0 656.9 496.34 540.33 20.8 18.0 13.7 14.2
LPC 18:0 755.1 524.37 568.36 19.7 20.0 20.8 17.0
LPC 18:1 679.9 522.36 566.35 23.3 24.0 18.5 17.2
LPC 18:2 613.4 520.34 564.33 22.0 22.5 12.6 16.0
a For ESI+ mode, observed ions are [M+H]+, except for bile acids: [M-2H2O+H]
+ for TCA and TCDCA and [M-3H2O+H]
+ for CA. For
ESI- mode, observed ions are [M-H]- (aqueous extracts) or [M+HCOO]- (organic extracts).
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ABSTRACT: The relative importance of technical versus bio-
logical variation inUPLC-MS livermetabolic proﬁling studieswas
assessed on liver samples collected as part of an in vivo hepato-
toxicity study. Biological variability within and between two treat-
ment groups (three rats treated with galactosamine and three with
galactosamineþuridine) was compared with sampling/extraction
variability (three portions extracted from each rat liver section) and
UPLC-MS platform variability (triplicate injections of each
extract) for aqueous and organic extracts. The impact of scaling
on errormeasurement was investigated on replicate injections of a quality control sample, and consequently started log-transformation was
used to stabilize the variance across the ion intensity range. For aqueous extracts, technical variability was two to four times lower thanwithin
group interanimal variability. Similar results were obtained for organic extracts for the galactosamine group, sampling/extraction variability
being more elevated in the galactosamineþuridine group. For both extract types, diﬀerences between treatment groups were the principal
source of observed variation, and triplicate injections clustered closely in PCA plots and in HCA dendrograms, indicating small instrument
variability compared to observed biological variation. This protocol can be applied to investigate diﬀerences in liver metabolic proﬁles
between animal groups in toxicology studies and clinical investigations of liver disease.
Untargeted metabolic proﬁling of biological samples aims todetermine simultaneously and comprehensively the levels of
all metabolites present and monitor their ﬂuctuations over time due
to stimuli such as diet, environment, diseases, or pharmaceutical
interventions.1,2 Exploratory metabolic proﬁling is commonly per-
formed using nuclear magnetic resonance (NMR) spectroscopy
and/or mass spectrometry (MS), the latter being generally coupled
with gas chromatography (GC) or liquid chromatography (LC).3
Interpretation of the complex resulting spectroscopic data sets is
usually performed using chemometric mathematical modeling
methods, such as principal components analysis (PCA) and partial
least-squares discriminant analysis (PLS-DA).4,5Metabolic proﬁling
has been applied to a broad range of environmental, preclinical, and
clinical investigations,6 e.g., monitoring exposure to environmental
chemicals,7 diagnosing and monitoring disease,8,9 and identifying
mechanisms and biomarkers of xenobiotic toxicity.10-12
The liver plays a major role in the metabolism of many
endogenous and exogenous compounds, such as drugs, food
additives, bile acids, fatty acids, and steroids.13-16 Thus, in the study
of drug toxicity or liver disease, untargetedmetabolic proﬁling of liver
samples is likely to generate useful biological information, e.g.,
revealing aﬀected metabolic pathways. This proﬁling can be per-
formed on intact tissues by high-resolution magic angle spinning
NMR (MAS NMR) spectroscopy17-20 or on liquid metabolite
extracts by conventional NMR spectroscopy18,21,22 or by MS.23,24
Among these techniques, Ultra Performance LC-MS (UPLC-
MS) oﬀers high sensitivity and resolution for a broad range of
metabolites and has therefore been applied to various biological
sample types.3,25-31 To cover the large variability of metabolites in
terms of chemical properties in the liver, polar and nonpolar
metabolites are generally extracted into two distinct fractions and
analyzed in two separate analytical runs,23 allowing the use of
optimized UPLC-MS conditions for each type of extract.
The ability to distinguish biological, i.e., “true”, variation from
technical variation is a key concern in metabolic proﬁling studies,
regardless of the analytical platform and the sample type.12,32-38
In the case of untargeted metabolic proﬁling of liver samples by
UPLC-MS, technical variation can arise among others from
sampling, metabolite extraction, and instrumental platform varia-
bility. Concerning sampling, metabolite extracts are generally ob-
tained from a small liver portion, cut from a section collected during
in vivo studies at time of termination. These sections, although taken
from a small, predeﬁned part of the liver, are often not homogeneous
andmay lead to variable results depending on the sampled portion.39
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Additional variation arises from the sample preparation step, i.e.,
liquid extraction of metabolites from the samples.Whenmetabolites
are extracted from replicate portions of a liver section to investigate
reproducibility, these two sources of variation overlap. This sam-
pling/extraction variability is likely to be higher for tissue samples
compared to bioﬂuids, which are more homogeneous and usually
necessitate a simpler preparation step. Platform variability can arise
from variations in sample injection, LC conditions (e.g., column
degradation, contaminant build-up, pressure/temperature changes),
MS conditions (e.g., source contamination, ionization eﬃciency
ﬂuctuations, matrix eﬀect, detector sensitivity decrease), and detector
electronic noise.37 To monitor this instrument variability, a wide-
spread strategy in MS metabolic proﬁling studies is to prepare a
quality control (QC) sample representative of the entire sample
batch, typically by combining equal aliquots from all samples in the
study, and inject this sample at regular intervals throughout the
analytical run (e.g., every 5-10 samples).35,40-43Data obtained from
the repeated injections of this QC sample are used to assess platform
stability over the run, through examination of chromatograms as well
as univariate and multivariate analysis. This QC sample can also be
used to condition the analytical column before starting analysis of the
actual samples, as the ﬁrst injections are often not reproducible.35,42
Untargeted metabolic proﬁling of samples by UPLC-MS
generates large data sets, containing typically thousands of
metabolite features. PCA, PLS-DA, and orthogonal-PLS-DA
(OPLS-DA)44,45 are widely used to extract information from
these data sets.28,46-51 Before performing PCA or PLS-DA, data are
usually mean-centered to remove the inﬂuence of the mean of the
variables and to focus on the variation between samples.52-54 PCA
assumes that the measurement errors are homoscedastic (i.e., have
homogeneous variance across the data set).55 This is generally not
the case in LC-MS data sets, in which the absolute noise is elevated
at high ion intensities.56 If these data sets are not scaled, PCA is likely
to focus on the high intensity metabolite features, which exhibit
higher variance, although they are not necessarily the most biologi-
cally relevant in metabolic proﬁling studies. To avoid this, unit
variance (UV) scaling can be applied.52-54 This scaling approach
gives equal importance to all the variables by dividing each one by its
standard deviation. However, UV scaling inﬂates the impact of
background noise and artifacts in the model. Pareto scaling,54 which
consists of dividing each variable by the square of its standard
deviation and is intermediate between no scaling and UV scaling, is
commonly used for metabolic proﬁling data sets.28,38,49,50,57,58 The
choice of scaling has a large impact on PCA models, as has been
reported previously for NMR spectroscopy52 and GC-MS53 meta-
bolic proﬁling data sets. Another approach to stabilize the variance of
high intensities is to perform logarithmic transformation.56 As this
may inﬂate the variance for low intensities (close to zero), a constant
is sometimes added to all the values before applying the logarithm
(“started logarithm”59) to avoid this possible drawback. This
approach was used in our study rather than Pareto scaling, because
measurement errors still exhibited high levels of heteroscedasticity
after Pareto scaling, as shown in the results.
The study reported here was designed to compare sample
preparation and UPLC-MS platform variability with interani-
mal variability within and between treatment groups using
methods developed in-house for metabolite extraction23 and
UPLC-MS untargeted metabolic proﬁling of liver samples
(these methods are detailed in Experimental Section). Sections
of liver used as test samples were part of a toxicity study
investigating galactosamine hepatotoxicity and the protective
eﬀects of cotreatment with uridine and had previously been
analyzed by MASNMR spectroscopy.60Galactosamine has been
used historically as a model hepatotoxin, but its toxicity mechan-
ism is still unclear. It is believed to form conjugates with uridine-
50-diphosphate sugars, resulting in depletion of the hepatic
uridine nucleotide pool and inhibition of RNA and protein
synthesis.60 The metabolic proﬁling data obtained by NMR
spectroscopy reﬂected the protective eﬀects of cotreatment with
uridine,60 and it appeared of interest to also analyze the liver
samples by UPLC-MS to provide complementary information
and enhance mechanistic understanding of toxicity. The aim of
the study reported here was to assess our UPLC-MS liver
metabolic proﬁling protocol on a small subset of samples before
extending it to the complete set of samples from the study. For
three rats from two treatment groups (inter-rat variability within
and between groups), three liver portions were cut and under-
wentmetabolite extraction (sampling/extraction variability), and
each of the 18 resulting extracts (6 rats ! 3 portions) was
analyzed in triplicate by UPLC-MS (instrument variability).
’EXPERIMENTAL SECTION
Materials. HPLC grade water, methanol, dichloromethane,
2-propanol, formic acid, leucine enkephalin, and sodium formate
were obtained from Sigma (Gillingham, UK). Homogenization of
liver samples was performed using a TissueLyser with 5mm stainless
steel beads from Qiagen (West Sussex, UK). For UPLC-MS
analyses, 96-well plates and vials were from Waters (Hertfordshire,
UK); well plate cap mats were from VWR (Leicestershire, UK).
Test Samples. Liver left lobe sections from six male Sprague-
Dawley rats from a galactosamine (galN) toxicology studywere used
as test samples (full study details can be found in Coen et al.60). Rats
were housed in temperature- and humidity-controlled rooms with a
12-h light cycle. Food (powdered Lab Diet 5002, Purian Mills,
Richmond, IN) and water were available ad libitum throughout the
study. After 6 days of acclimatization, all rats received a single
intraperitoneal injection of 415 mg/kg galN, and 2 h after this dose,
threewere given 0mg/kg uridine (treatmentA) and three 2000mg/
kg uridine (treatment B). The six rats were euthanized 24 h after the
galN injection. Clear galN-induced toxicity was observed for the
three rats dosed with treatment A, while only minimal toxic effects
was detected for the three rats dosed with treatment B.60
Liver Metabolite Extraction. For each of the six rats, three
50 mg portions were taken from the liver section and treated
separately, resulting in 18 portions. Portions were homogenized in
1.5mLof prechilledmethanol/water (1:1) in theTissueLyser (25Hz,
5 min). Supernatants were collected after centrifugation and 650 μL
transferred to Eppendorf tubes and dried in a Savant Speedvac
(aqueous extracts). The remaining pellets were homogenized in
1.5 mL of prechilled dichloromethane/methanol (3:1) in the Tissue-
Lyser (25Hz, 5min). Supernatants were collected after centrifugation
and 650 μL transferred in glass vials and dried overnight in a fume
cupboard (organic extracts). Dried aqueous and organic extracts were
stored at-40 C until UPLC-MS analysis. Before analysis, aqueous
extracts were resuspended in 200 μL of methanol/water (1:1) and
organic extracts in 1 mL of methanol/water (1:1).23
UPLC-MS Analysis. Analyses were performed separately for
aqueous and organic extracts using an Acquity UPLC System
(Waters, Elstree, UK) coupled to a LCT Premier time-of-flight
mass spectrometer (Waters, Manchester, UK), operated in the
positive (ESIþ) and negative (ESI-) electrospray ionization
modes. The injection volume was 5 μL. Reversed-phase chro-
matography was carried out on a Waters Acquity UPLC HSS T3
1118 dx.doi.org/10.1021/ac103011b |Anal. Chem. 2011, 83, 1116–1123
Analytical Chemistry ARTICLE
column (1.8 μm, 2.1  100 mm) for the aqueous extracts and
on a Waters Acquity UPLC BEH C8 column (1.7 μm, 2.1  
100mm) for the organic extracts. AnHSST3 columnwas chosen
for the aqueous extracts, as it provides a more efficient retention
and separation of polar organic compounds comparedwith the BEH
C18 columns commonly used in reversed-phase chromatography.
A C8 column was chosen for the organic extracts, as it retains less
strongly the lipophilic compounds than C18 columns, resulting in
improved washing of the column between injections and less
carryover.61 Chromatography was carried out at 50 C with a 0.4
mL/min flow rate, using optimized gradients detailed in the
Supporting Information (Table S-1 and S-2) For the aqueous
extracts, A was 0.1% formic acid in water and B was 0.1% formic
acid inmethanol (23min gradient for ESIþmode, 21min for ESI-
mode). For the organic extracts, mobile phase A was 0.1% formic
acid in water and mobile phase B was 15% 2-propanol/0.1% formic
acid in methanol (32 min for ESIþmode, 20 min for ESI-mode).
All gradients were followed by a 3 min re-equilibration phase. ESI
conditions were as follows: source temperature 120 C, desolvation
temperature 350 C, cone gas flow 25 L/h, desolvation gas flow
900 L/h, capillary voltage for ESI- 2400 V, for ESIþ 3200 V, cone
voltage 35 V. The instrument was set to acquire over the m/z range
50-1000 with scan time of 0.2 s and an interscan delay of 0.01 s.
Data were collected in centroid mode. Leucine enkephalin (MW =
555.62 Da) (200 pg/μL in acetonitrile/water 50:50) was used as a
lock mass with an analyte-to-reference scan ratio of 24:1. The
instrument was calibrated before analyses using 0.5 mM sodium
formate solution.
The 18 samples were injected in triplicate, resulting in 54 samples,
with an injection order set tominimize its correlationwith the factors
of interest. For each analysis, a quality control sample (QC),
prepared by combining equal aliquots of all samples, was injected
every 9 samples to monitor UPLC-MS platform reproducibi-
lity.35,40-43 This QC sample was also used to condition the column
at the beginning of each analysis (10 injections).
Data Preprocessing. UPLC-MS analyses resulted in four
data sets, two for the aqueous extracts and two for the organic
extracts (ESI- and ESIþ modes). Each data set was preprocessed
using the freely available XCMS software62 (version 1.20.0) in order
to convert the three-dimensional LC-MS raw data into a table of
time-aligned detected features, with their retention time, m/z ratio
and intensity in each sample. Concerning XCMS parameters, the
centWave algorithm63 was used for peak picking with a peak width
window of 3-20 s, the m/z width for the grouping was changed to
0.1 Da, and the bandwidth parameter was kept to default (30 s) for
the first grouping and then determined from the time deviation
profile after retention time correction. Isotope peaks, fragments, and
adducts were treated as separate features. Four output tables were
thereby obtained (one for each data set), listing m/z ratio and
retention time of the detected features with their intensities in each
liver and QC sample. After normalizing the data in R using an in-
house script, features with a coefficient of variation (CV = standard
deviation/mean) higher than 30% in replicated injections of the QC
samples were removed. Before mean-centering the variables, log
transformation (with a 20 offset) was performed to stabilize the
variance throughout the intensity range.59
Data Analysis. The four preprocessed data sets were used as
an input for Simca Pþ11.5 (Umetrics, Ume"a, Sweden) to perform
principal components analysis (PCA) and for Matlab (The Math-
Works, Natick, MA) to perform agglomerative hierarchical cluster
analysis (HCA). Euclidian distances and ward linkage were used for
HCA.PCA2Dand3Dscores plotswere used to visualize the relative
importance of the different sources of variation. In order to quantify
this importance and to take into accountmore variation in these data
than that contained only in the first three principal components
(PCs), distances between samples were calculated in the PCA space
formed by the number of PCs obtained in models optimized using
cross-validation. Let tak and tbk be the scores of samples a and b on
the kth PC, and n the total number of PCs in the optimized model.
The distance between samples a and b was calculated as the square
root of the sum of the n squared differences between tak and tbk
(Euclidean distance in n-dimensional space). Scores for each liver
portion were calculated as the mean of the three replicate injections,
scores for each rat were calculated as the mean of the three
corresponding portions, and finally scores for each treatment group
were calculated as the mean of the three rats in the group. To assess
the instrument variability, the mean of pairwise distances between
triplicate injections was calculated for each portion. To assess the
sampling/extraction variability, the mean of pairwise distances
between portions of a single rat was calculated for each rat. To
assess the intragroup biological variability, the mean of pairwise
distances between rats within a treatment group was calculated for
each group. Finally, to assess the intergroup biological variability, the
distance between both treatment groups was calculated. The
different levels of variation were compared by calculating the ratios
of these distances, and permutation tests were performed to evaluate
the statistical significance of these ratios. For instance, to compare
intragroup variability with extraction variability for treatment A, the
ratio of the distance between rats in group A to the mean of the
distance between portions of each rat in the group was calculated.
This ratio was also calculated for each of the 279 possible permuta-
tions allocating the nine liver portions to three rats, and these 279
ratios were ranked from highest to lowest. The rank of the real
observed ratio in this list was calculated and divided by 279 to obtain
the p-value. If the observed ratio was bigger than all the ratios
calculated by permutations, it meant that the probability of obtaining
this ratio by chance was less than 0.0036 (1/279).
’RESULTS AND DISCUSSION
Data Pretreatment. For each of the four runs, inspection of
the chromatograms of the repeatedQC sample injectionswith regard
to retention times, intensities, and peak shapes indicated overall good
analytical platform stability. The gradients optimized for each analysis
allowed separation of a high number of peaks (Supporting Informa-
tion, Figure S-1). After data preprocessingwith XCMS, 3268 (ESI-)
and3570 (ESIþ)metabolite features (m/z_RTpairs) were obtained
for the aqueous extracts, and 3450 (ESI-) and 4354 (ESIþ) for the
organic extracts (including adducts and isotopes). PCA was used to
extractmeaningful information from these large data sets. Toproduce
adequate models of the data, PCA requires that the measurement
errors have a uniform variance across the data set (homoscedastic
noise).64 To investigate this measurement error, the standard devia-
tion of each feature was calculated for the replicate injections of the
QC sample, representative of the UPLC-MS platform variability.
A perfectly reproducible platform would result in all these injections
being absolutely identical, and the standard deviation of each feature
would be zero. This can obviously not be achieved in an actual system
due to inevitable variation in the platform response (e.g., detector
electronic noise and ionization efficiency fluctuation). In Figure 1A,
these standard deviations are plotted versus the rank of the mean
intensity for each metabolite feature for the organic extracts analyzed
in ESIþmode (the plot appearance was similar for the four data sets,
so only one is displayed). This figure shows that the most intense
1119 dx.doi.org/10.1021/ac103011b |Anal. Chem. 2011, 83, 1116–1123
Analytical Chemistry ARTICLE
features (on the right) exhibited high standard deviation compared to
the rest of the data set. These features would therefore have
dominated the PCA if data were not scaled. Because of the large
range of metabolite concentrations in liver samples and differences in
ionization efficiency between metabolites, MS feature intensities can
vary from a few dozens of ion counts to hundreds of thousands of ion
counts. Focusing on the subset consisting of the most intense ions
could result in loss of interesting and important biological informa-
tion, as metabolite features exhibiting lower intensities might have
higher biological relevance. To reduce the importance of these ions,
pareto scaling is often used in MS metabolic profiling studies.
However, as shown in Figure 1B, pareto scaling of the data did not
change the overall appearance of the plot, with high intensity features
still exhibitinghigh standarddeviation in analytical replicates, although
the range of variation was smaller. Although UV scaling would avoid
this domination of the most intense features in the PCA, a drawback,
in addition to inflating background noise, is that if a variable exhibits
high intensity in one treatment group and low intensity in another
one, all these intensities are divided by the same value (despite the
variable being likely to exhibit high variance in one group and low
variance in the other one due to the difference in intensity ranges). A
simple approach to stabilize the variance across the intensity
range is to perform logarithmic transformation.56 Figure 1C
shows the same plot as Figure 1A,B after log-transforming the
raw data with an offset of 20 (this value was chosen to avoid an
increase in standard deviation for low intensity signals59) and
mean-centering the variables. After this transformation, stan-
dard deviations were uniform across the range of intensities and
focus would not be on high intensity signals when applying
PCA. Similar effects were observed for all four data sets, and
log-transformation was therefore used for all of them.
Principal Components Analysis (PCA) of Liver Extracts. Aqu-
eous Extracts. PC1 vs PC2 scores plots of the aqueous liver extracts
analyzed in ESI- (Figure 2A) and ESIþ (Figure 2B) modes were
similar. Replicate injections of the QC sample clustered tightly,
Figure 1. Standard deviations vs rank of mean intensities for the
replicate injections of the QC sample for the organic extracts analyzed
in ESIþ mode. Each dot represents one feature. Features are sorted by
increasing mean intensities calculated on raw data. Standard deviations
are calculated on (A) mean-centered data, (B) pareto-scaled data, (C)
mean-centered data after log-transformation with a 20-oﬀset.
Figure 2. PC1 vs PC2 scores plot for the aqueous liver extracts analyzed
by UPLC-MS. (A) ESI- mode, mean-centered data after log-trans-
formation; (B) ESIþ mode, mean-centered data after log-transforma-
tion; (C) ESIþ mode, pareto-scaled data with no log transformation.
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illustrating the stability of the UPLC-MS platform throughout the
whole run. The first PC separated the two treatment groups, the
major source of variation in the samples. The nine injections from the
same animal (triplicate injections of each of the three liver portions)
clustered together, meaning that sampling/extraction and UP-
LC-MS platform variability could not be distinguished in the first
twoPCs.The three animals fromeachgroupwere separated, showing
that, in terms of polar metabolites, interanimal variability was higher
than the variability observed between the three portions from a single
rat liver section.
The amount of variation in the data set explained by the ﬁrst
two PCs was 67% and 60% for ESI- and ESIþ mode, respec-
tively. Optimization of the number of PCs by cross-validation
resulted in nine PCs, corresponding to 89% and 85% for ESI-
and ESIþ mode, respectively. To take into account all this
explained variation, distances between samples were calculated
in these nine-dimensional PCA spaces, as detailed in Experi-
mental Section (Figure 3 for ESI- mode, Supporting Informa-
tion Figure S-2 for ESIþ mode). For ESI- mode, the ratios of
distances between animals within a group to distances between
liver portions from a single animal were 4.4 for treatment A (p <
0.0036) and 2.3 for treatment B (p < 0.0036). These ratios were
almost identical for ESIþmode (4.4 for A and 2.2 for B with both
p < 0.0036). This conﬁrmed that interanimal variability within a
group was higher than sampling/extraction variability for polar
metabolites, as observed with the ﬁrst two PCs.
To illustrate the impact of the transformation/scaling step on the
PCA, Figure 2C shows the same data set as Figure 2B (aqueous
extracts, ESIþ mode) without variance stabilizing transformation,
but using pareto scaling. PC1 still distinguished between the two
treatment groups. For treatment A, animals were separated as with
mean-centered log-transformed data, but injections from each single
animal were more spread. For treatment B, samples from diﬀerent
animals overlapped and liver portions from animal 5 did not cluster
together. This was also true for some replicate injections of a single
liver portion, e.g., from rats 5 and 6.
Organic Extracts. PC1 vs PC2 scores plots of the organic
liver extracts are shown in Figure 4 (A and C). As with the
aqueous extracts, replicate injections of the QC sample clustered
tightly and triplicate injections of each portion clustered to-
gether. PC1 separated the two treatment groups. For ESI-
mode, the PC1 vs PC2 scores plot (Figure 4A) was similar to that
observed with aqueous extracts, except that rats in treatment B
group overlapped. For rats 5 and 6, some separation could be seen
between liver portions coming from the same animal. By adding a
third PC (Figure 4B), all rats were separated. For ESIþ mode
(Figure 4C), overlap between animals from the same treatment
group was seen in the PC1 vs PC2 scores plot and portions from
individuals rats did not cluster, especially for treatment B. By adding
a third PC (Figure 4D), separation could be seen between rats,
except for rats 5 and 6, which overlapped. This difference between
ESI modes was confirmed by calculation of distances and ratios of
these distances in the PCA space formed by the first six PCs
(Supporting Information Figures S-3 and S-4). For ESI-mode, the
ratios of distances between animals within a group to distances
between portions of a single animal were 3.5 for treatment A (p <
0.0036) and 1.7 for treatment B (p<0.0036), showing that variation
between rats within a group was bigger than sampling/extraction
variability. This was also the case in ESIþ mode for treatment A
(ratio = 3.1, p<0.0036), but not treatment B, forwhich the ratiowas
equal to 1.0, meaning that distance between rats was similar to
distance between portions of a single rat. For ESIþ mode,
sampling/extraction variability was clearly bigger than instrument
variability (distance ratios from 2 to 14, p < 0.0072), while these two
sources of variability could not be distinguished in ESI- mode
(most ratios were ∼1).
Hierachical Cluster Analysis (HCA). To further investigate
similarities between samples, agglomerative HCA65-67 was
performed on the log-transformed data. A dendrogram resulting
from HCA of the aqueous extracts in ESI- mode is shown in
Figure 5A. Triplicate injections were grouped together, and then
portions were grouped, except for rats 2 and 6, for which the
replicate injections of two portions from the same liver section
were merged (portions 2A-2C and 6B-6C), illustrating that
UPLC-MS platform and sampling/extraction variability could
barely be distinguished for these portions. The nine injections
from each rat were grouped, and treatment groups were sepa-
rated, as observed with PCA.
Figure 3. Distances between samples calculated in the nine-dimensional PCA space for the aqueous liver extracts analyzed in ESI-mode and ratios of
these distances. The distance displayed at the center of the triangles corresponds to the mean of the pairwise distances between the samples indicated at
the apexes. Ratios displayed between levels correspond to the ratio of the distance at the level below to the mean of the distances at the level above.
Replicate UPLC-MS injections of an extracted liver portion are labeled a, b, and c; the three portions sampled and extracted from each single rat are
labeled A, B, and C. The color-code is the same as in Figure 2. Abbreviations: Pn = portion, Rep = UPLC-MS replicate, Treat = treatment.
1121 dx.doi.org/10.1021/ac103011b |Anal. Chem. 2011, 83, 1116–1123
Analytical Chemistry ARTICLE
For the organic extracts (Figure 5B), triplicate injections
clustered together. Portions from the same rat were then
grouped, with the exception of portions B of rat 4 and A of rat
6, which clustered together for ESIþ mode. These two portions
shared more similarities with each other than with the other two
portions from their respective animal. This was consistent with
observations from the corresponding PC1 vs PC2 scores plot
(Figure 4C), in which these two portions were very close. Rats
given the same treatment were then grouped together, resulting
in separation between the two treatments.
Discussion. PCA and HCA sample clustering behaviors were
similar. For both aqueous and organic liver extracts, triplicate
injections of the same extract were closely clustered in PCA plots
and grouped together in HCA dendrograms, indicating low
UPLC-MS platform variability compared to biological varia-
tion. The stability of the UPLC-MSplatformwas also supported
by the clustering of the multiple injections of the QC sample over
the runs. A key question that often arises when analyzing samples
from metabolic profiling studies by UPLC-MS is that of replicate
injections. Although it is useful to have triplicate values for each
sample, which makes these data more reliable, this is not always
practically feasible. Indeed, it requires increased sample volume and
amplifies the length of the run, which raises the issues of stability of
the samples in the autosampler (even at 4 C), as well as stability of
the analytical platform over a longer period of time (and also
consequently decreases the sample throughput). This is especially
truewhen the study contains a substantial number of samples, which
is not unusual inmetabolic profiling investigations. Given the results
obtained in this study, it seems that a single injection of each sample
might be sufficient, as long as a stringent QC approach is used to
monitor platform stability. This QC approach also offers the
possibility of investigating the error measurement for all variables.
If this error is not homoscedastic, appropriate transformation/
scaling should be used to stabilize the variance before applying
Figure 4. PCA scores plot for the organic liver extracts analyzed by
UPLC-MS. (A) ESI- mode, mean-centered log-transformed data,
PC1 vs PC2; (B) ESI- mode, mean-centered log-transformed data,
PC1 vs PC2 vs PC3; (C) ESIþ mode, mean-centered log-transformed
data, PC1 vs PC2; (D) ESIþ mode, mean-centered log-transformed
data, PC1 vs PC2 vs PC3.
Figure 5. Dendrograms resulting from agglomerative hierarchical clus-
tering analysis of (A) aqueous extracts in ESI- mode, and (B) organic
extracts in ESIþ mode. Sample labeling: 2-B_c = rat 2, portion B,
UPLC injection c. The color-code is the same as Figures 2, 3 and 4.
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PCA. Plotting the standard deviations of the intensities among
replicate QC injections for various transformations/scalings can
help in this choice, as shown inFigure 1. In our liverMSdata sets, we
observed that started log-transformation gave satisfactory results in
terms of variance stabilization, clearly improved compared to pareto
scaling.
For the aqueous liver extracts, the nine injections from each rat
liver section clustered, resulting in separation between the three
animals from each group. This showed that, in terms of polar
metabolites, the interanimal variability was higher than the
technical variability (sampling/extraction and UPLC-MS
platform). Thus, if diﬀerences are seen between rats within a
group when analyzing aqueous liver extracts using the approach
detailed here, they may merit further investigation.
While extraction variability could barely be distinguished from
UPLC-MS platform variability for the aqueous extracts, the
former was higher than the latter for the organic liver extracts in
ESIþmode, resulting in three groups (=portions) of three points
(replicated injections) for some rats. This could come from the
nonhomogeneity of liver sections in terms of lipid content or
from the sample preparation step. Therefore, it will be diﬃcult to
draw conclusions from within group diﬀerences observed in
organic extracts without having replicate metabolite extractions
for each rat. Nevertheless, the technical variability was lower than
diﬀerences between treatment groups, which were clearly sepa-
rated, so diﬀerences between treatment groups in nonpolar
metabolic proﬁles could be investigated.
For practical reasons, the number of samples analyzed in this
preliminary experiment was small and would need to be scaled up
to investigate more deeply the sampling/extraction variability
observed for the organic extracts in ESIþ mode. Nevertheless,
the results obtained here are very encouraging, as technical
variation was shown to be smaller than the information of interest
in the study, which was the diﬀerence in liver metabolic proﬁles
between the treatment groups. Although this protocol was de-
signed for toxicity studies, where large diﬀerencesmay be expected
between groups, it would be worth applying to liver samples from
studies likely to present more subtle animal diﬀerences, such as
dietary studies. The excellent separation observed here between
animals within a single group for aqueous extracts indicates that
small diﬀerences in metabolic proﬁles can be observed. Therefore,
it would be of value to extend this investigation to explore technical
versus biological variability where less obvious diﬀerences are
expected between groups, in order to provide valuable information
regarding diﬀerences between metabolic proﬁles.
’CONCLUSION
This experiment was designed to assess the reproducibility of
our UPLC-MS metabolic proﬁling protocol of rat liver samples
before applying it to large toxicology studies. For both aqueous
and organic liver extracts, we showed that UPLC-MS platform
variability was small compared to biological variation. We high-
lighted the utility of QC sample injections for monitoring plat-
form stability and investigating error measurement before
applying PCA. For both types of extracts, biological diﬀerences
between the two treatment groups were the principal source of
variation in the data sets. Analysis of the whole set of samples in
this galactosamine toxicity study will allow deep investigation of
liver metabolic proﬁle diﬀerences between the treatment groups,
with the aim of gaining better understanding of underlying
mechanisms of toxicity.
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Chapter 17
Processing and Analysis of GC/LC-MS-Based
Metabolomics Data
Elizabeth Want and Perrine Masson
Abstract
Data processing forms a crucial step in metabolomics studies, impacting upon data output quality, analysis
potential and subsequent biological interpretation. This chapter provides an overview of data processing
and analysis of GC-MS- and LC-MS-based metabolomics data. Data preprocessing steps are described,
including the different software available for dealing with such complex datasets. Multivariate techniques
for the subsequent analysis of metabolomics data, including principal components analysis (PCA) and
partial least squares discriminant analysis (PLS-DA), are described with illustrations. Steps for the identi-
fication of potential biomarkers and the use of metabolite databases are also outlined.
Key words: GC-MS, LC-MS, metabolomics, metabolite, alignment, multivariate, PCA, PLS-DA.
1. Introduction
Mass spectrometry (MS) technologies, often coupled with
metabolite separation via liquid chromatography (LC) or gas
chromatography (GC), offer high sensitivity and reproducibil-
ity for metabolomics studies, together with quantitative metabo-
lite analyses. Data generated through metabolomics studies can
yield important metabolic insights into disease onset and progres-
sion, mechanisms of drug toxicity, or growth and ageing (1–3).
Advances in sample separation techniques and MS instrumenta-
tion in metabolomics studies have resulted in the generation of
large, complex datasets, which in turn has led to a demand for
improved data analysis approaches, including preprocessing and
advanced chemometric approaches (4). However, this complexity
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means that the data must undergo stringent processing steps in
order to afford meaningful interpretation. The purpose of this
chapter is to provide an overview of both data preprocessing and
multivariate analysis in MS-based metabolomics studies. The use
of principal components analysis (PCA) and partial least squares
discriminant analysis (PLS-DA) in metabolomics studies is illus-
trated using a biological dataset. Metabolite characterization is
also discussed, through the application of high mass accuracy
measurements, fragmentation and database consultation.
2. Materials
2.1. Data
Preprocessing
Software
Key to data processing and analysis is the ability to distinguish
genuine biological variation and metabolic changes from ana-
lytical interferences. It is therefore essential that data processing
is sufficiently robust to enable the researcher to analyze and
interpret metabolomics data properly. Most MS manufacturers
Table 17.1
Commercial software for processing of MS metabolomics data
Software Manufacturer Capabilities Link
Bluefuse BlueGnome MS and NMR data: filtering,
feature detection, alignment,
multivariate data analysis
http://www.cambridge
bluegnome.com/
Markerlynx Waters LC-MS data: feature detection,
alignment, PCA
http://www.waters.com
MarkerView Applied
Biosystems
LC-MS data: feature detection,
alignment, PCA
https://products.applied
biosystems.com
MassHunter Agilent
Technologies
LC-MS data: detection/
extraction, alignment
http://www.chem.
agilent.com
Metabolic
Profiler
Bruker Daltonic MS and NMR data: data bucket-
ing (retention time, m/z
values), PCA
http://www.bruker-
biospin.com/
metabolicprofiler.html
Metabolyzer Metabolon Automated chromatographic
peak alignment tools. Used as
part of proprietary data pro-
cessing system in commercial
studies
http://www.metabolon.
com/services/
technology.php
metAlign PlanResearch
International
LC-MS, GC-MS data: filtering,
baseline correction, feature
detection, alignment
http://www.metalign.
wur.nl/UK/
Phenomenome
Profiler
Shimadzu/
Phenomenome
Discoveries
MS data: feature detection,
alignment, statistical analysis
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now offer software for metabolomics data analysis, with options
for feature detection and alignment, as well as visualization and
evaluation (Table 17.1). As the metabolomics field is growing,
so are the number of available software preprocessing packages,
and there is also freeware available for MS metabolomics data
processing (Table 17.2). For processing with freeware, data will
need to be converted into the appropriate format, e.g. netCDF,
mzXML or mzData, which can often be achieved using the
manufacturer’s own software. Freeware is available for file con-
version (e.g. trapper for conversion of MassHunter (Agilent) raw
data (.d directories) into mzXML files (http://tools.proteome
center.org/wiki/index.php?title=Software:trapper); and mass
wolf for conversion of Masslynx (Waters) (.raw) files into mzXML
files (http://tools.proteomecenter.org/wiki/index.php?title=
Software:massWolf)).
2.2. Requirements for
Multivariate Analyses
All multivariate analyses shown in this chapter were performed
using SIMCA-P (11.5) software (Umetrics, Umea, Sweden).
Other programmes such as MATLABTM package (Math-
works, Natick, MA; http://www.mathworks.co.uk/) and R
(http://www.r-project.org/) also offer similar functions for mul-
tivariate data analysis.
3. Methods
3.1. Data
Preprocessing
LC-MS and GC-MS data will be stored as (instrument specific)
raw data files, the size of which will depend on the instrument, the
scan rate employed and other parameters. The complex, multi-
dimensional MS metabolomics datasets need careful treatment,
as the data preprocessing steps employed will affect the potential
for metabolite identification, as well as subsequent quantification
capabilities and biological interpretation. Metabolomics datasets
must be extensively preprocessed and converted into organized
data matrices prior to multivariate analysis and subsequent visual-
ization of important (discriminatory) metabolites. Key factors in
data preprocessing are the following:
a. Initial raw data quality
b. Choice of preprocessing software
c. Preprocessing parameter settings (including parameter opti-
mization (see Note 1))
d. Data normalization method
An example of MS metabolomics data preprocessing work-
flow is shown in Fig. 17.1, which can be divided broadly into
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Fig. 17.1. Metabolomics data preprocessing workflow, outlining the main steps.
six main steps as detailed below (Sections 3.1.1, 3.1.2, 3.1.3,
3.1.4, 3.1.5 and 3.1.6).
3.1.1. Peak Picking
(Detection)
Accurate peak detection and peak matching between samples are
crucial to enable the comparison of metabolites between different
samples, as well as for precise quantitative metabolite analysis (if
required). Therefore, the initial data preprocessing step for both
LC-MS and GC-MS data concentrates on distinguishing metabo-
lite features from other peaks and background noise in the sam-
ple/chromatogram. This is termed peak picking or peak detection.
For the purpose of this chapter, a metabolite feature is defined
as a “mass-to-charge ratio/retention time pair” (m/z_RT pair).
Depending on the software used, isotopes, fragments, adducts
and dimers may be reported for LC-MS data, the latter two partic-
ularly where electrospray ionization (ESI) is used. Fragments are
also observed in GC-MS data due to the electron ionization (EI)
process. There is also the potential for artefact formation during
GC-MS sample preparation, through incomplete derivatization,
possible analyte conversion, by-product formation or degradation
of the final product(s). LC-MS and GC-MS data can be simplified
through the detection and grouping of some of these features, as
described in Section 3.1.2. Depending on the data being ana-
lyzed, additional steps that may be included at this peak picking
stage are the following:
1. Baseline correction. Baseline variation across samples in a
batch may be due to instrumentation problems, external
282 Want and Masson
environmental sources or the separation process. Baseline
drift can result from mobile phase interferences, column
temperature changes or contaminant build up on the col-
umn. A repeatable drift between chromatographic runs indi-
cates that the problem is most likely mobile phase related. In
GC-MS analyses, variability in carrier gas flow rate can cause
baseline drift. A baseline correction step can be employed
to eliminate such background drift and may aid in the
introduction of a threshold to obtain noise reduction (see
Note 2).
2. Noise removal/reduction. In LC-MS analyses, solvent impu-
rities or solvent clusters formed in the ESI source may com-
plicate the data, while in GC-MS analyses, peaks known
to be artefacts from the analytical process (e.g. siloxanes
from the sample vial septum) may be present. Therefore,
in order to reduce spectral complexity, a separate noise
removal/filtering step may be implemented prior to the peak
picking/detection stage (see Note 2).
3. Smoothing. It may be necessary to smooth the data, and
some software contains an optional smoothing stage in data
processing, such as a moving average filter or a Savitzky –
Golay filter. However, smoothing may not be necessary if
the data are not noisy or if the input data are in centroid
form. Smoothing may affect the final feature intensity out-
put and therefore care is needed when using a smoothing
step if quantitation is required.
3.1.2. Deconvolution Ideally, a single detected peak will equate to a single metabolite
feature; however, this is not usually the case, particularly with soft
ionization techniques such as ESI, which is used commonly in
LC-MS studies. Realistically, metabolite features detected from
LC-MS experiments can comprise isotopes, adducts (e.g. Na+, K+
in ESI+ mode; Cl– in ESI– mode), fragments (e.g. loss of water)
and dimers. Fragments will also be observed in GC-MS spectra
and, although ultimately useful for metabolite identification, may
complicate the metabolomics data. Multiple metabolite features
originating from the same molecule may also make quantitative
analysis problematic. A further challenge in LC-MS and GC-MS
metabolomics studies (where complex mixtures are usually ana-
lyzed) is the co-elution of two or more analytes, resulting in over-
lapping chromatographic peaks with similar retention times and
perhaps overlapping isotope patterns. This can make the extrac-
tion of pure components and their corresponding mass spectra
difficult, in turn hampering unambiguous metabolite identifica-
tion. Deconvolution approaches are therefore needed to
a. assign different ions/metabolite features to the same
metabolite and
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b. address the problem of extracting pure component signals in
cases of incomplete chromatographic separation
Deconvolution is used widely in GC-MS data preprocess-
ing, and specific software exists, e.g. the Automated Mass Spec-
tral Deconvolution and Identification System (AMDIS) software
available from The National Institute of Standards and Technol-
ogy (NIST). Deconvolution algorithms often utilize the fact that
different fragments from the same molecule have the same reten-
tion time. Algorithms based on a model peak approach may be
used, where ions with similar peak shapes are extracted. These
algorithms may also assume high correlation between multiple
chromatographic profiles within a batch, considering them sub-
ject to the same biological and analytical variation. However, in a
particular biological system, several metabolites may be subject to
the same regulatory mechanisms, meaning that their levels will be
highly correlated. This may make separating biological variabil-
ity and analytical variation difficult, which is needed for success-
ful deconvolution. It is important to consider noise at this point
(Section 3.1.1) to enable the detection of small signals. Isotope
pattern detection may be included already in the peak detection
step of an algorithm and can be performed by
1. fitting a generic isotope pattern model to the raw signal/
pattern matching with raw data and
2. grouping detected features with suitable m/z differences
However, this is not a feature in all software and so further
processing with different software or perhaps using additional in-
house scripts may be required. For example, a GC-MS add-on for
XCMS (5), “Flagme,” detects fragments and uses the fragment
intensities to calculate an overall integrated intensity for the par-
ent ion.
3.1.3. Alignment
(Chromatographic
or Peak)
A typical metabolomics study may involve the comparison of two
or more sample classes such as healthy vs. disease populations or
control vs. dosed animals, with each group comprising tens or
hundreds of individual samples. Retention time drifts between
samples must be accounted for, as detected metabolite features
must be aligned correctly across all samples in a batch in order to
match the corresponding features between the multiple GC/LC-
MS runs. During LC separation, retention time drifts can arise
due to (i) variations in temperature, pressure and mobile phase
(composition and flow rates), (ii) changes in the column station-
ary phase (saturation/degradation), or (iii) sample matrix effects
(due to variations in sample composition, e.g. solvent and salts)
(6). Importantly, the use of ultra-performance (UP) LC and other
sub 2 µm particle column technologies has meant that reten-
tion time shifts and analyte co-elution are reduced. Experimental
sources of variability in GC-MS analyses are similar and include
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(i) column ageing, (ii) temperature changes and (iii) changes
in the stationary phase and experimental conditions. Therefore,
retention time correction issues are similar in both GC-MS and
LC-MS metabolomics studies. Deviations may also be observed
in the m/z dimension, but these are generally smaller, and with
the advent of lock mass calibration correction methods, they are
smaller still. The overall change in RT and m/z is called warp.
Retention time shifts can be corrected through
1. chromatographic profile alignment prior to peak detection
(profile or chromatogram alignment) and
2. matching signal peaks/metabolite features after peak detec-
tion (peak alignment).
Automated retention time correction is particularly important
in non-targeted profiling studies, due to data size and complex-
ity. The retention time correction approach used will depend on
which software is employed and thus may rely on solely the reten-
tion time data or may incorporate m/z information.
3.1.4. Peak Integration Detected peaks must then be integrated to enable the compari-
son of relative metabolite abundances, in order to be able to elu-
cidate differences between the sample groups. Both peak height
and peak area can be used and may be software dependent. Peak
area is often used as it is more robust than peak height alone. Sev-
eral peak integration methods have been developed and are often
coupled to the peak detection process.
3.1.5. Normalization Normalization procedures enable more accurate metabolite fea-
ture matching to be achieved and can permit quantitation
between samples. Normalization entails the removal of unwanted
changes in ion intensities between sample runs, thus reducing the
systematic error. These changes may be due to technical or analyt-
ical variation, or alterations in sample or column composition, and
are dependent on the sample type, batch size and instrumenta-
tion. For example, ion intensities may change due to source con-
tamination, column degradation or sample degradation. Quality
control procedures for monitoring such changes are detailed in
Section 3.2.3.3. Metabolomics data normalization should there-
fore enable biological variation to be observed more clearly, but
in reality this can be challenging due to the chemical diversity of
metabolites in biological samples, resulting in varying extraction
recoveries or differing ionization responses during MS analysis.
Normalization can be performed through the following:
1. The addition of one or more internal standards to the sam-
ple (prior to extraction) or external standards (after extrac-
tion). Limitations include ion suppression, challenges in the
choice of standards and which particular standard to use to
normalize each endogenous metabolite for an untargeted
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metabolomics study. Further, this approach is not sufficiently
versatile when there are very pronounced deviations from
the ideal, i.e. severe cases of baseline drift and changes in
peak shapes.
2. The utilization of statistical models to obtain optimal scal-
ing factors for each sample based on the whole dataset, e.g.
normalization by intensity unit norm or median (7, 8) or the
maximum likelihood method (9).
3.1.6. Output of Results Results must be output in a format suitable for subsequent multi-
variate statistical analysis and visualization of features that discrim-
inate sample groups. Typically, this is in the form of a data matrix
with the metabolite features (m/z_RT pairs) in rows and the sam-
ples in columns, with corresponding feature intensity reported (as
height or area) for each detected feature (Section 3.2.1).
3.2. Multivariate
Analysis
3.2.1. Introduction
The output table obtained during the data preprocessing step is
a large matrix of dimensions N (samples) ∗ K (variables), with N
being mostly small compared to K (typically tens to hundreds of
samples vs. thousands of metabolite features (variables)). These
features are often highly correlated and information is likely to be
found in combinations of features rather than in individual ones.
Analysing the variables one by one using univariate statistics may
lead to important information being overlooked. Moreover, spu-
rious results can be produced if differences between groups are
tested using all variables independently (there is an increased risk
of false positives due to the high number of variables). Therefore,
as metabolomics data are multivariate, multivariate techniques
should be used to analyze the multiple variables simultaneously.
This increases the power of detecting meaningful information in
the data and facilitates the identification of deviating samples.
However, certain characteristics of metabolomics data, such as
the high number of variables compared to the number of sam-
ples, high correlation between variables, and noisy, incomplete
data, are problematic for classical statistics methods, e.g. multi-
ple linear regression and linear discriminant analysis. Appropri-
ate multivariate statistics techniques are needed to handle these
characteristics and analyze the multiple variables simultaneously
in order to extract comprehensive information from the large
data table and to subsequently visualize and interpret it. These
techniques can be used to overview a data table (e.g. to identify
relationships between observations, relationships between vari-
ables, deviating observations, trends in the data), to model dif-
ferences between groups of observations and classify unknown
observations, and to link two blocks of variables. They are usu-
ally divided into unsupervised and supervised methods. Unsuper-
vised methods are used to analyze the data without any a priori
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information concerning sample groups/classes and are therefore
a good way of revealing groups or clustering in the data. Typi-
cal unsupervised techniques applied to metabolomics data include
principal components analysis (PCA) (10–12), independent com-
ponent analysis (ICA), multi-dimensional scaling (MDS), hier-
archical clustering, k-means clustering and self-organising maps
(SOMs). Conversely, in supervised analysis, information related to
the dataset (e.g. sample classes, biological/experimental param-
eters, metadata such as clinical chemistry) is used to construct
a predictive model from a training dataset, this model being
then used to predict class or parameter value for observations
not included in the training set. Typical supervised techniques
applied to metabolomics data include partial least squares (PLS)
regression (13), orthogonal PLS (OPLS) (14–16), partial least
squares discriminant analysis (PLS-DA), random forests, sup-
port vector machines (SVMs) and k-nearest neighbour algorithm
(kNN). The choice of some techniques over others depends on
the objective sought in the data analysis and on the type of
dataset. This chapter does not aim to review all these techniques;
it focuses on how to practically apply some of them to MS-based
metabolomics datasets. The working examples used in this chap-
ter are XCMS output datasets obtained from UPLC-MS analy-
sis of rat serum samples from toxicological metabolomics stud-
ies. The study objectives are to investigate possible differences
between animal groups in terms of metabolic profiles and dis-
cover biomarkers of toxic effects. Two projection methods, PCA
and PLS-DA, are frequently used for this purpose and so are illus-
trated in this chapter. These techniques can handle incomplete
and noisy data containing more variables than samples, as well as
highly correlated variables.
3.2.2. Data Scaling After data preprocessing but before performing PCA or PLS-
DA, MS data are usually centred, i.e. variable averages are sub-
tracted from the data to centre it on 0. This is essential to remove
the influence of the variable averages and focus on the variation
among the data. The question that arises next is: Should the data
be scaled? If scaling is not performed, focus is on metabolite fea-
tures with high intensities. This is because variables with high
intensities are likely to show higher variance than variables with
low intensities, and PCA projects onto the direction of maximum
variance. As the range of metabolite classes and concentrations in
biofluids and tissues is large (e.g. from millimolar to nanomolar
or below), MS feature intensities can vary from tens to hundreds
of thousands of counts (arbitrary units dependent on detector).
Thus, the most relevant metabolites in a particular study may not
necessarily be the most abundant. In order to give equal weights
to the variables, unit variance (UV) scaling is often applied after
centring the data. Here, each variable is divided by its standard
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deviation, resulting in a variance of 1 for all metabolite features.
All features then become equally important in PCA. However, the
drawback is that background features (noise) are inflated as well
and are thus given the same importance as metabolite features.
This is not a problem if the preprocessing step removed the noise
efficiently (Section 3.1.1). If this is not the case, Pareto scaling
might be a good alternative. Pareto scaling, often applied for spec-
troscopic data, is similar to UV scaling, the difference being that
the square root of the standard deviation is used as the scaling
factor rather than the standard deviation itself. Compared to no
scaling, this reduces the relative importance of metabolites with
high intensities by decreasing large fold changes more than small
ones. Additionally, the impact of MS noise is reduced compared
to UV scaling.
3.2.3. Unsupervised
Approaches: PCA
After the scaling step, PCA can be performed on the data. PCA
is the most widely used unsupervised chemometric technique for
the analysis of MS-based metabolomics data. It is a useful tool to
obtain an overview of the large datasets, visualize similarities and
differences between observations and gain information about the
metabolite features responsible for the observed patterns. PCA fits
a model that approximates the data as well as possible with only a
few uncorrelated (orthogonal) principal components (PCs), these
components explaining most of the variance in the data. This
allows for the reduction of data dimensionality, while retaining
maximum information. Each PC is a linear combination of the
original variables and explains the maximum amount of variance
possible, not accounted for by the previous PCs.
3.2.3.1. Scores
and Loadings
Conversion of the data into PCs results in a scores matrix and
a loadings matrix. Scores represent the coordinates of the sam-
ples in the PCA model; loadings define the contribution of the
original variables to form the scores. The directions are the same
in both scores and loadings spaces so that an interesting pattern
identified in the scores space can be interpreted by looking at
the corresponding direction in the loadings space. The example
in Fig. 17.2 shows PC1 vs. PC2 scores and loadings plots of
data from the UPLC-MS analysis of 26 biological samples from
a metabolomics study involving two groups of animals. In the
scores plot (Fig. 17.2a), each point represents one sample from
the study (circles=group 1, triangles=group 2). There is clear
separation between the two groups of animals along the first PC,
which explains the most variance in the data (55%). This indicates
that the metabolic profiles from the two groups are different. The
specific metabolite features responsible for this differentiation can
be identified using the corresponding loadings plots (Fig. 17.2b),
in which each point represents one feature. Variables far from the
origin play a crucial role on the model, while variables around
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Fig. 17.2. PCA of 26 rat serum UPLC-MS metabolic profiles from a toxicological study. (a) PC1 vs. PC2 scores plot;
(b) PC1 vs. PC2 loadings plots. There are two sample groups: G1 and G2. Metabolite feature M1 is higher in G2 than in
G1, whereas metabolite features M2 and M3 are higher in G1 than in G2.
the origin have little or no influence. Here, features with high-
positive x-coordinate in loadings plots, such as M1, have higher
intensities in group 2 than in group 1. Conversely, features at
the far left, such as M2 and M3, have higher intensities in group
1 than in group 2. Hence, scores plots can be used to investi-
gate the degree of similarity between samples, and loadings plots
to interpret these observations in terms of metabolic profiles (see
Note 3).
The scaling of the data (Section 3.2.2) has a large impact on
the PCA model and therefore on the scores and loadings plots,
as illustrated in Fig. 17.3. Here it can be seen that while the
two experimental groups are separated in the scores plots using
all three scaling methods, the plots differ, with a similar pattern
seen with the centred data with no scaling and the Pareto-scaled
data plots. Interpretation of loadings plots can be challenging
with UV scaling, due to the density of metabolite features plotted
(Fig. 17.3b2).
3.2.3.2. Detection
of Outliers
PCA scores plots are also useful for the detection of outliers in
the data. Outliers are observations that are extreme or do not fit
the model. In PCA, strong outliers are found outside of the 95%
Hotelling’s T2 confidence ellipse in the scores plot (17), e.g. sam-
ple 9 in Fig. 17.4. If they are far from the ellipse, they have a large
effect on the model as they may require a whole PC to account
for themselves. It is important to examine closely the outliers and
investigate the features responsible for their outlier status to try
to determine if they are due to experimental/analytical issues or
if they reflect real metabolic/biological differences between a par-
ticular animal and the rest of the group. One should not forget
though that the ellipse is a 95% confidence interval, so 5 observa-
tions out of 100 are expected to be outside the ellipse. Moderate
outliers are observations for which the residual (distance to the
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Fig. 17.3. Effect of different data scaling on the PCA of UPLC-MS metabolic profiles of 36 rat serum samples. Column A:
PC1 vs. PC2 scores plot, column B: corresponding loadings plots. Top (1): centred data (no scaling), Middle (2): centred
data with UV scaling, Bottom (3): centred data with Pareto scaling.
model) is large, but compared to strong outliers, they do not have
a large impact on the model. However, they do not fit the model
very well, so care is needed when drawing conclusions for these
observations from the model.
3.2.3.3. Assessment
of Data Quality
Scores plots can also be used to interrogate trends detected in
the data, which may be attributed to either analytical or technical
variation. When analysing large batches of samples using GC/LC-
MS (typically around 100 samples – but this largely depends on
the sample type), differences observed between the first and the
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Fig. 17.4. Effect of an outlier sample on the PCA scores plot (PC1 vs. PC2) of serum
metabolic profiles from a metabolomics study with 19 animals divided into two groups.
Sample 9 is an outlier and takes up the first principal component; separation between
the two groups of rats is seen along the second PC.
last injection of the batch might be due to analytical changes
(e.g. variation in GC/LC conditions, column degradation, mass
spectrometer source contamination) or to metabolite decay in
the samples over time rather than to real biological differences
(Section 3.1.3). It is useful to check in the scores plot that the
distribution of the points (samples) in the plot is not linked with
the sample injection order during the analytical run. Quality con-
trol (QC) samples can be extremely helpful for this purpose and
this approach is becoming more and more widespread in MS-
based metabolomics studies (18, 19). This QC approach consists
of preparing a sample representative of the sample batch by com-
bining equal aliquots from each sample in the study. This QC
sample is then injected periodically throughout the analytical run
(typically every 6–10 injections) to assess analytical reproducibil-
ity. In the PCA scores plot, multiple injections of the QC sample
should be tightly clustered (Fig. 17.5a) and show no/minimal
drift over time. Injecting the QC sample several times (typically
5–15 injections) before starting the analysis of the actual samples
– to condition the analytical column – is also a common practice
in metabolomics studies, as the first injections are often not repro-
ducible, particularly with a new chromatographic column. There-
fore, observing a drift in the first conditioning QC injections in
the PCA scores plot is common. The clustering of the last condi-
tioning QC injections with the periodical QC injections through-
out the analytical run ensures that the system had achieved stabil-
ity prior to analysing the samples of interest. These conditioning
samples can then be excluded from further analysis.
If the injection order of the QCs analyzed within the batch
of samples can be clearly identified in the PC1 vs. PC2 scores
plot (Fig. 17.5b), it indicates that there has been a change in
the analytical platform during the run (e.g. increase/decrease in
metabolite feature intensities, retention time shifts) or in the QC
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Fig. 17.5. PC1 vs. PC2 scores plots of metabolic profiles from two different studies modelled by PCA. In addition to rat
serum samples, multiple injections of the QC samples during the run are also shown (conditioning QC injections have
been removed). (a) QC injections are tightly clustered and no time trend can be seen on the plot. (b) The order of the
injections of the QC sample can be clearly identified in the plot and is following the second PC. This indicates a drift
during the analytical run.
sample itself (e.g. metabolite decay, sample evaporation leading
to changes in metabolite concentrations). If this is the case, a
new model can be constructed including only the QC samples
in order to identify the metabolite feature(s) responsible for the
observed drift. Sometimes, this drift can be corrected, either by
preprocessing the data again with refined alignment step parame-
ters (if the drift is due to retention time shift(s)) or by normalizing
the data (Section 3.1.5). Alternatively, the features responsible
for the drift can be excluded as if they are not reproducible in
the QC samples, then they will not give reliable results through-
out the run and so could not be used as discriminatory markers.
Therefore, some researchers retain only metabolite features with a
coefficient of variation (CV) of <20 or 30% in the QC injections.
3.2.4. Supervised
Approaches: PLS-DA
and OPLS-DA
PCA is a good starting point for the analysis of multivariate data,
providing an overview of similarities and differences between sam-
ples. When a clear separation between the investigated groups is
seen (e.g. Fig. 17.2a), it certifies that there is a real separation
between the groups, as the separation is seen despite no class
data being included in the algorithm. However, principal compo-
nents model the largest variation(s) in the dataset and these direc-
tions may not coincide with the maximum separation between
groups. Other directions might be more pertinent for discrimi-
nating between groups of samples. For this purpose, supervised
multivariate approaches, such as PLS-DA and OPLS-DA, can be
used. In this kind of approach, the algorithm takes into account
sample class information and tries to construct a model that pre-
dicts this membership from the data.
PLS-DA is a classification method based on a regression tech-
nique called PLS, often regarded as a regression extension of
PCA. PLS models the association between the data table X and a
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matrix of responses Y, containing sample information (responses
can be either categorical or continuous, e.g. age, growth, compo-
sition, chemistry parameters). While PCA is a projection of max-
imum variance in X, PLS is a maximum covariance model of the
relationship between X and Y. In PLS-DA, the Y matrix defines
class membership. Hence, PLS-DA attempts to construct a model
that separates the different groups of samples on the basis of their
X variables (metabolite features). Similar to PCA, X scores plot
can be investigated to look at similarities/differences between
samples. The PLS-DA model can be interpreted by considering
the PLS weights for the X and Y variables. The interpretation
of these weights, which gives information about how the vari-
ables combine to form the scores, is similar to the PCA loadings.
Metabolite features highly correlated with the Y matrix (i.e. with
the class separation) have high X weights. The X and Y weights
are often plotted in the same graph, which gives the possibility
to assess the relationship between X and Y. PLS-DA works well
for separated homogenous classes, but PLS-DA models are neg-
atively affected by systematic variation in the X matrix that is not
related to the Y matrix, such as high within-class variance.
When the direction separating the classes in PLS-DA is a com-
bination of components, models might be difficult to interpret as
between-class and within-class variations are mixed. A modifica-
tion of the PLS method, named OPLS (orthogonal PLS), can
be used to facilitate the interpretation. OPLS separates the varia-
tion in the data matrix X into two parts: one part correlated to Y
and one part orthogonal to Y. The OPLS model thus comprises
two modelled variations, the Y-predictive and the Y-orthogonal
components. This partitioning facilitates the interpretation of the
model, as linear between-class and within-class variations are sep-
arated. When performing OPLS-DA with two classes for instance,
all the information relevant for the explanation of the membership
are summarized in one component. OPLS-DA makes the inter-
pretation of the model more straightforward while maintaining
the predictive ability of PLS-DA (see Note 4).
Figure 17.6 shows the PCA, PLS-DA and OPLS-DA scores
plot of the same metabolomics dataset including two experimen-
tal groups. Separation is seen between the two groups of animals
by PCA (a), with a small overlap of the two classes. This sepa-
ration is well defined using PLS-DA (b) and follows a direction
combining the first and second components. Using OPLS-DA
(c), the first component (predictive component) separates the two
classes, facilitating the identification of metabolite features differ-
entially expressed between both groups.
3.2.5. Model Validation When creating a model, it is important to determine how well this
model reflects the data and to what extent the conclusions based
on this model can be relied on. For this purpose, it is necessary
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Fig. 17.6. PC1 vs. PC2 scores plot of 33 metabolic profiles of rat serum samples modelled by (a) PCA, (b) PLS-DA,
(c) OPLS-DA. Separation between the two groups of animals is seen with PCA, which indicates that there are differences
in metabolic profiles between the groups. The separation is amplified using PLS-DA as the algorithm is taking into
account the class membership to construct the model. Using OPLS-DA, the predictive component separates the two
groups, which facilitates the interpretation of the model.
to check 1) the goodness of fit to the data and 2) the predictive
ability of the model. Assessing the goodness of fit is essential as
it indicates how well the model fits the observations. However,
by increasing the number of PCs in a model, the fit of the data
will improve. Therefore checking only the goodness of fit is not
sufficient; it is crucial to also assess the predictive power of the
model. This can be done using either data included to construct
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the model (cross-validation) (see Note 5) or a new set of observa-
tions (test set) (see Note 6) (20, 21). There is a trade-off between
the goodness of fit and the predictive ability. By increasing the
number of PCs, noise gets modelled by the PCs, which decreases
the predictive ability of the model. This decrease in predictive
power is characteristic of an over-fitted model. Therefore the pre-
dictive capacity of a model is often used as a criterion to determine
the optimal number of components. A good model should fit well
the data and be predictive of new data.
3.3. Metabolite
Identification
3.3.1. Databases
Whilst data preprocessing tools (Section 3.1) and ensu-
ing multivariate analysis approaches (Section 3.2) become
more sophisticated and robust, structural characterization
of discriminatory metabolites remains a significant chal-
lenge. Consultation with metabolite databases forms the
initial step in metabolite characterization. These databases
include HumanCyc (http://biocyc.org) (22), the Human
Metabolome Database (HMDB; http://www.hmdb.ca/)
(23), Kyoto Encyclopedia of Genes and Genomes (KEGG;
http://www.genome.jp/kegg/ligand.html) (24), METLIN
(http://metlin.scripps.edu/) (25) and the NIST database
(http://www.nist.gov/srd/index.htm) (26). Although incom-
plete, these databases contain information regarding thousands
of endogenous and drug metabolites, including MS spectra
and in some cases MS/MS spectra. Importantly for metabolite
identification, the HMDB contains experimental and predicted
metabolite 1H- and 13C-NMR data, and the Spectral Database
for Organic Compounds (SDBS) possesses NMR, MS and
IR spectra for organic compounds – useful information, as
often MS alone is not sufficient for unambiguous metabolite
identification. The NIST (26) and the Wiley databases focus on
EI data; the NIST database contains >220,000 spectra of nearly
200,000 unique compounds (often with chemical structures)
and >224,000 Kovats retention index values for ∼22,000 com-
pounds, while the Wiley database contains ∼400,000 EI mass
spectra and >180,000 chemical structures. Together these two
databases form an important resource for metabolite identifica-
tion using GC-MS. The GOLM open access database (27) at the
Max Planck Institute of Molecular Plant Physiology focuses on
EI data and also acts as a GC-MS data repository.
3.3.2. Metabolite
Identification
Approaches
Well-characterized metabolites may be identified through
database searches, and if samples are analyzed using high-
resolution MS, many candidates can be excluded at this stage. For
unambiguous metabolite identification, co-chromatography and
comparison of MS/MS data with the authentic compound are
necessary (28, 29). In the case of an unknown molecule, de novo
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identification is required – a significant challenge given the often
trace quantities of some metabolites and limited sample amount.
Elemental composition can be obtained using a combination of
the following:
1. Accurate mass determinations using high-resolution FTMS
or Orbitrap instrumentation
2. High accurate tandem mass measurements (e.g. on a
Q-TOF, LTQ-FT or LTQ-Orbitrap) for structural charac-
terization
However, despite recent advances, the lack of comprehen-
sive MS libraries and databases often hinders metabolite identi-
fication based solely on MS information. Ultimately, a combina-
tion of technologies will be required for metabolite identification.
These include high-sensitivity capillary NMR, chemical modifica-
tion for functional group identification and finally independent
compound synthesis for verification.
4. Notes
1. Parameter optimization. It is crucial to optimize the data
preprocessing parameters for each metabolomics study, as
every dataset will differ. Parameter optimization is not
straightforward and can be time consuming, as some input
parameters that need to be selected for peak alignment are
not always simple to determine. Key peak picking parame-
ters include the signal-to-noise (S/N) threshold, peak width
parameters and peak shape parameters. The optimum values
for settings such as peak width should be easy to determine
and in general are constant for all chromatograms within a
dataset. Conversely, parameters that define real chromato-
graphic peaks vs. noise or window sizes in which peaks in
two chromatograms are considered the same are more diffi-
cult to determine. Criteria have to be set for determining the
alignment quality, which can be subjective. Some studies use
control samples that are analyzed both spiked with known
compounds and unspiked to check the analytical system and
the method, as well as evaluating peak alignment quality.
2. Baseline correction, noise reduction and smoothing. Correct
use of baseline correction and noise reduction tools is essen-
tial. Different GC-MS and LC-MS technologies may require
specific parameter settings and algorithms, which should be
optimized by each vendor, or perhaps the instrument opera-
tor. Therefore, as a rule, smoothing and baseline correction
are best performed by vendor and system-specific software
applications.
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3. Scores and loadings plots. Scores and loadings plots are 2D
representations of the scores and loadings space. It is impor-
tant to keep in mind how much variation is explained by the
plotted PCs. When many principal components are neces-
sary to explain all the variations in the data, precaution is
needed when interpreting the plots.
4. Predictive performance. It is important to note that OPLS
and PLS have equivalent prediction performance: an OPLS
model that uses 1 predictive component and n orthogonal
components is equivalent in terms of prediction quality to
a PLS model using n+1 components. However, the model
interpretation is easier with OPLS.
5. Cross-validation. The basic idea of cross-validation is to
exclude part of the data, construct a new model on remain-
ing data, predict the omitted data with this model and com-
pare the predictions with the actual values, this being done
until all data have been removed once. The sum of the
squared differences between predicted and observed values
can be used as a measure of the predictive power of the
model.
6. Model validation. A good way of validating a model, if the
number of samples is sufficient, is to split the dataset into
two parts: a training set and a test set (the latter containing
typically at least one-third of the samples). A model is con-
structed and optimised using only the training set. Then,
the developed model is used to predict the samples in the
test set, which have not influenced the model. The goodness
of fit on the test data is an indicator of the predictive ability
of the model.
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